id,llm_model_name,edge,context_input_data,schema_dep_validity,verb,num_options,correct,prompt,reasoning,evidences,answer,answer_choice_probablities,critique_consistent,critique_answer,critique_reasoning
0,gpt-4o,"PET_Scan_Results_10,Number_of_Affected_Lymph_Nodes_2","""{'NODE1': {'id': 'PET_Scan_Results_10', 'label': 'Positron Emission Tomography Scan Results', 'description': 'This node represents the results of a PET scan, which is an imaging test used to observe metabolic processes in the body. The results are crucial for assessing the involvement of lymph nodes, which is important in cancer diagnosis, staging, and treatment planning. The PET scan can reveal whether there is extracapsular spread, unilateral or bilateral lymph node involvement, or absence of lymph node involvement, as well as the size of lymph nodes.', 'type': 'Examination Result', 'observability': 'Observed', 'states': [{'state_name': 'extracapsular_spread_of_lymph_nodes', 'state_description': 'This state indicates that the cancer has spread beyond the capsule of the lymph nodes, which can be a sign of more advanced disease.'}, {'state_name': 'unilateral_lymph_node_involvement', 'state_description': 'This state indicates that cancer involvement is present in the lymph nodes on one side of the body.'}, {'state_name': 'bilateral_lymph_node_involvement', 'state_description': 'This state indicates that cancer involvement is present in the lymph nodes on both sides of the body.'}, {'state_name': 'absence_of_lymph_node_involvement', 'state_description': 'This state indicates that there is no detectable cancer involvement in the lymph nodes.'}, {'state_name': 'enlarged_lymph_node_size', 'state_description': 'This state indicates that the lymph nodes are enlarged, which can be a sign of cancer or other pathological processes.'}, {'state_name': 'present', 'state_description': 'This state indicates the presence of a finding or condition as detected by the PET scan.'}, {'state_name': 'absent', 'state_description': 'This state indicates the absence of a finding or condition as detected by the PET scan.'}]}, 'NODE2': {'id': 'Number_of_Affected_Lymph_Nodes_2', 'label': 'Number of Affected Lymph Nodes', 'description': 'This node represents the clinical assessment of whether there are affected lymph nodes in the patient, which is crucial for staging cancer and determining the extent of metastasis.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'present', 'state_description': 'There are affected lymph nodes, indicating potential metastasis and a more advanced stage of cancer.'}, {'state_name': 'absent', 'state_description': 'There are no affected lymph nodes, suggesting no metastasis to the lymphatic system and potentially an earlier stage of cancer.'}]}, 'EDGE1': {'edges_ids': ['PET_Scan_Results_10', 'Number_of_Affected_Lymph_Nodes_2'], 'edge': '(PET_Scan_Results_10) causes (Number_of_Affected_Lymph_Nodes_2)', 'explanation': ['The edge `(PET_Scan_Results_10) causes (Number_of_Affected_Lymph_Nodes_2)` is not valid as a causal relationship.', 'PET scan results provide information about the current state of lymph node involvement but do not cause changes in the number of affected lymph nodes.', 'The PET scan is a diagnostic tool that detects the presence or absence of lymph node involvement, which is crucial for cancer staging.', 'The number of affected lymph nodes is determined by the underlying disease process, not by the PET scan results.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}, 'EDGE2': {'edges_ids': ['Number_of_Affected_Lymph_Nodes_2', 'PET_Scan_Results_10'], 'edge': '(Number_of_Affected_Lymph_Nodes_2) causes (PET_Scan_Results_10)', 'explanation': ['The edge suggests that the number of affected lymph nodes causes the PET scan results.', 'In clinical practice, the PET scan results are used to assess the number of affected lymph nodes, not the other way around.', 'Therefore, the causal direction is likely reversed, and the given edge is not valid.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}, 'ENTITIES_MATCHING_PAGES_INFO': {'94': {'matching_entities': [{'LYMPH NODE METASTASIS': 0.9812612}, {'LYMPHATIC METASTASIS': 0.9677353}, {'POSITRON-EMISSION TOMOGRAPHY': 0.9655257}, {'NEOPLASM METASTASIS': 0.95823944}, {'POSITRON EMISSION TOMOGRAPHY': 0.9552841}, {'POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY': 0.94104874}, {'MAGNETIC RESONANCE IMAGING': 0.9216922}], 'count': 7}, '92': {'matching_entities': [{'POSITRON EMISSION TOMOGRAPHY (PROCEDURE)': 0.9864658}, {'POSITRON-EMISSION TOMOGRAPHY': 0.9655257}, {'POSITRON EMISSION TOMOGRAPHY': 0.9552841}, {'METASTASIS': 0.9265935}, {'MAGNETIC RESONANCE IMAGING': 0.9216922}], 'count': 5}, '55': {'matching_entities': [{'NEOPLASM METASTASIS': 0.95823944}, {'METASTATIC NEOPLASM': 0.9350836}, {'LYMPHATIC INVASION': 0.9282598}, {'METASTASIS': 0.9265935}, {'EXTRANODAL EXTENSION': 0.9208998}], 'count': 5}, '130': {'matching_entities': [{'LYMPH NODE STRUCTURE': 0.99134904}, {'LYMPH NODE': 0.98570025}, {'LYMPH NODES': 0.97445965}, {'NEOPLASM METASTASIS': 0.95823944}, {'METASTASIS': 0.9265935}], 'count': 5}, '96': {'matching_entities': [{'POSITRON-EMISSION TOMOGRAPHY': 0.9655257}, {'POSITRON EMISSION TOMOGRAPHY': 0.9552841}, {'LOCOREGIONAL RECURRENCE OF TUMOR': 0.92573977}, {'MAGNETIC RESONANCE IMAGING': 0.9216922}], 'count': 4}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 94\\n\\nSection Name: Head and Neck Cancers - Principles of Imaging\\n====================\\nEntities:-\\nPositron Emission Tomography Computed Tomography : A medical imaging technique combining PET and CT capabilities to provide detailed information about the body\\'s function and structure.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\nHead And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\n\\nRelationships:-\\n1. Entity1: \""PET/CT\"", Entity2: \""PET scan\"", Relationship: \""preferred over\""\\n2. Entity1: \""PET-CT\"", Entity2: \""head neck cancers\"", Relationship: \""used in study of\""\\n\\nCausalities:-\\n<A> PET/CT is preferred over PET scan alone (i.e., without superimposed CT scan) </A>. <C> PET/CT provides more accurate anatomical localization of abnormalities </C> <E> more accurate anatomical localization of abnormalities </E>.\\n\\nSection Name: Initial Workup - Nodal Metastases\\n====================\\nEntities:-\\nLymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site via the lymphatic system.\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine\\'s computer to generate cross-sectional images.\\nMagnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.\\nLymph Node Metastasis : The spread of cancer cells to lymph nodes, which are part of the lymphatic system.\\nCt Of Neck : A computed tomography scan of the neck region.\\nMri Of Neck : A magnetic resonance imaging scan of the neck region.\\nFdg-Pet Scan : A type of positron emission tomography using fluorodeoxyglucose to assess metabolic activity.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""lymph node metastases\"", Relationship: \""used to evaluate\""\\n2. Entity1: \""MRI\"", Entity2: \""lymph node metastases\"", Relationship: \""used to evaluate\""\\n3. Entity1: \""FDG-PET/CT\"", Entity2: \""lymph node metastases\"", Relationship: \""used for detection\""\\n4. Entity1: \""FDG-PET/CT\"", Entity2: \""surgical primary approach\"", Relationship: \""used to determine\""\\n5. Entity1: \""FDG-PET/CT\"", Entity2: \""definitive RT approach\"", Relationship: \""used to identify\""\\n\\nCausalities:-\\n<A> Evaluation of lymph node metastases should be conducted with CT or MRI of the neck </A>, using whichever imaging study is suitable for primary site evaluation (IMG-A, 1 of 4).\\n<CO> For patients with multistation or lower neck nodal involvement or high-grade tumor histology </CO>, <A> consider CT of the chest to assess for mediastinal lymph node metastases or FDG-PET/CT </A>, <C> which is associated with higher sensitivity for both nodal and distant metastases </C>.\\n<CO> For patients who are under consideration for a surgical primary approach </CO>, <A> the higher sensitivity of FDG-PET/CT is warranted for tumors approaching the midline, to determine the surgical approach to the contralateral neck </A>. <CO> Similarly, patients who are scheduled for a definitive RT approach </CO> <A> may benefit from the higher sensitivity of FDG-PET/CT for identifying involved lymph nodes </A>.\\n\\nSection Name: Initial Workup - Distant Metastases\\n====================\\nEntities:-\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.\\nMagnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine\\'s computer to generate cross-sectional images.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nLung Neoplasms : Tumors or cancer of the lung.\\nSmoking : The inhalation of the smoke of burning tobacco encased in cigarettes, pipes, and cigars.\\n\\nRelationships:-\\n1. Entity1: \""FDG-PET/CT\"", Entity2: \""Distant Metastases\"", Relationship: \""used to evaluate\""\\n2. Entity1: \""Contrast-enhanced brain MRI\"", Entity2: \""Brain Metastasis\"", Relationship: \""recommended for evaluation\""\\n3. Entity1: \""CT of the chest\"", Entity2: \""Pulmonary Metastases\"", Relationship: \""performed to assess\""\\n4. Entity1: \""Non-contrast CT of the chest\"", Entity2: \""Lung Parenchymal Metastases\"", Relationship: \""used to screen\""\\n5. Entity1: \""Annual CT screening\"", Entity2: \""Lung Metastasis\"", Relationship: \""considered for high risk\""\\n6. Entity1: \""Directed CT or MRI\"", Entity2: \""Distant Disease\"", Relationship: \""used for assessment\""\\n7. Entity1: \""FDG-PET/CT\"", Entity2: \""Recurrent Disease\"", Relationship: \""used for staging\""\\n\\nCausalities:-\\n<C> Patients with locoregionally advanced cancer (e.g., T3\u2013T4 primary or \u2265N1 nodal staging) </C>, <A> FDG-PET/CT is preferred to evaluate for distant disease and thoracic metastases </A>. <CO> For cancers where brain metastasis is a concern, such as mucosal melanoma or high-grade neuroendocrine carcinomas or adenocarcinomas </CO>, <A> contrast-enhanced brain MRI should be additionally obtained </A>.\\n<CO> If FDG-PET/CT is not performed </CO>, <A> CT of the chest should be performed to assess for presence of pulmonary metastases as well as mediastinal lymph node involvement </A>.\\n<CO> Non-contrast CT of the chest can be sufficient to screen for lung parenchymal metastases </CO> but <CO> is not adequate for assessment of mediastinal adenopathy </CO>. <CO> This is an appropriate lung cancer screening intervention for patients with a history of smoking </CO>.\\n<CO> Following primary definitive treatment (surgery, RT, or systemic therapy/RT) </CO> the role of annual CT screening for lung metastasis is controversial. <E> While this approach does detect early metastasis </E>, <CO> further study is needed to determine the extent of the positive effect and/or cost-effectiveness of this approach in specific subpopulations and timepoints post-treatment </CO>. <CO> For patients with a substantial smoking history or who are at high risk for lung metastases </CO>, <A> annual chest CT can be considered </A>.\\n<CO> If clinical concern for metastatic disease is confined to a specific anatomical area </CO>, <A> the assessment of distant disease can be performed with directed CT or MRI examination </A>.\\n<CO> FDG-PET/CT may complement or replace other imaging modalities when staging recurrent disease before any therapy for relapsed/refractory disease </CO> <A> in order to explore distant disease or second primaries that may significantly impact choice of therapy </A>.\\n--------------------------------------------------\\nPage Number: 92\\n\\nSection Name: NCCN Guidelines Overview\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nMalignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.\\nHead And Neck Cancer : A group of cancers that originate in the head and neck region.\\nAntineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nRadiation Therapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\n\\nRelationships:-\\n1. Entity1: \""Head and neck cancers\"", Entity2: \""Systemic therapy\"", Relationship: \""follow-up recommendations after\""\\n2. Entity1: \""Head and neck cancers\"", Entity2: \""Radiation therapy\"", Relationship: \""follow-up recommendations after\""\\n\\nCausalities:-\\nThe image presents a flowchart from the National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2024, especially focusing on <A> follow-up recommendations </A> for <CO> patients with head and neck cancers after systemic therapy or radiation therapy (RT) </CO>. All recommendations are categorized as level A unless stated otherwise, highlighting the importance of clinical trials in cancer management.\\n\\nSection Name: Imaging and Assessment Protocols\\n====================\\nEntities:-\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nClinical Assessment : A systematic evaluation of a patient\\'s health status, often involving a physical examination and medical history.\\nPositron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.\\nComputed Tomography : A medical imaging technique used in radiology to obtain detailed internal images of the body.\\nMagnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis.\\nDisease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nResidual Neoplasm : Remaining cancer cells after treatment.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Clinical Assessment\"", Relationship: \""occurs before\""\\n2. Entity1: \""FDG-PET/CT Scan\"", Entity2: \""Distant Metastases\"", Relationship: \""assesses\""\\n3. Entity1: \""FDG-PET/CT Scan\"", Entity2: \""Observation\"", Relationship: \""leads to if negative\""\\n4. Entity1: \""FDG-PET/CT Scan\"", Entity2: \""CT Scan\"", Relationship: \""leads to if strongly positive\""\\n5. Entity1: \""CT Scan\"", Entity2: \""Neck Dissection\"", Relationship: \""leads to if positive\""\\n\\nCausalities:-\\n<CO> After systemic therapy or RT </CO>, <A> a clinical assessment should occur 4 to 8 weeks later </A>. <CO> If there is a response </CO>, <A> it is necessary to assess the extent of disease or distant metastases, preferably through a FDG-PET/CT scan at a minimum of 12 weeks post-treatment </A>. <CO> If the FDG-PET/CT results are negative </CO>, <A> the patient may continue with monitoring through observation </A>. <CO> In cases where the results are equivocal </CO>, <A> observation or repeat FDG-PET/CT within 3 to 6 months is prescribed </A>.\\n\\n<CO> In cases where the FDG-PET/CT results are strongly positive </CO>, <A> further imaging via CT scan with contrast of the primary site and neck, or MRI with and without contrast, becomes necessary </A>. <CO> If these imaging results confirm positive findings </CO>, <A> neck dissection may be considered, depending on the evidence of residual or persistent disease </A>. <CO> If the imaging findings are negative </CO>, <A> the patient might continue in observation </A>.\\n\\nSection Name: Outcomes Based on Disease Resectability\\n====================\\nEntities:-\\nDisease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.\\nResectable : Capable of being surgically removed.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis.\\n\\nRelationships:-\\n1. Entity1: \""Disease\"", Entity2: \""Resectable\"", Relationship: \""Classification\""\\n2. Entity1: \""Unresectable\"", Entity2: \""Treatment plans (ADV-3)\"", Relationship: \""Treatment recommendation\""\\n3. Entity1: \""Resectable\"", Entity2: \""Resection and/or Neck dissection\"", Relationship: \""Surgical procedure\""\\n\\nCausalities:-\\n<CO> If there is confirmed residual or persistent disease </CO>, the options split into two pathways: \\'Unresectable\\' or \\'Resectable.\\' <CO> If the disease is classified as unresectable </CO>, <A> advances in treatment plans (labeled ADV-3) are called for </A>. Conversely, <CO> if it is deemed resectable </CO>, <A> a resection of the primary and/or neck dissection may occur </A>, <CO> contingent upon the disease status </CO>.\\n\\nSection Name: Important Notes\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nPositron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.\\nPositron Emission Tomography (Procedure) : A diagnostic imaging procedure that uses a radioactive tracer to visualize and measure changes in metabolic processes.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique used to observe metabolic processes in the body.\\nNeoplasms : New abnormal growth of tissue in animals or plants; a tumor.\\nMalignant Neoplasm : A cancerous growth that has the potential to spread to other parts of the body.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""NCCN\"", Entity2: \""Clinical trials\"", Relationship: \""emphasizes participation in\""\\n2. Entity1: \""FDG-PET/CT\"", Entity2: \""Persistent cancer\"", Relationship: \""used to detect\""\\n3. Entity1: \""FDG-PET/CT\"", Entity2: \""PET negative\"", Relationship: \""interpretation of results\""\\n4. Entity1: \""FDG-PET/CT\"", Entity2: \""PET positive\"", Relationship: \""interpretation of results\""\\n\\nCausalities:-\\n<A> NCCN emphasizes that the best management for any cancer patient is participation in clinical trials </A>, especially encouraged for all patients. Additional notes clarify that <CO> if the FDG-PET/CT is negative for persistent cancer </CO>, <A> further cross-sectional imaging is optional </A>. The interpretations define <CO> PET negative as no or low-grade uptake not suspicious for disease </CO>, while <CO> PET positive implies suspicion for disease </CO>.\\n--------------------------------------------------\\nPage Number: 55\\n\\nSection Name: General Information\\n====================\\nEntities:-\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""National Comprehensive Cancer Network\"", Relationship: \""produced by\""\\n\\nSection Name: Important Notes\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNeoplasms : New abnormal growth of tissue that can be benign or malignant.\\nMalignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Trials\"", Entity2: \""Cancer\"", Relationship: \""recommended for\""\\n2. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n\\nCausalities:-\\n<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nChemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n2. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n3. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n\\nCausalities:-\\n### Principles\\n\\n- **Principles of Surgery (SURG-A)**\\n- **Principles of Radiation Therapy (SUPRA-A)**\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nPerineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The invasion of cancer cells into blood vessels.\\nLymphatic Invasion : The invasion of cancer cells into lymphatic vessels.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n2. Entity1: \""Positive margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n3. Entity1: \""Close margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n4. Entity1: \""pT3 or pT4 primary\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n5. Entity1: \""pN2 or pN3 nodal disease\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n6. Entity1: \""Perineural invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n7. Entity1: \""Vascular invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n8. Entity1: \""Lymphatic invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n\\nCausalities:-\\n<C> Extranodal extension </C>\\n<C> Positive margins </C>\\n<C> Close margins </C>\\n<C> pT3 or pT4 primary </C>\\n<C> pN2 or pN3 nodal disease </C>\\n<C> Perineural invasion </C>\\n<C> Vascular invasion </C>\\n<C> Lymphatic invasion </C>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nPrimary Site : The original location where a tumor or cancer begins.\\nComplete Remission : The disappearance of all signs of cancer in response to treatment.\\nPartial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""induction chemotherapy\"", Entity2: \""Primary site\"", Relationship: \""treatment outcome\""\\n2. Entity1: \""Definitive RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n3. Entity1: \""RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n4. Entity1: \""Surgery\"", Entity2: \""unresectable nodal disease\"", Relationship: \""treatment option\""\\n\\nCausalities:-\\n<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.\\nFollow-Up (Medicine) : The process of monitoring a patient\\'s health over time after treatment or diagnosis.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : A disease that returns after a period of remission.\\nRecurrence (Medicine) : The return of a disease or condition after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n### Follow-up\\n\\n- **Follow-up** (FOLL-A, 1 of 2)\\n- **Recurrent or persistent disease** (ADV-3)\\n\\nSection Name: Risk Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""RT\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Adverse pathologic features\"", Entity2: \""Systemic therapy\"", Relationship: \""Consideration for treatment\""\\n\\nCausalities:-\\n- **No adverse pathologic features**\\n- **Other risk features**\\n- **Adverse pathologic features**:\\n  - <C> Extranodal extension and/or positive margin </C>\\n  - <A> RT or consider systemic therapy/RT </A>\\n\\nSection Name: Post-Therapy Evaluation\\n====================\\nEntities:-\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nNeck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n2. Entity1: \""RT\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n\\nCausalities:-\\n<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>\\n\\nSection Name: Flowchart Overview\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nSupraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""guides management of\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""healthcare professionals\"", Relationship: \""used by\""\\n\\nCausalities:-\\n<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.\\n\\nSection Name: Assessment and Treatment Decisions\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nComplete Response : The disappearance of all signs of cancer in response to treatment.\\nPartial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Complete Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n2. Entity1: \""Complete Response\"", Entity2: \""Surgery\"", Relationship: \""leads to\""\\n3. Entity1: \""Partial Response\"", Entity2: \""Systemic Therapy\"", Relationship: \""leads to\""\\n4. Entity1: \""Partial Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n\\nCausalities:-\\n<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.\\n\\nSection Name: Adverse Pathologic Features and Follow-up\\n====================\\nEntities:-\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nNeoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nRecurrent Neoplasm : A neoplasm that has returned after treatment.\\nMetastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.\\nMetastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""Treatment decisions\"", Relationship: \""Influence\""\\n2. Entity1: \""Adverse features\"", Entity2: \""Surgical intervention\"", Relationship: \""Recommendation\""\\n3. Entity1: \""Absence of adverse features\"", Entity2: \""Radiation therapy\"", Relationship: \""Pathway\""\\n4. Entity1: \""Follow-up process\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""Detection\""\\n5. Entity1: \""Recurrent or persistent disease\"", Entity2: \""Advanced disease management\"", Relationship: \""Necessity\""\\n\\nCausalities:-\\n<C> The presence of adverse pathologic features \u2014 such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient\\'s disease characteristics.\\n\\nFurthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.\\n--------------------------------------------------\\nPage Number: 130\\n\\nSection Name: Pathological N (pN)\\n====================\\nEntities:-\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nTnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system.\\n\\nRelationships:-\\n1. Entity1: \""Lymph Nodes\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""involved in\""\\n2. Entity1: \""TNM Staging\"", Entity2: \""Lymph Nodes\"", Relationship: \""includes\""\\n3. Entity1: \""TNM Staging\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""describes\""\\n\\nCausalities:-\\n<CO> NX: Regional lymph nodes cannot be assessed </CO>\\n<CO> N0: No regional lymph node metastasis </CO>\\n<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(\u2013) </CO>\\n<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(\u2212); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> Note: A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+). </CO>\\n\\nSection Name: Distant Metastasis (M)\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""M0\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n2. Entity1: \""M1\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n\\nCausalities:-\\n### Distant Metastasis (M)\\n\\n- **M0**: No distant metastasis\\n- **M1**: Distant metastasis\\n\\nSection Name: Histologic Grade (G)\\n====================\\nEntities:-\\nNeoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.\\nHistologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.\\n\\nRelationships:-\\n1. Entity1: \""GX\"", Entity2: \""Grade cannot be assessed\"", Relationship: \""is described as\""\\n2. Entity1: \""G1\"", Entity2: \""Well differentiated\"", Relationship: \""is described as\""\\n3. Entity1: \""G2\"", Entity2: \""Moderately differentiated\"", Relationship: \""is described as\""\\n4. Entity1: \""G3\"", Entity2: \""Poorly differentiated\"", Relationship: \""is described as\""\\n\\nCausalities:-\\n<CO>GX</CO>: <E>Grade cannot be assessed</E>\\n<CO>G1</CO>: <E>Well differentiated</E>\\n<CO>G2</CO>: <E>Moderately differentiated</E>\\n<CO>G3</CO>: <E>Poorly differentiated</E>\\n\\nSection Name: Prognostic Stage Groups\\n====================\\nEntities:-\\nNeoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.\\nTumor Staging : A system for describing the size and spread of cancer within the body.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\n\\nRelationships:-\\n1. Entity1: \""Stage 0\"", Entity2: \""Tis N0 M0\"", Relationship: \""defined by\""\\n2. Entity1: \""Stage I\"", Entity2: \""T1 N0 M0\"", Relationship: \""defined by\""\\n3. Entity1: \""Stage II\"", Entity2: \""T2 N0 M0\"", Relationship: \""defined by\""\\n4. Entity1: \""Stage III\"", Entity2: \""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0\"", Relationship: \""defined by\""\\n5. Entity1: \""Stage IVA\"", Entity2: \""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0\"", Relationship: \""defined by\""\\n6. Entity1: \""Stage IVB\"", Entity2: \""Any T N3 M0, T4b Any N M0\"", Relationship: \""defined by\""\\n7. Entity1: \""Stage IVC\"", Entity2: \""Any T Any N M1\"", Relationship: \""defined by\""\\n--------------------------------------------------\\nPage Number: 96\\n\\nSection Name: Head and Neck Cancers\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes.\\nSurveillance : The ongoing systematic collection, analysis, and interpretation of health data essential to the planning, implementation, and evaluation of public health practice.\\nLocoregional Recurrence Of Tumor : The return of cancer in the original tumor location or nearby lymph nodes after treatment.\\nAsymptomatic : A condition or a person showing no symptoms of disease.\\nMagnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nUltrasound : A medical imaging technique that uses high-frequency sound waves to visualize soft tissues such as muscles and internal organs.\\n\\nRelationships:-\\n1. Entity1: \""FDG-PET/CT\"", Entity2: \""Head and Neck Neoplasms\"", Relationship: \""used for surveillance imaging\""\\n2. Entity1: \""Recurrence\"", Entity2: \""Post-treatment period\"", Relationship: \""occurs within\""\\n3. Entity1: \""Imaging Modalities\"", Entity2: \""Surveillance\"", Relationship: \""used for\""\\n\\nCausalities:-\\n<C> The majority of recurrences after treatment of head and neck cancer occur in the first 2 years </C>. <C> Surveillance can be challenging </C> <C> because of altered anatomy and/or fibrosis from surgery, radiation, and/or chemotherapy </C>. <CO> There are no consensus guidelines on the frequency and modality of routine post-treatment imaging in the asymptomatic patient </CO>. <A> Practice varies widely across institutions </A>.\\n\\n<C> US, CT, MRI, and PET/CT all have unique advantages and disadvantages when used as surveillance imaging </C>. <C> There is evidence that FDG-PET/CT may be the most sensitive of these modalities </C>. <E> A 12-month PET has been shown to reveal recurrent or second primary cancers in approximately 10% of treated patients </E>; <E> a 24-month FDG-PET/CT imaging revealed these findings in approximately 5% of treated cases </E>. <CO> Most cases of asymptomatic FDG-PET/CT lesion localization occur at distant sites </CO>. <CO> Whether earlier detection leads to improved disease-specific survival is not established </CO>.\\n\\n<A> Standardized multi-institutional imaging-based trials are needed to clearly elucidate the value of routine imaging in the clinically asymptomatic patient </A>. <CO> There may be little proven benefit in further imaging if the initial 3-month FDG-PET/CT scan was negative </CO>. <C> Ho et al reported no significant difference in 3-year disease-free survival in patients undergoing imaging surveillance versus those only receiving clinical surveillance </C> <E> (41% vs. 46%, P = .91) in this setting </E>.\\n\\n<CO> If an FDG-PET/CT at 3 months post-treatment is negative </CO>, <CO> there are no data to support substantial benefit for further routine imaging in an asymptomatic patient with negative exam </CO>. <A> In the absence of multi-institutional prospective data, a tailored approach to surveillance with attention to tumor type, stage, prognostic factors, symptomatology, and physical exam changes or restrictions is appropriate </A>.\\n\\n<A> US of the neck is a well-established tool for nodal surveillance </A>. <C> US is generally widely available, safe, fast, inexpensive, and an accurate modality for examination of the neck for any suspicious nodal disease </C>.\\n\\n<CO> Additional post-treatment imaging is indicated for worrisome or equivocal signs/symptoms </CO>.\\n\\n<CO> Routine annual imaging (repeat use of pretreatment imaging modality) may be indicated to visualize areas inaccessible to routine clinical examination </CO> <CO> (deep-seated anatomic locations or areas obscured by extensive treatment change) </CO>.\\n\\nSection Name: Principles of Imaging\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nHead And Neck Cancer : A group of cancers that originate in the head and neck region.\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes.\\nPositron Emission Tomography : A type of nuclear medicine imaging that uses small amounts of radioactive materials to diagnose or treat a variety of diseases.\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the computer to generate cross-sectional images.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images.\\nNeck : The part of the body on many vertebrates that separates the head from the torso or trunk.\\n\\nRelationships:-\\n1. Entity1: \""Surveillance imaging\"", Entity2: \""Head and neck cancer\"", Relationship: \""used for monitoring\""\\n2. Entity1: \""PET-CT\"", Entity2: \""Head and neck cancer\"", Relationship: \""used for detection\""\\n3. Entity1: \""Positron emission tomography/computed tomography\"", Entity2: \""Head and neck cancer\"", Relationship: \""used for surveillance\""\\n\\nSection Name: NCCN Guidelines\\n====================\\nEntities:-\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nClinical Trial : A clinical trial is a research study conducted with patients to evaluate a new medical treatment, drug, or device.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""Neoplasms\"", Entity2: \""Clinical trial\"", Relationship: \""best management through\""\\n\\nCausalities:-\\n<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.\\n'}""",invalid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: PET_Scan_Results_10
label: Positron Emission Tomography Scan Results
description: This node represents the results of a PET scan, which is an imaging test used to observe metabolic processes in the body. The results are crucial for assessing the involvement of lymph nodes, which is important in cancer diagnosis, staging, and treatment planning. The PET scan can reveal whether there is extracapsular spread, unilateral or bilateral lymph node involvement, or absence of lymph node involvement, as well as the size of lymph nodes.
type: Examination Result
observability: Observed
states: [{'state_name': 'extracapsular_spread_of_lymph_nodes', 'state_description': 'This state indicates that the cancer has spread beyond the capsule of the lymph nodes, which can be a sign of more advanced disease.'}, {'state_name': 'unilateral_lymph_node_involvement', 'state_description': 'This state indicates that cancer involvement is present in the lymph nodes on one side of the body.'}, {'state_name': 'bilateral_lymph_node_involvement', 'state_description': 'This state indicates that cancer involvement is present in the lymph nodes on both sides of the body.'}, {'state_name': 'absence_of_lymph_node_involvement', 'state_description': 'This state indicates that there is no detectable cancer involvement in the lymph nodes.'}, {'state_name': 'enlarged_lymph_node_size', 'state_description': 'This state indicates that the lymph nodes are enlarged, which can be a sign of cancer or other pathological processes.'}, {'state_name': 'present', 'state_description': 'This state indicates the presence of a finding or condition as detected by the PET scan.'}, {'state_name': 'absent', 'state_description': 'This state indicates the absence of a finding or condition as detected by the PET scan.'}]

`NODE2`:
id: Number_of_Affected_Lymph_Nodes_2
label: Number of Affected Lymph Nodes
description: This node represents the clinical assessment of whether there are affected lymph nodes in the patient, which is crucial for staging cancer and determining the extent of metastasis.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'present', 'state_description': 'There are affected lymph nodes, indicating potential metastasis and a more advanced stage of cancer.'}, {'state_name': 'absent', 'state_description': 'There are no affected lymph nodes, suggesting no metastasis to the lymphatic system and potentially an earlier stage of cancer.'}]

`EDGE1`:
{'edges_ids': ['PET_Scan_Results_10', 'Number_of_Affected_Lymph_Nodes_2'], 'edge': '(PET_Scan_Results_10) causes (Number_of_Affected_Lymph_Nodes_2)', 'explanation': ['The edge `(PET_Scan_Results_10) causes (Number_of_Affected_Lymph_Nodes_2)` is not valid as a causal relationship.', 'PET scan results provide information about the current state of lymph node involvement but do not cause changes in the number of affected lymph nodes.', 'The PET scan is a diagnostic tool that detects the presence or absence of lymph node involvement, which is crucial for cancer staging.', 'The number of affected lymph nodes is determined by the underlying disease process, not by the PET scan results.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}

`EDGE2`:
{'edges_ids': ['Number_of_Affected_Lymph_Nodes_2', 'PET_Scan_Results_10'], 'edge': '(Number_of_Affected_Lymph_Nodes_2) causes (PET_Scan_Results_10)', 'explanation': ['The edge suggests that the number of affected lymph nodes causes the PET scan results.', 'In clinical practice, the PET scan results are used to assess the number of affected lymph nodes, not the other way around.', 'Therefore, the causal direction is likely reversed, and the given edge is not valid.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 94

Section Name: Head and Neck Cancers - Principles of Imaging
====================
Entities:-
Positron Emission Tomography Computed Tomography : A medical imaging technique combining PET and CT capabilities to provide detailed information about the body's function and structure.
Positron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.
Head And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.

Relationships:-
1. Entity1: ""PET/CT"", Entity2: ""PET scan"", Relationship: ""preferred over""
2. Entity1: ""PET-CT"", Entity2: ""head neck cancers"", Relationship: ""used in study of""

Causalities:-
<A> PET/CT is preferred over PET scan alone (i.e., without superimposed CT scan) </A>. <C> PET/CT provides more accurate anatomical localization of abnormalities </C> <E> more accurate anatomical localization of abnormalities </E>.

Section Name: Initial Workup - Nodal Metastases
====================
Entities:-
Lymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site via the lymphatic system.
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine's computer to generate cross-sectional images.
Magnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.
Lymph Node Metastasis : The spread of cancer cells to lymph nodes, which are part of the lymphatic system.
Ct Of Neck : A computed tomography scan of the neck region.
Mri Of Neck : A magnetic resonance imaging scan of the neck region.
Fdg-Pet Scan : A type of positron emission tomography using fluorodeoxyglucose to assess metabolic activity.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.
Positron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.

Relationships:-
1. Entity1: ""CT"", Entity2: ""lymph node metastases"", Relationship: ""used to evaluate""
2. Entity1: ""MRI"", Entity2: ""lymph node metastases"", Relationship: ""used to evaluate""
3. Entity1: ""FDG-PET/CT"", Entity2: ""lymph node metastases"", Relationship: ""used for detection""
4. Entity1: ""FDG-PET/CT"", Entity2: ""surgical primary approach"", Relationship: ""used to determine""
5. Entity1: ""FDG-PET/CT"", Entity2: ""definitive RT approach"", Relationship: ""used to identify""

Causalities:-
<A> Evaluation of lymph node metastases should be conducted with CT or MRI of the neck </A>, using whichever imaging study is suitable for primary site evaluation (IMG-A, 1 of 4).
<CO> For patients with multistation or lower neck nodal involvement or high-grade tumor histology </CO>, <A> consider CT of the chest to assess for mediastinal lymph node metastases or FDG-PET/CT </A>, <C> which is associated with higher sensitivity for both nodal and distant metastases </C>.
<CO> For patients who are under consideration for a surgical primary approach </CO>, <A> the higher sensitivity of FDG-PET/CT is warranted for tumors approaching the midline, to determine the surgical approach to the contralateral neck </A>. <CO> Similarly, patients who are scheduled for a definitive RT approach </CO> <A> may benefit from the higher sensitivity of FDG-PET/CT for identifying involved lymph nodes </A>.

Section Name: Initial Workup - Distant Metastases
====================
Entities:-
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.
Magnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine's computer to generate cross-sectional images.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Lung Neoplasms : Tumors or cancer of the lung.
Smoking : The inhalation of the smoke of burning tobacco encased in cigarettes, pipes, and cigars.

Relationships:-
1. Entity1: ""FDG-PET/CT"", Entity2: ""Distant Metastases"", Relationship: ""used to evaluate""
2. Entity1: ""Contrast-enhanced brain MRI"", Entity2: ""Brain Metastasis"", Relationship: ""recommended for evaluation""
3. Entity1: ""CT of the chest"", Entity2: ""Pulmonary Metastases"", Relationship: ""performed to assess""
4. Entity1: ""Non-contrast CT of the chest"", Entity2: ""Lung Parenchymal Metastases"", Relationship: ""used to screen""
5. Entity1: ""Annual CT screening"", Entity2: ""Lung Metastasis"", Relationship: ""considered for high risk""
6. Entity1: ""Directed CT or MRI"", Entity2: ""Distant Disease"", Relationship: ""used for assessment""
7. Entity1: ""FDG-PET/CT"", Entity2: ""Recurrent Disease"", Relationship: ""used for staging""

Causalities:-
<C> Patients with locoregionally advanced cancer (e.g., T3–T4 primary or ≥N1 nodal staging) </C>, <A> FDG-PET/CT is preferred to evaluate for distant disease and thoracic metastases </A>. <CO> For cancers where brain metastasis is a concern, such as mucosal melanoma or high-grade neuroendocrine carcinomas or adenocarcinomas </CO>, <A> contrast-enhanced brain MRI should be additionally obtained </A>.
<CO> If FDG-PET/CT is not performed </CO>, <A> CT of the chest should be performed to assess for presence of pulmonary metastases as well as mediastinal lymph node involvement </A>.
<CO> Non-contrast CT of the chest can be sufficient to screen for lung parenchymal metastases </CO> but <CO> is not adequate for assessment of mediastinal adenopathy </CO>. <CO> This is an appropriate lung cancer screening intervention for patients with a history of smoking </CO>.
<CO> Following primary definitive treatment (surgery, RT, or systemic therapy/RT) </CO> the role of annual CT screening for lung metastasis is controversial. <E> While this approach does detect early metastasis </E>, <CO> further study is needed to determine the extent of the positive effect and/or cost-effectiveness of this approach in specific subpopulations and timepoints post-treatment </CO>. <CO> For patients with a substantial smoking history or who are at high risk for lung metastases </CO>, <A> annual chest CT can be considered </A>.
<CO> If clinical concern for metastatic disease is confined to a specific anatomical area </CO>, <A> the assessment of distant disease can be performed with directed CT or MRI examination </A>.
<CO> FDG-PET/CT may complement or replace other imaging modalities when staging recurrent disease before any therapy for relapsed/refractory disease </CO> <A> in order to explore distant disease or second primaries that may significantly impact choice of therapy </A>.
--------------------------------------------------
Page Number: 92

Section Name: NCCN Guidelines Overview
====================
Entities:-
Head And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Malignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.
Head And Neck Cancer : A group of cancers that originate in the head and neck region.
Antineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Radiation Therapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.

Relationships:-
1. Entity1: ""Head and neck cancers"", Entity2: ""Systemic therapy"", Relationship: ""follow-up recommendations after""
2. Entity1: ""Head and neck cancers"", Entity2: ""Radiation therapy"", Relationship: ""follow-up recommendations after""

Causalities:-
The image presents a flowchart from the National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2024, especially focusing on <A> follow-up recommendations </A> for <CO> patients with head and neck cancers after systemic therapy or radiation therapy (RT) </CO>. All recommendations are categorized as level A unless stated otherwise, highlighting the importance of clinical trials in cancer management.

Section Name: Imaging and Assessment Protocols
====================
Entities:-
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Clinical Assessment : A systematic evaluation of a patient's health status, often involving a physical examination and medical history.
Positron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.
Computed Tomography : A medical imaging technique used in radiology to obtain detailed internal images of the body.
Magnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis.
Disease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Residual Neoplasm : Remaining cancer cells after treatment.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Clinical Assessment"", Relationship: ""occurs before""
2. Entity1: ""FDG-PET/CT Scan"", Entity2: ""Distant Metastases"", Relationship: ""assesses""
3. Entity1: ""FDG-PET/CT Scan"", Entity2: ""Observation"", Relationship: ""leads to if negative""
4. Entity1: ""FDG-PET/CT Scan"", Entity2: ""CT Scan"", Relationship: ""leads to if strongly positive""
5. Entity1: ""CT Scan"", Entity2: ""Neck Dissection"", Relationship: ""leads to if positive""

Causalities:-
<CO> After systemic therapy or RT </CO>, <A> a clinical assessment should occur 4 to 8 weeks later </A>. <CO> If there is a response </CO>, <A> it is necessary to assess the extent of disease or distant metastases, preferably through a FDG-PET/CT scan at a minimum of 12 weeks post-treatment </A>. <CO> If the FDG-PET/CT results are negative </CO>, <A> the patient may continue with monitoring through observation </A>. <CO> In cases where the results are equivocal </CO>, <A> observation or repeat FDG-PET/CT within 3 to 6 months is prescribed </A>.

<CO> In cases where the FDG-PET/CT results are strongly positive </CO>, <A> further imaging via CT scan with contrast of the primary site and neck, or MRI with and without contrast, becomes necessary </A>. <CO> If these imaging results confirm positive findings </CO>, <A> neck dissection may be considered, depending on the evidence of residual or persistent disease </A>. <CO> If the imaging findings are negative </CO>, <A> the patient might continue in observation </A>.

Section Name: Outcomes Based on Disease Resectability
====================
Entities:-
Disease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.
Resectable : Capable of being surgically removed.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis.

Relationships:-
1. Entity1: ""Disease"", Entity2: ""Resectable"", Relationship: ""Classification""
2. Entity1: ""Unresectable"", Entity2: ""Treatment plans (ADV-3)"", Relationship: ""Treatment recommendation""
3. Entity1: ""Resectable"", Entity2: ""Resection and/or Neck dissection"", Relationship: ""Surgical procedure""

Causalities:-
<CO> If there is confirmed residual or persistent disease </CO>, the options split into two pathways: 'Unresectable' or 'Resectable.' <CO> If the disease is classified as unresectable </CO>, <A> advances in treatment plans (labeled ADV-3) are called for </A>. Conversely, <CO> if it is deemed resectable </CO>, <A> a resection of the primary and/or neck dissection may occur </A>, <CO> contingent upon the disease status </CO>.

Section Name: Important Notes
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
Positron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.
Positron Emission Tomography (Procedure) : A diagnostic imaging procedure that uses a radioactive tracer to visualize and measure changes in metabolic processes.
Positron Emission Tomography : A nuclear medicine functional imaging technique used to observe metabolic processes in the body.
Neoplasms : New abnormal growth of tissue in animals or plants; a tumor.
Malignant Neoplasm : A cancerous growth that has the potential to spread to other parts of the body.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""NCCN"", Entity2: ""Clinical trials"", Relationship: ""emphasizes participation in""
2. Entity1: ""FDG-PET/CT"", Entity2: ""Persistent cancer"", Relationship: ""used to detect""
3. Entity1: ""FDG-PET/CT"", Entity2: ""PET negative"", Relationship: ""interpretation of results""
4. Entity1: ""FDG-PET/CT"", Entity2: ""PET positive"", Relationship: ""interpretation of results""

Causalities:-
<A> NCCN emphasizes that the best management for any cancer patient is participation in clinical trials </A>, especially encouraged for all patients. Additional notes clarify that <CO> if the FDG-PET/CT is negative for persistent cancer </CO>, <A> further cross-sectional imaging is optional </A>. The interpretations define <CO> PET negative as no or low-grade uptake not suspicious for disease </CO>, while <CO> PET positive implies suspicion for disease </CO>.
--------------------------------------------------
Page Number: 55

Section Name: General Information
====================
Entities:-
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Nccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""National Comprehensive Cancer Network"", Relationship: ""produced by""

Section Name: Important Notes
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Neoplasms : New abnormal growth of tissue that can be benign or malignant.
Malignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Clinical Trials"", Entity2: ""Cancer"", Relationship: ""recommended for""
2. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""

Causalities:-
<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles
====================
Entities:-
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Chemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""Both are principles of cancer treatment methods.""
2. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""
3. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""

Causalities:-
### Principles

- **Principles of Surgery (SURG-A)**
- **Principles of Radiation Therapy (SUPRA-A)**
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**

Section Name: Adverse Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Perineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The invasion of cancer cells into blood vessels.
Lymphatic Invasion : The invasion of cancer cells into lymphatic vessels.

Relationships:-
1. Entity1: ""Extranodal extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
2. Entity1: ""Positive margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
3. Entity1: ""Close margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
4. Entity1: ""pT3 or pT4 primary"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
5. Entity1: ""pN2 or pN3 nodal disease"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
6. Entity1: ""Perineural invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
7. Entity1: ""Vascular invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
8. Entity1: ""Lymphatic invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""

Causalities:-
<C> Extranodal extension </C>
<C> Positive margins </C>
<C> Close margins </C>
<C> pT3 or pT4 primary </C>
<C> pN2 or pN3 nodal disease </C>
<C> Perineural invasion </C>
<C> Vascular invasion </C>
<C> Lymphatic invasion </C>

Section Name: Response Assessment
====================
Entities:-
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Primary Site : The original location where a tumor or cancer begins.
Complete Remission : The disappearance of all signs of cancer in response to treatment.
Partial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.

Relationships:-
1. Entity1: ""induction chemotherapy"", Entity2: ""Primary site"", Relationship: ""treatment outcome""
2. Entity1: ""Definitive RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
3. Entity1: ""RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
4. Entity1: ""Surgery"", Entity2: ""unresectable nodal disease"", Relationship: ""treatment option""

Causalities:-
<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.
Follow-Up (Medicine) : The process of monitoring a patient's health over time after treatment or diagnosis.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : A disease that returns after a period of remission.
Recurrence (Medicine) : The return of a disease or condition after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
### Follow-up

- **Follow-up** (FOLL-A, 1 of 2)
- **Recurrent or persistent disease** (ADV-3)

Section Name: Risk Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""RT"", Relationship: ""Consideration for treatment""
2. Entity1: ""Adverse pathologic features"", Entity2: ""Systemic therapy"", Relationship: ""Consideration for treatment""

Causalities:-
- **No adverse pathologic features**
- **Other risk features**
- **Adverse pathologic features**:
  - <C> Extranodal extension and/or positive margin </C>
  - <A> RT or consider systemic therapy/RT </A>

Section Name: Post-Therapy Evaluation
====================
Entities:-
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Neck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""
2. Entity1: ""RT"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""

Causalities:-
<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>

Section Name: Flowchart Overview
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Supraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""guides management of""
2. Entity1: ""NCCN Guidelines"", Entity2: ""healthcare professionals"", Relationship: ""used by""

Causalities:-
<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.

Section Name: Assessment and Treatment Decisions
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Complete Response : The disappearance of all signs of cancer in response to treatment.
Partial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Complete Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""
2. Entity1: ""Complete Response"", Entity2: ""Surgery"", Relationship: ""leads to""
3. Entity1: ""Partial Response"", Entity2: ""Systemic Therapy"", Relationship: ""leads to""
4. Entity1: ""Partial Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""

Causalities:-
<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.

Section Name: Adverse Pathologic Features and Follow-up
====================
Entities:-
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Neoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Recurrent Neoplasm : A neoplasm that has returned after treatment.
Metastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.
Metastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""Treatment decisions"", Relationship: ""Influence""
2. Entity1: ""Adverse features"", Entity2: ""Surgical intervention"", Relationship: ""Recommendation""
3. Entity1: ""Absence of adverse features"", Entity2: ""Radiation therapy"", Relationship: ""Pathway""
4. Entity1: ""Follow-up process"", Entity2: ""Recurrent or persistent disease"", Relationship: ""Detection""
5. Entity1: ""Recurrent or persistent disease"", Entity2: ""Advanced disease management"", Relationship: ""Necessity""

Causalities:-
<C> The presence of adverse pathologic features — such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient's disease characteristics.

Furthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.
--------------------------------------------------
Page Number: 130

Section Name: Pathological N (pN)
====================
Entities:-
Lymph Nodes : Small, bean-shaped structures that are part of the body's lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.
Lymph Node : An organ of the lymphatic system and the adaptive immune system.

Relationships:-
1. Entity1: ""Lymph Nodes"", Entity2: ""Neoplasm Metastasis"", Relationship: ""involved in""
2. Entity1: ""TNM Staging"", Entity2: ""Lymph Nodes"", Relationship: ""includes""
3. Entity1: ""TNM Staging"", Entity2: ""Neoplasm Metastasis"", Relationship: ""describes""

Causalities:-
<CO> NX: Regional lymph nodes cannot be assessed </CO>
<CO> N0: No regional lymph node metastasis </CO>
<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(–) </CO>
<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> Note: A designation of “U” or “L” may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(−) or ENE(+). </CO>

Section Name: Distant Metastasis (M)
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""M0"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""
2. Entity1: ""M1"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""

Causalities:-
### Distant Metastasis (M)

- **M0**: No distant metastasis
- **M1**: Distant metastasis

Section Name: Histologic Grade (G)
====================
Entities:-
Neoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.
Histologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.

Relationships:-
1. Entity1: ""GX"", Entity2: ""Grade cannot be assessed"", Relationship: ""is described as""
2. Entity1: ""G1"", Entity2: ""Well differentiated"", Relationship: ""is described as""
3. Entity1: ""G2"", Entity2: ""Moderately differentiated"", Relationship: ""is described as""
4. Entity1: ""G3"", Entity2: ""Poorly differentiated"", Relationship: ""is described as""

Causalities:-
<CO>GX</CO>: <E>Grade cannot be assessed</E>
<CO>G1</CO>: <E>Well differentiated</E>
<CO>G2</CO>: <E>Moderately differentiated</E>
<CO>G3</CO>: <E>Poorly differentiated</E>

Section Name: Prognostic Stage Groups
====================
Entities:-
Neoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.
Tumor Staging : A system for describing the size and spread of cancer within the body.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.

Relationships:-
1. Entity1: ""Stage 0"", Entity2: ""Tis N0 M0"", Relationship: ""defined by""
2. Entity1: ""Stage I"", Entity2: ""T1 N0 M0"", Relationship: ""defined by""
3. Entity1: ""Stage II"", Entity2: ""T2 N0 M0"", Relationship: ""defined by""
4. Entity1: ""Stage III"", Entity2: ""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0"", Relationship: ""defined by""
5. Entity1: ""Stage IVA"", Entity2: ""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0"", Relationship: ""defined by""
6. Entity1: ""Stage IVB"", Entity2: ""Any T N3 M0, T4b Any N M0"", Relationship: ""defined by""
7. Entity1: ""Stage IVC"", Entity2: ""Any T Any N M1"", Relationship: ""defined by""
--------------------------------------------------
Page Number: 96

Section Name: Head and Neck Cancers
====================
Entities:-
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes.
Surveillance : The ongoing systematic collection, analysis, and interpretation of health data essential to the planning, implementation, and evaluation of public health practice.
Locoregional Recurrence Of Tumor : The return of cancer in the original tumor location or nearby lymph nodes after treatment.
Asymptomatic : A condition or a person showing no symptoms of disease.
Magnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Ultrasound : A medical imaging technique that uses high-frequency sound waves to visualize soft tissues such as muscles and internal organs.

Relationships:-
1. Entity1: ""FDG-PET/CT"", Entity2: ""Head and Neck Neoplasms"", Relationship: ""used for surveillance imaging""
2. Entity1: ""Recurrence"", Entity2: ""Post-treatment period"", Relationship: ""occurs within""
3. Entity1: ""Imaging Modalities"", Entity2: ""Surveillance"", Relationship: ""used for""

Causalities:-
<C> The majority of recurrences after treatment of head and neck cancer occur in the first 2 years </C>. <C> Surveillance can be challenging </C> <C> because of altered anatomy and/or fibrosis from surgery, radiation, and/or chemotherapy </C>. <CO> There are no consensus guidelines on the frequency and modality of routine post-treatment imaging in the asymptomatic patient </CO>. <A> Practice varies widely across institutions </A>.

<C> US, CT, MRI, and PET/CT all have unique advantages and disadvantages when used as surveillance imaging </C>. <C> There is evidence that FDG-PET/CT may be the most sensitive of these modalities </C>. <E> A 12-month PET has been shown to reveal recurrent or second primary cancers in approximately 10% of treated patients </E>; <E> a 24-month FDG-PET/CT imaging revealed these findings in approximately 5% of treated cases </E>. <CO> Most cases of asymptomatic FDG-PET/CT lesion localization occur at distant sites </CO>. <CO> Whether earlier detection leads to improved disease-specific survival is not established </CO>.

<A> Standardized multi-institutional imaging-based trials are needed to clearly elucidate the value of routine imaging in the clinically asymptomatic patient </A>. <CO> There may be little proven benefit in further imaging if the initial 3-month FDG-PET/CT scan was negative </CO>. <C> Ho et al reported no significant difference in 3-year disease-free survival in patients undergoing imaging surveillance versus those only receiving clinical surveillance </C> <E> (41% vs. 46%, P = .91) in this setting </E>.

<CO> If an FDG-PET/CT at 3 months post-treatment is negative </CO>, <CO> there are no data to support substantial benefit for further routine imaging in an asymptomatic patient with negative exam </CO>. <A> In the absence of multi-institutional prospective data, a tailored approach to surveillance with attention to tumor type, stage, prognostic factors, symptomatology, and physical exam changes or restrictions is appropriate </A>.

<A> US of the neck is a well-established tool for nodal surveillance </A>. <C> US is generally widely available, safe, fast, inexpensive, and an accurate modality for examination of the neck for any suspicious nodal disease </C>.

<CO> Additional post-treatment imaging is indicated for worrisome or equivocal signs/symptoms </CO>.

<CO> Routine annual imaging (repeat use of pretreatment imaging modality) may be indicated to visualize areas inaccessible to routine clinical examination </CO> <CO> (deep-seated anatomic locations or areas obscured by extensive treatment change) </CO>.

Section Name: Principles of Imaging
====================
Entities:-
Head And Neck Neoplasms : Tumors or cancer of the head and neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Head And Neck Cancer : A group of cancers that originate in the head and neck region.
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes.
Positron Emission Tomography : A type of nuclear medicine imaging that uses small amounts of radioactive materials to diagnose or treat a variety of diseases.
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the computer to generate cross-sectional images.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images.
Neck : The part of the body on many vertebrates that separates the head from the torso or trunk.

Relationships:-
1. Entity1: ""Surveillance imaging"", Entity2: ""Head and neck cancer"", Relationship: ""used for monitoring""
2. Entity1: ""PET-CT"", Entity2: ""Head and neck cancer"", Relationship: ""used for detection""
3. Entity1: ""Positron emission tomography/computed tomography"", Entity2: ""Head and neck cancer"", Relationship: ""used for surveillance""

Section Name: NCCN Guidelines
====================
Entities:-
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Clinical Trial : A clinical trial is a research study conducted with patients to evaluate a new medical treatment, drug, or device.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""Neoplasms"", Entity2: ""Clinical trial"", Relationship: ""best management through""

Causalities:-
<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.


Among these two options which one is the most likely true:

(A) `PET_Scan_Results_10` increases risk `Number_of_Affected_Lymph_Nodes_2`
(B) `Number_of_Affected_Lymph_Nodes_2` `increases risk `PET_Scan_Results_10`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge '(PET_Scan_Results_10) causes (Number_of_Affected_Lymph_Nodes_2)' is not valid as a causal relationship. PET scan results provide information about the current state of lymph node involvement but do not cause changes in the number of affected lymph nodes.
2. The PET scan is a diagnostic tool that detects the presence or absence of lymph node involvement, which is crucial for cancer staging.
3. The number of affected lymph nodes is determined by the underlying disease process, not by the PET scan results.
4. The edge '(Number_of_Affected_Lymph_Nodes_2) causes (PET_Scan_Results_10)' suggests that the number of affected lymph nodes causes the PET scan results.
5. In clinical practice, the PET scan results are used to assess the number of affected lymph nodes, not the other way around.
6. Therefore, the causal direction is likely reversed, and the given edge is not valid.
7. From the knowledge base, PET/CT is used to evaluate lymph node metastases, which aligns with the role of PET scans in assessing the number of affected lymph nodes.
8. The PET scan is a diagnostic tool that provides information about the current state of lymph node involvement, not a factor that influences the number of affected lymph nodes.
","1. Page Number: 94, Section Name: Head and Neck Cancers - Principles of Imaging, Entity1: 'PET/CT', Entity2: 'PET scan', Relationship: 'preferred over'
2. Page Number: 94, Section Name: Initial Workup - Nodal Metastases, Entity1: 'FDG-PET/CT', Entity2: 'lymph node metastases', Relationship: 'used for detection'
3. Page Number: 96, Section Name: Head and Neck Cancers, Entity1: 'FDG-PET/CT', Entity2: 'Head and Neck Neoplasms', Relationship: 'used for surveillance imaging'
",B,"{'A': 34.86, 'B': 65.14}",yes,B,"1. The AI assistant's reasoning is based on the understanding that PET scans are diagnostic tools used to assess the current state of lymph node involvement, not to influence or cause changes in the number of affected lymph nodes.
2. The explanation provided for EDGE1 clearly states that the PET scan results do not cause changes in the number of affected lymph nodes, which aligns with the understanding that diagnostic tools assess rather than influence disease states.
3. For EDGE2, the assistant correctly identifies that the number of affected lymph nodes does not cause PET scan results, as the scan is used to detect and assess the state of lymph nodes, not the other way around.
4. The assistant references the knowledge base, which supports the role of PET/CT in evaluating lymph node metastases, further reinforcing the idea that PET scans are used for assessment rather than causation.
5. The final answer (B) is consistent with the reasoning provided, as it correctly identifies that the number of affected lymph nodes does not increase the risk of PET scan results, but rather, the PET scan is used to assess the state of lymph nodes.
"
1,gpt-4o,"PET_Scan_Results_10,Number_of_Lymph_Nodes_Metastasis_3","""{'NODE1': {'id': 'PET_Scan_Results_10', 'label': 'Positron Emission Tomography Scan Results', 'description': 'This node represents the results of a PET scan, which is an imaging test used to observe metabolic processes in the body. The results are crucial for assessing the involvement of lymph nodes, which is important in cancer diagnosis, staging, and treatment planning. The PET scan can reveal whether there is extracapsular spread, unilateral or bilateral lymph node involvement, or absence of lymph node involvement, as well as the size of lymph nodes.', 'type': 'Examination Result', 'observability': 'Observed', 'states': [{'state_name': 'extracapsular_spread_of_lymph_nodes', 'state_description': 'This state indicates that the cancer has spread beyond the capsule of the lymph nodes, which can be a sign of more advanced disease.'}, {'state_name': 'unilateral_lymph_node_involvement', 'state_description': 'This state indicates that cancer involvement is present in the lymph nodes on one side of the body.'}, {'state_name': 'bilateral_lymph_node_involvement', 'state_description': 'This state indicates that cancer involvement is present in the lymph nodes on both sides of the body.'}, {'state_name': 'absence_of_lymph_node_involvement', 'state_description': 'This state indicates that there is no detectable cancer involvement in the lymph nodes.'}, {'state_name': 'enlarged_lymph_node_size', 'state_description': 'This state indicates that the lymph nodes are enlarged, which can be a sign of cancer or other pathological processes.'}, {'state_name': 'present', 'state_description': 'This state indicates the presence of a finding or condition as detected by the PET scan.'}, {'state_name': 'absent', 'state_description': 'This state indicates the absence of a finding or condition as detected by the PET scan.'}]}, 'NODE2': {'id': 'Number_of_Lymph_Nodes_Metastasis_3', 'label': 'Assessment of Lymph Node Metastasis', 'description': 'This node represents the assessment of whether metastasis is present in the lymph nodes. It is crucial for staging cancer and determining the extent of its spread, which impacts treatment decisions and prognosis.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'present', 'state_description': 'Metastasis is present in the lymph nodes, indicating that cancer has spread to these nodes.'}, {'state_name': 'absent', 'state_description': 'Metastasis is absent in the lymph nodes, indicating that cancer has not spread to these nodes.'}]}, 'EDGE1': {'edges_ids': ['PET_Scan_Results_10', 'Number_of_Lymph_Nodes_Metastasis_3'], 'edge': '(PET_Scan_Results_10) causes (Number_of_Lymph_Nodes_Metastasis_3)', 'explanation': ['The PET scan results provide direct information about the involvement of lymph nodes, which is used to assess the presence or absence of metastasis.', 'The edge is valid because the PET scan results are used to determine the state of lymph node metastasis, making it a direct causal relationship.', 'The causal direction is positive because the presence of findings in the PET scan correlates with the presence of metastasis, and absence correlates with no metastasis.', 'The PET scan results are not necessary for metastasis to occur, but they are sufficient for assessing its presence.', 'The causal distance is proximal because the PET scan results directly inform the assessment of lymph node metastasis.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': True}, 'causal_distance': 'Proximal'}, 'EDGE2': {'edges_ids': ['Number_of_Lymph_Nodes_Metastasis_3', 'PET_Scan_Results_10'], 'edge': '(Number_of_Lymph_Nodes_Metastasis_3) causes (PET_Scan_Results_10)', 'explanation': ['The edge represents the causal relationship where the presence of lymph node metastasis (Number_of_Lymph_Nodes_Metastasis_3) leads to positive findings on a PET scan (PET_Scan_Results_10).', 'The PET scan is used to detect metabolic activity associated with cancer, and if metastasis is present in the lymph nodes, it will likely be detected by the PET scan.', 'The causal direction is positive because the presence of metastasis would lead to positive PET scan results.', 'The presence of metastasis is necessary for the PET scan to show positive results related to lymph node involvement, but it is not sufficient because other factors could also cause positive PET scan results.', 'The causal distance is proximal because the presence of metastasis directly affects the PET scan results.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': True, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'ENTITIES_MATCHING_PAGES_INFO': {'92': {'matching_entities': [{'POSITRON EMISSION TOMOGRAPHY (PROCEDURE)': 0.9864658}, {'POSITRON-EMISSION TOMOGRAPHY': 0.9655257}, {'METASTASIS': 0.9630129}, {'POSITRON EMISSION TOMOGRAPHY': 0.9552841}, {'MALIGNANT NEOPLASM': 0.9448747}, {'CANCER': 0.92851335}, {'MAGNETIC RESONANCE IMAGING': 0.9216922}], 'count': 7}, '94': {'matching_entities': [{'NEOPLASM METASTASIS': 1.0}, {'LYMPH NODE METASTASIS': 0.9812612}, {'LYMPHATIC METASTASIS': 0.97019297}, {'POSITRON-EMISSION TOMOGRAPHY': 0.9655257}, {'POSITRON EMISSION TOMOGRAPHY': 0.9552841}, {'POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY': 0.94104874}, {'MAGNETIC RESONANCE IMAGING': 0.9216922}], 'count': 7}, '55': {'matching_entities': [{'NEOPLASM METASTASIS': 1.0}, {'METASTASIS': 0.9630129}, {'METASTATIC NEOPLASM': 0.96172774}, {'MALIGNANT NEOPLASTIC DISEASE': 0.9424237}, {'CANCER': 0.92851335}, {'LYMPHATIC INVASION': 0.9282598}, {'EXTRANODAL EXTENSION': 0.9208998}], 'count': 7}, '44': {'matching_entities': [{'LYMPHATIC METASTASIS': 0.97019297}, {'MALIGNANT NEOPLASTIC DISEASE': 0.9424237}, {'CANCER': 0.92851335}, {'MAGNETIC RESONANCE IMAGING': 0.9216922}, {'EXTRANODAL EXTENSION': 0.9208998}], 'count': 5}, '130': {'matching_entities': [{'NEOPLASM METASTASIS': 1.0}, {'LYMPH NODE STRUCTURE': 0.99134904}, {'LYMPH NODE': 0.98570025}, {'LYMPH NODES': 0.97445965}, {'METASTASIS': 0.9630129}], 'count': 5}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 92\\n\\nSection Name: NCCN Guidelines Overview\\n====================\\nEntities:-\\nHead And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\nMalignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.\\nHead And Neck Cancer : A group of cancers that originate in the head and neck region.\\nAntineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nRadiation Therapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\n\\nRelationships:-\\n1. Entity1: \""Head and neck cancers\"", Entity2: \""Systemic therapy\"", Relationship: \""follow-up recommendations after\""\\n2. Entity1: \""Head and neck cancers\"", Entity2: \""Radiation therapy\"", Relationship: \""follow-up recommendations after\""\\n\\nCausalities:-\\nThe image presents a flowchart from the National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2024, especially focusing on <A> follow-up recommendations </A> for <CO> patients with head and neck cancers after systemic therapy or radiation therapy (RT) </CO>. All recommendations are categorized as level A unless stated otherwise, highlighting the importance of clinical trials in cancer management.\\n\\nSection Name: Imaging and Assessment Protocols\\n====================\\nEntities:-\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.\\nClinical Assessment : A systematic evaluation of a patient\\'s health status, often involving a physical examination and medical history.\\nPositron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.\\nComputed Tomography : A medical imaging technique used in radiology to obtain detailed internal images of the body.\\nMagnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis.\\nDisease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nResidual Neoplasm : Remaining cancer cells after treatment.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Clinical Assessment\"", Relationship: \""occurs before\""\\n2. Entity1: \""FDG-PET/CT Scan\"", Entity2: \""Distant Metastases\"", Relationship: \""assesses\""\\n3. Entity1: \""FDG-PET/CT Scan\"", Entity2: \""Observation\"", Relationship: \""leads to if negative\""\\n4. Entity1: \""FDG-PET/CT Scan\"", Entity2: \""CT Scan\"", Relationship: \""leads to if strongly positive\""\\n5. Entity1: \""CT Scan\"", Entity2: \""Neck Dissection\"", Relationship: \""leads to if positive\""\\n\\nCausalities:-\\n<CO> After systemic therapy or RT </CO>, <A> a clinical assessment should occur 4 to 8 weeks later </A>. <CO> If there is a response </CO>, <A> it is necessary to assess the extent of disease or distant metastases, preferably through a FDG-PET/CT scan at a minimum of 12 weeks post-treatment </A>. <CO> If the FDG-PET/CT results are negative </CO>, <A> the patient may continue with monitoring through observation </A>. <CO> In cases where the results are equivocal </CO>, <A> observation or repeat FDG-PET/CT within 3 to 6 months is prescribed </A>.\\n\\n<CO> In cases where the FDG-PET/CT results are strongly positive </CO>, <A> further imaging via CT scan with contrast of the primary site and neck, or MRI with and without contrast, becomes necessary </A>. <CO> If these imaging results confirm positive findings </CO>, <A> neck dissection may be considered, depending on the evidence of residual or persistent disease </A>. <CO> If the imaging findings are negative </CO>, <A> the patient might continue in observation </A>.\\n\\nSection Name: Outcomes Based on Disease Resectability\\n====================\\nEntities:-\\nDisease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.\\nResectable : Capable of being surgically removed.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis.\\n\\nRelationships:-\\n1. Entity1: \""Disease\"", Entity2: \""Resectable\"", Relationship: \""Classification\""\\n2. Entity1: \""Unresectable\"", Entity2: \""Treatment plans (ADV-3)\"", Relationship: \""Treatment recommendation\""\\n3. Entity1: \""Resectable\"", Entity2: \""Resection and/or Neck dissection\"", Relationship: \""Surgical procedure\""\\n\\nCausalities:-\\n<CO> If there is confirmed residual or persistent disease </CO>, the options split into two pathways: \\'Unresectable\\' or \\'Resectable.\\' <CO> If the disease is classified as unresectable </CO>, <A> advances in treatment plans (labeled ADV-3) are called for </A>. Conversely, <CO> if it is deemed resectable </CO>, <A> a resection of the primary and/or neck dissection may occur </A>, <CO> contingent upon the disease status </CO>.\\n\\nSection Name: Important Notes\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nPositron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.\\nPositron Emission Tomography (Procedure) : A diagnostic imaging procedure that uses a radioactive tracer to visualize and measure changes in metabolic processes.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique used to observe metabolic processes in the body.\\nNeoplasms : New abnormal growth of tissue in animals or plants; a tumor.\\nMalignant Neoplasm : A cancerous growth that has the potential to spread to other parts of the body.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""NCCN\"", Entity2: \""Clinical trials\"", Relationship: \""emphasizes participation in\""\\n2. Entity1: \""FDG-PET/CT\"", Entity2: \""Persistent cancer\"", Relationship: \""used to detect\""\\n3. Entity1: \""FDG-PET/CT\"", Entity2: \""PET negative\"", Relationship: \""interpretation of results\""\\n4. Entity1: \""FDG-PET/CT\"", Entity2: \""PET positive\"", Relationship: \""interpretation of results\""\\n\\nCausalities:-\\n<A> NCCN emphasizes that the best management for any cancer patient is participation in clinical trials </A>, especially encouraged for all patients. Additional notes clarify that <CO> if the FDG-PET/CT is negative for persistent cancer </CO>, <A> further cross-sectional imaging is optional </A>. The interpretations define <CO> PET negative as no or low-grade uptake not suspicious for disease </CO>, while <CO> PET positive implies suspicion for disease </CO>.\\n--------------------------------------------------\\nPage Number: 94\\n\\nSection Name: Head and Neck Cancers - Principles of Imaging\\n====================\\nEntities:-\\nPositron Emission Tomography Computed Tomography : A medical imaging technique combining PET and CT capabilities to provide detailed information about the body\\'s function and structure.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\nHead And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\n\\nRelationships:-\\n1. Entity1: \""PET/CT\"", Entity2: \""PET scan\"", Relationship: \""preferred over\""\\n2. Entity1: \""PET-CT\"", Entity2: \""head neck cancers\"", Relationship: \""used in study of\""\\n\\nCausalities:-\\n<A> PET/CT is preferred over PET scan alone (i.e., without superimposed CT scan) </A>. <C> PET/CT provides more accurate anatomical localization of abnormalities </C> <E> more accurate anatomical localization of abnormalities </E>.\\n\\nSection Name: Initial Workup - Nodal Metastases\\n====================\\nEntities:-\\nLymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site via the lymphatic system.\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine\\'s computer to generate cross-sectional images.\\nMagnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.\\nLymph Node Metastasis : The spread of cancer cells to lymph nodes, which are part of the lymphatic system.\\nCt Of Neck : A computed tomography scan of the neck region.\\nMri Of Neck : A magnetic resonance imaging scan of the neck region.\\nFdg-Pet Scan : A type of positron emission tomography using fluorodeoxyglucose to assess metabolic activity.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""lymph node metastases\"", Relationship: \""used to evaluate\""\\n2. Entity1: \""MRI\"", Entity2: \""lymph node metastases\"", Relationship: \""used to evaluate\""\\n3. Entity1: \""FDG-PET/CT\"", Entity2: \""lymph node metastases\"", Relationship: \""used for detection\""\\n4. Entity1: \""FDG-PET/CT\"", Entity2: \""surgical primary approach\"", Relationship: \""used to determine\""\\n5. Entity1: \""FDG-PET/CT\"", Entity2: \""definitive RT approach\"", Relationship: \""used to identify\""\\n\\nCausalities:-\\n<A> Evaluation of lymph node metastases should be conducted with CT or MRI of the neck </A>, using whichever imaging study is suitable for primary site evaluation (IMG-A, 1 of 4).\\n<CO> For patients with multistation or lower neck nodal involvement or high-grade tumor histology </CO>, <A> consider CT of the chest to assess for mediastinal lymph node metastases or FDG-PET/CT </A>, <C> which is associated with higher sensitivity for both nodal and distant metastases </C>.\\n<CO> For patients who are under consideration for a surgical primary approach </CO>, <A> the higher sensitivity of FDG-PET/CT is warranted for tumors approaching the midline, to determine the surgical approach to the contralateral neck </A>. <CO> Similarly, patients who are scheduled for a definitive RT approach </CO> <A> may benefit from the higher sensitivity of FDG-PET/CT for identifying involved lymph nodes </A>.\\n\\nSection Name: Initial Workup - Distant Metastases\\n====================\\nEntities:-\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.\\nMagnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine\\'s computer to generate cross-sectional images.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nLung Neoplasms : Tumors or cancer of the lung.\\nSmoking : The inhalation of the smoke of burning tobacco encased in cigarettes, pipes, and cigars.\\n\\nRelationships:-\\n1. Entity1: \""FDG-PET/CT\"", Entity2: \""Distant Metastases\"", Relationship: \""used to evaluate\""\\n2. Entity1: \""Contrast-enhanced brain MRI\"", Entity2: \""Brain Metastasis\"", Relationship: \""recommended for evaluation\""\\n3. Entity1: \""CT of the chest\"", Entity2: \""Pulmonary Metastases\"", Relationship: \""performed to assess\""\\n4. Entity1: \""Non-contrast CT of the chest\"", Entity2: \""Lung Parenchymal Metastases\"", Relationship: \""used to screen\""\\n5. Entity1: \""Annual CT screening\"", Entity2: \""Lung Metastasis\"", Relationship: \""considered for high risk\""\\n6. Entity1: \""Directed CT or MRI\"", Entity2: \""Distant Disease\"", Relationship: \""used for assessment\""\\n7. Entity1: \""FDG-PET/CT\"", Entity2: \""Recurrent Disease\"", Relationship: \""used for staging\""\\n\\nCausalities:-\\n<C> Patients with locoregionally advanced cancer (e.g., T3\u2013T4 primary or \u2265N1 nodal staging) </C>, <A> FDG-PET/CT is preferred to evaluate for distant disease and thoracic metastases </A>. <CO> For cancers where brain metastasis is a concern, such as mucosal melanoma or high-grade neuroendocrine carcinomas or adenocarcinomas </CO>, <A> contrast-enhanced brain MRI should be additionally obtained </A>.\\n<CO> If FDG-PET/CT is not performed </CO>, <A> CT of the chest should be performed to assess for presence of pulmonary metastases as well as mediastinal lymph node involvement </A>.\\n<CO> Non-contrast CT of the chest can be sufficient to screen for lung parenchymal metastases </CO> but <CO> is not adequate for assessment of mediastinal adenopathy </CO>. <CO> This is an appropriate lung cancer screening intervention for patients with a history of smoking </CO>.\\n<CO> Following primary definitive treatment (surgery, RT, or systemic therapy/RT) </CO> the role of annual CT screening for lung metastasis is controversial. <E> While this approach does detect early metastasis </E>, <CO> further study is needed to determine the extent of the positive effect and/or cost-effectiveness of this approach in specific subpopulations and timepoints post-treatment </CO>. <CO> For patients with a substantial smoking history or who are at high risk for lung metastases </CO>, <A> annual chest CT can be considered </A>.\\n<CO> If clinical concern for metastatic disease is confined to a specific anatomical area </CO>, <A> the assessment of distant disease can be performed with directed CT or MRI examination </A>.\\n<CO> FDG-PET/CT may complement or replace other imaging modalities when staging recurrent disease before any therapy for relapsed/refractory disease </CO> <A> in order to explore distant disease or second primaries that may significantly impact choice of therapy </A>.\\n--------------------------------------------------\\nPage Number: 55\\n\\nSection Name: General Information\\n====================\\nEntities:-\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""National Comprehensive Cancer Network\"", Relationship: \""produced by\""\\n\\nSection Name: Important Notes\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNeoplasms : New abnormal growth of tissue that can be benign or malignant.\\nMalignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Trials\"", Entity2: \""Cancer\"", Relationship: \""recommended for\""\\n2. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n\\nCausalities:-\\n<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nChemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n2. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n3. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n\\nCausalities:-\\n### Principles\\n\\n- **Principles of Surgery (SURG-A)**\\n- **Principles of Radiation Therapy (SUPRA-A)**\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nPerineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The invasion of cancer cells into blood vessels.\\nLymphatic Invasion : The invasion of cancer cells into lymphatic vessels.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n2. Entity1: \""Positive margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n3. Entity1: \""Close margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n4. Entity1: \""pT3 or pT4 primary\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n5. Entity1: \""pN2 or pN3 nodal disease\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n6. Entity1: \""Perineural invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n7. Entity1: \""Vascular invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n8. Entity1: \""Lymphatic invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n\\nCausalities:-\\n<C> Extranodal extension </C>\\n<C> Positive margins </C>\\n<C> Close margins </C>\\n<C> pT3 or pT4 primary </C>\\n<C> pN2 or pN3 nodal disease </C>\\n<C> Perineural invasion </C>\\n<C> Vascular invasion </C>\\n<C> Lymphatic invasion </C>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nPrimary Site : The original location where a tumor or cancer begins.\\nComplete Remission : The disappearance of all signs of cancer in response to treatment.\\nPartial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""induction chemotherapy\"", Entity2: \""Primary site\"", Relationship: \""treatment outcome\""\\n2. Entity1: \""Definitive RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n3. Entity1: \""RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n4. Entity1: \""Surgery\"", Entity2: \""unresectable nodal disease\"", Relationship: \""treatment option\""\\n\\nCausalities:-\\n<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.\\nFollow-Up (Medicine) : The process of monitoring a patient\\'s health over time after treatment or diagnosis.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : A disease that returns after a period of remission.\\nRecurrence (Medicine) : The return of a disease or condition after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n### Follow-up\\n\\n- **Follow-up** (FOLL-A, 1 of 2)\\n- **Recurrent or persistent disease** (ADV-3)\\n\\nSection Name: Risk Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""RT\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Adverse pathologic features\"", Entity2: \""Systemic therapy\"", Relationship: \""Consideration for treatment\""\\n\\nCausalities:-\\n- **No adverse pathologic features**\\n- **Other risk features**\\n- **Adverse pathologic features**:\\n  - <C> Extranodal extension and/or positive margin </C>\\n  - <A> RT or consider systemic therapy/RT </A>\\n\\nSection Name: Post-Therapy Evaluation\\n====================\\nEntities:-\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nNeck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n2. Entity1: \""RT\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n\\nCausalities:-\\n<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>\\n\\nSection Name: Flowchart Overview\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nSupraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""guides management of\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""healthcare professionals\"", Relationship: \""used by\""\\n\\nCausalities:-\\n<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.\\n\\nSection Name: Assessment and Treatment Decisions\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nComplete Response : The disappearance of all signs of cancer in response to treatment.\\nPartial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Complete Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n2. Entity1: \""Complete Response\"", Entity2: \""Surgery\"", Relationship: \""leads to\""\\n3. Entity1: \""Partial Response\"", Entity2: \""Systemic Therapy\"", Relationship: \""leads to\""\\n4. Entity1: \""Partial Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n\\nCausalities:-\\n<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.\\n\\nSection Name: Adverse Pathologic Features and Follow-up\\n====================\\nEntities:-\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nNeoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nRecurrent Neoplasm : A neoplasm that has returned after treatment.\\nMetastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.\\nMetastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""Treatment decisions\"", Relationship: \""Influence\""\\n2. Entity1: \""Adverse features\"", Entity2: \""Surgical intervention\"", Relationship: \""Recommendation\""\\n3. Entity1: \""Absence of adverse features\"", Entity2: \""Radiation therapy\"", Relationship: \""Pathway\""\\n4. Entity1: \""Follow-up process\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""Detection\""\\n5. Entity1: \""Recurrent or persistent disease\"", Entity2: \""Advanced disease management\"", Relationship: \""Necessity\""\\n\\nCausalities:-\\n<C> The presence of adverse pathologic features \u2014 such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient\\'s disease characteristics.\\n\\nFurthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.\\n--------------------------------------------------\\nPage Number: 44\\n\\nSection Name: Flowchart Structure\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms based on extent of tumor spread according to standardized criteria.\\nLaryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.\\nChemotherapy, Adjuvant : Drug therapy given in addition to the primary treatment to enhance its effectiveness.\\nRadiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nNeoplasm Recurrence, Local : The return of a tumor at the original site after treatment.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Staging\"", Entity2: \""T3 tumors\"", Relationship: \""determines treatment approach\""\\n2. Entity1: \""Adverse Pathologic Features\"", Entity2: \""Systemic Therapy\"", Relationship: \""directs to\""\\n3. Entity1: \""Adverse Pathologic Features\"", Entity2: \""Radiation Treatment\"", Relationship: \""directs to\""\\n4. Entity1: \""Induction Chemotherapy\"", Entity2: \""Imaging (CT or MRI)\"", Relationship: \""leads to\""\\n\\nCausalities:-\\n1. <A> The flow begins with the clinical staging of T3 tumors </A> <C> that require total laryngectomy (N2\u20133) </C>. <CO> This staging </CO> <E> is crucial for determining the appropriate therapeutic approach </E>.\\n\\n2. The flowchart provides multiple pathways for treatment, indicating that <CO> patients </CO> <A> may undergo either \""Concurrent systemic therapy/RT\"" or \""Surgery\"" </A>. There is also an <A> option for \""Induction chemotherapy,\"" leading to further imaging (CT or MRI) to assess the primary site and neck status </A>.\\n\\n3. For <CO> patients who have surgery </CO>, the flowchart distinguishes between those with adverse pathologic features and those without. <CO> Patients with adverse features\u2014such as extranodal extension or positive margins </CO>\u2014are <A> directed toward systemic therapy or radiation treatment </A>, while those without may follow a different management path.\\n\\n4. The flowchart concludes by <A> outlining follow-up procedures for recurrent or persistent disease </A>, suggesting additional assessments and treatments based on the risk features identified during earlier stages.\\n\\nSection Name: Detailed Explanation\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nAdverse Pathological Feature : A pathological feature that indicates a worse prognosis or outcome.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\n\\nRelationships:-\\n1. Entity1: \""Systemic therapy\"", Entity2: \""Radiation\"", Relationship: \""Concurrent treatment\""\\n2. Entity1: \""Clinical trials\"", Entity2: \""Personalized treatment plans\"", Relationship: \""Development of\""\\n\\nCausalities:-\\n<A> The flowchart is designed to provide healthcare professionals with a systematic pathway for managing glottic larynx cancer </A>. Each step is meticulously organized to ensure that important factors are considered, such as <C> the presence of adverse pathological features </C>, which <E> strongly influence treatment decisions </E>.\\n\\n<A> The emphasis on concurrent treatments, such as systemic therapy combined with radiation </A>, reflects current best practices in oncology, where multimodal approaches are often necessary to achieve better outcomes. <A> The inclusion of clinical trials </A> indicates an emphasis on maintaining up-to-date practices and personalized treatment plans as part of patient management strategies.\\n\\nFurthermore, <A> the chart\\'s organization into treatment and follow-up segments </A> allows for a straightforward interpretation, guiding oncologists through complex decisions in a logical manner. This can <E> improve consistency in care and enhance patient safety through meticulous monitoring and responses to treatment efficacy or disease progression </E>.\\n\\nIn summary, <E> this flowchart serves as an essential resource for oncologists, facilitating a better understanding of treatment protocols for glottic larynx cancer while promoting a patient-centered approach to oncological care </E>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nNeoplasms : New abnormal growth of tissue that may be benign or malignant.\\nMalignant Neoplastic Disease : A disease in which abnormal cells divide uncontrollably and destroy body tissue.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nNational Comprehensive Cancer Network : An alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""NCCN Guidelines\"", Relationship: \""publishes\""\\n2. Entity1: \""Clinical trial\"", Entity2: \""Cancer\"", Relationship: \""manages\""\\n\\nCausalities:-\\n<C> any patient with cancer </C> <E> the best management is in a clinical trial </E>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles of Treatment\\n====================\\nEntities:-\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margins : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.\\nPerineural Invasion : Cancer cells are found surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The presence of cancer cells within blood vessels.\\nLymphatic Metastasis : The spread of cancer cells through the lymphatic system to distant sites.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Extranodal Extension\"", Relationship: \""management of\""\\n2. Entity1: \""Principles of Surgery\"", Entity2: \""Positive Surgical Margins\"", Relationship: \""concerned with avoiding\""\\n3. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Perineural Invasion\"", Relationship: \""consideration in treatment planning\""\\n\\nCausalities:-\\n<C> Extranodal extension </C> <C> Positive margins </C> <C> Close margins </C> <C> pT4 primary </C> <C> pN2 or pN3 nodal disease </C> <C> Perineural invasion </C> <C> Vascular invasion </C> <C> Lymphatic invasion </C> <C> Subglottic extension </C>\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to enhance its effectiveness.\\nAdjuvant Therapy : A therapy given in addition to the primary or initial therapy to maximize its effectiveness.\\nFollow-Up Studies : Studies that continue to monitor patients after treatment to assess long-term outcomes.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient after initial treatment.\\nFollow-Up : The act of monitoring a patient\\'s health over time after treatment.\\nNeoplasm Recurrence, Local : The return of a tumor at the original site after treatment.\\nRecurrent Disease : A disease that has returned after a period of remission.\\n\\nRelationships:-\\n1. Entity1: \""Adjuvant Treatment\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""prevention\""\\n2. Entity1: \""Follow-up\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""monitoring\""\\n\\nSection Name: Treatment Options\\n====================\\nEntities:-\\nLaryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.\\nTotal Laryngectomy : A surgical procedure to remove the entire larynx.\\nChemotherapy, Adjuvant : Drug therapy given in addition to the primary treatment to enhance its effectiveness.\\nInduction Chemotherapy : Chemotherapy given as a first step to shrink a tumor before the main treatment.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""T3 requiring total laryngectomy\"", Entity2: \""Concurrent systemic therapy/RT\"", Relationship: \""treatment option\""\\n2. Entity1: \""T3 requiring total laryngectomy\"", Entity2: \""Induction chemotherapy\"", Relationship: \""treatment option\""\\n3. Entity1: \""T3 requiring total laryngectomy\"", Entity2: \""Clinical trials\"", Relationship: \""research option\""\\n\\nCausalities:-\\n<CO> T3 requiring (amenable to) total laryngectomy (N2\u20133) </CO> <A> Concurrent systemic therapy/RT </A> <A> Surgery </A> <A> Induction chemotherapy </A> <A> Clinical trials </A>\\n\\nSection Name: Surgical Considerations\\n====================\\nEntities:-\\nLaryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.\\nThyroidectomy : Surgical removal of all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue in the neck.\\nLymph Node Excision : Surgical removal of one or more lymph nodes.\\nLymph Node Dissection : A surgical procedure to remove lymph nodes.\\nLymphadenectomy : Surgical removal of one or more groups of lymph nodes.\\n\\nRelationships:-\\n1. Entity1: \""Laryngectomy\"", Entity2: \""Thyroidectomy\"", Relationship: \""performed with\""\\n2. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Excision\"", Relationship: \""includes\""\\n3. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Excision\"", Relationship: \""includes specific types\""\\n\\nCausalities:-\\n<A> Laryngectomy with thyroidectomy as indicated, ipsilateral or bilateral neck dissection, and pretracheal and ipsilateral paratracheal lymph node dissection </A>\\n\\nSection Name: Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margins : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.\\nPositive Margin : A surgical margin that contains residual tumor cells.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""Extranodal extension\"", Relationship: \""includes\""\\n2. Entity1: \""Adverse pathologic features\"", Entity2: \""Positive margin\"", Relationship: \""includes\""\\n\\nCausalities:-\\n- **No adverse pathologic features**\\n- **Adverse pathologic features**\\n  - <C> Extranodal extension and/or positive margin </C>\\n  - Other risk features\\n\\nSection Name: Systemic Therapy\\n====================\\nEntities:-\\nAntineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.\\nSystemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\n\\nRelationships:-\\n1. Entity1: \""Systemic therapy\"", Entity2: \""RT\"", Relationship: \""Consideration\""\\n\\nCausalities:-\\n<A> Systemic therapy/RT (category 1) </A>\\n<A> RT </A>\\n<A> Consider systemic therapy/RT </A>\\n\\nSection Name: Imaging\\n====================\\nEntities:-\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nNeck : Part of the body, on many terrestrial or secondarily aquatic vertebrates, that distinguishes the head from the torso or trunk.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images (often called slices), both horizontally and vertically, of the body.\\nNeck Structure : The anatomical structure that connects the head to the torso.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""Neck\"", Relationship: \""imaging of\""\\n2. Entity1: \""MRI\"", Entity2: \""Neck\"", Relationship: \""imaging of\""\\n\\nCausalities:-\\n<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>\\n\\nSection Name: Post-Treatment Evaluation\\n====================\\nEntities:-\\nRadiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.\\nPn1 Category : A pathological classification indicating regional lymph node metastasis in cancer staging.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\n\\nRelationships:-\\n1. Entity1: \""Post Systemic Therapy/RT or RT Neck Evaluation\"", Entity2: \""pN1\"", Relationship: \""evaluation of cancer staging\""\\n2. Entity1: \""pN1\"", Entity2: \""Consider RT\"", Relationship: \""treatment recommendation\""\\n\\nCausalities:-\\n<CO> pN1 without other risk features </CO> <A> Consider RT </A>\\n\\nSection Name: Additional Notes\\n====================\\nEntities:-\\nAntineoplastic Combined Chemotherapy Protocols : Protocols for the administration of more than one antineoplastic agent in combination to treat malignant neoplasms.\\nCisplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Non-Nasopharyngeal Cancers\"", Relationship: \""used for\""\\n2. Entity1: \""Cisplatin\"", Entity2: \""Systemic Therapy\"", Relationship: \""preferred agent in\""\\n3. Entity1: \""Induction Chemotherapy\"", Entity2: \""Systemic Therapy\"", Relationship: \""discussed in context of\""\\n\\nCausalities:-\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n- **<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>. See Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A).**\\n- **<A> See Discussion on induction chemotherapy. </A>**\\n--------------------------------------------------\\nPage Number: 130\\n\\nSection Name: Pathological N (pN)\\n====================\\nEntities:-\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nTnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system.\\n\\nRelationships:-\\n1. Entity1: \""Lymph Nodes\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""involved in\""\\n2. Entity1: \""TNM Staging\"", Entity2: \""Lymph Nodes\"", Relationship: \""includes\""\\n3. Entity1: \""TNM Staging\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""describes\""\\n\\nCausalities:-\\n<CO> NX: Regional lymph nodes cannot be assessed </CO>\\n<CO> N0: No regional lymph node metastasis </CO>\\n<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(\u2013) </CO>\\n<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(\u2212); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> Note: A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+). </CO>\\n\\nSection Name: Distant Metastasis (M)\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""M0\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n2. Entity1: \""M1\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n\\nCausalities:-\\n### Distant Metastasis (M)\\n\\n- **M0**: No distant metastasis\\n- **M1**: Distant metastasis\\n\\nSection Name: Histologic Grade (G)\\n====================\\nEntities:-\\nNeoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.\\nHistologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.\\n\\nRelationships:-\\n1. Entity1: \""GX\"", Entity2: \""Grade cannot be assessed\"", Relationship: \""is described as\""\\n2. Entity1: \""G1\"", Entity2: \""Well differentiated\"", Relationship: \""is described as\""\\n3. Entity1: \""G2\"", Entity2: \""Moderately differentiated\"", Relationship: \""is described as\""\\n4. Entity1: \""G3\"", Entity2: \""Poorly differentiated\"", Relationship: \""is described as\""\\n\\nCausalities:-\\n<CO>GX</CO>: <E>Grade cannot be assessed</E>\\n<CO>G1</CO>: <E>Well differentiated</E>\\n<CO>G2</CO>: <E>Moderately differentiated</E>\\n<CO>G3</CO>: <E>Poorly differentiated</E>\\n\\nSection Name: Prognostic Stage Groups\\n====================\\nEntities:-\\nNeoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.\\nTumor Staging : A system for describing the size and spread of cancer within the body.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\n\\nRelationships:-\\n1. Entity1: \""Stage 0\"", Entity2: \""Tis N0 M0\"", Relationship: \""defined by\""\\n2. Entity1: \""Stage I\"", Entity2: \""T1 N0 M0\"", Relationship: \""defined by\""\\n3. Entity1: \""Stage II\"", Entity2: \""T2 N0 M0\"", Relationship: \""defined by\""\\n4. Entity1: \""Stage III\"", Entity2: \""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0\"", Relationship: \""defined by\""\\n5. Entity1: \""Stage IVA\"", Entity2: \""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0\"", Relationship: \""defined by\""\\n6. Entity1: \""Stage IVB\"", Entity2: \""Any T N3 M0, T4b Any N M0\"", Relationship: \""defined by\""\\n7. Entity1: \""Stage IVC\"", Entity2: \""Any T Any N M1\"", Relationship: \""defined by\""\\n'}""",invalid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: PET_Scan_Results_10
label: Positron Emission Tomography Scan Results
description: This node represents the results of a PET scan, which is an imaging test used to observe metabolic processes in the body. The results are crucial for assessing the involvement of lymph nodes, which is important in cancer diagnosis, staging, and treatment planning. The PET scan can reveal whether there is extracapsular spread, unilateral or bilateral lymph node involvement, or absence of lymph node involvement, as well as the size of lymph nodes.
type: Examination Result
observability: Observed
states: [{'state_name': 'extracapsular_spread_of_lymph_nodes', 'state_description': 'This state indicates that the cancer has spread beyond the capsule of the lymph nodes, which can be a sign of more advanced disease.'}, {'state_name': 'unilateral_lymph_node_involvement', 'state_description': 'This state indicates that cancer involvement is present in the lymph nodes on one side of the body.'}, {'state_name': 'bilateral_lymph_node_involvement', 'state_description': 'This state indicates that cancer involvement is present in the lymph nodes on both sides of the body.'}, {'state_name': 'absence_of_lymph_node_involvement', 'state_description': 'This state indicates that there is no detectable cancer involvement in the lymph nodes.'}, {'state_name': 'enlarged_lymph_node_size', 'state_description': 'This state indicates that the lymph nodes are enlarged, which can be a sign of cancer or other pathological processes.'}, {'state_name': 'present', 'state_description': 'This state indicates the presence of a finding or condition as detected by the PET scan.'}, {'state_name': 'absent', 'state_description': 'This state indicates the absence of a finding or condition as detected by the PET scan.'}]

`NODE2`:
id: Number_of_Lymph_Nodes_Metastasis_3
label: Assessment of Lymph Node Metastasis
description: This node represents the assessment of whether metastasis is present in the lymph nodes. It is crucial for staging cancer and determining the extent of its spread, which impacts treatment decisions and prognosis.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'present', 'state_description': 'Metastasis is present in the lymph nodes, indicating that cancer has spread to these nodes.'}, {'state_name': 'absent', 'state_description': 'Metastasis is absent in the lymph nodes, indicating that cancer has not spread to these nodes.'}]

`EDGE1`:
{'edges_ids': ['PET_Scan_Results_10', 'Number_of_Lymph_Nodes_Metastasis_3'], 'edge': '(PET_Scan_Results_10) causes (Number_of_Lymph_Nodes_Metastasis_3)', 'explanation': ['The PET scan results provide direct information about the involvement of lymph nodes, which is used to assess the presence or absence of metastasis.', 'The edge is valid because the PET scan results are used to determine the state of lymph node metastasis, making it a direct causal relationship.', 'The causal direction is positive because the presence of findings in the PET scan correlates with the presence of metastasis, and absence correlates with no metastasis.', 'The PET scan results are not necessary for metastasis to occur, but they are sufficient for assessing its presence.', 'The causal distance is proximal because the PET scan results directly inform the assessment of lymph node metastasis.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': True}, 'causal_distance': 'Proximal'}

`EDGE2`:
{'edges_ids': ['Number_of_Lymph_Nodes_Metastasis_3', 'PET_Scan_Results_10'], 'edge': '(Number_of_Lymph_Nodes_Metastasis_3) causes (PET_Scan_Results_10)', 'explanation': ['The edge represents the causal relationship where the presence of lymph node metastasis (Number_of_Lymph_Nodes_Metastasis_3) leads to positive findings on a PET scan (PET_Scan_Results_10).', 'The PET scan is used to detect metabolic activity associated with cancer, and if metastasis is present in the lymph nodes, it will likely be detected by the PET scan.', 'The causal direction is positive because the presence of metastasis would lead to positive PET scan results.', 'The presence of metastasis is necessary for the PET scan to show positive results related to lymph node involvement, but it is not sufficient because other factors could also cause positive PET scan results.', 'The causal distance is proximal because the presence of metastasis directly affects the PET scan results.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': True, 'sufficient': False}, 'causal_distance': 'Proximal'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 92

Section Name: NCCN Guidelines Overview
====================
Entities:-
Head And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Malignant Neoplasm Of Head And Neck : A malignant tumor located in the head and neck region.
Head And Neck Cancer : A group of cancers that originate in the head and neck region.
Antineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Radiation Therapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.

Relationships:-
1. Entity1: ""Head and neck cancers"", Entity2: ""Systemic therapy"", Relationship: ""follow-up recommendations after""
2. Entity1: ""Head and neck cancers"", Entity2: ""Radiation therapy"", Relationship: ""follow-up recommendations after""

Causalities:-
The image presents a flowchart from the National Comprehensive Cancer Network (NCCN) Guidelines Version 2.2024, especially focusing on <A> follow-up recommendations </A> for <CO> patients with head and neck cancers after systemic therapy or radiation therapy (RT) </CO>. All recommendations are categorized as level A unless stated otherwise, highlighting the importance of clinical trials in cancer management.

Section Name: Imaging and Assessment Protocols
====================
Entities:-
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The treatment of disease, especially cancer, using X-rays or similar forms of radiation.
Clinical Assessment : A systematic evaluation of a patient's health status, often involving a physical examination and medical history.
Positron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.
Computed Tomography : A medical imaging technique used in radiology to obtain detailed internal images of the body.
Magnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis.
Disease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Residual Neoplasm : Remaining cancer cells after treatment.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Clinical Assessment"", Relationship: ""occurs before""
2. Entity1: ""FDG-PET/CT Scan"", Entity2: ""Distant Metastases"", Relationship: ""assesses""
3. Entity1: ""FDG-PET/CT Scan"", Entity2: ""Observation"", Relationship: ""leads to if negative""
4. Entity1: ""FDG-PET/CT Scan"", Entity2: ""CT Scan"", Relationship: ""leads to if strongly positive""
5. Entity1: ""CT Scan"", Entity2: ""Neck Dissection"", Relationship: ""leads to if positive""

Causalities:-
<CO> After systemic therapy or RT </CO>, <A> a clinical assessment should occur 4 to 8 weeks later </A>. <CO> If there is a response </CO>, <A> it is necessary to assess the extent of disease or distant metastases, preferably through a FDG-PET/CT scan at a minimum of 12 weeks post-treatment </A>. <CO> If the FDG-PET/CT results are negative </CO>, <A> the patient may continue with monitoring through observation </A>. <CO> In cases where the results are equivocal </CO>, <A> observation or repeat FDG-PET/CT within 3 to 6 months is prescribed </A>.

<CO> In cases where the FDG-PET/CT results are strongly positive </CO>, <A> further imaging via CT scan with contrast of the primary site and neck, or MRI with and without contrast, becomes necessary </A>. <CO> If these imaging results confirm positive findings </CO>, <A> neck dissection may be considered, depending on the evidence of residual or persistent disease </A>. <CO> If the imaging findings are negative </CO>, <A> the patient might continue in observation </A>.

Section Name: Outcomes Based on Disease Resectability
====================
Entities:-
Disease : A disorder of structure or function in a human, animal, or plant, especially one that produces specific symptoms.
Resectable : Capable of being surgically removed.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis.

Relationships:-
1. Entity1: ""Disease"", Entity2: ""Resectable"", Relationship: ""Classification""
2. Entity1: ""Unresectable"", Entity2: ""Treatment plans (ADV-3)"", Relationship: ""Treatment recommendation""
3. Entity1: ""Resectable"", Entity2: ""Resection and/or Neck dissection"", Relationship: ""Surgical procedure""

Causalities:-
<CO> If there is confirmed residual or persistent disease </CO>, the options split into two pathways: 'Unresectable' or 'Resectable.' <CO> If the disease is classified as unresectable </CO>, <A> advances in treatment plans (labeled ADV-3) are called for </A>. Conversely, <CO> if it is deemed resectable </CO>, <A> a resection of the primary and/or neck dissection may occur </A>, <CO> contingent upon the disease status </CO>.

Section Name: Important Notes
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
Positron-Emission Tomography : An imaging technique using a radioactive substance called a tracer to look for disease in the body.
Positron Emission Tomography (Procedure) : A diagnostic imaging procedure that uses a radioactive tracer to visualize and measure changes in metabolic processes.
Positron Emission Tomography : A nuclear medicine functional imaging technique used to observe metabolic processes in the body.
Neoplasms : New abnormal growth of tissue in animals or plants; a tumor.
Malignant Neoplasm : A cancerous growth that has the potential to spread to other parts of the body.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""NCCN"", Entity2: ""Clinical trials"", Relationship: ""emphasizes participation in""
2. Entity1: ""FDG-PET/CT"", Entity2: ""Persistent cancer"", Relationship: ""used to detect""
3. Entity1: ""FDG-PET/CT"", Entity2: ""PET negative"", Relationship: ""interpretation of results""
4. Entity1: ""FDG-PET/CT"", Entity2: ""PET positive"", Relationship: ""interpretation of results""

Causalities:-
<A> NCCN emphasizes that the best management for any cancer patient is participation in clinical trials </A>, especially encouraged for all patients. Additional notes clarify that <CO> if the FDG-PET/CT is negative for persistent cancer </CO>, <A> further cross-sectional imaging is optional </A>. The interpretations define <CO> PET negative as no or low-grade uptake not suspicious for disease </CO>, while <CO> PET positive implies suspicion for disease </CO>.
--------------------------------------------------
Page Number: 94

Section Name: Head and Neck Cancers - Principles of Imaging
====================
Entities:-
Positron Emission Tomography Computed Tomography : A medical imaging technique combining PET and CT capabilities to provide detailed information about the body's function and structure.
Positron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.
Head And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.

Relationships:-
1. Entity1: ""PET/CT"", Entity2: ""PET scan"", Relationship: ""preferred over""
2. Entity1: ""PET-CT"", Entity2: ""head neck cancers"", Relationship: ""used in study of""

Causalities:-
<A> PET/CT is preferred over PET scan alone (i.e., without superimposed CT scan) </A>. <C> PET/CT provides more accurate anatomical localization of abnormalities </C> <E> more accurate anatomical localization of abnormalities </E>.

Section Name: Initial Workup - Nodal Metastases
====================
Entities:-
Lymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site via the lymphatic system.
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine's computer to generate cross-sectional images.
Magnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.
Lymph Node Metastasis : The spread of cancer cells to lymph nodes, which are part of the lymphatic system.
Ct Of Neck : A computed tomography scan of the neck region.
Mri Of Neck : A magnetic resonance imaging scan of the neck region.
Fdg-Pet Scan : A type of positron emission tomography using fluorodeoxyglucose to assess metabolic activity.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.
Positron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.

Relationships:-
1. Entity1: ""CT"", Entity2: ""lymph node metastases"", Relationship: ""used to evaluate""
2. Entity1: ""MRI"", Entity2: ""lymph node metastases"", Relationship: ""used to evaluate""
3. Entity1: ""FDG-PET/CT"", Entity2: ""lymph node metastases"", Relationship: ""used for detection""
4. Entity1: ""FDG-PET/CT"", Entity2: ""surgical primary approach"", Relationship: ""used to determine""
5. Entity1: ""FDG-PET/CT"", Entity2: ""definitive RT approach"", Relationship: ""used to identify""

Causalities:-
<A> Evaluation of lymph node metastases should be conducted with CT or MRI of the neck </A>, using whichever imaging study is suitable for primary site evaluation (IMG-A, 1 of 4).
<CO> For patients with multistation or lower neck nodal involvement or high-grade tumor histology </CO>, <A> consider CT of the chest to assess for mediastinal lymph node metastases or FDG-PET/CT </A>, <C> which is associated with higher sensitivity for both nodal and distant metastases </C>.
<CO> For patients who are under consideration for a surgical primary approach </CO>, <A> the higher sensitivity of FDG-PET/CT is warranted for tumors approaching the midline, to determine the surgical approach to the contralateral neck </A>. <CO> Similarly, patients who are scheduled for a definitive RT approach </CO> <A> may benefit from the higher sensitivity of FDG-PET/CT for identifying involved lymph nodes </A>.

Section Name: Initial Workup - Distant Metastases
====================
Entities:-
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.
Magnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine's computer to generate cross-sectional images.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Lung Neoplasms : Tumors or cancer of the lung.
Smoking : The inhalation of the smoke of burning tobacco encased in cigarettes, pipes, and cigars.

Relationships:-
1. Entity1: ""FDG-PET/CT"", Entity2: ""Distant Metastases"", Relationship: ""used to evaluate""
2. Entity1: ""Contrast-enhanced brain MRI"", Entity2: ""Brain Metastasis"", Relationship: ""recommended for evaluation""
3. Entity1: ""CT of the chest"", Entity2: ""Pulmonary Metastases"", Relationship: ""performed to assess""
4. Entity1: ""Non-contrast CT of the chest"", Entity2: ""Lung Parenchymal Metastases"", Relationship: ""used to screen""
5. Entity1: ""Annual CT screening"", Entity2: ""Lung Metastasis"", Relationship: ""considered for high risk""
6. Entity1: ""Directed CT or MRI"", Entity2: ""Distant Disease"", Relationship: ""used for assessment""
7. Entity1: ""FDG-PET/CT"", Entity2: ""Recurrent Disease"", Relationship: ""used for staging""

Causalities:-
<C> Patients with locoregionally advanced cancer (e.g., T3–T4 primary or ≥N1 nodal staging) </C>, <A> FDG-PET/CT is preferred to evaluate for distant disease and thoracic metastases </A>. <CO> For cancers where brain metastasis is a concern, such as mucosal melanoma or high-grade neuroendocrine carcinomas or adenocarcinomas </CO>, <A> contrast-enhanced brain MRI should be additionally obtained </A>.
<CO> If FDG-PET/CT is not performed </CO>, <A> CT of the chest should be performed to assess for presence of pulmonary metastases as well as mediastinal lymph node involvement </A>.
<CO> Non-contrast CT of the chest can be sufficient to screen for lung parenchymal metastases </CO> but <CO> is not adequate for assessment of mediastinal adenopathy </CO>. <CO> This is an appropriate lung cancer screening intervention for patients with a history of smoking </CO>.
<CO> Following primary definitive treatment (surgery, RT, or systemic therapy/RT) </CO> the role of annual CT screening for lung metastasis is controversial. <E> While this approach does detect early metastasis </E>, <CO> further study is needed to determine the extent of the positive effect and/or cost-effectiveness of this approach in specific subpopulations and timepoints post-treatment </CO>. <CO> For patients with a substantial smoking history or who are at high risk for lung metastases </CO>, <A> annual chest CT can be considered </A>.
<CO> If clinical concern for metastatic disease is confined to a specific anatomical area </CO>, <A> the assessment of distant disease can be performed with directed CT or MRI examination </A>.
<CO> FDG-PET/CT may complement or replace other imaging modalities when staging recurrent disease before any therapy for relapsed/refractory disease </CO> <A> in order to explore distant disease or second primaries that may significantly impact choice of therapy </A>.
--------------------------------------------------
Page Number: 55

Section Name: General Information
====================
Entities:-
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Nccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""National Comprehensive Cancer Network"", Relationship: ""produced by""

Section Name: Important Notes
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Neoplasms : New abnormal growth of tissue that can be benign or malignant.
Malignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Clinical Trials"", Entity2: ""Cancer"", Relationship: ""recommended for""
2. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""

Causalities:-
<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles
====================
Entities:-
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Chemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""Both are principles of cancer treatment methods.""
2. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""
3. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""

Causalities:-
### Principles

- **Principles of Surgery (SURG-A)**
- **Principles of Radiation Therapy (SUPRA-A)**
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**

Section Name: Adverse Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Perineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The invasion of cancer cells into blood vessels.
Lymphatic Invasion : The invasion of cancer cells into lymphatic vessels.

Relationships:-
1. Entity1: ""Extranodal extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
2. Entity1: ""Positive margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
3. Entity1: ""Close margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
4. Entity1: ""pT3 or pT4 primary"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
5. Entity1: ""pN2 or pN3 nodal disease"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
6. Entity1: ""Perineural invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
7. Entity1: ""Vascular invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
8. Entity1: ""Lymphatic invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""

Causalities:-
<C> Extranodal extension </C>
<C> Positive margins </C>
<C> Close margins </C>
<C> pT3 or pT4 primary </C>
<C> pN2 or pN3 nodal disease </C>
<C> Perineural invasion </C>
<C> Vascular invasion </C>
<C> Lymphatic invasion </C>

Section Name: Response Assessment
====================
Entities:-
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Primary Site : The original location where a tumor or cancer begins.
Complete Remission : The disappearance of all signs of cancer in response to treatment.
Partial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.

Relationships:-
1. Entity1: ""induction chemotherapy"", Entity2: ""Primary site"", Relationship: ""treatment outcome""
2. Entity1: ""Definitive RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
3. Entity1: ""RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
4. Entity1: ""Surgery"", Entity2: ""unresectable nodal disease"", Relationship: ""treatment option""

Causalities:-
<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.
Follow-Up (Medicine) : The process of monitoring a patient's health over time after treatment or diagnosis.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : A disease that returns after a period of remission.
Recurrence (Medicine) : The return of a disease or condition after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
### Follow-up

- **Follow-up** (FOLL-A, 1 of 2)
- **Recurrent or persistent disease** (ADV-3)

Section Name: Risk Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""RT"", Relationship: ""Consideration for treatment""
2. Entity1: ""Adverse pathologic features"", Entity2: ""Systemic therapy"", Relationship: ""Consideration for treatment""

Causalities:-
- **No adverse pathologic features**
- **Other risk features**
- **Adverse pathologic features**:
  - <C> Extranodal extension and/or positive margin </C>
  - <A> RT or consider systemic therapy/RT </A>

Section Name: Post-Therapy Evaluation
====================
Entities:-
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Neck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""
2. Entity1: ""RT"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""

Causalities:-
<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>

Section Name: Flowchart Overview
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Supraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""guides management of""
2. Entity1: ""NCCN Guidelines"", Entity2: ""healthcare professionals"", Relationship: ""used by""

Causalities:-
<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.

Section Name: Assessment and Treatment Decisions
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Complete Response : The disappearance of all signs of cancer in response to treatment.
Partial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Complete Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""
2. Entity1: ""Complete Response"", Entity2: ""Surgery"", Relationship: ""leads to""
3. Entity1: ""Partial Response"", Entity2: ""Systemic Therapy"", Relationship: ""leads to""
4. Entity1: ""Partial Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""

Causalities:-
<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.

Section Name: Adverse Pathologic Features and Follow-up
====================
Entities:-
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Neoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Recurrent Neoplasm : A neoplasm that has returned after treatment.
Metastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.
Metastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""Treatment decisions"", Relationship: ""Influence""
2. Entity1: ""Adverse features"", Entity2: ""Surgical intervention"", Relationship: ""Recommendation""
3. Entity1: ""Absence of adverse features"", Entity2: ""Radiation therapy"", Relationship: ""Pathway""
4. Entity1: ""Follow-up process"", Entity2: ""Recurrent or persistent disease"", Relationship: ""Detection""
5. Entity1: ""Recurrent or persistent disease"", Entity2: ""Advanced disease management"", Relationship: ""Necessity""

Causalities:-
<C> The presence of adverse pathologic features — such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient's disease characteristics.

Furthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.
--------------------------------------------------
Page Number: 44

Section Name: Flowchart Structure
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms based on extent of tumor spread according to standardized criteria.
Laryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.
Chemotherapy, Adjuvant : Drug therapy given in addition to the primary treatment to enhance its effectiveness.
Radiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Neoplasm Recurrence, Local : The return of a tumor at the original site after treatment.

Relationships:-
1. Entity1: ""Clinical Staging"", Entity2: ""T3 tumors"", Relationship: ""determines treatment approach""
2. Entity1: ""Adverse Pathologic Features"", Entity2: ""Systemic Therapy"", Relationship: ""directs to""
3. Entity1: ""Adverse Pathologic Features"", Entity2: ""Radiation Treatment"", Relationship: ""directs to""
4. Entity1: ""Induction Chemotherapy"", Entity2: ""Imaging (CT or MRI)"", Relationship: ""leads to""

Causalities:-
1. <A> The flow begins with the clinical staging of T3 tumors </A> <C> that require total laryngectomy (N2–3) </C>. <CO> This staging </CO> <E> is crucial for determining the appropriate therapeutic approach </E>.

2. The flowchart provides multiple pathways for treatment, indicating that <CO> patients </CO> <A> may undergo either ""Concurrent systemic therapy/RT"" or ""Surgery"" </A>. There is also an <A> option for ""Induction chemotherapy,"" leading to further imaging (CT or MRI) to assess the primary site and neck status </A>.

3. For <CO> patients who have surgery </CO>, the flowchart distinguishes between those with adverse pathologic features and those without. <CO> Patients with adverse features—such as extranodal extension or positive margins </CO>—are <A> directed toward systemic therapy or radiation treatment </A>, while those without may follow a different management path.

4. The flowchart concludes by <A> outlining follow-up procedures for recurrent or persistent disease </A>, suggesting additional assessments and treatments based on the risk features identified during earlier stages.

Section Name: Detailed Explanation
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
Adverse Pathological Feature : A pathological feature that indicates a worse prognosis or outcome.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.

Relationships:-
1. Entity1: ""Systemic therapy"", Entity2: ""Radiation"", Relationship: ""Concurrent treatment""
2. Entity1: ""Clinical trials"", Entity2: ""Personalized treatment plans"", Relationship: ""Development of""

Causalities:-
<A> The flowchart is designed to provide healthcare professionals with a systematic pathway for managing glottic larynx cancer </A>. Each step is meticulously organized to ensure that important factors are considered, such as <C> the presence of adverse pathological features </C>, which <E> strongly influence treatment decisions </E>.

<A> The emphasis on concurrent treatments, such as systemic therapy combined with radiation </A>, reflects current best practices in oncology, where multimodal approaches are often necessary to achieve better outcomes. <A> The inclusion of clinical trials </A> indicates an emphasis on maintaining up-to-date practices and personalized treatment plans as part of patient management strategies.

Furthermore, <A> the chart's organization into treatment and follow-up segments </A> allows for a straightforward interpretation, guiding oncologists through complex decisions in a logical manner. This can <E> improve consistency in care and enhance patient safety through meticulous monitoring and responses to treatment efficacy or disease progression </E>.

In summary, <E> this flowchart serves as an essential resource for oncologists, facilitating a better understanding of treatment protocols for glottic larynx cancer while promoting a patient-centered approach to oncological care </E>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Neoplasms : New abnormal growth of tissue that may be benign or malignant.
Malignant Neoplastic Disease : A disease in which abnormal cells divide uncontrollably and destroy body tissue.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
National Comprehensive Cancer Network : An alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""NCCN Guidelines"", Relationship: ""publishes""
2. Entity1: ""Clinical trial"", Entity2: ""Cancer"", Relationship: ""manages""

Causalities:-
<C> any patient with cancer </C> <E> the best management is in a clinical trial </E>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles of Treatment
====================
Entities:-
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Extranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margins : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.
Perineural Invasion : Cancer cells are found surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The presence of cancer cells within blood vessels.
Lymphatic Metastasis : The spread of cancer cells through the lymphatic system to distant sites.

Relationships:-
1. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Extranodal Extension"", Relationship: ""management of""
2. Entity1: ""Principles of Surgery"", Entity2: ""Positive Surgical Margins"", Relationship: ""concerned with avoiding""
3. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Perineural Invasion"", Relationship: ""consideration in treatment planning""

Causalities:-
<C> Extranodal extension </C> <C> Positive margins </C> <C> Close margins </C> <C> pT4 primary </C> <C> pN2 or pN3 nodal disease </C> <C> Perineural invasion </C> <C> Vascular invasion </C> <C> Lymphatic invasion </C> <C> Subglottic extension </C>

Section Name: Clinical Staging
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to enhance its effectiveness.
Adjuvant Therapy : A therapy given in addition to the primary or initial therapy to maximize its effectiveness.
Follow-Up Studies : Studies that continue to monitor patients after treatment to assess long-term outcomes.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient after initial treatment.
Follow-Up : The act of monitoring a patient's health over time after treatment.
Neoplasm Recurrence, Local : The return of a tumor at the original site after treatment.
Recurrent Disease : A disease that has returned after a period of remission.

Relationships:-
1. Entity1: ""Adjuvant Treatment"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""prevention""
2. Entity1: ""Follow-up"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""monitoring""

Section Name: Treatment Options
====================
Entities:-
Laryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.
Total Laryngectomy : A surgical procedure to remove the entire larynx.
Chemotherapy, Adjuvant : Drug therapy given in addition to the primary treatment to enhance its effectiveness.
Induction Chemotherapy : Chemotherapy given as a first step to shrink a tumor before the main treatment.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""T3 requiring total laryngectomy"", Entity2: ""Concurrent systemic therapy/RT"", Relationship: ""treatment option""
2. Entity1: ""T3 requiring total laryngectomy"", Entity2: ""Induction chemotherapy"", Relationship: ""treatment option""
3. Entity1: ""T3 requiring total laryngectomy"", Entity2: ""Clinical trials"", Relationship: ""research option""

Causalities:-
<CO> T3 requiring (amenable to) total laryngectomy (N2–3) </CO> <A> Concurrent systemic therapy/RT </A> <A> Surgery </A> <A> Induction chemotherapy </A> <A> Clinical trials </A>

Section Name: Surgical Considerations
====================
Entities:-
Laryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.
Thyroidectomy : Surgical removal of all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue in the neck.
Lymph Node Excision : Surgical removal of one or more lymph nodes.
Lymph Node Dissection : A surgical procedure to remove lymph nodes.
Lymphadenectomy : Surgical removal of one or more groups of lymph nodes.

Relationships:-
1. Entity1: ""Laryngectomy"", Entity2: ""Thyroidectomy"", Relationship: ""performed with""
2. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Excision"", Relationship: ""includes""
3. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Excision"", Relationship: ""includes specific types""

Causalities:-
<A> Laryngectomy with thyroidectomy as indicated, ipsilateral or bilateral neck dissection, and pretracheal and ipsilateral paratracheal lymph node dissection </A>

Section Name: Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margins : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.
Positive Margin : A surgical margin that contains residual tumor cells.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""Extranodal extension"", Relationship: ""includes""
2. Entity1: ""Adverse pathologic features"", Entity2: ""Positive margin"", Relationship: ""includes""

Causalities:-
- **No adverse pathologic features**
- **Adverse pathologic features**
  - <C> Extranodal extension and/or positive margin </C>
  - Other risk features

Section Name: Systemic Therapy
====================
Entities:-
Antineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.
Systemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.

Relationships:-
1. Entity1: ""Systemic therapy"", Entity2: ""RT"", Relationship: ""Consideration""

Causalities:-
<A> Systemic therapy/RT (category 1) </A>
<A> RT </A>
<A> Consider systemic therapy/RT </A>

Section Name: Imaging
====================
Entities:-
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Neck : Part of the body, on many terrestrial or secondarily aquatic vertebrates, that distinguishes the head from the torso or trunk.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images (often called slices), both horizontally and vertically, of the body.
Neck Structure : The anatomical structure that connects the head to the torso.

Relationships:-
1. Entity1: ""CT"", Entity2: ""Neck"", Relationship: ""imaging of""
2. Entity1: ""MRI"", Entity2: ""Neck"", Relationship: ""imaging of""

Causalities:-
<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>

Section Name: Post-Treatment Evaluation
====================
Entities:-
Radiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.
Pn1 Category : A pathological classification indicating regional lymph node metastasis in cancer staging.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.

Relationships:-
1. Entity1: ""Post Systemic Therapy/RT or RT Neck Evaluation"", Entity2: ""pN1"", Relationship: ""evaluation of cancer staging""
2. Entity1: ""pN1"", Entity2: ""Consider RT"", Relationship: ""treatment recommendation""

Causalities:-
<CO> pN1 without other risk features </CO> <A> Consider RT </A>

Section Name: Additional Notes
====================
Entities:-
Antineoplastic Combined Chemotherapy Protocols : Protocols for the administration of more than one antineoplastic agent in combination to treat malignant neoplasms.
Cisplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Non-Nasopharyngeal Cancers"", Relationship: ""used for""
2. Entity1: ""Cisplatin"", Entity2: ""Systemic Therapy"", Relationship: ""preferred agent in""
3. Entity1: ""Induction Chemotherapy"", Entity2: ""Systemic Therapy"", Relationship: ""discussed in context of""

Causalities:-
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**
- **<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>. See Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A).**
- **<A> See Discussion on induction chemotherapy. </A>**
--------------------------------------------------
Page Number: 130

Section Name: Pathological N (pN)
====================
Entities:-
Lymph Nodes : Small, bean-shaped structures that are part of the body's lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.
Lymph Node : An organ of the lymphatic system and the adaptive immune system.

Relationships:-
1. Entity1: ""Lymph Nodes"", Entity2: ""Neoplasm Metastasis"", Relationship: ""involved in""
2. Entity1: ""TNM Staging"", Entity2: ""Lymph Nodes"", Relationship: ""includes""
3. Entity1: ""TNM Staging"", Entity2: ""Neoplasm Metastasis"", Relationship: ""describes""

Causalities:-
<CO> NX: Regional lymph nodes cannot be assessed </CO>
<CO> N0: No regional lymph node metastasis </CO>
<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(–) </CO>
<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> Note: A designation of “U” or “L” may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(−) or ENE(+). </CO>

Section Name: Distant Metastasis (M)
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""M0"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""
2. Entity1: ""M1"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""

Causalities:-
### Distant Metastasis (M)

- **M0**: No distant metastasis
- **M1**: Distant metastasis

Section Name: Histologic Grade (G)
====================
Entities:-
Neoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.
Histologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.

Relationships:-
1. Entity1: ""GX"", Entity2: ""Grade cannot be assessed"", Relationship: ""is described as""
2. Entity1: ""G1"", Entity2: ""Well differentiated"", Relationship: ""is described as""
3. Entity1: ""G2"", Entity2: ""Moderately differentiated"", Relationship: ""is described as""
4. Entity1: ""G3"", Entity2: ""Poorly differentiated"", Relationship: ""is described as""

Causalities:-
<CO>GX</CO>: <E>Grade cannot be assessed</E>
<CO>G1</CO>: <E>Well differentiated</E>
<CO>G2</CO>: <E>Moderately differentiated</E>
<CO>G3</CO>: <E>Poorly differentiated</E>

Section Name: Prognostic Stage Groups
====================
Entities:-
Neoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.
Tumor Staging : A system for describing the size and spread of cancer within the body.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.

Relationships:-
1. Entity1: ""Stage 0"", Entity2: ""Tis N0 M0"", Relationship: ""defined by""
2. Entity1: ""Stage I"", Entity2: ""T1 N0 M0"", Relationship: ""defined by""
3. Entity1: ""Stage II"", Entity2: ""T2 N0 M0"", Relationship: ""defined by""
4. Entity1: ""Stage III"", Entity2: ""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0"", Relationship: ""defined by""
5. Entity1: ""Stage IVA"", Entity2: ""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0"", Relationship: ""defined by""
6. Entity1: ""Stage IVB"", Entity2: ""Any T N3 M0, T4b Any N M0"", Relationship: ""defined by""
7. Entity1: ""Stage IVC"", Entity2: ""Any T Any N M1"", Relationship: ""defined by""


Among these two options which one is the most likely true:

(A) `PET_Scan_Results_10` increases risk `Number_of_Lymph_Nodes_Metastasis_3`
(B) `Number_of_Lymph_Nodes_Metastasis_3` `increases risk `PET_Scan_Results_10`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge (PET_Scan_Results_10) causes (Number_of_Lymph_Nodes_Metastasis_3) suggests that PET scan results are used to assess lymph node metastasis.
2. The edge (Number_of_Lymph_Nodes_Metastasis_3) causes (PET_Scan_Results_10) suggests that the presence of metastasis leads to positive PET scan results.
3. The explanation for EDGE1 indicates that PET scan results provide direct information about lymph node involvement, which is used to assess metastasis.
4. The explanation for EDGE2 indicates that the presence of metastasis leads to positive findings on a PET scan.
5. The causal direction for EDGE1 is positive, indicating that PET scan results correlate with metastasis presence.
6. The causal direction for EDGE2 is also positive, indicating that metastasis presence leads to positive PET scan results.
7. The causal factor for EDGE1 is sufficient but not necessary, meaning PET scan results are enough to assess metastasis but not required for metastasis to occur.
8. The causal factor for EDGE2 is necessary but not sufficient, meaning metastasis presence is needed for positive PET scan results but not enough on its own.
9. The causal distance for both edges is proximal, indicating a direct relationship between the nodes.
10. The NCCN Guidelines emphasize the use of PET/CT scans for assessing lymph node metastasis, supporting the role of PET scans in evaluating metastasis presence.
11. The NCCN Guidelines do not suggest that metastasis presence causes PET scan results, but rather that PET scans are used to detect metastasis.
","1. Page 92, Section: Imaging and Assessment Protocols, Entity: FDG-PET/CT Scan, Relationship: assesses Distant Metastases.
2. Page 94, Section: Initial Workup - Nodal Metastases, Entity: FDG-PET/CT, Relationship: used for detection of lymph node metastases.
3. Page 130, Section: Pathological N (pN), Entity: Lymph Nodes, Relationship: involved in Neoplasm Metastasis.
",A,"{'A': 99.98, 'B': 0.02}",yes,A,"1. The AI assistant's reasoning for option (A) is based on the explanation that PET scan results provide direct information about lymph node involvement, which is used to assess metastasis. This aligns with the causal direction being positive, indicating that PET scan results correlate with the presence of metastasis.
2. The assistant also notes that the causal factor for EDGE1 is sufficient but not necessary, meaning PET scan results are enough to assess metastasis but not required for metastasis to occur. This supports the idea that PET scan results can indicate metastasis presence, but metastasis can occur without PET scan results.
3. The assistant references the NCCN Guidelines, which emphasize the use of PET/CT scans for assessing lymph node metastasis, supporting the role of PET scans in evaluating metastasis presence. This aligns with the explanation for EDGE1, where PET scan results are used to determine the state of lymph node metastasis.
4. For option (B), the assistant notes that the explanation for EDGE2 indicates that the presence of metastasis leads to positive findings on a PET scan. However, the causal factor is necessary but not sufficient, meaning metastasis presence is needed for positive PET scan results but not enough on its own.
5. The NCCN Guidelines do not suggest that metastasis presence causes PET scan results, but rather that PET scans are used to detect metastasis. This supports the reasoning for option (A) over option (B).
6. Overall, the assistant's reasoning is consistent with the evidence provided, and the final answer (A) is supported by the explanations and guidelines referenced.
"
2,gpt-4o,"Histopathological_Examination_7,Extranodal_Extension_5","""{'NODE1': {'id': 'Histopathological_Examination_7', 'label': 'Histology Pathology Examination', 'description': 'This node represents the result of a histopathological examination, which is a diagnostic procedure where tissue samples are examined under a microscope to look for disease, such as cancer. It is crucial for diagnosing and understanding the nature of various diseases, particularly cancers.', 'type': 'Examination Result', 'observability': 'Observed', 'states': [{'state_name': 'present', 'state_description': \""The 'present' state indicates that the histopathological examination has found evidence of disease or abnormality in the tissue sample.\""}, {'state_name': 'absent', 'state_description': \""The 'absent' state indicates that the histopathological examination has not found any evidence of disease or abnormality in the tissue sample.\""}]}, 'NODE2': {'id': 'Extranodal_Extension_5', 'label': 'Extranodal Extension', 'description': 'Extranodal extension refers to the spread of cancer beyond the lymph node capsule into surrounding tissues. It is a significant factor in cancer staging and prognosis, as it indicates a more advanced disease and may influence treatment decisions.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'present', 'state_description': 'Extranodal extension is present, indicating that cancer has spread beyond the lymph node into surrounding tissues.'}, {'state_name': 'absent', 'state_description': 'Extranodal extension is absent, indicating that cancer is contained within the lymph node and has not spread to surrounding tissues.'}]}, 'EDGE1': {'edges_ids': ['Histopathological_Examination_7', 'Extranodal_Extension_5'], 'edge': '(Histopathological_Examination_7) causes (Extranodal_Extension_5)', 'explanation': ['The edge suggests that the result of a histopathological examination causes extranodal extension.', 'Histopathological examinations are diagnostic tools used to detect the presence of disease, such as cancer, in tissue samples.', 'Extranodal extension is a condition where cancer spreads beyond the lymph node capsule into surrounding tissues.', 'The examination itself does not cause the spread of cancer; it merely detects it.', 'Therefore, the edge is not valid as the examination does not cause extranodal extension.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}, 'EDGE2': {'edges_ids': ['Extranodal_Extension_5', 'Histopathological_Examination_7'], 'edge': '(Extranodal_Extension_5) causes (Histopathological_Examination_7)', 'explanation': ['The edge `(Extranodal_Extension_5) causes (Histopathological_Examination_7)` is not valid because the histopathological examination is a diagnostic procedure that identifies the presence of extranodal extension, not the other way around.', 'Extranodal extension is a condition that is detected by the histopathological examination, which means the examination is used to observe the state of extranodal extension.', 'The causal relationship is reversed; the examination does not cause extranodal extension, but rather detects it.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'ENTITIES_MATCHING_PAGES_INFO': {'55': {'matching_entities': [{'EXTRANODAL EXTENSION': 0.97547734}, {'NEOPLASM METASTASIS': 0.95823944}, {'METASTATIC NEOPLASM': 0.9350836}, {'METASTASIS': 0.9265935}, {'SURGERY': 0.9258238}], 'count': 5}, '51': {'matching_entities': [{'EXTRANODAL EXTENSION': 0.97547734}, {'LYMPHATIC METASTASIS': 0.94701207}, {'EXTRAMURAL EXTENSION': 0.94649863}, {'SURGERY': 0.9258238}], 'count': 4}, '41': {'matching_entities': [{'LYMPHATIC METASTASIS': 0.94701207}, {'METASTASIS': 0.9265935}, {'BIOPSY': 0.92350703}], 'count': 3}, '94': {'matching_entities': [{'NEOPLASM METASTASIS': 0.95823944}, {'LYMPHATIC METASTASIS': 0.94701207}, {'LYMPH NODE METASTASIS': 0.9418514}], 'count': 3}, '102': {'matching_entities': [{'METASTASIS': 0.9265935}, {'SURGERY': 0.9258238}, {'BIOPSY': 0.92350703}], 'count': 3}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 55\\n\\nSection Name: General Information\\n====================\\nEntities:-\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""National Comprehensive Cancer Network\"", Relationship: \""produced by\""\\n\\nSection Name: Important Notes\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNeoplasms : New abnormal growth of tissue that can be benign or malignant.\\nMalignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Trials\"", Entity2: \""Cancer\"", Relationship: \""recommended for\""\\n2. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n\\nCausalities:-\\n<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nChemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n2. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n3. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n\\nCausalities:-\\n### Principles\\n\\n- **Principles of Surgery (SURG-A)**\\n- **Principles of Radiation Therapy (SUPRA-A)**\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nPerineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The invasion of cancer cells into blood vessels.\\nLymphatic Invasion : The invasion of cancer cells into lymphatic vessels.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n2. Entity1: \""Positive margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n3. Entity1: \""Close margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n4. Entity1: \""pT3 or pT4 primary\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n5. Entity1: \""pN2 or pN3 nodal disease\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n6. Entity1: \""Perineural invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n7. Entity1: \""Vascular invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n8. Entity1: \""Lymphatic invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n\\nCausalities:-\\n<C> Extranodal extension </C>\\n<C> Positive margins </C>\\n<C> Close margins </C>\\n<C> pT3 or pT4 primary </C>\\n<C> pN2 or pN3 nodal disease </C>\\n<C> Perineural invasion </C>\\n<C> Vascular invasion </C>\\n<C> Lymphatic invasion </C>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nPrimary Site : The original location where a tumor or cancer begins.\\nComplete Remission : The disappearance of all signs of cancer in response to treatment.\\nPartial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""induction chemotherapy\"", Entity2: \""Primary site\"", Relationship: \""treatment outcome\""\\n2. Entity1: \""Definitive RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n3. Entity1: \""RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n4. Entity1: \""Surgery\"", Entity2: \""unresectable nodal disease\"", Relationship: \""treatment option\""\\n\\nCausalities:-\\n<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.\\nFollow-Up (Medicine) : The process of monitoring a patient\\'s health over time after treatment or diagnosis.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : A disease that returns after a period of remission.\\nRecurrence (Medicine) : The return of a disease or condition after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n### Follow-up\\n\\n- **Follow-up** (FOLL-A, 1 of 2)\\n- **Recurrent or persistent disease** (ADV-3)\\n\\nSection Name: Risk Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""RT\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Adverse pathologic features\"", Entity2: \""Systemic therapy\"", Relationship: \""Consideration for treatment\""\\n\\nCausalities:-\\n- **No adverse pathologic features**\\n- **Other risk features**\\n- **Adverse pathologic features**:\\n  - <C> Extranodal extension and/or positive margin </C>\\n  - <A> RT or consider systemic therapy/RT </A>\\n\\nSection Name: Post-Therapy Evaluation\\n====================\\nEntities:-\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nNeck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n2. Entity1: \""RT\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n\\nCausalities:-\\n<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>\\n\\nSection Name: Flowchart Overview\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nSupraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""guides management of\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""healthcare professionals\"", Relationship: \""used by\""\\n\\nCausalities:-\\n<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.\\n\\nSection Name: Assessment and Treatment Decisions\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nComplete Response : The disappearance of all signs of cancer in response to treatment.\\nPartial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Complete Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n2. Entity1: \""Complete Response\"", Entity2: \""Surgery\"", Relationship: \""leads to\""\\n3. Entity1: \""Partial Response\"", Entity2: \""Systemic Therapy\"", Relationship: \""leads to\""\\n4. Entity1: \""Partial Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n\\nCausalities:-\\n<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.\\n\\nSection Name: Adverse Pathologic Features and Follow-up\\n====================\\nEntities:-\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nNeoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nRecurrent Neoplasm : A neoplasm that has returned after treatment.\\nMetastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.\\nMetastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""Treatment decisions\"", Relationship: \""Influence\""\\n2. Entity1: \""Adverse features\"", Entity2: \""Surgical intervention\"", Relationship: \""Recommendation\""\\n3. Entity1: \""Absence of adverse features\"", Entity2: \""Radiation therapy\"", Relationship: \""Pathway\""\\n4. Entity1: \""Follow-up process\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""Detection\""\\n5. Entity1: \""Recurrent or persistent disease\"", Entity2: \""Advanced disease management\"", Relationship: \""Necessity\""\\n\\nCausalities:-\\n<C> The presence of adverse pathologic features \u2014 such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient\\'s disease characteristics.\\n\\nFurthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.\\n--------------------------------------------------\\nPage Number: 51\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\nSupraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network (NCCN)\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""provides guidelines for\""\\n2. Entity1: \""healthcare professionals\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""manage\""\\n\\nCausalities:-\\nThe provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nTotal Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nCancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.\\nTnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging criteria\"", Entity2: \""Total laryngectomy\"", Relationship: \""determines necessity of\""\\n2. Entity1: \""T3, N0\"", Entity2: \""Clinical staging criteria\"", Relationship: \""is a categorization of\""\\n\\nCausalities:-\\nThe flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.\\n\\nSection Name: Treatment of Primary and Neck\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nLymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""combined with\""\\n2. Entity1: \""Laryngectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n3. Entity1: \""Thyroidectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n4. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n\\nCausalities:-\\n<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.\\n\\nSection Name: Surgical Options\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nLymph Node Excision : Surgical removal of one or more lymph nodes.\\nLymphadenectomy : Surgical removal of one or more groups of lymph nodes.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Laryngectomy\"", Entity2: \""Thyroidectomy\"", Relationship: \""combined with\""\\n2. Entity1: \""Lymph Node Dissection\"", Entity2: \""Surgical Intervention\"", Relationship: \""extent of\""\\n3. Entity1: \""Surgical Intervention\"", Entity2: \""Advanced Cases\"", Relationship: \""management option for\""\\n\\nCausalities:-\\n<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.\\n\\nSection Name: Induction Chemotherapy\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nTherapeutic Approach : A method or strategy used in the treatment of disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Induction Chemotherapy\"", Entity2: \""Surgical Intervention\"", Relationship: \""alternative or sequential treatment option\""\\n\\nCausalities:-\\n<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.\\n\\nSection Name: Adjuvant Treatment\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nNeoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.\\nDisease Progression : The worsening of a disease over time.\\n\\nRelationships:-\\n1. Entity1: \""Primary Treatment\"", Entity2: \""Adjuvant Treatment\"", Relationship: \""followed by\""\\n2. Entity1: \""Adjuvant Treatment\"", Entity2: \""Systemic Therapy\"", Relationship: \""includes\""\\n3. Entity1: \""Adjuvant Treatment\"", Entity2: \""Radiotherapy\"", Relationship: \""includes\""\\n4. Entity1: \""Follow-up Assessments\"", Entity2: \""Treatment Efficacy\"", Relationship: \""used to evaluate\""\\n\\nCausalities:-\\n<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient\\'s response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.\\n\\nSection Name: Risk Features and Response Assessment\\n====================\\nEntities:-\\nNeoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.\\nSurgical Margins : The edge or border of the tissue removed in cancer surgery.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nExtramural Extension : Extension of a tumor beyond the wall of an organ.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nCancer Management : The process of planning and coordinating the treatment of cancer.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Extramural extension\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n2. Entity1: \""Positive surgical margin\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n3. Entity1: \""Ongoing assessment\"", Entity2: \""Response evaluation\"", Relationship: \""leads to\""\\n4. Entity1: \""Response evaluation\"", Entity2: \""Adjustments to treatment\"", Relationship: \""leads to\""\\n5. Entity1: \""Management of cancer\"", Entity2: \""Treatment decisions\"", Relationship: \""involves\""\\n6. Entity1: \""Management of cancer\"", Entity2: \""Ongoing assessment\"", Relationship: \""involves\""\\n7. Entity1: \""Management of cancer\"", Entity2: \""Adjustments to treatment\"", Relationship: \""involves\""\\n\\nCausalities:-\\nThe chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nMalignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""NCCN Guidelines\"", Relationship: \""provides\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""Clinical Trials\"", Relationship: \""recommend\""\\n3. Entity1: \""NCCN Guidelines\"", Entity2: \""Cancer\"", Relationship: \""related to management of\""\\n\\nCausalities:-\\n<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: SUPRA-3\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nClinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""Total laryngectomy\"", Entity2: \""Laryngectomy\"", Relationship: \""is a type of\""\\n2. Entity1: \""Systemic therapy\"", Entity2: \""RT\"", Relationship: \""concurrent treatment option\""\\n3. Entity1: \""Induction chemotherapy\"", Entity2: \""Other treatments\"", Relationship: \""initial treatment option before\""\\n\\nCausalities:-\\n<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>\\n  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>\\n  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>\\n  - or\\n  - <A> Induction chemotherapy </A>\\n  - or\\n  - <A> Clinical trials </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient\\'s condition after initial treatment.\\nFollow-Up : Medical care given to a patient over time after initial treatment.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : The reappearance of a disease after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n- **Follow-up (FOLL-A, 1 of 2)**\\n  - <CO> Recurrent or persistent disease </CO> (ADV-3)\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""pN1\"", Entity2: \""Radiotherapy\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Extranodal extension\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n3. Entity1: \""Extranodal extension\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n4. Entity1: \""Positive surgical margin\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n5. Entity1: \""Positive surgical margin\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n\\nCausalities:-\\n- <CO>pN1 without other risk features</CO>\\n  - <C>Adverse pathologic features</C>\\n  - <A>Consider RT</A>\\n  - <CO>Extranodal extension and/or positive margin</CO>\\n  - <CO>Other risk features</CO>\\n  - <A>Systemic therapy/RT (category 1)</A>\\n  - <A>RT or Consider systemic therapy/RT</A>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nResponse Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.\\nResponse To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.\\n\\nRelationships:-\\n\\nSection Name: Principles of Surgery and Radiation Therapy\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""complementary treatments\""\\n\\nCausalities:-\\n**Principles of Surgery (SURG-A).**\\n\\n**Principles of Radiation Therapy (SUPRA-A).**\\n\\nSection Name: Principles of Systemic Therapy\\n====================\\nEntities:-\\nCisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Cisplatin\"", Entity2: \""Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""preferred agent\""\\n2. Entity1: \""Cisplatin\"", Entity2: \""Concurrent Systemic Therapy/RT\"", Relationship: \""used in\""\\n\\nCausalities:-\\n<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.\\n--------------------------------------------------\\nPage Number: 41\\n\\nSection Name: Workup\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nHistory And Physical Examination : A comprehensive assessment of a patient\\'s medical history and physical condition.\\nTobacco Smoking : The act of smoking tobacco products, which is a risk factor for many diseases.\\nAlcohol Drinking : The consumption of beverages containing ethyl alcohol.\\nSmoking Cessation : The process of discontinuing tobacco smoking.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nLaryngoscopy : A procedure to examine the larynx, often using a scope.\\nComputed Tomography (Ct) : A diagnostic imaging procedure that uses computer-processed combinations of many X-ray measurements taken from different angles to produce cross-sectional images of specific areas of a scanned object.\\nMagnetic Resonance Imaging (Mri) : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nPositron-Emission Tomography : A type of nuclear medicine imaging that measures metabolic activity of the cells of body tissues.\\nPulmonary Function Test : Tests that measure how well the lungs are working.\\nDental Examination : An evaluation of the teeth and gums to assess oral health.\\nNutritional Support : Therapies to provide nutrition to patients who cannot obtain nutrition by mouth.\\nSpeech Therapy : Therapy to improve speech and communication skills.\\nSwallowing Therapy : Therapy to help individuals with swallowing difficulties.\\nMultidisciplinary Care Team : A group of healthcare professionals from different specialties working together to manage patient care.\\n\\nRelationships:-\\n1. Entity1: \""glottic larynx cancer\"", Entity2: \""history and physical examination\"", Relationship: \""initial diagnostic step\""\\n2. Entity1: \""glottic larynx cancer\"", Entity2: \""biopsy\"", Relationship: \""required diagnostic procedure\""\\n3. Entity1: \""glottic larynx cancer\"", Entity2: \""direct laryngoscopy\"", Relationship: \""recommended procedure\""\\n4. Entity1: \""glottic larynx cancer\"", Entity2: \""CT scans\"", Relationship: \""imaging study\""\\n5. Entity1: \""glottic larynx cancer\"", Entity2: \""MRI\"", Relationship: \""imaging study\""\\n6. Entity1: \""glottic larynx cancer\"", Entity2: \""multidisciplinary consultation\"", Relationship: \""advised as clinically indicated\""\\n\\nCausalities:-\\nThe workup section outlines the initial steps for diagnosing <C>glottic larynx cancer</C>. It includes <A>a comprehensive history and physical examination (H&P)</A>, which should document tobacco and alcohol use, and provide counseling for smoking cessation. <A>A biopsy of the primary site is required</A>, and <A>direct laryngoscopy under anesthesia is generally recommended</A>. <A>Imaging studies such as CT scans with contrast and possibly MRI are used to evaluate the larynx and neck</A>. Additional evaluations may include <A>chest CT, FDG-PET/CT, pulmonary function tests, dental evaluation, and nutrition, speech, and swallowing therapy</A>. <A>Multidisciplinary consultation is advised</A> <CO>as clinically indicated</CO>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nCarcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nLaryngectomy : A surgical procedure to remove the larynx.\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging\"", Entity2: \""Cancer\"", Relationship: \""involves\""\\n2. Entity1: \""Carcinoma in situ\"", Entity2: \""Stages T1-T4\"", Relationship: \""is a stage of\""\\n3. Entity1: \""Biopsy\"", Entity2: \""Cancer\"", Relationship: \""used in staging\""\\n4. Entity1: \""Larynx-preserving surgeries\"", Entity2: \""Stages T1-T2\"", Relationship: \""considered for\""\\n5. Entity1: \""Total laryngectomy\"", Entity2: \""Stages T3-T4\"", Relationship: \""required for\""\\n\\nCausalities:-\\n<C> Clinical staging involves categorizing the cancer based on its aggressiveness </C>. It starts with carcinoma in situ, which is non-invasive, and progresses through stages T1-T4. <CO> Staging is based on H&P, biopsy, and imaging studies </CO>. <CO> For T1-T2 </CO>, <A> larynx-preserving surgeries are considered </A>, while <CO> more advanced stages like T3 or T4 </CO> <A> may require total laryngectomy </A>. <A> Additional evaluations such as videostrobe, audiogram, and fertility counseling may be considered </A>.\\n\\nSection Name: Treatment\\n====================\\nEntities:-\\nCarcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.\\nLaryngectomy : A surgical procedure to remove the larynx.\\nMetastasis : The transfer of a disease from one organ or part to another not directly connected with it.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\n\\nRelationships:-\\n1. Entity1: \""Carcinoma in situ\"", Entity2: \""Larynx-preserving surgery\"", Relationship: \""treated with\""\\n2. Entity1: \""T1-T2 stages\"", Entity2: \""Conservation surgery\"", Relationship: \""treated with\""\\n3. Entity1: \""T3 stages\"", Entity2: \""Total laryngectomy\"", Relationship: \""may require\""\\n4. Entity1: \""T4a disease\"", Entity2: \""Complex interventions\"", Relationship: \""require\""\\n5. Entity1: \""Guidelines\"", Entity2: \""Multidisciplinary consultations\"", Relationship: \""emphasize importance of\""\\n6. Entity1: \""Guidelines\"", Entity2: \""Clinical trials\"", Relationship: \""consider as best option\""\\n\\nCausalities:-\\n<CO>Treatment recommendations vary by stage</CO>. <CO>Carcinoma in situ</CO> <A>may be treated with larynx-preserving surgery</A>. <CO>T1-T2 stages</CO> <A>may also be amenable to conservation surgery</A>. <CO>T3 stages</CO> <A>may require total laryngectomy</A>, <CO>especially if nodal involvement is present</CO>. <CO>T4a disease and unresectable or metastatic cases</CO> <A>require more complex interventions</A>. <A>The guidelines emphasize the importance of multidisciplinary consultations</A> and <A>consider clinical trials as the best management option</A>.\\n\\nSection Name: Additional Notes\\n====================\\nEntities:-\\nBiopsy, Needle : A procedure to remove a small sample of tissue for examination under a microscope.\\nImage-Guided Biopsy : A biopsy procedure that uses imaging techniques to guide the needle to the precise location of the tissue to be sampled.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nDiagnostic Techniques And Procedures : Methods and procedures for the diagnosis of disease or dysfunction.\\nImaging : The process of producing images of the body for clinical purposes.\\nDental Care : The total of dental diagnostic, preventive, and corrective procedures.\\nNutritional Physiological Phenomena : The functions and properties of nutrients in living organisms.\\nFertility : The capacity to conceive or induce conception.\\nReproductive Health : A state of physical, mental, and social well-being in all matters relating to the reproductive system.\\nLymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nGlottis : The part of the larynx consisting of the vocal cords and the opening between them.\\n\\nRelationships:-\\n1. Entity1: \""image-guided needle biopsy\"", Entity2: \""diagnostic yield\"", Relationship: \""used for\""\\n2. Entity1: \""nodal disease\"", Entity2: \""glottic tumors\"", Relationship: \""is rare in\""\\n\\nCausalities:-\\n<A> use of image-guided needle biopsy </A> for <E> better diagnostic yield </E>, principles of imaging, dental evaluation, and nutrition management. The guidelines also address fertility and reproductive considerations, and note that <CO> nodal disease in glottic tumors is rare </CO>.\\n--------------------------------------------------\\nPage Number: 94\\n\\nSection Name: Head and Neck Cancers - Principles of Imaging\\n====================\\nEntities:-\\nPositron Emission Tomography Computed Tomography : A medical imaging technique combining PET and CT capabilities to provide detailed information about the body\\'s function and structure.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\nHead And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.\\n\\nRelationships:-\\n1. Entity1: \""PET/CT\"", Entity2: \""PET scan\"", Relationship: \""preferred over\""\\n2. Entity1: \""PET-CT\"", Entity2: \""head neck cancers\"", Relationship: \""used in study of\""\\n\\nCausalities:-\\n<A> PET/CT is preferred over PET scan alone (i.e., without superimposed CT scan) </A>. <C> PET/CT provides more accurate anatomical localization of abnormalities </C> <E> more accurate anatomical localization of abnormalities </E>.\\n\\nSection Name: Initial Workup - Nodal Metastases\\n====================\\nEntities:-\\nLymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site via the lymphatic system.\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine\\'s computer to generate cross-sectional images.\\nMagnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.\\nLymph Node Metastasis : The spread of cancer cells to lymph nodes, which are part of the lymphatic system.\\nCt Of Neck : A computed tomography scan of the neck region.\\nMri Of Neck : A magnetic resonance imaging scan of the neck region.\\nFdg-Pet Scan : A type of positron emission tomography using fluorodeoxyglucose to assess metabolic activity.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\nPositron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""lymph node metastases\"", Relationship: \""used to evaluate\""\\n2. Entity1: \""MRI\"", Entity2: \""lymph node metastases\"", Relationship: \""used to evaluate\""\\n3. Entity1: \""FDG-PET/CT\"", Entity2: \""lymph node metastases\"", Relationship: \""used for detection\""\\n4. Entity1: \""FDG-PET/CT\"", Entity2: \""surgical primary approach\"", Relationship: \""used to determine\""\\n5. Entity1: \""FDG-PET/CT\"", Entity2: \""definitive RT approach\"", Relationship: \""used to identify\""\\n\\nCausalities:-\\n<A> Evaluation of lymph node metastases should be conducted with CT or MRI of the neck </A>, using whichever imaging study is suitable for primary site evaluation (IMG-A, 1 of 4).\\n<CO> For patients with multistation or lower neck nodal involvement or high-grade tumor histology </CO>, <A> consider CT of the chest to assess for mediastinal lymph node metastases or FDG-PET/CT </A>, <C> which is associated with higher sensitivity for both nodal and distant metastases </C>.\\n<CO> For patients who are under consideration for a surgical primary approach </CO>, <A> the higher sensitivity of FDG-PET/CT is warranted for tumors approaching the midline, to determine the surgical approach to the contralateral neck </A>. <CO> Similarly, patients who are scheduled for a definitive RT approach </CO> <A> may benefit from the higher sensitivity of FDG-PET/CT for identifying involved lymph nodes </A>.\\n\\nSection Name: Initial Workup - Distant Metastases\\n====================\\nEntities:-\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.\\nMagnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine\\'s computer to generate cross-sectional images.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nLung Neoplasms : Tumors or cancer of the lung.\\nSmoking : The inhalation of the smoke of burning tobacco encased in cigarettes, pipes, and cigars.\\n\\nRelationships:-\\n1. Entity1: \""FDG-PET/CT\"", Entity2: \""Distant Metastases\"", Relationship: \""used to evaluate\""\\n2. Entity1: \""Contrast-enhanced brain MRI\"", Entity2: \""Brain Metastasis\"", Relationship: \""recommended for evaluation\""\\n3. Entity1: \""CT of the chest\"", Entity2: \""Pulmonary Metastases\"", Relationship: \""performed to assess\""\\n4. Entity1: \""Non-contrast CT of the chest\"", Entity2: \""Lung Parenchymal Metastases\"", Relationship: \""used to screen\""\\n5. Entity1: \""Annual CT screening\"", Entity2: \""Lung Metastasis\"", Relationship: \""considered for high risk\""\\n6. Entity1: \""Directed CT or MRI\"", Entity2: \""Distant Disease\"", Relationship: \""used for assessment\""\\n7. Entity1: \""FDG-PET/CT\"", Entity2: \""Recurrent Disease\"", Relationship: \""used for staging\""\\n\\nCausalities:-\\n<C> Patients with locoregionally advanced cancer (e.g., T3\u2013T4 primary or \u2265N1 nodal staging) </C>, <A> FDG-PET/CT is preferred to evaluate for distant disease and thoracic metastases </A>. <CO> For cancers where brain metastasis is a concern, such as mucosal melanoma or high-grade neuroendocrine carcinomas or adenocarcinomas </CO>, <A> contrast-enhanced brain MRI should be additionally obtained </A>.\\n<CO> If FDG-PET/CT is not performed </CO>, <A> CT of the chest should be performed to assess for presence of pulmonary metastases as well as mediastinal lymph node involvement </A>.\\n<CO> Non-contrast CT of the chest can be sufficient to screen for lung parenchymal metastases </CO> but <CO> is not adequate for assessment of mediastinal adenopathy </CO>. <CO> This is an appropriate lung cancer screening intervention for patients with a history of smoking </CO>.\\n<CO> Following primary definitive treatment (surgery, RT, or systemic therapy/RT) </CO> the role of annual CT screening for lung metastasis is controversial. <E> While this approach does detect early metastasis </E>, <CO> further study is needed to determine the extent of the positive effect and/or cost-effectiveness of this approach in specific subpopulations and timepoints post-treatment </CO>. <CO> For patients with a substantial smoking history or who are at high risk for lung metastases </CO>, <A> annual chest CT can be considered </A>.\\n<CO> If clinical concern for metastatic disease is confined to a specific anatomical area </CO>, <A> the assessment of distant disease can be performed with directed CT or MRI examination </A>.\\n<CO> FDG-PET/CT may complement or replace other imaging modalities when staging recurrent disease before any therapy for relapsed/refractory disease </CO> <A> in order to explore distant disease or second primaries that may significantly impact choice of therapy </A>.\\n--------------------------------------------------\\nPage Number: 102\\n\\nSection Name: Head and Neck Cancers - Principles of Surgery\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.\\nLymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.\\nNeoplasms : New abnormal growth of tissue in animals or plants; a tumor.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nNeoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSurgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nLymphatic Structure : Anatomical structure that is part of the lymphatic system.\\nTumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.\\nStaging : The process of determining the size and spread of cancer within the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.\\n\\nRelationships:-\\n1. Entity1: \""surgical management\"", Entity2: \""regional lymphatics\"", Relationship: \""dictated by tumor staging\""\\n2. Entity1: \""neck dissections\"", Entity2: \""primary tumor\"", Relationship: \""part of treatment\""\\n3. Entity1: \""surgery\"", Entity2: \""ipsilateral side of the neck\"", Relationship: \""risk for metastases\""\\n\\nCausalities:-\\n<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.\\n\\nSection Name: Neck Management\\n====================\\nEntities:-\\nTongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.\\nPalate : The roof of the mouth, separating the oral and nasal cavities.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\nHypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.\\nNasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSquamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.\\nBiopsy : The removal of cells or tissues for examination under a microscope.\\n\\nRelationships:-\\n1. Entity1: \""Tumor sites\"", Entity2: \""Bilateral lymphatic drainage\"", Relationship: \""associated with\""\\n2. Entity1: \""Elective neck dissection\"", Entity2: \""Risk of occult metastasis\"", Relationship: \""based on\""\\n3. Entity1: \""SLN biopsy\"", Entity2: \""Elective neck dissection\"", Relationship: \""guides decision-making for\""\\n\\nCausalities:-\\n- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.\\n\\n- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.\\n\\n- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.\\n\\n  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2\u20134 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.\\n\\nSection Name: Types of Neck Dissection\\n====================\\nEntities:-\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\n\\nRelationships:-\\n1. Entity1: \""N0\"", Entity2: \""Selective neck dissection\"", Relationship: \""associated with\""\\n2. Entity1: \""N3\"", Entity2: \""Comprehensive neck dissection\"", Relationship: \""associated with\""\\n3. Entity1: \""Level VI neck dissection\"", Entity2: \""Larynx\"", Relationship: \""performed for\""\\n4. Entity1: \""Level VI neck dissection\"", Entity2: \""Hypopharynx\"", Relationship: \""performed for\""\\n\\nCausalities:-\\n- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:\\n  - **N0:** <A> Selective neck dissection </A>\\n    - Oral cavity at least levels I\u2013III\\n    - Oropharynx at least levels II\u2013IV\\n    - Hypopharynx at least levels II\u2013IV and level VI when appropriate\\n    - Larynx at least levels II\u2013IV and level VI when appropriate\\n  - **N1\u2013N2a\u2013c:** <A> Selective or comprehensive neck dissection </A> (Discussion)\\n  - **N3:** <A> Comprehensive neck dissection </A>\\n\\n- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.\\n\\n- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.\\n'}""",invalid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: Histopathological_Examination_7
label: Histology Pathology Examination
description: This node represents the result of a histopathological examination, which is a diagnostic procedure where tissue samples are examined under a microscope to look for disease, such as cancer. It is crucial for diagnosing and understanding the nature of various diseases, particularly cancers.
type: Examination Result
observability: Observed
states: [{'state_name': 'present', 'state_description': ""The 'present' state indicates that the histopathological examination has found evidence of disease or abnormality in the tissue sample.""}, {'state_name': 'absent', 'state_description': ""The 'absent' state indicates that the histopathological examination has not found any evidence of disease or abnormality in the tissue sample.""}]

`NODE2`:
id: Extranodal_Extension_5
label: Extranodal Extension
description: Extranodal extension refers to the spread of cancer beyond the lymph node capsule into surrounding tissues. It is a significant factor in cancer staging and prognosis, as it indicates a more advanced disease and may influence treatment decisions.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'present', 'state_description': 'Extranodal extension is present, indicating that cancer has spread beyond the lymph node into surrounding tissues.'}, {'state_name': 'absent', 'state_description': 'Extranodal extension is absent, indicating that cancer is contained within the lymph node and has not spread to surrounding tissues.'}]

`EDGE1`:
{'edges_ids': ['Histopathological_Examination_7', 'Extranodal_Extension_5'], 'edge': '(Histopathological_Examination_7) causes (Extranodal_Extension_5)', 'explanation': ['The edge suggests that the result of a histopathological examination causes extranodal extension.', 'Histopathological examinations are diagnostic tools used to detect the presence of disease, such as cancer, in tissue samples.', 'Extranodal extension is a condition where cancer spreads beyond the lymph node capsule into surrounding tissues.', 'The examination itself does not cause the spread of cancer; it merely detects it.', 'Therefore, the edge is not valid as the examination does not cause extranodal extension.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}

`EDGE2`:
{'edges_ids': ['Extranodal_Extension_5', 'Histopathological_Examination_7'], 'edge': '(Extranodal_Extension_5) causes (Histopathological_Examination_7)', 'explanation': ['The edge `(Extranodal_Extension_5) causes (Histopathological_Examination_7)` is not valid because the histopathological examination is a diagnostic procedure that identifies the presence of extranodal extension, not the other way around.', 'Extranodal extension is a condition that is detected by the histopathological examination, which means the examination is used to observe the state of extranodal extension.', 'The causal relationship is reversed; the examination does not cause extranodal extension, but rather detects it.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 55

Section Name: General Information
====================
Entities:-
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Nccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""National Comprehensive Cancer Network"", Relationship: ""produced by""

Section Name: Important Notes
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Neoplasms : New abnormal growth of tissue that can be benign or malignant.
Malignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Clinical Trials"", Entity2: ""Cancer"", Relationship: ""recommended for""
2. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""

Causalities:-
<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles
====================
Entities:-
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Chemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""Both are principles of cancer treatment methods.""
2. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""
3. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""

Causalities:-
### Principles

- **Principles of Surgery (SURG-A)**
- **Principles of Radiation Therapy (SUPRA-A)**
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**

Section Name: Adverse Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Perineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The invasion of cancer cells into blood vessels.
Lymphatic Invasion : The invasion of cancer cells into lymphatic vessels.

Relationships:-
1. Entity1: ""Extranodal extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
2. Entity1: ""Positive margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
3. Entity1: ""Close margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
4. Entity1: ""pT3 or pT4 primary"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
5. Entity1: ""pN2 or pN3 nodal disease"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
6. Entity1: ""Perineural invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
7. Entity1: ""Vascular invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
8. Entity1: ""Lymphatic invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""

Causalities:-
<C> Extranodal extension </C>
<C> Positive margins </C>
<C> Close margins </C>
<C> pT3 or pT4 primary </C>
<C> pN2 or pN3 nodal disease </C>
<C> Perineural invasion </C>
<C> Vascular invasion </C>
<C> Lymphatic invasion </C>

Section Name: Response Assessment
====================
Entities:-
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Primary Site : The original location where a tumor or cancer begins.
Complete Remission : The disappearance of all signs of cancer in response to treatment.
Partial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.

Relationships:-
1. Entity1: ""induction chemotherapy"", Entity2: ""Primary site"", Relationship: ""treatment outcome""
2. Entity1: ""Definitive RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
3. Entity1: ""RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
4. Entity1: ""Surgery"", Entity2: ""unresectable nodal disease"", Relationship: ""treatment option""

Causalities:-
<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.
Follow-Up (Medicine) : The process of monitoring a patient's health over time after treatment or diagnosis.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : A disease that returns after a period of remission.
Recurrence (Medicine) : The return of a disease or condition after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
### Follow-up

- **Follow-up** (FOLL-A, 1 of 2)
- **Recurrent or persistent disease** (ADV-3)

Section Name: Risk Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""RT"", Relationship: ""Consideration for treatment""
2. Entity1: ""Adverse pathologic features"", Entity2: ""Systemic therapy"", Relationship: ""Consideration for treatment""

Causalities:-
- **No adverse pathologic features**
- **Other risk features**
- **Adverse pathologic features**:
  - <C> Extranodal extension and/or positive margin </C>
  - <A> RT or consider systemic therapy/RT </A>

Section Name: Post-Therapy Evaluation
====================
Entities:-
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Neck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""
2. Entity1: ""RT"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""

Causalities:-
<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>

Section Name: Flowchart Overview
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Supraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""guides management of""
2. Entity1: ""NCCN Guidelines"", Entity2: ""healthcare professionals"", Relationship: ""used by""

Causalities:-
<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.

Section Name: Assessment and Treatment Decisions
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Complete Response : The disappearance of all signs of cancer in response to treatment.
Partial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Complete Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""
2. Entity1: ""Complete Response"", Entity2: ""Surgery"", Relationship: ""leads to""
3. Entity1: ""Partial Response"", Entity2: ""Systemic Therapy"", Relationship: ""leads to""
4. Entity1: ""Partial Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""

Causalities:-
<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.

Section Name: Adverse Pathologic Features and Follow-up
====================
Entities:-
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Neoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Recurrent Neoplasm : A neoplasm that has returned after treatment.
Metastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.
Metastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""Treatment decisions"", Relationship: ""Influence""
2. Entity1: ""Adverse features"", Entity2: ""Surgical intervention"", Relationship: ""Recommendation""
3. Entity1: ""Absence of adverse features"", Entity2: ""Radiation therapy"", Relationship: ""Pathway""
4. Entity1: ""Follow-up process"", Entity2: ""Recurrent or persistent disease"", Relationship: ""Detection""
5. Entity1: ""Recurrent or persistent disease"", Entity2: ""Advanced disease management"", Relationship: ""Necessity""

Causalities:-
<C> The presence of adverse pathologic features — such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient's disease characteristics.

Furthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.
--------------------------------------------------
Page Number: 51

Section Name: Introduction
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.
Supraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network (NCCN)"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""provides guidelines for""
2. Entity1: ""healthcare professionals"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""manage""

Causalities:-
The provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.

Section Name: Clinical Staging
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Total Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Cancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.
Tnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).

Relationships:-
1. Entity1: ""Clinical staging criteria"", Entity2: ""Total laryngectomy"", Relationship: ""determines necessity of""
2. Entity1: ""T3, N0"", Entity2: ""Clinical staging criteria"", Relationship: ""is a categorization of""

Causalities:-
The flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.

Section Name: Treatment of Primary and Neck
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Lymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Radiation Therapy"", Relationship: ""combined with""
2. Entity1: ""Laryngectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
3. Entity1: ""Thyroidectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
4. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""

Causalities:-
<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.

Section Name: Surgical Options
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Lymph Node Excision : Surgical removal of one or more lymph nodes.
Lymphadenectomy : Surgical removal of one or more groups of lymph nodes.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.

Relationships:-
1. Entity1: ""Laryngectomy"", Entity2: ""Thyroidectomy"", Relationship: ""combined with""
2. Entity1: ""Lymph Node Dissection"", Entity2: ""Surgical Intervention"", Relationship: ""extent of""
3. Entity1: ""Surgical Intervention"", Entity2: ""Advanced Cases"", Relationship: ""management option for""

Causalities:-
<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.

Section Name: Induction Chemotherapy
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Therapeutic Approach : A method or strategy used in the treatment of disease or injury.

Relationships:-
1. Entity1: ""Induction Chemotherapy"", Entity2: ""Surgical Intervention"", Relationship: ""alternative or sequential treatment option""

Causalities:-
<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.

Section Name: Adjuvant Treatment
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Neoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.
Disease Progression : The worsening of a disease over time.

Relationships:-
1. Entity1: ""Primary Treatment"", Entity2: ""Adjuvant Treatment"", Relationship: ""followed by""
2. Entity1: ""Adjuvant Treatment"", Entity2: ""Systemic Therapy"", Relationship: ""includes""
3. Entity1: ""Adjuvant Treatment"", Entity2: ""Radiotherapy"", Relationship: ""includes""
4. Entity1: ""Follow-up Assessments"", Entity2: ""Treatment Efficacy"", Relationship: ""used to evaluate""

Causalities:-
<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient's response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.

Section Name: Risk Features and Response Assessment
====================
Entities:-
Neoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.
Surgical Margins : The edge or border of the tissue removed in cancer surgery.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Extramural Extension : Extension of a tumor beyond the wall of an organ.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Cancer Management : The process of planning and coordinating the treatment of cancer.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Extramural extension"", Entity2: ""Treatment decisions"", Relationship: ""influences""
2. Entity1: ""Positive surgical margin"", Entity2: ""Treatment decisions"", Relationship: ""influences""
3. Entity1: ""Ongoing assessment"", Entity2: ""Response evaluation"", Relationship: ""leads to""
4. Entity1: ""Response evaluation"", Entity2: ""Adjustments to treatment"", Relationship: ""leads to""
5. Entity1: ""Management of cancer"", Entity2: ""Treatment decisions"", Relationship: ""involves""
6. Entity1: ""Management of cancer"", Entity2: ""Ongoing assessment"", Relationship: ""involves""
7. Entity1: ""Management of cancer"", Entity2: ""Adjustments to treatment"", Relationship: ""involves""

Causalities:-
The chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Malignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""NCCN Guidelines"", Relationship: ""provides""
2. Entity1: ""NCCN Guidelines"", Entity2: ""Clinical Trials"", Relationship: ""recommend""
3. Entity1: ""NCCN Guidelines"", Entity2: ""Cancer"", Relationship: ""related to management of""

Causalities:-
<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: SUPRA-3
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Clinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""Total laryngectomy"", Entity2: ""Laryngectomy"", Relationship: ""is a type of""
2. Entity1: ""Systemic therapy"", Entity2: ""RT"", Relationship: ""concurrent treatment option""
3. Entity1: ""Induction chemotherapy"", Entity2: ""Other treatments"", Relationship: ""initial treatment option before""

Causalities:-
<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>
  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>
  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>
  - or
  - <A> Induction chemotherapy </A>
  - or
  - <A> Clinical trials </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient's condition after initial treatment.
Follow-Up : Medical care given to a patient over time after initial treatment.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : The reappearance of a disease after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
- **Follow-up (FOLL-A, 1 of 2)**
  - <CO> Recurrent or persistent disease </CO> (ADV-3)

Section Name: Adverse Pathologic Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer beyond the lymph node capsule.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""pN1"", Entity2: ""Radiotherapy"", Relationship: ""Consideration for treatment""
2. Entity1: ""Extranodal extension"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
3. Entity1: ""Extranodal extension"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""
4. Entity1: ""Positive surgical margin"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
5. Entity1: ""Positive surgical margin"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""

Causalities:-
- <CO>pN1 without other risk features</CO>
  - <C>Adverse pathologic features</C>
  - <A>Consider RT</A>
  - <CO>Extranodal extension and/or positive margin</CO>
  - <CO>Other risk features</CO>
  - <A>Systemic therapy/RT (category 1)</A>
  - <A>RT or Consider systemic therapy/RT</A>

Section Name: Response Assessment
====================
Entities:-
Response Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.
Response To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.

Relationships:-

Section Name: Principles of Surgery and Radiation Therapy
====================
Entities:-
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""complementary treatments""

Causalities:-
**Principles of Surgery (SURG-A).**

**Principles of Radiation Therapy (SUPRA-A).**

Section Name: Principles of Systemic Therapy
====================
Entities:-
Cisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Cisplatin"", Entity2: ""Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""preferred agent""
2. Entity1: ""Cisplatin"", Entity2: ""Concurrent Systemic Therapy/RT"", Relationship: ""used in""

Causalities:-
<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.
--------------------------------------------------
Page Number: 41

Section Name: Workup
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
History And Physical Examination : A comprehensive assessment of a patient's medical history and physical condition.
Tobacco Smoking : The act of smoking tobacco products, which is a risk factor for many diseases.
Alcohol Drinking : The consumption of beverages containing ethyl alcohol.
Smoking Cessation : The process of discontinuing tobacco smoking.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Laryngoscopy : A procedure to examine the larynx, often using a scope.
Computed Tomography (Ct) : A diagnostic imaging procedure that uses computer-processed combinations of many X-ray measurements taken from different angles to produce cross-sectional images of specific areas of a scanned object.
Magnetic Resonance Imaging (Mri) : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Positron-Emission Tomography : A type of nuclear medicine imaging that measures metabolic activity of the cells of body tissues.
Pulmonary Function Test : Tests that measure how well the lungs are working.
Dental Examination : An evaluation of the teeth and gums to assess oral health.
Nutritional Support : Therapies to provide nutrition to patients who cannot obtain nutrition by mouth.
Speech Therapy : Therapy to improve speech and communication skills.
Swallowing Therapy : Therapy to help individuals with swallowing difficulties.
Multidisciplinary Care Team : A group of healthcare professionals from different specialties working together to manage patient care.

Relationships:-
1. Entity1: ""glottic larynx cancer"", Entity2: ""history and physical examination"", Relationship: ""initial diagnostic step""
2. Entity1: ""glottic larynx cancer"", Entity2: ""biopsy"", Relationship: ""required diagnostic procedure""
3. Entity1: ""glottic larynx cancer"", Entity2: ""direct laryngoscopy"", Relationship: ""recommended procedure""
4. Entity1: ""glottic larynx cancer"", Entity2: ""CT scans"", Relationship: ""imaging study""
5. Entity1: ""glottic larynx cancer"", Entity2: ""MRI"", Relationship: ""imaging study""
6. Entity1: ""glottic larynx cancer"", Entity2: ""multidisciplinary consultation"", Relationship: ""advised as clinically indicated""

Causalities:-
The workup section outlines the initial steps for diagnosing <C>glottic larynx cancer</C>. It includes <A>a comprehensive history and physical examination (H&P)</A>, which should document tobacco and alcohol use, and provide counseling for smoking cessation. <A>A biopsy of the primary site is required</A>, and <A>direct laryngoscopy under anesthesia is generally recommended</A>. <A>Imaging studies such as CT scans with contrast and possibly MRI are used to evaluate the larynx and neck</A>. Additional evaluations may include <A>chest CT, FDG-PET/CT, pulmonary function tests, dental evaluation, and nutrition, speech, and swallowing therapy</A>. <A>Multidisciplinary consultation is advised</A> <CO>as clinically indicated</CO>.

Section Name: Clinical Staging
====================
Entities:-
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Carcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Laryngectomy : A surgical procedure to remove the larynx.

Relationships:-
1. Entity1: ""Clinical staging"", Entity2: ""Cancer"", Relationship: ""involves""
2. Entity1: ""Carcinoma in situ"", Entity2: ""Stages T1-T4"", Relationship: ""is a stage of""
3. Entity1: ""Biopsy"", Entity2: ""Cancer"", Relationship: ""used in staging""
4. Entity1: ""Larynx-preserving surgeries"", Entity2: ""Stages T1-T2"", Relationship: ""considered for""
5. Entity1: ""Total laryngectomy"", Entity2: ""Stages T3-T4"", Relationship: ""required for""

Causalities:-
<C> Clinical staging involves categorizing the cancer based on its aggressiveness </C>. It starts with carcinoma in situ, which is non-invasive, and progresses through stages T1-T4. <CO> Staging is based on H&P, biopsy, and imaging studies </CO>. <CO> For T1-T2 </CO>, <A> larynx-preserving surgeries are considered </A>, while <CO> more advanced stages like T3 or T4 </CO> <A> may require total laryngectomy </A>. <A> Additional evaluations such as videostrobe, audiogram, and fertility counseling may be considered </A>.

Section Name: Treatment
====================
Entities:-
Carcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.
Laryngectomy : A surgical procedure to remove the larynx.
Metastasis : The transfer of a disease from one organ or part to another not directly connected with it.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.

Relationships:-
1. Entity1: ""Carcinoma in situ"", Entity2: ""Larynx-preserving surgery"", Relationship: ""treated with""
2. Entity1: ""T1-T2 stages"", Entity2: ""Conservation surgery"", Relationship: ""treated with""
3. Entity1: ""T3 stages"", Entity2: ""Total laryngectomy"", Relationship: ""may require""
4. Entity1: ""T4a disease"", Entity2: ""Complex interventions"", Relationship: ""require""
5. Entity1: ""Guidelines"", Entity2: ""Multidisciplinary consultations"", Relationship: ""emphasize importance of""
6. Entity1: ""Guidelines"", Entity2: ""Clinical trials"", Relationship: ""consider as best option""

Causalities:-
<CO>Treatment recommendations vary by stage</CO>. <CO>Carcinoma in situ</CO> <A>may be treated with larynx-preserving surgery</A>. <CO>T1-T2 stages</CO> <A>may also be amenable to conservation surgery</A>. <CO>T3 stages</CO> <A>may require total laryngectomy</A>, <CO>especially if nodal involvement is present</CO>. <CO>T4a disease and unresectable or metastatic cases</CO> <A>require more complex interventions</A>. <A>The guidelines emphasize the importance of multidisciplinary consultations</A> and <A>consider clinical trials as the best management option</A>.

Section Name: Additional Notes
====================
Entities:-
Biopsy, Needle : A procedure to remove a small sample of tissue for examination under a microscope.
Image-Guided Biopsy : A biopsy procedure that uses imaging techniques to guide the needle to the precise location of the tissue to be sampled.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Diagnostic Techniques And Procedures : Methods and procedures for the diagnosis of disease or dysfunction.
Imaging : The process of producing images of the body for clinical purposes.
Dental Care : The total of dental diagnostic, preventive, and corrective procedures.
Nutritional Physiological Phenomena : The functions and properties of nutrients in living organisms.
Fertility : The capacity to conceive or induce conception.
Reproductive Health : A state of physical, mental, and social well-being in all matters relating to the reproductive system.
Lymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Glottis : The part of the larynx consisting of the vocal cords and the opening between them.

Relationships:-
1. Entity1: ""image-guided needle biopsy"", Entity2: ""diagnostic yield"", Relationship: ""used for""
2. Entity1: ""nodal disease"", Entity2: ""glottic tumors"", Relationship: ""is rare in""

Causalities:-
<A> use of image-guided needle biopsy </A> for <E> better diagnostic yield </E>, principles of imaging, dental evaluation, and nutrition management. The guidelines also address fertility and reproductive considerations, and note that <CO> nodal disease in glottic tumors is rare </CO>.
--------------------------------------------------
Page Number: 94

Section Name: Head and Neck Cancers - Principles of Imaging
====================
Entities:-
Positron Emission Tomography Computed Tomography : A medical imaging technique combining PET and CT capabilities to provide detailed information about the body's function and structure.
Positron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.
Head And Neck Neoplasms : Cancers that arise in the head or neck region, including the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.

Relationships:-
1. Entity1: ""PET/CT"", Entity2: ""PET scan"", Relationship: ""preferred over""
2. Entity1: ""PET-CT"", Entity2: ""head neck cancers"", Relationship: ""used in study of""

Causalities:-
<A> PET/CT is preferred over PET scan alone (i.e., without superimposed CT scan) </A>. <C> PET/CT provides more accurate anatomical localization of abnormalities </C> <E> more accurate anatomical localization of abnormalities </E>.

Section Name: Initial Workup - Nodal Metastases
====================
Entities:-
Lymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site via the lymphatic system.
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine's computer to generate cross-sectional images.
Magnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.
Lymph Node Metastasis : The spread of cancer cells to lymph nodes, which are part of the lymphatic system.
Ct Of Neck : A computed tomography scan of the neck region.
Mri Of Neck : A magnetic resonance imaging scan of the neck region.
Fdg-Pet Scan : A type of positron emission tomography using fluorodeoxyglucose to assess metabolic activity.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.
Positron Emission Tomography : A nuclear medicine functional imaging technique that is used to observe metabolic processes in the body.

Relationships:-
1. Entity1: ""CT"", Entity2: ""lymph node metastases"", Relationship: ""used to evaluate""
2. Entity1: ""MRI"", Entity2: ""lymph node metastases"", Relationship: ""used to evaluate""
3. Entity1: ""FDG-PET/CT"", Entity2: ""lymph node metastases"", Relationship: ""used for detection""
4. Entity1: ""FDG-PET/CT"", Entity2: ""surgical primary approach"", Relationship: ""used to determine""
5. Entity1: ""FDG-PET/CT"", Entity2: ""definitive RT approach"", Relationship: ""used to identify""

Causalities:-
<A> Evaluation of lymph node metastases should be conducted with CT or MRI of the neck </A>, using whichever imaging study is suitable for primary site evaluation (IMG-A, 1 of 4).
<CO> For patients with multistation or lower neck nodal involvement or high-grade tumor histology </CO>, <A> consider CT of the chest to assess for mediastinal lymph node metastases or FDG-PET/CT </A>, <C> which is associated with higher sensitivity for both nodal and distant metastases </C>.
<CO> For patients who are under consideration for a surgical primary approach </CO>, <A> the higher sensitivity of FDG-PET/CT is warranted for tumors approaching the midline, to determine the surgical approach to the contralateral neck </A>. <CO> Similarly, patients who are scheduled for a definitive RT approach </CO> <A> may benefit from the higher sensitivity of FDG-PET/CT for identifying involved lymph nodes </A>.

Section Name: Initial Workup - Distant Metastases
====================
Entities:-
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes, and in other physiological activities including blood flow, regional chemical composition, and absorption.
Magnetic Resonance Imaging : A non-invasive imaging technique that uses magnetic fields and radio waves to create detailed images of the organs and tissues within the body.
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient, producing signals that are processed by the machine's computer to generate cross-sectional images.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Lung Neoplasms : Tumors or cancer of the lung.
Smoking : The inhalation of the smoke of burning tobacco encased in cigarettes, pipes, and cigars.

Relationships:-
1. Entity1: ""FDG-PET/CT"", Entity2: ""Distant Metastases"", Relationship: ""used to evaluate""
2. Entity1: ""Contrast-enhanced brain MRI"", Entity2: ""Brain Metastasis"", Relationship: ""recommended for evaluation""
3. Entity1: ""CT of the chest"", Entity2: ""Pulmonary Metastases"", Relationship: ""performed to assess""
4. Entity1: ""Non-contrast CT of the chest"", Entity2: ""Lung Parenchymal Metastases"", Relationship: ""used to screen""
5. Entity1: ""Annual CT screening"", Entity2: ""Lung Metastasis"", Relationship: ""considered for high risk""
6. Entity1: ""Directed CT or MRI"", Entity2: ""Distant Disease"", Relationship: ""used for assessment""
7. Entity1: ""FDG-PET/CT"", Entity2: ""Recurrent Disease"", Relationship: ""used for staging""

Causalities:-
<C> Patients with locoregionally advanced cancer (e.g., T3–T4 primary or ≥N1 nodal staging) </C>, <A> FDG-PET/CT is preferred to evaluate for distant disease and thoracic metastases </A>. <CO> For cancers where brain metastasis is a concern, such as mucosal melanoma or high-grade neuroendocrine carcinomas or adenocarcinomas </CO>, <A> contrast-enhanced brain MRI should be additionally obtained </A>.
<CO> If FDG-PET/CT is not performed </CO>, <A> CT of the chest should be performed to assess for presence of pulmonary metastases as well as mediastinal lymph node involvement </A>.
<CO> Non-contrast CT of the chest can be sufficient to screen for lung parenchymal metastases </CO> but <CO> is not adequate for assessment of mediastinal adenopathy </CO>. <CO> This is an appropriate lung cancer screening intervention for patients with a history of smoking </CO>.
<CO> Following primary definitive treatment (surgery, RT, or systemic therapy/RT) </CO> the role of annual CT screening for lung metastasis is controversial. <E> While this approach does detect early metastasis </E>, <CO> further study is needed to determine the extent of the positive effect and/or cost-effectiveness of this approach in specific subpopulations and timepoints post-treatment </CO>. <CO> For patients with a substantial smoking history or who are at high risk for lung metastases </CO>, <A> annual chest CT can be considered </A>.
<CO> If clinical concern for metastatic disease is confined to a specific anatomical area </CO>, <A> the assessment of distant disease can be performed with directed CT or MRI examination </A>.
<CO> FDG-PET/CT may complement or replace other imaging modalities when staging recurrent disease before any therapy for relapsed/refractory disease </CO> <A> in order to explore distant disease or second primaries that may significantly impact choice of therapy </A>.
--------------------------------------------------
Page Number: 102

Section Name: Head and Neck Cancers - Principles of Surgery
====================
Entities:-
Surgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.
Lymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.
Neoplasms : New abnormal growth of tissue in animals or plants; a tumor.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Neoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Surgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Lymphatic Structure : Anatomical structure that is part of the lymphatic system.
Tumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.
Staging : The process of determining the size and spread of cancer within the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.

Relationships:-
1. Entity1: ""surgical management"", Entity2: ""regional lymphatics"", Relationship: ""dictated by tumor staging""
2. Entity1: ""neck dissections"", Entity2: ""primary tumor"", Relationship: ""part of treatment""
3. Entity1: ""surgery"", Entity2: ""ipsilateral side of the neck"", Relationship: ""risk for metastases""

Causalities:-
<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.

Section Name: Neck Management
====================
Entities:-
Tongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.
Palate : The roof of the mouth, separating the oral and nasal cavities.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.
Hypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.
Nasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Squamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.
Biopsy : The removal of cells or tissues for examination under a microscope.

Relationships:-
1. Entity1: ""Tumor sites"", Entity2: ""Bilateral lymphatic drainage"", Relationship: ""associated with""
2. Entity1: ""Elective neck dissection"", Entity2: ""Risk of occult metastasis"", Relationship: ""based on""
3. Entity1: ""SLN biopsy"", Entity2: ""Elective neck dissection"", Relationship: ""guides decision-making for""

Causalities:-
- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.

- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.

- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.

  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2–4 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.

Section Name: Types of Neck Dissection
====================
Entities:-
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.

Relationships:-
1. Entity1: ""N0"", Entity2: ""Selective neck dissection"", Relationship: ""associated with""
2. Entity1: ""N3"", Entity2: ""Comprehensive neck dissection"", Relationship: ""associated with""
3. Entity1: ""Level VI neck dissection"", Entity2: ""Larynx"", Relationship: ""performed for""
4. Entity1: ""Level VI neck dissection"", Entity2: ""Hypopharynx"", Relationship: ""performed for""

Causalities:-
- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:
  - **N0:** <A> Selective neck dissection </A>
    - Oral cavity at least levels I–III
    - Oropharynx at least levels II–IV
    - Hypopharynx at least levels II–IV and level VI when appropriate
    - Larynx at least levels II–IV and level VI when appropriate
  - **N1–N2a–c:** <A> Selective or comprehensive neck dissection </A> (Discussion)
  - **N3:** <A> Comprehensive neck dissection </A>

- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.

- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.


Among these two options which one is the most likely true:

(A) `Histopathological_Examination_7` increases risk `Extranodal_Extension_5`
(B) `Extranodal_Extension_5` `increases risk `Histopathological_Examination_7`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge (Histopathological_Examination_7) causes (Extranodal_Extension_5) is not valid because histopathological examination is a diagnostic tool, not a causal factor for extranodal extension.
2. Histopathological examination is used to detect the presence of disease, such as cancer, in tissue samples, but it does not cause the spread of cancer.
3. Extranodal extension is a condition where cancer spreads beyond the lymph node capsule into surrounding tissues, which is detected by histopathological examination.
4. The edge (Extranodal_Extension_5) causes (Histopathological_Examination_7) is also not valid because extranodal extension is a condition detected by the examination, not a cause of the examination.
5. The causal relationship is reversed; the examination does not cause extranodal extension, but rather detects it.
6. The causal direction for both edges is marked as 'Unknown', indicating no direct causal relationship is established.
7. The causal factor for both edges is marked as neither necessary nor sufficient, further supporting the lack of a causal relationship.
8. The causal distance for EDGE2 is marked as 'Proximal', indicating a direct observation rather than a causal influence.
9. From the INFORMATION FROM KNOWLEDGE BASE, extranodal extension is listed as an adverse pathologic feature, which is a condition rather than a cause.
10. The NCCN guidelines emphasize the role of histopathological examination in diagnosing and staging cancer, not causing it.
","1. Page Number: 55, Section Name: Adverse Pathologic Features, Entity: Extranodal Extension, Relationship: is a type of Adverse Pathologic Features.
2. Page Number: 51, Section Name: Introduction, Entity: National Comprehensive Cancer Network, Relationship: provides guidelines for cancer of the supraglottic larynx.
3. Page Number: 102, Section Name: Principles of Surgery, Entity: Surgical Procedures, Operative, Relationship: used in the treatment of disease, injuries, or deformities.
",B,"{'A': 43.78, 'B': 56.22}",yes,B,"1. The AI assistant's reasoning is based on the understanding that histopathological examination is a diagnostic tool, not a causal factor for extranodal extension. This is consistent with the explanation provided in the EDGE1 and EDGE2 descriptions.
2. The assistant correctly identifies that the histopathological examination is used to detect the presence of disease, such as cancer, in tissue samples, but it does not cause the spread of cancer. This aligns with the explanation that the examination detects extranodal extension rather than causing it.
3. The causal direction for both edges is marked as 'Unknown', which supports the assistant's conclusion that there is no direct causal relationship between the histopathological examination and extranodal extension.
4. The causal factor for both edges is marked as neither necessary nor sufficient, further supporting the lack of a causal relationship. This is consistent with the assistant's reasoning that the examination is not a cause of extranodal extension.
5. The causal distance for EDGE2 is marked as 'Proximal', indicating a direct observation rather than a causal influence. This supports the assistant's conclusion that the examination detects rather than causes extranodal extension.
6. The assistant references the INFORMATION FROM KNOWLEDGE BASE, noting that extranodal extension is listed as an adverse pathologic feature, which is a condition rather than a cause. This supports the conclusion that the examination detects rather than causes extranodal extension.
7. The NCCN guidelines emphasize the role of histopathological examination in diagnosing and staging cancer, not causing it. This aligns with the assistant's reasoning that the examination is a diagnostic tool.
"
3,gpt-4o,"Imaging_Test_Results_8,Extranodal_Extension_5","""{'NODE1': {'id': 'Imaging_Test_Results_8', 'label': 'Diagnostic Imaging Test Results', 'description': 'This node represents the results of a diagnostic imaging test, which is used to observe and assess specific clinical findings. The test results can indicate whether certain findings are present or absent, providing crucial information for diagnosis and treatment planning.', 'type': 'Examination Result', 'observability': 'Observed', 'states': [{'state_name': 'present', 'state_description': 'The imaging test has detected the presence of specific findings or abnormalities.'}, {'state_name': 'absent', 'state_description': 'The imaging test has not detected any specific findings or abnormalities.'}]}, 'NODE2': {'id': 'Extranodal_Extension_5', 'label': 'Extranodal Extension', 'description': 'Extranodal extension refers to the spread of cancer beyond the lymph node capsule into surrounding tissues. It is a significant factor in cancer staging and prognosis, as it indicates a more advanced disease and may influence treatment decisions.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'present', 'state_description': 'Extranodal extension is present, indicating that cancer has spread beyond the lymph node into surrounding tissues.'}, {'state_name': 'absent', 'state_description': 'Extranodal extension is absent, indicating that cancer is contained within the lymph node and has not spread to surrounding tissues.'}]}, 'EDGE1': {'edges_ids': ['Imaging_Test_Results_8', 'Extranodal_Extension_5'], 'edge': '(Imaging_Test_Results_8) causes (Extranodal_Extension_5)', 'explanation': ['The edge suggests that the results of a diagnostic imaging test (Imaging_Test_Results_8) cause extranodal extension (Extranodal_Extension_5).', 'Imaging tests are diagnostic tools that detect existing conditions, such as extranodal extension, but they do not cause these conditions.', 'Extranodal extension is a result of cancer spreading beyond the lymph node capsule, which is a biological process independent of imaging test results.', 'Therefore, the edge is not valid as imaging test results do not cause extranodal extension.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}, 'EDGE2': {'edges_ids': ['Extranodal_Extension_5', 'Imaging_Test_Results_8'], 'edge': '(Extranodal_Extension_5) causes (Imaging_Test_Results_8)', 'explanation': ['Extranodal extension refers to the spread of cancer beyond the lymph node capsule into surrounding tissues, which is a significant factor in cancer staging and prognosis.', 'Imaging test results are used to detect such abnormalities, and if extranodal extension is present, it is likely to be detected by imaging tests.', 'Therefore, the presence of extranodal extension can cause imaging test results to show abnormalities, making the edge valid.', 'The causal direction is positive because the presence of extranodal extension leads to the imaging test detecting abnormalities.', 'Extranodal extension is neither a necessary nor a sufficient condition for imaging test results to show abnormalities, as there could be other causes or limitations in detection.', 'The causal distance is proximal because extranodal extension directly affects the imaging test results.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'ENTITIES_MATCHING_PAGES_INFO': {'51': {'matching_entities': [{'EXTRANODAL EXTENSION': 0.97547734}, {'LYMPHATIC METASTASIS': 0.94701207}, {'EXTRAMURAL EXTENSION': 0.94649863}, {'CLINICAL TRIALS': 0.9367982}, {'CLINICAL TRIALS AS TOPIC': 0.9333815}, {'RESPONSE EVALUATION': 0.9307092}, {'FOLLOW-UP PROCEDURE': 0.9293796}, {'CLINICAL TRIAL': 0.9271055}, {'SURGERY': 0.9264304}, {'SURGICAL PROCEDURE': 0.9255254}, {'RESPONSE TO TREATMENT': 0.9204324}], 'count': 11}, '53': {'matching_entities': [{'EXTRANODAL EXTENSION': 0.97547734}, {'IMAGING': 0.95010704}, {'CLINICAL TRIALS AS TOPIC': 0.9333815}, {'COMPUTED TOMOGRAPHY': 0.9316812}, {'MAGNETIC RESONANCE IMAGING': 0.93168116}, {'FOLLOW-UP PROCEDURE': 0.9293796}, {'TREATMENT STRATEGIES': 0.92767245}, {'CLINICAL TRIAL': 0.9271055}, {'SURGICAL PROCEDURE': 0.9255254}, {'FOLLOW-UP EVALUATIONS': 0.9244507}], 'count': 10}, '55': {'matching_entities': [{'EXTRANODAL EXTENSION': 0.97547734}, {'NEOPLASM METASTASIS': 0.95823944}, {'METASTATIC NEOPLASM': 0.9350836}, {'CLINICAL TRIALS AS TOPIC': 0.9333815}, {'FOLLOW-UP PROCEDURE': 0.9293796}, {'CLINICAL TRIAL': 0.9271055}, {'METASTASIS': 0.9265935}, {'SURGERY': 0.9264304}, {'SURGICAL PROCEDURE': 0.9255254}], 'count': 9}, '70': {'matching_entities': [{'NEOPLASM METASTASIS': 0.95823944}, {'CLINICAL TRIALS': 0.9367982}, {'CLINICAL TRIALS AS TOPIC': 0.9333815}, {'CLINICAL TRIAL': 0.9271055}, {'BIOMARKERS': 0.9266646}, {'SURGERY': 0.9264304}, {'BIOMARKER': 0.9259977}, {'SUPPORTIVE CARE': 0.92568463}, {'SURGICAL PROCEDURE': 0.9255254}], 'count': 9}, '46': {'matching_entities': [{'EXTRANODAL EXTENSION': 0.97547734}, {'CLINICAL TRIALS': 0.9367982}, {'CLINICAL TRIALS AS TOPIC': 0.9333815}, {'COMPUTED TOMOGRAPHY': 0.9316812}, {'MAGNETIC RESONANCE IMAGING': 0.93168116}, {'MAGNETIC RESONANCE IMAGING (MRI)': 0.9294916}, {'CLINICAL TRIAL': 0.9271055}, {'COMPUTED TOMOGRAPHY (CT)': 0.926514}], 'count': 8}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 51\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\nSupraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network (NCCN)\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""provides guidelines for\""\\n2. Entity1: \""healthcare professionals\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""manage\""\\n\\nCausalities:-\\nThe provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nTotal Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nCancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.\\nTnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging criteria\"", Entity2: \""Total laryngectomy\"", Relationship: \""determines necessity of\""\\n2. Entity1: \""T3, N0\"", Entity2: \""Clinical staging criteria\"", Relationship: \""is a categorization of\""\\n\\nCausalities:-\\nThe flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.\\n\\nSection Name: Treatment of Primary and Neck\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nLymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""combined with\""\\n2. Entity1: \""Laryngectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n3. Entity1: \""Thyroidectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n4. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n\\nCausalities:-\\n<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.\\n\\nSection Name: Surgical Options\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nLymph Node Excision : Surgical removal of one or more lymph nodes.\\nLymphadenectomy : Surgical removal of one or more groups of lymph nodes.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Laryngectomy\"", Entity2: \""Thyroidectomy\"", Relationship: \""combined with\""\\n2. Entity1: \""Lymph Node Dissection\"", Entity2: \""Surgical Intervention\"", Relationship: \""extent of\""\\n3. Entity1: \""Surgical Intervention\"", Entity2: \""Advanced Cases\"", Relationship: \""management option for\""\\n\\nCausalities:-\\n<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.\\n\\nSection Name: Induction Chemotherapy\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nTherapeutic Approach : A method or strategy used in the treatment of disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Induction Chemotherapy\"", Entity2: \""Surgical Intervention\"", Relationship: \""alternative or sequential treatment option\""\\n\\nCausalities:-\\n<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.\\n\\nSection Name: Adjuvant Treatment\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nNeoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.\\nDisease Progression : The worsening of a disease over time.\\n\\nRelationships:-\\n1. Entity1: \""Primary Treatment\"", Entity2: \""Adjuvant Treatment\"", Relationship: \""followed by\""\\n2. Entity1: \""Adjuvant Treatment\"", Entity2: \""Systemic Therapy\"", Relationship: \""includes\""\\n3. Entity1: \""Adjuvant Treatment\"", Entity2: \""Radiotherapy\"", Relationship: \""includes\""\\n4. Entity1: \""Follow-up Assessments\"", Entity2: \""Treatment Efficacy\"", Relationship: \""used to evaluate\""\\n\\nCausalities:-\\n<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient\\'s response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.\\n\\nSection Name: Risk Features and Response Assessment\\n====================\\nEntities:-\\nNeoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.\\nSurgical Margins : The edge or border of the tissue removed in cancer surgery.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nExtramural Extension : Extension of a tumor beyond the wall of an organ.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nCancer Management : The process of planning and coordinating the treatment of cancer.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Extramural extension\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n2. Entity1: \""Positive surgical margin\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n3. Entity1: \""Ongoing assessment\"", Entity2: \""Response evaluation\"", Relationship: \""leads to\""\\n4. Entity1: \""Response evaluation\"", Entity2: \""Adjustments to treatment\"", Relationship: \""leads to\""\\n5. Entity1: \""Management of cancer\"", Entity2: \""Treatment decisions\"", Relationship: \""involves\""\\n6. Entity1: \""Management of cancer\"", Entity2: \""Ongoing assessment\"", Relationship: \""involves\""\\n7. Entity1: \""Management of cancer\"", Entity2: \""Adjustments to treatment\"", Relationship: \""involves\""\\n\\nCausalities:-\\nThe chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nMalignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""NCCN Guidelines\"", Relationship: \""provides\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""Clinical Trials\"", Relationship: \""recommend\""\\n3. Entity1: \""NCCN Guidelines\"", Entity2: \""Cancer\"", Relationship: \""related to management of\""\\n\\nCausalities:-\\n<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: SUPRA-3\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nClinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""Total laryngectomy\"", Entity2: \""Laryngectomy\"", Relationship: \""is a type of\""\\n2. Entity1: \""Systemic therapy\"", Entity2: \""RT\"", Relationship: \""concurrent treatment option\""\\n3. Entity1: \""Induction chemotherapy\"", Entity2: \""Other treatments\"", Relationship: \""initial treatment option before\""\\n\\nCausalities:-\\n<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>\\n  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>\\n  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>\\n  - or\\n  - <A> Induction chemotherapy </A>\\n  - or\\n  - <A> Clinical trials </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient\\'s condition after initial treatment.\\nFollow-Up : Medical care given to a patient over time after initial treatment.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : The reappearance of a disease after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n- **Follow-up (FOLL-A, 1 of 2)**\\n  - <CO> Recurrent or persistent disease </CO> (ADV-3)\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""pN1\"", Entity2: \""Radiotherapy\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Extranodal extension\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n3. Entity1: \""Extranodal extension\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n4. Entity1: \""Positive surgical margin\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n5. Entity1: \""Positive surgical margin\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n\\nCausalities:-\\n- <CO>pN1 without other risk features</CO>\\n  - <C>Adverse pathologic features</C>\\n  - <A>Consider RT</A>\\n  - <CO>Extranodal extension and/or positive margin</CO>\\n  - <CO>Other risk features</CO>\\n  - <A>Systemic therapy/RT (category 1)</A>\\n  - <A>RT or Consider systemic therapy/RT</A>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nResponse Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.\\nResponse To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.\\n\\nRelationships:-\\n\\nSection Name: Principles of Surgery and Radiation Therapy\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""complementary treatments\""\\n\\nCausalities:-\\n**Principles of Surgery (SURG-A).**\\n\\n**Principles of Radiation Therapy (SUPRA-A).**\\n\\nSection Name: Principles of Systemic Therapy\\n====================\\nEntities:-\\nCisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Cisplatin\"", Entity2: \""Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""preferred agent\""\\n2. Entity1: \""Cisplatin\"", Entity2: \""Concurrent Systemic Therapy/RT\"", Relationship: \""used in\""\\n\\nCausalities:-\\n<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.\\n--------------------------------------------------\\nPage Number: 53\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""Malignant neoplasm of supraglottis\"", Relationship: \""provides guidelines for\""\\n2. Entity1: \""clinical staging\"", Entity2: \""treatment strategies\"", Relationship: \""part of flowchart for\""\\n\\nCausalities:-\\nThe provided image is a flowchart outlining the <C> NCCN (National Comprehensive Cancer Network) guidelines </C> for the treatment of <CO> cancers of the supraglottic larynx </CO>. This flowchart <A> utilizes a highly structured approach to convey clinical staging and treatment strategies </A>, indicating the various pathways based on <CO> patient conditions and disease features </CO>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\nSupraglottic Cancer : Cancer that occurs in the supraglottic region of the larynx, above the vocal cords.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""Cancer of the Supraglottic Larynx\"", Entity2: \""Clinical Trials\"", Relationship: \""recommended management strategy\""\\n\\nCausalities:-\\n- All recommendations are category 2A unless otherwise indicated.\\n- <A> Participation in clinical trials </A> is especially encouraged.\\n\\nSection Name: Key Components of the Flowchart\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nRadiotherapy : The use of ionizing radiation to treat cancer.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nNeoplasm Recurrence, Local : The return of a tumor at the original site after treatment.\\nClinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Staging\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""determines\""\\n2. Entity1: \""Evaluation and Follow-Up\"", Entity2: \""Adverse and No Adverse Features\"", Relationship: \""leads to decision based on\""\\n3. Entity1: \""Adjuvant Treatment\"", Entity2: \""Adverse pathologic features\"", Relationship: \""considered if present\""\\n4. Entity1: \""Clinical Trials\"", Entity2: \""Treatment Pathway\"", Relationship: \""part of\""\\n\\nCausalities:-\\n### Key Components of the Flowchart\\n\\n1. **Clinical Staging**: The flowchart starts with <A>clinical staging</A>, indicating that <CO>patients must first be evaluated to determine the extent of cancer</CO>. This is essential for <E>deciding on appropriate treatment options</E>.\\n\\n2. **Treatment of Primary and Neck**: The flowchart details multiple treatment strategies, including:\\n   - <A>**Concurrent systemic therapy/RT**</A>: This suggests a combination approach for <CO>patients eligible for such treatment</CO>.\\n   - <A>**Definitive Radiation Therapy (RT)**</A>: Recommended for <CO>low-volume diseases or patients who cannot tolerate systemic therapy</CO>.\\n   - <A>**Surgical Options**</A>: It highlights options such as endoscopic or open partial laryngectomy and neck dissection, which are <CO>contingent on clinical evaluations</CO>.\\n\\n3. **Evaluation and Follow-Up**: After initial treatment approaches, the chart directs clinicians to perform a <A>\""Post Systemic Therapy/RT or RT Neck Evaluation\""</A>. This step <E>assesses whether there are adverse pathologic features</E>, guiding subsequent treatment decisions.\\n\\n4. **Adverse and No Adverse Features**: The decision pathway diverges based on findings:\\n   - <CO>Patients with **adverse pathologic features**</CO> may have <A>additional diagnostic imaging (CT or MRI)</A> and may require <A>further systemic treatment</A>.\\n   - <CO>Patients with **no adverse features**</CO> may be directed towards <A>considerations for radiation therapy</A>.\\n\\n5. **Adjuvant Treatment and Recurrence**: The chart also addresses <E>management of any recurrent or persistent disease</E>, emphasizing the importance of <A>regular follow-up assessments</A>. Various options for <A>adjuvant treatment</A> are mentioned, focusing on tailored approaches towards ongoing management of the disease.\\n\\n6. **Clinical Trials**: The flowchart encourages <A>participation in clinical trials</A>, indicating a commitment to <E>exploring new treatments and improving patient outcomes</E>.\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nImaging : The process of producing images of the body or parts of the body to diagnose or examine disease.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nRadiation Therapy : The use of ionizing radiation to treat cancer and other diseases.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Imaging\"", Entity2: \""Surgery\"", Relationship: \""Both are foundational principles in medical practice.\""\\n2. Entity1: \""Radiation therapy\"", Entity2: \""Systemic Therapy\"", Relationship: \""Both are treatment modalities for cancer.\""\\n\\nCausalities:-\\n#### Principles\\n- **Principles of Imaging (IMG-A)**\\n- **Principles of Surgery (SURG-A)**\\n- **Principles of Radiation Therapy (SUPRA-A)**\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margins : The presence of cancer cells at the edge of the tissue removed during surgery.\\nPerineural Invasion : Cancer cells found surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The presence of cancer cells within blood vessels.\\nLymphatic Invasion : The presence of cancer cells within lymphatic vessels.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal Extension\"", Entity2: \""Positive Surgical Margins\"", Relationship: \""Both indicate cancer spread beyond original site.\""\\n2. Entity1: \""Perineural Invasion\"", Entity2: \""Vascular Invasion\"", Relationship: \""Both are pathways for cancer spread.\""\\n3. Entity1: \""pT3 or pT4 primary\"", Entity2: \""pN2 or pN3 nodal disease\"", Relationship: \""Both indicate advanced cancer stages.\""\\n\\nCausalities:-\\n<C> Extranodal extension </C>\\n<C> Positive margins </C>\\n<C> Close margins </C>\\n<C> pT3 or pT4 primary </C>\\n<C> pN2 or pN3 nodal disease </C>\\n<C> Perineural invasion </C>\\n<C> Vascular invasion </C>\\n<C> Lymphatic invasion </C>\\n\\nSection Name: Clinical Staging and Treatment of Primary and Neck\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient after treatment.\\nRecurrent Disease : A disease that returns after a period of remission.\\nLaryngectomy : Surgical removal of the larynx, often used to treat cancer.\\nRadiation Therapy : The use of ionizing radiation to treat cancer and other diseases.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat cancer.\\nChemotherapy : Treatment of disease by the use of chemical substances, especially cancer by cytotoxic drugs.\\n\\nRelationships:-\\n1. Entity1: \""Adjuvant Treatment\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""part of\""\\n2. Entity1: \""Follow-up\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""part of\""\\n3. Entity1: \""Recurrent or Persistent Disease\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""part of\""\\n4. Entity1: \""Larynx-Preserving Surgery\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n5. Entity1: \""Concurrent Systemic Therapy/RT\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n6. Entity1: \""Clinical Trials or Definitive RT\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n7. Entity1: \""Endoscopic or Open Partial Laryngectomy and Neck Dissection(s)\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n8. Entity1: \""Induction Chemotherapy\"", Entity2: \""Treatment Options\"", Relationship: \""is a treatment option for\""\\n\\nCausalities:-\\n<A> Amenable to Larynx-Preserving (Conservation) Surgery </A>: <CO> T1\u20132, N+ and selected T3, N1 </CO>\\n<A> Concurrent Systemic Therapy/RT </A>: <CO> i, k, l </CO>\\n<A> Clinical Trials or Definitive RT </A>: <CO> i </CO>\\n<A> Endoscopic or Open Partial Laryngectomy and Neck Dissection(s) </A>: <CO> h </CO>\\n<A> Induction Chemotherapy </A>: <CO> k, m </CO>\\n\\nSection Name: Pathologic Features and Response Assessment\\n====================\\nEntities:-\\nRadiation Therapy : The use of ionizing radiation to treat cancer and other diseases.\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n2. Entity1: \""Positive margin\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n3. Entity1: \""Systemic Therapy\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""considered in response to\""\\n4. Entity1: \""Radiation Therapy\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""considered in response to\""\\n\\nCausalities:-\\n#### Pathologic Features\\n- **No Adverse Pathologic Features**: j\\n  - <A> Consider RT </A>: i\\n- **Adverse Pathologic Features**: j\\n  - <CO> Extranodal extension and/or positive margin </CO>: n\\n  - Other risk features\\n  - <A> Systemic therapy/RT </A>: i, k (category 1)\\n  - <A> Consider systemic therapy/RT </A>: i, k\\n\\n#### Response Assessment\\n- **Response Assessment** (SUPRA-7)\\n\\nSection Name: Imaging and Recurrent or Persistent Disease\\n====================\\nEntities:-\\nTomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient.\\nMagnetic Resonance Imaging : Medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nComputed Tomography : Medical imaging technique used in radiology to obtain detailed internal images of the body.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""primary and neck\"", Relationship: \""used for imaging\""\\n2. Entity1: \""MRI\"", Entity2: \""primary and neck\"", Relationship: \""used for imaging\""\\n3. Entity1: \""Post Systemic Therapy/RT\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""evaluation after treatment\""\\n4. Entity1: \""RT Neck Evaluation\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""evaluation after treatment\""\\n\\nCausalities:-\\n<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>\\n\\n<CO> Recurrent or Persistent Disease </CO>\\n\\n<CO> Post Systemic Therapy/RT or RT Neck Evaluation </CO>\\n\\nSection Name: Conclusion\\n====================\\nEntities:-\\nOncologists : Medical doctors who specialize in the diagnosis and treatment of cancer.\\nSupraglottic Larynx Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is the area above the vocal cords.\\nClinical Staging : The process of determining the extent of cancer in the body, usually based on physical examination, imaging tests, and biopsies.\\nTreatment Strategies : Plans or methods developed to treat diseases, including cancer, which may involve surgery, chemotherapy, radiation therapy, or other modalities.\\nFollow-Up Evaluations : Medical assessments conducted after initial treatment to monitor a patient\\'s progress and detect any recurrence of disease.\\nClinical Efficacy : The ability of a treatment to produce the desired therapeutic effect in clinical settings.\\nResearch : Systematic investigation and study conducted to establish facts and reach new conclusions.\\nTreatment Paradigms : Standard models or patterns of treatment used in medical practice, often based on clinical guidelines and research findings.\\n\\nRelationships:-\\n1. Entity1: \""Oncologists\"", Entity2: \""Supraglottic Larynx Cancer\"", Relationship: \""use flowchart for decision-making\""\\n2. Entity1: \""Clinical Staging\"", Entity2: \""Treatment Strategies\"", Relationship: \""part of management process\""\\n3. Entity1: \""Treatment Strategies\"", Entity2: \""Follow-Up Evaluations\"", Relationship: \""part of management process\""\\n\\nCausalities:-\\n<A> The flowchart serves as a comprehensive guide for oncologists and healthcare providers </A>, <A> facilitating informed decision-making in the treatment of supraglottic larynx cancer </A>. <A> By visualizing the complex interactions between clinical staging, treatment strategies, and follow-up evaluations </A>, <E> it streamlines the management process </E>, <E> ensuring that patients receive appropriate care tailored to their specific needs </E>. <E> The detailed pathways not only enhance clinical efficacy </E> but also <E> underscore the importance of ongoing research and adaptation of treatment paradigms in oncology </E>.\\n--------------------------------------------------\\nPage Number: 55\\n\\nSection Name: General Information\\n====================\\nEntities:-\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""National Comprehensive Cancer Network\"", Relationship: \""produced by\""\\n\\nSection Name: Important Notes\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNeoplasms : New abnormal growth of tissue that can be benign or malignant.\\nMalignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Trials\"", Entity2: \""Cancer\"", Relationship: \""recommended for\""\\n2. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n\\nCausalities:-\\n<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nChemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n2. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n3. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n\\nCausalities:-\\n### Principles\\n\\n- **Principles of Surgery (SURG-A)**\\n- **Principles of Radiation Therapy (SUPRA-A)**\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nPerineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The invasion of cancer cells into blood vessels.\\nLymphatic Invasion : The invasion of cancer cells into lymphatic vessels.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n2. Entity1: \""Positive margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n3. Entity1: \""Close margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n4. Entity1: \""pT3 or pT4 primary\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n5. Entity1: \""pN2 or pN3 nodal disease\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n6. Entity1: \""Perineural invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n7. Entity1: \""Vascular invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n8. Entity1: \""Lymphatic invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n\\nCausalities:-\\n<C> Extranodal extension </C>\\n<C> Positive margins </C>\\n<C> Close margins </C>\\n<C> pT3 or pT4 primary </C>\\n<C> pN2 or pN3 nodal disease </C>\\n<C> Perineural invasion </C>\\n<C> Vascular invasion </C>\\n<C> Lymphatic invasion </C>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nPrimary Site : The original location where a tumor or cancer begins.\\nComplete Remission : The disappearance of all signs of cancer in response to treatment.\\nPartial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""induction chemotherapy\"", Entity2: \""Primary site\"", Relationship: \""treatment outcome\""\\n2. Entity1: \""Definitive RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n3. Entity1: \""RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n4. Entity1: \""Surgery\"", Entity2: \""unresectable nodal disease\"", Relationship: \""treatment option\""\\n\\nCausalities:-\\n<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.\\nFollow-Up (Medicine) : The process of monitoring a patient\\'s health over time after treatment or diagnosis.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : A disease that returns after a period of remission.\\nRecurrence (Medicine) : The return of a disease or condition after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n### Follow-up\\n\\n- **Follow-up** (FOLL-A, 1 of 2)\\n- **Recurrent or persistent disease** (ADV-3)\\n\\nSection Name: Risk Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""RT\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Adverse pathologic features\"", Entity2: \""Systemic therapy\"", Relationship: \""Consideration for treatment\""\\n\\nCausalities:-\\n- **No adverse pathologic features**\\n- **Other risk features**\\n- **Adverse pathologic features**:\\n  - <C> Extranodal extension and/or positive margin </C>\\n  - <A> RT or consider systemic therapy/RT </A>\\n\\nSection Name: Post-Therapy Evaluation\\n====================\\nEntities:-\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nNeck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n2. Entity1: \""RT\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n\\nCausalities:-\\n<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>\\n\\nSection Name: Flowchart Overview\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nSupraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""guides management of\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""healthcare professionals\"", Relationship: \""used by\""\\n\\nCausalities:-\\n<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.\\n\\nSection Name: Assessment and Treatment Decisions\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nComplete Response : The disappearance of all signs of cancer in response to treatment.\\nPartial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Complete Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n2. Entity1: \""Complete Response\"", Entity2: \""Surgery\"", Relationship: \""leads to\""\\n3. Entity1: \""Partial Response\"", Entity2: \""Systemic Therapy\"", Relationship: \""leads to\""\\n4. Entity1: \""Partial Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n\\nCausalities:-\\n<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.\\n\\nSection Name: Adverse Pathologic Features and Follow-up\\n====================\\nEntities:-\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nNeoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nRecurrent Neoplasm : A neoplasm that has returned after treatment.\\nMetastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.\\nMetastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""Treatment decisions\"", Relationship: \""Influence\""\\n2. Entity1: \""Adverse features\"", Entity2: \""Surgical intervention\"", Relationship: \""Recommendation\""\\n3. Entity1: \""Absence of adverse features\"", Entity2: \""Radiation therapy\"", Relationship: \""Pathway\""\\n4. Entity1: \""Follow-up process\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""Detection\""\\n5. Entity1: \""Recurrent or persistent disease\"", Entity2: \""Advanced disease management\"", Relationship: \""Necessity\""\\n\\nCausalities:-\\n<C> The presence of adverse pathologic features \u2014 such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient\\'s disease characteristics.\\n\\nFurthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.\\n--------------------------------------------------\\nPage Number: 70\\n\\nSection Name: Diagnosis\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nPersonalized Medicine : A medical model that proposes the customization of healthcare, with medical decisions, practices, and/or products being tailored to the individual patient.\\n\\nRelationships:-\\n1. Entity1: \""recurrent or persistent disease\"", Entity2: \""distant metastases\"", Relationship: \""has condition\""\\n2. Entity1: \""Clinical trials\"", Entity2: \""recurrent or persistent disease with distant metastases\"", Relationship: \""recommended for\""\\n3. Entity1: \""locoregional failure\"", Entity2: \""locoregional treatment\"", Relationship: \""treatment response to\""\\n\\nCausalities:-\\nIn the **Diagnosis** section, the focus is on <C> recurrent or persistent disease with distant metastases </C>. <A> Clinical trials are preferred </A> for <CO> patients diagnosed at this stage </CO>. <CO> If there is locoregional failure </CO>, <A> locoregional treatment should be considered based on the extent of the disease and symptoms presented </A>. This highlights the importance of personalized treatment approaches, taking into account the unique circumstances of each patient.\\n\\nSection Name: Treatment\\n====================\\nEntities:-\\nTherapeutics : The branch of medicine concerned with the treatment of disease and the action of remedial agents.\\nPerformance Status : A measure of how well a patient is able to perform ordinary tasks and carry out daily activities.\\nSystemic Therapy : A type of treatment that uses substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nPalliative Care : An interdisciplinary medical caregiving approach aimed at optimizing quality of life and mitigating suffering among people with serious, complex illness.\\nRadiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Performance Status\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option for PS 0-1, PS 2, and PS 3 patients\""\\n2. Entity1: \""Performance Status\"", Entity2: \""Surgery\"", Relationship: \""Treatment option for PS 0-1 patients\""\\n3. Entity1: \""Performance Status\"", Entity2: \""Best Supportive Care\"", Relationship: \""Treatment option for PS 0-1 and PS 3 patients\""\\n4. Entity1: \""Performance Status\"", Entity2: \""Palliative Treatments\"", Relationship: \""Treatment option for PS 2 and PS 3 patients\""\\n5. Entity1: \""Performance Status\"", Entity2: \""Radiation Therapy\"", Relationship: \""Consideration for PS 3 patients\""\\n\\nCausalities:-\\nThe <C> Treatment section </C> outlines pathways based on <C> performance status (PS) </C>. For <CO> PS 0-1 patients </CO>, <A> options include combination systemic therapy, single-agent systemic therapy, surgery, or best supportive care for those with limited metastases </A>. For <CO> PS 2 patients </CO>, <A> recommendations include single-agent systemic therapy, supportive care, or palliative treatments </A>. For <CO> PS 3 patients </CO>, <A> the focus is on single-agent therapy and best supportive care, with consideration of palliative radiation therapy (RT) and palliative surgery </A>. This section addresses the evolving needs of patients as their <C> performance status declines </C>.\\n\\nSection Name: Persistent Disease or Progression\\n====================\\nEntities:-\\nDisease Progression : The worsening of a disease over time.\\nSystemic Therapy : A type of treatment that uses substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nClinical Trials : Research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nPalliative Care : An interdisciplinary medical caregiving approach aimed at optimizing quality of life and mitigating suffering among people with serious, complex illness.\\nQuality Of Life : An individual\\'s overall appraisal of their situation and well-being.\\nSupportive Care : Care given to improve the quality of life of patients who have a serious or life-threatening disease.\\n\\nRelationships:-\\n1. Entity1: \""Persistent Disease or Progression\"", Entity2: \""Systemic Therapy\"", Relationship: \""option for management\""\\n2. Entity1: \""Persistent Disease or Progression\"", Entity2: \""Clinical Trials\"", Relationship: \""option for management\""\\n3. Entity1: \""Persistent Disease or Progression\"", Entity2: \""Palliative Care\"", Relationship: \""option for management\""\\n4. Entity1: \""Best Supportive Care\"", Entity2: \""Quality of Life\"", Relationship: \""improves\""\\n5. Entity1: \""Best Supportive Care\"", Entity2: \""Advanced Illness\"", Relationship: \""applied in context of\""\\n\\nCausalities:-\\n<A> continued evaluation of treatment efficacy </A> is reiterated. <A> Options include systemic therapy, clinical trials, or palliative care </A> <CO> based on the specific patient condition </CO>. <A> Best supportive care is emphasized </A>, <E> prioritizing the patient\\'s quality of life </E>, <CO> particularly in the context of advanced illness </CO>.\\n\\nSection Name: NCCN Guidelines Overview\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nNeoplasms : New abnormal growth of tissue that may be benign or malignant.\\nMalignant Neoplastic Disease : A disease in which abnormal cells divide uncontrollably and destroy body tissue.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""cancer\"", Entity2: \""clinical trial\"", Relationship: \""best management through\""\\n\\nCausalities:-\\n<CO> any patient with cancer </CO> <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles and Considerations\\n====================\\nEntities:-\\nRadiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nSurgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nGenomic Profiling : The measurement of the activity (the expression) of thousands of genes at once, to create a global picture of cellular function.\\nBiomarkers : Biological molecules found in blood, other body fluids, or tissues that are a sign of a normal or abnormal process, or of a condition or disease.\\nBiomarker : A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease.\\nPalliative Care : An interdisciplinary medical caregiving approach aimed at optimizing quality of life and mitigating suffering among people with serious, complex illness.\\nBone Neoplasms : Tumors or cancer of the bone.\\nBone Metastasis : The spread of cancer cells from their original site to a bone.\\n\\nRelationships:-\\n1. Entity1: \""Palliative RT\"", Entity2: \""Bone Metastases\"", Relationship: \""treatment for\""\\n\\nCausalities:-\\n- **Principles of Radiation Therapy (ADV-A).**\\n- **Principles of Surgery (SURG-A).**\\n<A> Consider NGS genomic profiling for biomarker identification. </A>\\n<A> Consider palliative RT </A> <CO> as clinically indicated (e.g., bone metastases) </CO> (RAD-A).\\n- See Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A) or Systemic Therapy for Nasopharyngeal Cancers (NASO-B).\\n--------------------------------------------------\\nPage Number: 46\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, including the glottis.\\nMalignant Neoplasm Of Glottis : A malignant tumor located in the glottis, part of the larynx.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness, often used in cancer treatment.\\nAdjuvant Therapy : Treatment given in addition to the primary (main) treatment to enhance its effectiveness.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""Laryngeal Neoplasms\"", Relationship: \""provides treatment guidelines for\""\\n2. Entity1: \""treatment guidelines\"", Entity2: \""Adjuvant therapy\"", Relationship: \""guide clinical decision-making for\""\\n\\nCausalities:-\\n<C> cancer of the glottic larynx </C> <E> treatment guidelines </E> <CO> based on various clinical stages and specific patient conditions </CO> <A> guide healthcare professionals through clinical decision-making </A>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n\\nCausalities:-\\n<A>Participation in clinical trials</A> is especially encouraged.\\n\\nSection Name: Clinical Staging and Treatment\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging of neoplasms based on extent of tumor spread.\\nT4A : A clinical stage indicating a tumor that has grown into nearby structures.\\nN0\u20133 : A range of clinical stages indicating the extent of regional lymph node involvement.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue in the neck.\\nPathology : The study of the nature and cause of disease which involves changes in structure and function.\\nAntineoplastic Combined Chemotherapy Protocols : The use of drug combinations to treat cancer.\\nRadiotherapy : The use of ionizing radiation to treat cancer.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Staging\"", Entity2: \""Surgical Intervention\"", Relationship: \""determines\""\\n2. Entity1: \""T4a\"", Entity2: \""Surgical Intervention\"", Relationship: \""relates to\""\\n3. Entity1: \""Systemic Therapy\"", Entity2: \""Radiotherapy\"", Relationship: \""considered with\""\\n4. Entity1: \""Clinical Trials\"", Entity2: \""Treatment of Primary and Neck\"", Relationship: \""option for\""\\n\\nCausalities:-\\n<CO> Clinical staging indicator labeled \""T4a,N0\u20133\"" </CO> <A> emphasizes the importance of surgical intervention </A>, highlighting procedures such as bilateral neck dissection and the need to address certain pathologic features. <CO> Selected T4a patients who decline surgery </CO> <A> consider concurrent systemic therapy/RT or clinical trial for function-preserving surgical or RT management or induction chemotherapy </A>.\\n\\nSection Name: Principles of Treatment\\n====================\\nEntities:-\\nThyroidectomy : Surgical removal of the thyroid gland.\\nExtranodal Extension : Spread of cancer beyond the lymph node capsule.\\nRadiation Therapy : Medical use of ionizing radiation to treat cancer.\\n\\nRelationships:-\\n1. Entity1: \""Surgery\"", Entity2: \""Thyroidectomy\"", Relationship: \""involves\""\\n2. Entity1: \""Radiation therapy\"", Entity2: \""Adverse pathologic features\"", Relationship: \""treats\""\\n\\nCausalities:-\\n- **Principles of Radiation Therapy (GLOT-A):**  \\n  - <C> Adverse pathologic features: extranodal extension, positive margins, close margins, pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular invasion, lymphatic invasion, and subglottic extension </C> (Discussion).  \\n\\n- **Principles of Surgery (SURG-A):**  \\n  - <A> Surgery, including ipsilateral or bilateral neck dissection; thyroidectomy to clear central compartment nodes </A>, <CO> especially when there is thyroid cartilage with gross invasion of the thyroid gland and significant subglottic extension </CO>.\\n\\nSection Name: Adjuvant Treatment and Follow-up\\n====================\\nEntities:-\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nComputed Tomography (Ct) : A medical imaging technique used in radiology to obtain detailed internal images of the body noninvasively for diagnostic purposes.\\nMagnetic Resonance Imaging (Mri) : A noninvasive medical test that physicians use to diagnose and treat medical conditions.\\nRecurrent Disease : A disease that has returned after a period of remission.\\nRadiation Therapy (Rt) : The use of ionizing radiation to treat cancer and other diseases.\\n\\nRelationships:-\\n1. Entity1: \""Adverse Features\"", Entity2: \""Specific Treatments\"", Relationship: \""Suggests\""\\n2. Entity1: \""Systemic Therapy\"", Entity2: \""Patients who decline surgery\"", Relationship: \""Option for\""\\n3. Entity1: \""CT or MRI\"", Entity2: \""Primary and Neck\"", Relationship: \""Used for imaging\""\\n4. Entity1: \""Recurrent or Persistent Disease\"", Entity2: \""Follow-up\"", Relationship: \""Condition for\""\\n5. Entity1: \""pN1 without other risk features\"", Entity2: \""RT\"", Relationship: \""Suggests considering\""\\n\\nCausalities:-\\n<C> adverse features such as extralateral extension or positive margins </C> <E> specific treatments are suggested </E>. The guidelines recommend <A> considering options like concurrent systemic therapy or clinical trials </A> <CO> for patients who decline surgery </CO>.\\n\\n- **Adjuvant Treatment:**  \\n  - <A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>.  \\n\\n- **Follow-up (FOLL-A, 1 of 2):**  \\n  - <CO> Recurrent or persistent disease (ADV-3) </CO>.  \\n\\n- **Post Systemic Therapy/RT or RT Neck Evaluation (FOLL-A, 2 of 2):**  \\n  - <CO> pN1 without other risk features </CO>: <A> Consider RT </A>.\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness, often used in cancer treatment.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.\\nMagnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nNeoplasm Recurrence, Local : The return of a cancer, at the same site as the original (primary) tumor, after it had disappeared.\\n\\nRelationships:-\\n1. Entity1: \""Adjuvant treatment\"", Entity2: \""Treatment responses\"", Relationship: \""affects\""\\n2. Entity1: \""Follow-up assessments\"", Entity2: \""CT or MRI scans\"", Relationship: \""conducted using\""\\n3. Entity1: \""Response Assessment (GLOT-5)\"", Entity2: \""Recurrent or persistent disease (ADV-3)\"", Relationship: \""determines\""\\n\\nCausalities:-\\nAs the flowchart progresses to the adjuvant treatment section, it depicts further decision points based on treatment responses and disease recurrence. The inclusion of references to follow-up assessments, such as CT or MRI scans, underscores the emphasis on continuous monitoring and evaluation of treatment efficacy.  - **Response Assessment (GLOT-5):**   - <C>Recurrent or persistent disease (ADV-3)</C>.\\n'}""",invalid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: Imaging_Test_Results_8
label: Diagnostic Imaging Test Results
description: This node represents the results of a diagnostic imaging test, which is used to observe and assess specific clinical findings. The test results can indicate whether certain findings are present or absent, providing crucial information for diagnosis and treatment planning.
type: Examination Result
observability: Observed
states: [{'state_name': 'present', 'state_description': 'The imaging test has detected the presence of specific findings or abnormalities.'}, {'state_name': 'absent', 'state_description': 'The imaging test has not detected any specific findings or abnormalities.'}]

`NODE2`:
id: Extranodal_Extension_5
label: Extranodal Extension
description: Extranodal extension refers to the spread of cancer beyond the lymph node capsule into surrounding tissues. It is a significant factor in cancer staging and prognosis, as it indicates a more advanced disease and may influence treatment decisions.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'present', 'state_description': 'Extranodal extension is present, indicating that cancer has spread beyond the lymph node into surrounding tissues.'}, {'state_name': 'absent', 'state_description': 'Extranodal extension is absent, indicating that cancer is contained within the lymph node and has not spread to surrounding tissues.'}]

`EDGE1`:
{'edges_ids': ['Imaging_Test_Results_8', 'Extranodal_Extension_5'], 'edge': '(Imaging_Test_Results_8) causes (Extranodal_Extension_5)', 'explanation': ['The edge suggests that the results of a diagnostic imaging test (Imaging_Test_Results_8) cause extranodal extension (Extranodal_Extension_5).', 'Imaging tests are diagnostic tools that detect existing conditions, such as extranodal extension, but they do not cause these conditions.', 'Extranodal extension is a result of cancer spreading beyond the lymph node capsule, which is a biological process independent of imaging test results.', 'Therefore, the edge is not valid as imaging test results do not cause extranodal extension.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}

`EDGE2`:
{'edges_ids': ['Extranodal_Extension_5', 'Imaging_Test_Results_8'], 'edge': '(Extranodal_Extension_5) causes (Imaging_Test_Results_8)', 'explanation': ['Extranodal extension refers to the spread of cancer beyond the lymph node capsule into surrounding tissues, which is a significant factor in cancer staging and prognosis.', 'Imaging test results are used to detect such abnormalities, and if extranodal extension is present, it is likely to be detected by imaging tests.', 'Therefore, the presence of extranodal extension can cause imaging test results to show abnormalities, making the edge valid.', 'The causal direction is positive because the presence of extranodal extension leads to the imaging test detecting abnormalities.', 'Extranodal extension is neither a necessary nor a sufficient condition for imaging test results to show abnormalities, as there could be other causes or limitations in detection.', 'The causal distance is proximal because extranodal extension directly affects the imaging test results.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 51

Section Name: Introduction
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.
Supraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network (NCCN)"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""provides guidelines for""
2. Entity1: ""healthcare professionals"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""manage""

Causalities:-
The provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.

Section Name: Clinical Staging
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Total Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Cancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.
Tnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).

Relationships:-
1. Entity1: ""Clinical staging criteria"", Entity2: ""Total laryngectomy"", Relationship: ""determines necessity of""
2. Entity1: ""T3, N0"", Entity2: ""Clinical staging criteria"", Relationship: ""is a categorization of""

Causalities:-
The flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.

Section Name: Treatment of Primary and Neck
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Lymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Radiation Therapy"", Relationship: ""combined with""
2. Entity1: ""Laryngectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
3. Entity1: ""Thyroidectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
4. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""

Causalities:-
<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.

Section Name: Surgical Options
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Lymph Node Excision : Surgical removal of one or more lymph nodes.
Lymphadenectomy : Surgical removal of one or more groups of lymph nodes.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.

Relationships:-
1. Entity1: ""Laryngectomy"", Entity2: ""Thyroidectomy"", Relationship: ""combined with""
2. Entity1: ""Lymph Node Dissection"", Entity2: ""Surgical Intervention"", Relationship: ""extent of""
3. Entity1: ""Surgical Intervention"", Entity2: ""Advanced Cases"", Relationship: ""management option for""

Causalities:-
<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.

Section Name: Induction Chemotherapy
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Therapeutic Approach : A method or strategy used in the treatment of disease or injury.

Relationships:-
1. Entity1: ""Induction Chemotherapy"", Entity2: ""Surgical Intervention"", Relationship: ""alternative or sequential treatment option""

Causalities:-
<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.

Section Name: Adjuvant Treatment
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Neoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.
Disease Progression : The worsening of a disease over time.

Relationships:-
1. Entity1: ""Primary Treatment"", Entity2: ""Adjuvant Treatment"", Relationship: ""followed by""
2. Entity1: ""Adjuvant Treatment"", Entity2: ""Systemic Therapy"", Relationship: ""includes""
3. Entity1: ""Adjuvant Treatment"", Entity2: ""Radiotherapy"", Relationship: ""includes""
4. Entity1: ""Follow-up Assessments"", Entity2: ""Treatment Efficacy"", Relationship: ""used to evaluate""

Causalities:-
<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient's response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.

Section Name: Risk Features and Response Assessment
====================
Entities:-
Neoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.
Surgical Margins : The edge or border of the tissue removed in cancer surgery.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Extramural Extension : Extension of a tumor beyond the wall of an organ.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Cancer Management : The process of planning and coordinating the treatment of cancer.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Extramural extension"", Entity2: ""Treatment decisions"", Relationship: ""influences""
2. Entity1: ""Positive surgical margin"", Entity2: ""Treatment decisions"", Relationship: ""influences""
3. Entity1: ""Ongoing assessment"", Entity2: ""Response evaluation"", Relationship: ""leads to""
4. Entity1: ""Response evaluation"", Entity2: ""Adjustments to treatment"", Relationship: ""leads to""
5. Entity1: ""Management of cancer"", Entity2: ""Treatment decisions"", Relationship: ""involves""
6. Entity1: ""Management of cancer"", Entity2: ""Ongoing assessment"", Relationship: ""involves""
7. Entity1: ""Management of cancer"", Entity2: ""Adjustments to treatment"", Relationship: ""involves""

Causalities:-
The chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Malignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""NCCN Guidelines"", Relationship: ""provides""
2. Entity1: ""NCCN Guidelines"", Entity2: ""Clinical Trials"", Relationship: ""recommend""
3. Entity1: ""NCCN Guidelines"", Entity2: ""Cancer"", Relationship: ""related to management of""

Causalities:-
<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: SUPRA-3
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Clinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""Total laryngectomy"", Entity2: ""Laryngectomy"", Relationship: ""is a type of""
2. Entity1: ""Systemic therapy"", Entity2: ""RT"", Relationship: ""concurrent treatment option""
3. Entity1: ""Induction chemotherapy"", Entity2: ""Other treatments"", Relationship: ""initial treatment option before""

Causalities:-
<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>
  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>
  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>
  - or
  - <A> Induction chemotherapy </A>
  - or
  - <A> Clinical trials </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient's condition after initial treatment.
Follow-Up : Medical care given to a patient over time after initial treatment.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : The reappearance of a disease after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
- **Follow-up (FOLL-A, 1 of 2)**
  - <CO> Recurrent or persistent disease </CO> (ADV-3)

Section Name: Adverse Pathologic Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer beyond the lymph node capsule.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""pN1"", Entity2: ""Radiotherapy"", Relationship: ""Consideration for treatment""
2. Entity1: ""Extranodal extension"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
3. Entity1: ""Extranodal extension"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""
4. Entity1: ""Positive surgical margin"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
5. Entity1: ""Positive surgical margin"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""

Causalities:-
- <CO>pN1 without other risk features</CO>
  - <C>Adverse pathologic features</C>
  - <A>Consider RT</A>
  - <CO>Extranodal extension and/or positive margin</CO>
  - <CO>Other risk features</CO>
  - <A>Systemic therapy/RT (category 1)</A>
  - <A>RT or Consider systemic therapy/RT</A>

Section Name: Response Assessment
====================
Entities:-
Response Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.
Response To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.

Relationships:-

Section Name: Principles of Surgery and Radiation Therapy
====================
Entities:-
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""complementary treatments""

Causalities:-
**Principles of Surgery (SURG-A).**

**Principles of Radiation Therapy (SUPRA-A).**

Section Name: Principles of Systemic Therapy
====================
Entities:-
Cisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Cisplatin"", Entity2: ""Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""preferred agent""
2. Entity1: ""Cisplatin"", Entity2: ""Concurrent Systemic Therapy/RT"", Relationship: ""used in""

Causalities:-
<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.
--------------------------------------------------
Page Number: 53

Section Name: Introduction
====================
Entities:-
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""Malignant neoplasm of supraglottis"", Relationship: ""provides guidelines for""
2. Entity1: ""clinical staging"", Entity2: ""treatment strategies"", Relationship: ""part of flowchart for""

Causalities:-
The provided image is a flowchart outlining the <C> NCCN (National Comprehensive Cancer Network) guidelines </C> for the treatment of <CO> cancers of the supraglottic larynx </CO>. This flowchart <A> utilizes a highly structured approach to convey clinical staging and treatment strategies </A>, indicating the various pathways based on <CO> patient conditions and disease features </CO>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.
Supraglottic Cancer : Cancer that occurs in the supraglottic region of the larynx, above the vocal cords.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.

Relationships:-
1. Entity1: ""Cancer of the Supraglottic Larynx"", Entity2: ""Clinical Trials"", Relationship: ""recommended management strategy""

Causalities:-
- All recommendations are category 2A unless otherwise indicated.
- <A> Participation in clinical trials </A> is especially encouraged.

Section Name: Key Components of the Flowchart
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Radiotherapy : The use of ionizing radiation to treat cancer.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Neoplasm Recurrence, Local : The return of a tumor at the original site after treatment.
Clinical Trials As Topic : Pre-planned studies of the safety, efficacy, or optimum dosage schedule of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in humans selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects.

Relationships:-
1. Entity1: ""Clinical Staging"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""determines""
2. Entity1: ""Evaluation and Follow-Up"", Entity2: ""Adverse and No Adverse Features"", Relationship: ""leads to decision based on""
3. Entity1: ""Adjuvant Treatment"", Entity2: ""Adverse pathologic features"", Relationship: ""considered if present""
4. Entity1: ""Clinical Trials"", Entity2: ""Treatment Pathway"", Relationship: ""part of""

Causalities:-
### Key Components of the Flowchart

1. **Clinical Staging**: The flowchart starts with <A>clinical staging</A>, indicating that <CO>patients must first be evaluated to determine the extent of cancer</CO>. This is essential for <E>deciding on appropriate treatment options</E>.

2. **Treatment of Primary and Neck**: The flowchart details multiple treatment strategies, including:
   - <A>**Concurrent systemic therapy/RT**</A>: This suggests a combination approach for <CO>patients eligible for such treatment</CO>.
   - <A>**Definitive Radiation Therapy (RT)**</A>: Recommended for <CO>low-volume diseases or patients who cannot tolerate systemic therapy</CO>.
   - <A>**Surgical Options**</A>: It highlights options such as endoscopic or open partial laryngectomy and neck dissection, which are <CO>contingent on clinical evaluations</CO>.

3. **Evaluation and Follow-Up**: After initial treatment approaches, the chart directs clinicians to perform a <A>""Post Systemic Therapy/RT or RT Neck Evaluation""</A>. This step <E>assesses whether there are adverse pathologic features</E>, guiding subsequent treatment decisions.

4. **Adverse and No Adverse Features**: The decision pathway diverges based on findings:
   - <CO>Patients with **adverse pathologic features**</CO> may have <A>additional diagnostic imaging (CT or MRI)</A> and may require <A>further systemic treatment</A>.
   - <CO>Patients with **no adverse features**</CO> may be directed towards <A>considerations for radiation therapy</A>.

5. **Adjuvant Treatment and Recurrence**: The chart also addresses <E>management of any recurrent or persistent disease</E>, emphasizing the importance of <A>regular follow-up assessments</A>. Various options for <A>adjuvant treatment</A> are mentioned, focusing on tailored approaches towards ongoing management of the disease.

6. **Clinical Trials**: The flowchart encourages <A>participation in clinical trials</A>, indicating a commitment to <E>exploring new treatments and improving patient outcomes</E>.

Section Name: Principles
====================
Entities:-
Imaging : The process of producing images of the body or parts of the body to diagnose or examine disease.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Radiation Therapy : The use of ionizing radiation to treat cancer and other diseases.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Imaging"", Entity2: ""Surgery"", Relationship: ""Both are foundational principles in medical practice.""
2. Entity1: ""Radiation therapy"", Entity2: ""Systemic Therapy"", Relationship: ""Both are treatment modalities for cancer.""

Causalities:-
#### Principles
- **Principles of Imaging (IMG-A)**
- **Principles of Surgery (SURG-A)**
- **Principles of Radiation Therapy (SUPRA-A)**
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**

Section Name: Adverse Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margins : The presence of cancer cells at the edge of the tissue removed during surgery.
Perineural Invasion : Cancer cells found surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The presence of cancer cells within blood vessels.
Lymphatic Invasion : The presence of cancer cells within lymphatic vessels.

Relationships:-
1. Entity1: ""Extranodal Extension"", Entity2: ""Positive Surgical Margins"", Relationship: ""Both indicate cancer spread beyond original site.""
2. Entity1: ""Perineural Invasion"", Entity2: ""Vascular Invasion"", Relationship: ""Both are pathways for cancer spread.""
3. Entity1: ""pT3 or pT4 primary"", Entity2: ""pN2 or pN3 nodal disease"", Relationship: ""Both indicate advanced cancer stages.""

Causalities:-
<C> Extranodal extension </C>
<C> Positive margins </C>
<C> Close margins </C>
<C> pT3 or pT4 primary </C>
<C> pN2 or pN3 nodal disease </C>
<C> Perineural invasion </C>
<C> Vascular invasion </C>
<C> Lymphatic invasion </C>

Section Name: Clinical Staging and Treatment of Primary and Neck
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient after treatment.
Recurrent Disease : A disease that returns after a period of remission.
Laryngectomy : Surgical removal of the larynx, often used to treat cancer.
Radiation Therapy : The use of ionizing radiation to treat cancer and other diseases.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat cancer.
Chemotherapy : Treatment of disease by the use of chemical substances, especially cancer by cytotoxic drugs.

Relationships:-
1. Entity1: ""Adjuvant Treatment"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""part of""
2. Entity1: ""Follow-up"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""part of""
3. Entity1: ""Recurrent or Persistent Disease"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""part of""
4. Entity1: ""Larynx-Preserving Surgery"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
5. Entity1: ""Concurrent Systemic Therapy/RT"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
6. Entity1: ""Clinical Trials or Definitive RT"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
7. Entity1: ""Endoscopic or Open Partial Laryngectomy and Neck Dissection(s)"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""
8. Entity1: ""Induction Chemotherapy"", Entity2: ""Treatment Options"", Relationship: ""is a treatment option for""

Causalities:-
<A> Amenable to Larynx-Preserving (Conservation) Surgery </A>: <CO> T1–2, N+ and selected T3, N1 </CO>
<A> Concurrent Systemic Therapy/RT </A>: <CO> i, k, l </CO>
<A> Clinical Trials or Definitive RT </A>: <CO> i </CO>
<A> Endoscopic or Open Partial Laryngectomy and Neck Dissection(s) </A>: <CO> h </CO>
<A> Induction Chemotherapy </A>: <CO> k, m </CO>

Section Name: Pathologic Features and Response Assessment
====================
Entities:-
Radiation Therapy : The use of ionizing radiation to treat cancer and other diseases.
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Extranodal extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
2. Entity1: ""Positive margin"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
3. Entity1: ""Systemic Therapy"", Entity2: ""Adverse Pathologic Features"", Relationship: ""considered in response to""
4. Entity1: ""Radiation Therapy"", Entity2: ""Adverse Pathologic Features"", Relationship: ""considered in response to""

Causalities:-
#### Pathologic Features
- **No Adverse Pathologic Features**: j
  - <A> Consider RT </A>: i
- **Adverse Pathologic Features**: j
  - <CO> Extranodal extension and/or positive margin </CO>: n
  - Other risk features
  - <A> Systemic therapy/RT </A>: i, k (category 1)
  - <A> Consider systemic therapy/RT </A>: i, k

#### Response Assessment
- **Response Assessment** (SUPRA-7)

Section Name: Imaging and Recurrent or Persistent Disease
====================
Entities:-
Tomography, X-Ray Computed : A method of body imaging in which a thin X-ray beam rotates around the patient.
Magnetic Resonance Imaging : Medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Computed Tomography : Medical imaging technique used in radiology to obtain detailed internal images of the body.

Relationships:-
1. Entity1: ""CT"", Entity2: ""primary and neck"", Relationship: ""used for imaging""
2. Entity1: ""MRI"", Entity2: ""primary and neck"", Relationship: ""used for imaging""
3. Entity1: ""Post Systemic Therapy/RT"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""evaluation after treatment""
4. Entity1: ""RT Neck Evaluation"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""evaluation after treatment""

Causalities:-
<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>

<CO> Recurrent or Persistent Disease </CO>

<CO> Post Systemic Therapy/RT or RT Neck Evaluation </CO>

Section Name: Conclusion
====================
Entities:-
Oncologists : Medical doctors who specialize in the diagnosis and treatment of cancer.
Supraglottic Larynx Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is the area above the vocal cords.
Clinical Staging : The process of determining the extent of cancer in the body, usually based on physical examination, imaging tests, and biopsies.
Treatment Strategies : Plans or methods developed to treat diseases, including cancer, which may involve surgery, chemotherapy, radiation therapy, or other modalities.
Follow-Up Evaluations : Medical assessments conducted after initial treatment to monitor a patient's progress and detect any recurrence of disease.
Clinical Efficacy : The ability of a treatment to produce the desired therapeutic effect in clinical settings.
Research : Systematic investigation and study conducted to establish facts and reach new conclusions.
Treatment Paradigms : Standard models or patterns of treatment used in medical practice, often based on clinical guidelines and research findings.

Relationships:-
1. Entity1: ""Oncologists"", Entity2: ""Supraglottic Larynx Cancer"", Relationship: ""use flowchart for decision-making""
2. Entity1: ""Clinical Staging"", Entity2: ""Treatment Strategies"", Relationship: ""part of management process""
3. Entity1: ""Treatment Strategies"", Entity2: ""Follow-Up Evaluations"", Relationship: ""part of management process""

Causalities:-
<A> The flowchart serves as a comprehensive guide for oncologists and healthcare providers </A>, <A> facilitating informed decision-making in the treatment of supraglottic larynx cancer </A>. <A> By visualizing the complex interactions between clinical staging, treatment strategies, and follow-up evaluations </A>, <E> it streamlines the management process </E>, <E> ensuring that patients receive appropriate care tailored to their specific needs </E>. <E> The detailed pathways not only enhance clinical efficacy </E> but also <E> underscore the importance of ongoing research and adaptation of treatment paradigms in oncology </E>.
--------------------------------------------------
Page Number: 55

Section Name: General Information
====================
Entities:-
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Nccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""National Comprehensive Cancer Network"", Relationship: ""produced by""

Section Name: Important Notes
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Neoplasms : New abnormal growth of tissue that can be benign or malignant.
Malignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Clinical Trials"", Entity2: ""Cancer"", Relationship: ""recommended for""
2. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""

Causalities:-
<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles
====================
Entities:-
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Chemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""Both are principles of cancer treatment methods.""
2. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""
3. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""

Causalities:-
### Principles

- **Principles of Surgery (SURG-A)**
- **Principles of Radiation Therapy (SUPRA-A)**
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**

Section Name: Adverse Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Perineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The invasion of cancer cells into blood vessels.
Lymphatic Invasion : The invasion of cancer cells into lymphatic vessels.

Relationships:-
1. Entity1: ""Extranodal extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
2. Entity1: ""Positive margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
3. Entity1: ""Close margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
4. Entity1: ""pT3 or pT4 primary"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
5. Entity1: ""pN2 or pN3 nodal disease"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
6. Entity1: ""Perineural invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
7. Entity1: ""Vascular invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
8. Entity1: ""Lymphatic invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""

Causalities:-
<C> Extranodal extension </C>
<C> Positive margins </C>
<C> Close margins </C>
<C> pT3 or pT4 primary </C>
<C> pN2 or pN3 nodal disease </C>
<C> Perineural invasion </C>
<C> Vascular invasion </C>
<C> Lymphatic invasion </C>

Section Name: Response Assessment
====================
Entities:-
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Primary Site : The original location where a tumor or cancer begins.
Complete Remission : The disappearance of all signs of cancer in response to treatment.
Partial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.

Relationships:-
1. Entity1: ""induction chemotherapy"", Entity2: ""Primary site"", Relationship: ""treatment outcome""
2. Entity1: ""Definitive RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
3. Entity1: ""RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
4. Entity1: ""Surgery"", Entity2: ""unresectable nodal disease"", Relationship: ""treatment option""

Causalities:-
<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.
Follow-Up (Medicine) : The process of monitoring a patient's health over time after treatment or diagnosis.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : A disease that returns after a period of remission.
Recurrence (Medicine) : The return of a disease or condition after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
### Follow-up

- **Follow-up** (FOLL-A, 1 of 2)
- **Recurrent or persistent disease** (ADV-3)

Section Name: Risk Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""RT"", Relationship: ""Consideration for treatment""
2. Entity1: ""Adverse pathologic features"", Entity2: ""Systemic therapy"", Relationship: ""Consideration for treatment""

Causalities:-
- **No adverse pathologic features**
- **Other risk features**
- **Adverse pathologic features**:
  - <C> Extranodal extension and/or positive margin </C>
  - <A> RT or consider systemic therapy/RT </A>

Section Name: Post-Therapy Evaluation
====================
Entities:-
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Neck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""
2. Entity1: ""RT"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""

Causalities:-
<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>

Section Name: Flowchart Overview
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Supraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""guides management of""
2. Entity1: ""NCCN Guidelines"", Entity2: ""healthcare professionals"", Relationship: ""used by""

Causalities:-
<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.

Section Name: Assessment and Treatment Decisions
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Complete Response : The disappearance of all signs of cancer in response to treatment.
Partial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Complete Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""
2. Entity1: ""Complete Response"", Entity2: ""Surgery"", Relationship: ""leads to""
3. Entity1: ""Partial Response"", Entity2: ""Systemic Therapy"", Relationship: ""leads to""
4. Entity1: ""Partial Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""

Causalities:-
<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.

Section Name: Adverse Pathologic Features and Follow-up
====================
Entities:-
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Neoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Recurrent Neoplasm : A neoplasm that has returned after treatment.
Metastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.
Metastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""Treatment decisions"", Relationship: ""Influence""
2. Entity1: ""Adverse features"", Entity2: ""Surgical intervention"", Relationship: ""Recommendation""
3. Entity1: ""Absence of adverse features"", Entity2: ""Radiation therapy"", Relationship: ""Pathway""
4. Entity1: ""Follow-up process"", Entity2: ""Recurrent or persistent disease"", Relationship: ""Detection""
5. Entity1: ""Recurrent or persistent disease"", Entity2: ""Advanced disease management"", Relationship: ""Necessity""

Causalities:-
<C> The presence of adverse pathologic features — such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient's disease characteristics.

Furthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.
--------------------------------------------------
Page Number: 70

Section Name: Diagnosis
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Personalized Medicine : A medical model that proposes the customization of healthcare, with medical decisions, practices, and/or products being tailored to the individual patient.

Relationships:-
1. Entity1: ""recurrent or persistent disease"", Entity2: ""distant metastases"", Relationship: ""has condition""
2. Entity1: ""Clinical trials"", Entity2: ""recurrent or persistent disease with distant metastases"", Relationship: ""recommended for""
3. Entity1: ""locoregional failure"", Entity2: ""locoregional treatment"", Relationship: ""treatment response to""

Causalities:-
In the **Diagnosis** section, the focus is on <C> recurrent or persistent disease with distant metastases </C>. <A> Clinical trials are preferred </A> for <CO> patients diagnosed at this stage </CO>. <CO> If there is locoregional failure </CO>, <A> locoregional treatment should be considered based on the extent of the disease and symptoms presented </A>. This highlights the importance of personalized treatment approaches, taking into account the unique circumstances of each patient.

Section Name: Treatment
====================
Entities:-
Therapeutics : The branch of medicine concerned with the treatment of disease and the action of remedial agents.
Performance Status : A measure of how well a patient is able to perform ordinary tasks and carry out daily activities.
Systemic Therapy : A type of treatment that uses substances that travel through the bloodstream, reaching and affecting cells all over the body.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Palliative Care : An interdisciplinary medical caregiving approach aimed at optimizing quality of life and mitigating suffering among people with serious, complex illness.
Radiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Performance Status"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option for PS 0-1, PS 2, and PS 3 patients""
2. Entity1: ""Performance Status"", Entity2: ""Surgery"", Relationship: ""Treatment option for PS 0-1 patients""
3. Entity1: ""Performance Status"", Entity2: ""Best Supportive Care"", Relationship: ""Treatment option for PS 0-1 and PS 3 patients""
4. Entity1: ""Performance Status"", Entity2: ""Palliative Treatments"", Relationship: ""Treatment option for PS 2 and PS 3 patients""
5. Entity1: ""Performance Status"", Entity2: ""Radiation Therapy"", Relationship: ""Consideration for PS 3 patients""

Causalities:-
The <C> Treatment section </C> outlines pathways based on <C> performance status (PS) </C>. For <CO> PS 0-1 patients </CO>, <A> options include combination systemic therapy, single-agent systemic therapy, surgery, or best supportive care for those with limited metastases </A>. For <CO> PS 2 patients </CO>, <A> recommendations include single-agent systemic therapy, supportive care, or palliative treatments </A>. For <CO> PS 3 patients </CO>, <A> the focus is on single-agent therapy and best supportive care, with consideration of palliative radiation therapy (RT) and palliative surgery </A>. This section addresses the evolving needs of patients as their <C> performance status declines </C>.

Section Name: Persistent Disease or Progression
====================
Entities:-
Disease Progression : The worsening of a disease over time.
Systemic Therapy : A type of treatment that uses substances that travel through the bloodstream, reaching and affecting cells all over the body.
Clinical Trials : Research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
Palliative Care : An interdisciplinary medical caregiving approach aimed at optimizing quality of life and mitigating suffering among people with serious, complex illness.
Quality Of Life : An individual's overall appraisal of their situation and well-being.
Supportive Care : Care given to improve the quality of life of patients who have a serious or life-threatening disease.

Relationships:-
1. Entity1: ""Persistent Disease or Progression"", Entity2: ""Systemic Therapy"", Relationship: ""option for management""
2. Entity1: ""Persistent Disease or Progression"", Entity2: ""Clinical Trials"", Relationship: ""option for management""
3. Entity1: ""Persistent Disease or Progression"", Entity2: ""Palliative Care"", Relationship: ""option for management""
4. Entity1: ""Best Supportive Care"", Entity2: ""Quality of Life"", Relationship: ""improves""
5. Entity1: ""Best Supportive Care"", Entity2: ""Advanced Illness"", Relationship: ""applied in context of""

Causalities:-
<A> continued evaluation of treatment efficacy </A> is reiterated. <A> Options include systemic therapy, clinical trials, or palliative care </A> <CO> based on the specific patient condition </CO>. <A> Best supportive care is emphasized </A>, <E> prioritizing the patient's quality of life </E>, <CO> particularly in the context of advanced illness </CO>.

Section Name: NCCN Guidelines Overview
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Neoplasms : New abnormal growth of tissue that may be benign or malignant.
Malignant Neoplastic Disease : A disease in which abnormal cells divide uncontrollably and destroy body tissue.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""cancer"", Entity2: ""clinical trial"", Relationship: ""best management through""

Causalities:-
<CO> any patient with cancer </CO> <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles and Considerations
====================
Entities:-
Radiation Therapy : The medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgery : A medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Surgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Genomic Profiling : The measurement of the activity (the expression) of thousands of genes at once, to create a global picture of cellular function.
Biomarkers : Biological molecules found in blood, other body fluids, or tissues that are a sign of a normal or abnormal process, or of a condition or disease.
Biomarker : A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease.
Palliative Care : An interdisciplinary medical caregiving approach aimed at optimizing quality of life and mitigating suffering among people with serious, complex illness.
Bone Neoplasms : Tumors or cancer of the bone.
Bone Metastasis : The spread of cancer cells from their original site to a bone.

Relationships:-
1. Entity1: ""Palliative RT"", Entity2: ""Bone Metastases"", Relationship: ""treatment for""

Causalities:-
- **Principles of Radiation Therapy (ADV-A).**
- **Principles of Surgery (SURG-A).**
<A> Consider NGS genomic profiling for biomarker identification. </A>
<A> Consider palliative RT </A> <CO> as clinically indicated (e.g., bone metastases) </CO> (RAD-A).
- See Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A) or Systemic Therapy for Nasopharyngeal Cancers (NASO-B).
--------------------------------------------------
Page Number: 46

Section Name: Introduction
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, including the glottis.
Malignant Neoplasm Of Glottis : A malignant tumor located in the glottis, part of the larynx.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness, often used in cancer treatment.
Adjuvant Therapy : Treatment given in addition to the primary (main) treatment to enhance its effectiveness.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""Laryngeal Neoplasms"", Relationship: ""provides treatment guidelines for""
2. Entity1: ""treatment guidelines"", Entity2: ""Adjuvant therapy"", Relationship: ""guide clinical decision-making for""

Causalities:-
<C> cancer of the glottic larynx </C> <E> treatment guidelines </E> <CO> based on various clinical stages and specific patient conditions </CO> <A> guide healthcare professionals through clinical decision-making </A>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 30 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""

Causalities:-
<A>Participation in clinical trials</A> is especially encouraged.

Section Name: Clinical Staging and Treatment
====================
Entities:-
Neoplasm Staging : Methods used for staging of neoplasms based on extent of tumor spread.
T4A : A clinical stage indicating a tumor that has grown into nearby structures.
N0–3 : A range of clinical stages indicating the extent of regional lymph node involvement.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue in the neck.
Pathology : The study of the nature and cause of disease which involves changes in structure and function.
Antineoplastic Combined Chemotherapy Protocols : The use of drug combinations to treat cancer.
Radiotherapy : The use of ionizing radiation to treat cancer.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.

Relationships:-
1. Entity1: ""Clinical Staging"", Entity2: ""Surgical Intervention"", Relationship: ""determines""
2. Entity1: ""T4a"", Entity2: ""Surgical Intervention"", Relationship: ""relates to""
3. Entity1: ""Systemic Therapy"", Entity2: ""Radiotherapy"", Relationship: ""considered with""
4. Entity1: ""Clinical Trials"", Entity2: ""Treatment of Primary and Neck"", Relationship: ""option for""

Causalities:-
<CO> Clinical staging indicator labeled ""T4a,N0–3"" </CO> <A> emphasizes the importance of surgical intervention </A>, highlighting procedures such as bilateral neck dissection and the need to address certain pathologic features. <CO> Selected T4a patients who decline surgery </CO> <A> consider concurrent systemic therapy/RT or clinical trial for function-preserving surgical or RT management or induction chemotherapy </A>.

Section Name: Principles of Treatment
====================
Entities:-
Thyroidectomy : Surgical removal of the thyroid gland.
Extranodal Extension : Spread of cancer beyond the lymph node capsule.
Radiation Therapy : Medical use of ionizing radiation to treat cancer.

Relationships:-
1. Entity1: ""Surgery"", Entity2: ""Thyroidectomy"", Relationship: ""involves""
2. Entity1: ""Radiation therapy"", Entity2: ""Adverse pathologic features"", Relationship: ""treats""

Causalities:-
- **Principles of Radiation Therapy (GLOT-A):**  
  - <C> Adverse pathologic features: extranodal extension, positive margins, close margins, pT4 primary, pN2 or pN3 nodal disease, perineural invasion, vascular invasion, lymphatic invasion, and subglottic extension </C> (Discussion).  

- **Principles of Surgery (SURG-A):**  
  - <A> Surgery, including ipsilateral or bilateral neck dissection; thyroidectomy to clear central compartment nodes </A>, <CO> especially when there is thyroid cartilage with gross invasion of the thyroid gland and significant subglottic extension </CO>.

Section Name: Adjuvant Treatment and Follow-up
====================
Entities:-
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Computed Tomography (Ct) : A medical imaging technique used in radiology to obtain detailed internal images of the body noninvasively for diagnostic purposes.
Magnetic Resonance Imaging (Mri) : A noninvasive medical test that physicians use to diagnose and treat medical conditions.
Recurrent Disease : A disease that has returned after a period of remission.
Radiation Therapy (Rt) : The use of ionizing radiation to treat cancer and other diseases.

Relationships:-
1. Entity1: ""Adverse Features"", Entity2: ""Specific Treatments"", Relationship: ""Suggests""
2. Entity1: ""Systemic Therapy"", Entity2: ""Patients who decline surgery"", Relationship: ""Option for""
3. Entity1: ""CT or MRI"", Entity2: ""Primary and Neck"", Relationship: ""Used for imaging""
4. Entity1: ""Recurrent or Persistent Disease"", Entity2: ""Follow-up"", Relationship: ""Condition for""
5. Entity1: ""pN1 without other risk features"", Entity2: ""RT"", Relationship: ""Suggests considering""

Causalities:-
<C> adverse features such as extralateral extension or positive margins </C> <E> specific treatments are suggested </E>. The guidelines recommend <A> considering options like concurrent systemic therapy or clinical trials </A> <CO> for patients who decline surgery </CO>.

- **Adjuvant Treatment:**  
  - <A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>.  

- **Follow-up (FOLL-A, 1 of 2):**  
  - <CO> Recurrent or persistent disease (ADV-3) </CO>.  

- **Post Systemic Therapy/RT or RT Neck Evaluation (FOLL-A, 2 of 2):**  
  - <CO> pN1 without other risk features </CO>: <A> Consider RT </A>.

Section Name: Response Assessment
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness, often used in cancer treatment.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images of the body.
Magnetic Resonance Imaging : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Neoplasm Recurrence, Local : The return of a cancer, at the same site as the original (primary) tumor, after it had disappeared.

Relationships:-
1. Entity1: ""Adjuvant treatment"", Entity2: ""Treatment responses"", Relationship: ""affects""
2. Entity1: ""Follow-up assessments"", Entity2: ""CT or MRI scans"", Relationship: ""conducted using""
3. Entity1: ""Response Assessment (GLOT-5)"", Entity2: ""Recurrent or persistent disease (ADV-3)"", Relationship: ""determines""

Causalities:-
As the flowchart progresses to the adjuvant treatment section, it depicts further decision points based on treatment responses and disease recurrence. The inclusion of references to follow-up assessments, such as CT or MRI scans, underscores the emphasis on continuous monitoring and evaluation of treatment efficacy.  - **Response Assessment (GLOT-5):**   - <C>Recurrent or persistent disease (ADV-3)</C>.


Among these two options which one is the most likely true:

(A) `Imaging_Test_Results_8` increases risk `Extranodal_Extension_5`
(B) `Extranodal_Extension_5` `increases risk `Imaging_Test_Results_8`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge (A) suggests that imaging test results increase the risk of extranodal extension. However, imaging tests are diagnostic tools that detect existing conditions and do not cause them. Extranodal extension is a biological process related to cancer spread, independent of imaging results.
2. The edge (B) suggests that extranodal extension increases the risk of imaging test results showing abnormalities. This is more plausible because if extranodal extension is present, it is likely to be detected by imaging tests, leading to abnormal results.
3. The causal direction for edge (B) is positive, as the presence of extranodal extension leads to imaging tests detecting abnormalities. This aligns with the understanding that extranodal extension is a significant factor in cancer staging and prognosis, which imaging tests aim to detect.
4. The causal factor for edge (B) is neither necessary nor sufficient, as other factors can also lead to abnormal imaging results, and extranodal extension may not always be detected due to limitations in imaging.
5. The causal distance for edge (B) is proximal, as extranodal extension directly affects imaging test results.
6. The NCCN guidelines emphasize the role of imaging in detecting cancer spread, including extranodal extension, which supports the validity of edge (B).
","1. Page Number: 51, Section Name: Adverse Pathologic Features, Entities: Extranodal Extension, Imaging, Relationships: Extranodal extension is a type of adverse pathologic feature detected by imaging.
2. Page Number: 53, Section Name: Imaging and Recurrent or Persistent Disease, Entities: CT, MRI, Relationships: Used for imaging primary and neck, evaluation after treatment.
3. Page Number: 55, Section Name: Adverse Pathologic Features, Entities: Extranodal Extension, Positive Surgical Margin, Relationships: Both indicate cancer spread beyond the original site, detected by imaging.
",B,"{'A': 0.0, 'B': 100.0}",yes,B,"1. The AI assistant's reasoning for option (A) is consistent with the understanding that imaging tests are diagnostic tools and do not cause conditions like extranodal extension. This aligns with the explanation provided in the edge analysis, which states that imaging tests detect existing conditions rather than causing them.
2. For option (B), the AI assistant correctly identifies that extranodal extension can lead to imaging test results showing abnormalities. This is consistent with the explanation that extranodal extension is a significant factor in cancer staging and prognosis, which imaging tests aim to detect.
3. The causal direction for option (B) is positive, as the presence of extranodal extension leads to imaging tests detecting abnormalities. This is consistent with the explanation provided in the edge analysis, which states that extranodal extension directly affects imaging test results.
4. The causal factor for option (B) is neither necessary nor sufficient, as other factors can also lead to abnormal imaging results, and extranodal extension may not always be detected due to limitations in imaging. This is consistent with the explanation provided in the edge analysis.
5. The causal distance for option (B) is proximal, as extranodal extension directly affects imaging test results. This is consistent with the explanation provided in the edge analysis.
6. The AI assistant's reasoning is consistent with the information from the NCCN guidelines, which emphasize the role of imaging in detecting cancer spread, including extranodal extension. This supports the validity of option (B).
"
4,gpt-4o,"Lymph_Node_Biopsy_Results_9,Extranodal_Extension_5","""{'NODE1': {'id': 'Lymph_Node_Biopsy_Results_9', 'label': 'Lymph Node Biopsy Examination Results', 'description': 'This node represents the results of a biopsy performed on a lymph node to determine the presence or absence of pathological findings, such as cancer cells. It is a critical diagnostic examination used to assess the spread of cancer to the lymphatic system.', 'type': 'Examination Result', 'observability': 'Observed', 'states': [{'state_name': 'present', 'state_description': \""The 'present' state indicates that the biopsy results show the presence of pathological findings, such as cancer cells, in the lymph node.\""}, {'state_name': 'absent', 'state_description': \""The 'absent' state indicates that the biopsy results do not show any pathological findings in the lymph node, suggesting no presence of cancer cells.\""}]}, 'NODE2': {'id': 'Extranodal_Extension_5', 'label': 'Extranodal Extension', 'description': 'Extranodal extension refers to the spread of cancer beyond the lymph node capsule into surrounding tissues. It is a significant factor in cancer staging and prognosis, as it indicates a more advanced disease and may influence treatment decisions.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'present', 'state_description': 'Extranodal extension is present, indicating that cancer has spread beyond the lymph node into surrounding tissues.'}, {'state_name': 'absent', 'state_description': 'Extranodal extension is absent, indicating that cancer is contained within the lymph node and has not spread to surrounding tissues.'}]}, 'EDGE1': {'edges_ids': ['Lymph_Node_Biopsy_Results_9', 'Extranodal_Extension_5'], 'edge': '(Lymph_Node_Biopsy_Results_9) causes (Extranodal_Extension_5)', 'explanation': ['The edge represents the relationship between the results of a lymph node biopsy and the presence of extranodal extension.', 'A positive lymph node biopsy result (presence of cancer cells) is necessary for extranodal extension to occur, as cancer must be present in the lymph node before it can spread beyond it.', 'However, a positive biopsy result is not sufficient to cause extranodal extension, as not all cases with cancer in the lymph node will have extranodal extension.', 'The causal direction is positive because the presence of cancer cells in the lymph node increases the likelihood of extranodal extension.', 'The causal distance is proximal because the presence of cancer cells in the lymph node is directly related to the potential for extranodal extension.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': True, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'EDGE2': {'edges_ids': ['Extranodal_Extension_5', 'Lymph_Node_Biopsy_Results_9'], 'edge': '(Extranodal_Extension_5) causes (Lymph_Node_Biopsy_Results_9)', 'explanation': ['Extranodal extension indicates that cancer has spread beyond the lymph node capsule into surrounding tissues.', 'If extranodal extension is present, it is likely that a lymph node biopsy would show the presence of cancer cells, as the cancer has spread beyond the lymph node.', 'The edge is valid because extranodal extension can directly influence the results of a lymph node biopsy by indicating the presence of cancer cells.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'ENTITIES_MATCHING_PAGES_INFO': {'49': {'matching_entities': [{'BIOPSY': 0.98102695}, {'NEEDLE BIOPSY': 0.9470839}, {'BIOPSY, NEEDLE': 0.9454435}, {'CORE BIOPSY': 0.94171464}, {'CORE NEEDLE BIOPSY': 0.9415768}, {'FINE NEEDLE ASPIRATION BIOPSY': 0.9222763}], 'count': 6}, '130': {'matching_entities': [{'LYMPH NODE STRUCTURE': 0.99134904}, {'LYMPH NODE': 0.98570025}, {'LYMPH NODES': 0.97445965}, {'NEOPLASM METASTASIS': 0.95823944}, {'METASTASIS': 0.9265935}], 'count': 5}, '41': {'matching_entities': [{'BIOPSY': 0.98102695}, {'LYMPHATIC METASTASIS': 0.94701207}, {'BIOPSY, NEEDLE': 0.9454435}, {'METASTASIS': 0.9265935}], 'count': 4}, '102': {'matching_entities': [{'BIOPSY': 0.98102695}, {'LYMPHATIC SYSTEM': 0.95855314}, {'LYMPHATIC STRUCTURE': 0.9469132}, {'METASTASIS': 0.9265935}], 'count': 4}, '55': {'matching_entities': [{'EXTRANODAL EXTENSION': 0.97547734}, {'NEOPLASM METASTASIS': 0.95823944}, {'METASTATIC NEOPLASM': 0.9350836}, {'METASTASIS': 0.9265935}], 'count': 4}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 49\\n\\nSection Name: NCCN Guidelines Overview\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nNeoplasms : New abnormal growth of tissue that possesses no physiological function and arises from uncontrolled usually rapid cellular proliferation.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nMalignant Neoplastic Disease : A disease in which abnormal cells divide uncontrollably and destroy body tissue.\\nNccn Guidelines : Clinical practice guidelines developed by the National Comprehensive Cancer Network to ensure that patients receive preventive, diagnostic, treatment, and supportive services that are most likely to lead to optimal outcomes.\\nNational Comprehensive Cancer Network : An alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""National Comprehensive Cancer Network\"", Relationship: \""published by\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""Clinical Trials\"", Relationship: \""recommends\""\\n3. Entity1: \""Clinical Trials\"", Entity2: \""Cancer\"", Relationship: \""management strategy for\""\\n\\nCausalities:-\\n<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: SUPRA-1\\n====================\\nEntities:-\\nTobacco Use Disorder : A disorder characterized by the continued use of tobacco despite significant related problems.\\nTobacco Use : The act of using tobacco products.\\nTobacco Smoking : The practice of burning tobacco and inhaling the smoke.\\nAlcohol Drinking : The consumption of beverages containing ethyl alcohol.\\nAlcohol Use : The act of consuming alcoholic beverages.\\nAlcohol Consumption : The act of drinking beverages containing ethanol.\\nSmoking Cessation : The process of discontinuing tobacco smoking.\\nDepression : A mood disorder characterized by a persistent feeling of sadness and loss of interest.\\nDepressive Disorder : A mental disorder characterized by persistent low mood and loss of interest.\\nDepression (Mood) : A state of low mood and aversion to activity.\\nDistress, Psychological : A state of emotional suffering associated with stressors and demands that are difficult to cope with in daily life.\\nPsychological Distress : A state of emotional suffering typically characterized by symptoms of depression and anxiety.\\nPsychological Stress : A feeling of strain and pressure.\\nBiopsy, Needle : The removal of tissue or cells with a needle for examination under a microscope.\\nNeedle Biopsy : A procedure to extract tissue or fluid samples from the body using a needle.\\nNeck : The part of the body on many vertebrates that separates the head from the torso or trunk.\\nNeck Structure : Anatomical structure of the neck.\\nBiopsy : The removal and examination of tissue, cells, or fluids from the living body.\\nCore Biopsy : A biopsy procedure that uses a hollow needle to remove a core of tissue for examination.\\nCore Needle Biopsy : A procedure that uses a hollow needle to remove a sample of tissue for examination.\\nGenomics : An interdisciplinary field of biology focusing on the structure, function, evolution, mapping, and editing of genomes.\\nGenomic Testing : Testing that involves the analysis of the genome.\\n\\nRelationships:-\\n1. Entity1: \""Tobacco use\"", Entity2: \""Smoking cessation\"", Relationship: \""advised to quit\""\\n2. Entity1: \""Depression\"", Entity2: \""Distress management\"", Relationship: \""screening for\""\\n3. Entity1: \""Image-guided needle biopsy\"", Entity2: \""Cystic neck nodes\"", Relationship: \""used for\""\\n4. Entity1: \""Core biopsy\"", Entity2: \""Immune-genomic testing\"", Relationship: \""allows for\""\\n\\nCausalities:-\\n- <A> H&P should include documentation and quantification (pack years smoked) of tobacco use history, as well as alcohol use and counseling </A>. <A> All patients who currently smoke should be advised to quit smoking </A>, and <A> those who formerly smoked should be advised to remain abstinent from smoking </A>. <A> For additional cessation support, refer to the Patient/Provider Smoking Cessation and Treatment Resources in the [NCCN Guidelines for Smoking Cessation](#) </A>.\\n- <A> Screen for depression ([NCCN Guidelines for Distress Management](#)) </A>.\\n- <A> Image-guided (US or CT) needle biopsy of cystic neck nodes may offer better diagnostic yield than FNA by palpation alone for initial diagnosis in this setting </A>. <CO> For unresectable or metastatic disease where there is a plan for systemic therapy </CO>, <A> a core biopsy would allow for ancillary immune-genomic testing </A>.\\n\\nSection Name: WORKUP\\n====================\\nEntities:-\\nBiopsy : The removal and examination of tissue, cells, or fluids from the living body.\\nFine Needle Aspiration Biopsy : A type of biopsy procedure that uses a thin, hollow needle to extract cells or fluid from a lump or mass.\\nComputed Tomography : A medical imaging technique used in radiology to obtain detailed internal images of the body.\\nPositron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes.\\nEndoscopy : A procedure that uses an endoscope to examine the interior of a hollow organ or cavity of the body.\\nLaryngectomy : A surgical procedure to remove the larynx and separate the airway from the mouth, nose, and esophagus.\\n\\nRelationships:-\\n1. Entity1: \""Biopsy\"", Entity2: \""Primary tumor site\"", Relationship: \""performed on\""\\n2. Entity1: \""Fine needle aspiration biopsy\"", Entity2: \""Cervical lymph nodes\"", Relationship: \""samples\""\\n3. Entity1: \""Computed tomography\"", Entity2: \""Disease extent\"", Relationship: \""assesses\""\\n4. Entity1: \""Positron-Emission Tomography\"", Entity2: \""Advanced imaging\"", Relationship: \""considered for\""\\n5. Entity1: \""Endoscopy\"", Entity2: \""Examination\"", Relationship: \""used for\""\\n6. Entity1: \""Laryngectomy\"", Entity2: \""Disease stage\"", Relationship: \""required for\""\\n\\nCausalities:-\\n<A> The \""WORKUP\"" section details the essential initial assessments and procedures that must be conducted. </A> <A> It begins with a comprehensive history and physical examination, emphasizing the need for an exhaustive evaluation of both the head and neck, including any necessary biopsies of the primary tumor site or fine-needle aspiration (FNA) of cervical lymph nodes. </A> <A> Additional imaging techniques, such as chest CT scans and contrast-enhanced imaging (CT or MRI), are recommended to assess the extent of the disease. </A> <A> The guideline suggests considering advanced imaging methods like FDG-PET/CT and endoscopic examinations when clinically indicated. </A>\\n\\n<CO> Amenable to larynx-preserving (conservation) surgery (Most T1\u20132, N0; selected T3) </CO>\\n<A> Treatment of Primary and Neck (SUPRA-2) </A>\\n<A> H&P including a complete head and neck exam; mirror and/or fiberoptic examination as clinically indicated </A>\\n<A> Biopsy of primary site or FNA of the neck </A>\\n<A> Chest CT (with or without contrast) as clinically indicated </A>\\n<A> CT with contrast and thin angled cuts through larynx and/or MRI with and without contrast of primary and neck </A>\\n<A> Consider FDG-PET/CT </A>\\n<A> EUA with endoscopy </A>\\n<A> As clinically indicated: Preanesthesia studies, Consider PFTs for conservation surgery candidates, Consider videostrobe for select patients, Dental evaluation, Nutrition, speech and swallowing evaluation/therapy, Audiogram, Smoking cessation counseling, Fertility/reproductive counseling, Screening for hepatitis B </A>\\n<A> Multidisciplinary consultation as clinically indicated </A>\\n\\n<CO> Requiring (amenable to) total laryngectomy (T3, N0) </CO>\\n<CO> T4a, N0 </CO>\\n<CO> Node-positive disease </CO>\\n<CO> T4b, N0\u20133 </CO>\\n<CO> or Unresectable nodal disease or Unfit for surgery </CO>\\n<CO> Metastatic (M1) disease at initial presentation </CO>\\n<A> Treatment of Primary and Neck (SUPRA-3) </A>\\n<A> Treatment of Primary and Neck (SUPRA-8) </A>\\n<A> Clinical Staging (SUPRA-4) </A>\\n<A> Treatment of Very Advanced Head and Neck Cancer (ADV-1) </A>\\n<A> Treatment of Very Advanced Head and Neck Cancer (ADV-2) </A>\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nDiagnostic Imaging : The production of diagnostic images, commonly through the use of X-rays, ultrasound, or magnetic resonance imaging (MRI).\\nDental Examination : A clinical examination of the teeth and oral cavity.\\nNutrition Therapy : The use of specific nutrition services to treat an illness, injury, or condition.\\nNational Comprehensive Cancer Network : An alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Imaging\"", Entity2: \""Diagnostic Imaging\"", Relationship: \""is related to\""\\n2. Entity1: \""Principles of Dental Evaluation and Management\"", Entity2: \""Dental Examination\"", Relationship: \""is related to\""\\n3. Entity1: \""Principles of Nutrition: Management and Supportive Care\"", Entity2: \""Nutrition Therapy\"", Relationship: \""is related to\""\\n4. Entity1: \""NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology\"", Entity2: \""National Comprehensive Cancer Network\"", Relationship: \""is related to\""\\n\\nCausalities:-\\n### Principles\\n\\n- **Principles of Imaging (IMG-A)**\\n- **Principles of Dental Evaluation and Management (DENT-A)**\\n- **Principles of Nutrition: Management and Supportive Care (NUTR-A)**\\n- **See fertility and reproductive endocrine considerations in the [NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology](#).**\\n--------------------------------------------------\\nPage Number: 130\\n\\nSection Name: Pathological N (pN)\\n====================\\nEntities:-\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nTnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system.\\n\\nRelationships:-\\n1. Entity1: \""Lymph Nodes\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""involved in\""\\n2. Entity1: \""TNM Staging\"", Entity2: \""Lymph Nodes\"", Relationship: \""includes\""\\n3. Entity1: \""TNM Staging\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""describes\""\\n\\nCausalities:-\\n<CO> NX: Regional lymph nodes cannot be assessed </CO>\\n<CO> N0: No regional lymph node metastasis </CO>\\n<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(\u2013) </CO>\\n<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(\u2212); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> Note: A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+). </CO>\\n\\nSection Name: Distant Metastasis (M)\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""M0\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n2. Entity1: \""M1\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n\\nCausalities:-\\n### Distant Metastasis (M)\\n\\n- **M0**: No distant metastasis\\n- **M1**: Distant metastasis\\n\\nSection Name: Histologic Grade (G)\\n====================\\nEntities:-\\nNeoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.\\nHistologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.\\n\\nRelationships:-\\n1. Entity1: \""GX\"", Entity2: \""Grade cannot be assessed\"", Relationship: \""is described as\""\\n2. Entity1: \""G1\"", Entity2: \""Well differentiated\"", Relationship: \""is described as\""\\n3. Entity1: \""G2\"", Entity2: \""Moderately differentiated\"", Relationship: \""is described as\""\\n4. Entity1: \""G3\"", Entity2: \""Poorly differentiated\"", Relationship: \""is described as\""\\n\\nCausalities:-\\n<CO>GX</CO>: <E>Grade cannot be assessed</E>\\n<CO>G1</CO>: <E>Well differentiated</E>\\n<CO>G2</CO>: <E>Moderately differentiated</E>\\n<CO>G3</CO>: <E>Poorly differentiated</E>\\n\\nSection Name: Prognostic Stage Groups\\n====================\\nEntities:-\\nNeoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.\\nTumor Staging : A system for describing the size and spread of cancer within the body.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\n\\nRelationships:-\\n1. Entity1: \""Stage 0\"", Entity2: \""Tis N0 M0\"", Relationship: \""defined by\""\\n2. Entity1: \""Stage I\"", Entity2: \""T1 N0 M0\"", Relationship: \""defined by\""\\n3. Entity1: \""Stage II\"", Entity2: \""T2 N0 M0\"", Relationship: \""defined by\""\\n4. Entity1: \""Stage III\"", Entity2: \""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0\"", Relationship: \""defined by\""\\n5. Entity1: \""Stage IVA\"", Entity2: \""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0\"", Relationship: \""defined by\""\\n6. Entity1: \""Stage IVB\"", Entity2: \""Any T N3 M0, T4b Any N M0\"", Relationship: \""defined by\""\\n7. Entity1: \""Stage IVC\"", Entity2: \""Any T Any N M1\"", Relationship: \""defined by\""\\n--------------------------------------------------\\nPage Number: 41\\n\\nSection Name: Workup\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nHistory And Physical Examination : A comprehensive assessment of a patient\\'s medical history and physical condition.\\nTobacco Smoking : The act of smoking tobacco products, which is a risk factor for many diseases.\\nAlcohol Drinking : The consumption of beverages containing ethyl alcohol.\\nSmoking Cessation : The process of discontinuing tobacco smoking.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nLaryngoscopy : A procedure to examine the larynx, often using a scope.\\nComputed Tomography (Ct) : A diagnostic imaging procedure that uses computer-processed combinations of many X-ray measurements taken from different angles to produce cross-sectional images of specific areas of a scanned object.\\nMagnetic Resonance Imaging (Mri) : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.\\nPositron-Emission Tomography : A type of nuclear medicine imaging that measures metabolic activity of the cells of body tissues.\\nPulmonary Function Test : Tests that measure how well the lungs are working.\\nDental Examination : An evaluation of the teeth and gums to assess oral health.\\nNutritional Support : Therapies to provide nutrition to patients who cannot obtain nutrition by mouth.\\nSpeech Therapy : Therapy to improve speech and communication skills.\\nSwallowing Therapy : Therapy to help individuals with swallowing difficulties.\\nMultidisciplinary Care Team : A group of healthcare professionals from different specialties working together to manage patient care.\\n\\nRelationships:-\\n1. Entity1: \""glottic larynx cancer\"", Entity2: \""history and physical examination\"", Relationship: \""initial diagnostic step\""\\n2. Entity1: \""glottic larynx cancer\"", Entity2: \""biopsy\"", Relationship: \""required diagnostic procedure\""\\n3. Entity1: \""glottic larynx cancer\"", Entity2: \""direct laryngoscopy\"", Relationship: \""recommended procedure\""\\n4. Entity1: \""glottic larynx cancer\"", Entity2: \""CT scans\"", Relationship: \""imaging study\""\\n5. Entity1: \""glottic larynx cancer\"", Entity2: \""MRI\"", Relationship: \""imaging study\""\\n6. Entity1: \""glottic larynx cancer\"", Entity2: \""multidisciplinary consultation\"", Relationship: \""advised as clinically indicated\""\\n\\nCausalities:-\\nThe workup section outlines the initial steps for diagnosing <C>glottic larynx cancer</C>. It includes <A>a comprehensive history and physical examination (H&P)</A>, which should document tobacco and alcohol use, and provide counseling for smoking cessation. <A>A biopsy of the primary site is required</A>, and <A>direct laryngoscopy under anesthesia is generally recommended</A>. <A>Imaging studies such as CT scans with contrast and possibly MRI are used to evaluate the larynx and neck</A>. Additional evaluations may include <A>chest CT, FDG-PET/CT, pulmonary function tests, dental evaluation, and nutrition, speech, and swallowing therapy</A>. <A>Multidisciplinary consultation is advised</A> <CO>as clinically indicated</CO>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nCarcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nLaryngectomy : A surgical procedure to remove the larynx.\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging\"", Entity2: \""Cancer\"", Relationship: \""involves\""\\n2. Entity1: \""Carcinoma in situ\"", Entity2: \""Stages T1-T4\"", Relationship: \""is a stage of\""\\n3. Entity1: \""Biopsy\"", Entity2: \""Cancer\"", Relationship: \""used in staging\""\\n4. Entity1: \""Larynx-preserving surgeries\"", Entity2: \""Stages T1-T2\"", Relationship: \""considered for\""\\n5. Entity1: \""Total laryngectomy\"", Entity2: \""Stages T3-T4\"", Relationship: \""required for\""\\n\\nCausalities:-\\n<C> Clinical staging involves categorizing the cancer based on its aggressiveness </C>. It starts with carcinoma in situ, which is non-invasive, and progresses through stages T1-T4. <CO> Staging is based on H&P, biopsy, and imaging studies </CO>. <CO> For T1-T2 </CO>, <A> larynx-preserving surgeries are considered </A>, while <CO> more advanced stages like T3 or T4 </CO> <A> may require total laryngectomy </A>. <A> Additional evaluations such as videostrobe, audiogram, and fertility counseling may be considered </A>.\\n\\nSection Name: Treatment\\n====================\\nEntities:-\\nCarcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.\\nLaryngectomy : A surgical procedure to remove the larynx.\\nMetastasis : The transfer of a disease from one organ or part to another not directly connected with it.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\n\\nRelationships:-\\n1. Entity1: \""Carcinoma in situ\"", Entity2: \""Larynx-preserving surgery\"", Relationship: \""treated with\""\\n2. Entity1: \""T1-T2 stages\"", Entity2: \""Conservation surgery\"", Relationship: \""treated with\""\\n3. Entity1: \""T3 stages\"", Entity2: \""Total laryngectomy\"", Relationship: \""may require\""\\n4. Entity1: \""T4a disease\"", Entity2: \""Complex interventions\"", Relationship: \""require\""\\n5. Entity1: \""Guidelines\"", Entity2: \""Multidisciplinary consultations\"", Relationship: \""emphasize importance of\""\\n6. Entity1: \""Guidelines\"", Entity2: \""Clinical trials\"", Relationship: \""consider as best option\""\\n\\nCausalities:-\\n<CO>Treatment recommendations vary by stage</CO>. <CO>Carcinoma in situ</CO> <A>may be treated with larynx-preserving surgery</A>. <CO>T1-T2 stages</CO> <A>may also be amenable to conservation surgery</A>. <CO>T3 stages</CO> <A>may require total laryngectomy</A>, <CO>especially if nodal involvement is present</CO>. <CO>T4a disease and unresectable or metastatic cases</CO> <A>require more complex interventions</A>. <A>The guidelines emphasize the importance of multidisciplinary consultations</A> and <A>consider clinical trials as the best management option</A>.\\n\\nSection Name: Additional Notes\\n====================\\nEntities:-\\nBiopsy, Needle : A procedure to remove a small sample of tissue for examination under a microscope.\\nImage-Guided Biopsy : A biopsy procedure that uses imaging techniques to guide the needle to the precise location of the tissue to be sampled.\\nBiopsy : A medical test involving the extraction of sample cells or tissues for examination.\\nDiagnostic Techniques And Procedures : Methods and procedures for the diagnosis of disease or dysfunction.\\nImaging : The process of producing images of the body for clinical purposes.\\nDental Care : The total of dental diagnostic, preventive, and corrective procedures.\\nNutritional Physiological Phenomena : The functions and properties of nutrients in living organisms.\\nFertility : The capacity to conceive or induce conception.\\nReproductive Health : A state of physical, mental, and social well-being in all matters relating to the reproductive system.\\nLymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nGlottis : The part of the larynx consisting of the vocal cords and the opening between them.\\n\\nRelationships:-\\n1. Entity1: \""image-guided needle biopsy\"", Entity2: \""diagnostic yield\"", Relationship: \""used for\""\\n2. Entity1: \""nodal disease\"", Entity2: \""glottic tumors\"", Relationship: \""is rare in\""\\n\\nCausalities:-\\n<A> use of image-guided needle biopsy </A> for <E> better diagnostic yield </E>, principles of imaging, dental evaluation, and nutrition management. The guidelines also address fertility and reproductive considerations, and note that <CO> nodal disease in glottic tumors is rare </CO>.\\n--------------------------------------------------\\nPage Number: 102\\n\\nSection Name: Head and Neck Cancers - Principles of Surgery\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.\\nLymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.\\nNeoplasms : New abnormal growth of tissue in animals or plants; a tumor.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nNeoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSurgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nLymphatic Structure : Anatomical structure that is part of the lymphatic system.\\nTumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.\\nStaging : The process of determining the size and spread of cancer within the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.\\n\\nRelationships:-\\n1. Entity1: \""surgical management\"", Entity2: \""regional lymphatics\"", Relationship: \""dictated by tumor staging\""\\n2. Entity1: \""neck dissections\"", Entity2: \""primary tumor\"", Relationship: \""part of treatment\""\\n3. Entity1: \""surgery\"", Entity2: \""ipsilateral side of the neck\"", Relationship: \""risk for metastases\""\\n\\nCausalities:-\\n<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.\\n\\nSection Name: Neck Management\\n====================\\nEntities:-\\nTongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.\\nPalate : The roof of the mouth, separating the oral and nasal cavities.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\nHypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.\\nNasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSquamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.\\nBiopsy : The removal of cells or tissues for examination under a microscope.\\n\\nRelationships:-\\n1. Entity1: \""Tumor sites\"", Entity2: \""Bilateral lymphatic drainage\"", Relationship: \""associated with\""\\n2. Entity1: \""Elective neck dissection\"", Entity2: \""Risk of occult metastasis\"", Relationship: \""based on\""\\n3. Entity1: \""SLN biopsy\"", Entity2: \""Elective neck dissection\"", Relationship: \""guides decision-making for\""\\n\\nCausalities:-\\n- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.\\n\\n- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.\\n\\n- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.\\n\\n  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2\u20134 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.\\n\\nSection Name: Types of Neck Dissection\\n====================\\nEntities:-\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\n\\nRelationships:-\\n1. Entity1: \""N0\"", Entity2: \""Selective neck dissection\"", Relationship: \""associated with\""\\n2. Entity1: \""N3\"", Entity2: \""Comprehensive neck dissection\"", Relationship: \""associated with\""\\n3. Entity1: \""Level VI neck dissection\"", Entity2: \""Larynx\"", Relationship: \""performed for\""\\n4. Entity1: \""Level VI neck dissection\"", Entity2: \""Hypopharynx\"", Relationship: \""performed for\""\\n\\nCausalities:-\\n- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:\\n  - **N0:** <A> Selective neck dissection </A>\\n    - Oral cavity at least levels I\u2013III\\n    - Oropharynx at least levels II\u2013IV\\n    - Hypopharynx at least levels II\u2013IV and level VI when appropriate\\n    - Larynx at least levels II\u2013IV and level VI when appropriate\\n  - **N1\u2013N2a\u2013c:** <A> Selective or comprehensive neck dissection </A> (Discussion)\\n  - **N3:** <A> Comprehensive neck dissection </A>\\n\\n- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.\\n\\n- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.\\n--------------------------------------------------\\nPage Number: 55\\n\\nSection Name: General Information\\n====================\\nEntities:-\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""National Comprehensive Cancer Network\"", Relationship: \""produced by\""\\n\\nSection Name: Important Notes\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNeoplasms : New abnormal growth of tissue that can be benign or malignant.\\nMalignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Trials\"", Entity2: \""Cancer\"", Relationship: \""recommended for\""\\n2. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n\\nCausalities:-\\n<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nChemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n2. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n3. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n\\nCausalities:-\\n### Principles\\n\\n- **Principles of Surgery (SURG-A)**\\n- **Principles of Radiation Therapy (SUPRA-A)**\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nPerineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The invasion of cancer cells into blood vessels.\\nLymphatic Invasion : The invasion of cancer cells into lymphatic vessels.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n2. Entity1: \""Positive margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n3. Entity1: \""Close margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n4. Entity1: \""pT3 or pT4 primary\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n5. Entity1: \""pN2 or pN3 nodal disease\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n6. Entity1: \""Perineural invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n7. Entity1: \""Vascular invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n8. Entity1: \""Lymphatic invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n\\nCausalities:-\\n<C> Extranodal extension </C>\\n<C> Positive margins </C>\\n<C> Close margins </C>\\n<C> pT3 or pT4 primary </C>\\n<C> pN2 or pN3 nodal disease </C>\\n<C> Perineural invasion </C>\\n<C> Vascular invasion </C>\\n<C> Lymphatic invasion </C>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nPrimary Site : The original location where a tumor or cancer begins.\\nComplete Remission : The disappearance of all signs of cancer in response to treatment.\\nPartial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""induction chemotherapy\"", Entity2: \""Primary site\"", Relationship: \""treatment outcome\""\\n2. Entity1: \""Definitive RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n3. Entity1: \""RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n4. Entity1: \""Surgery\"", Entity2: \""unresectable nodal disease\"", Relationship: \""treatment option\""\\n\\nCausalities:-\\n<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.\\nFollow-Up (Medicine) : The process of monitoring a patient\\'s health over time after treatment or diagnosis.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : A disease that returns after a period of remission.\\nRecurrence (Medicine) : The return of a disease or condition after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n### Follow-up\\n\\n- **Follow-up** (FOLL-A, 1 of 2)\\n- **Recurrent or persistent disease** (ADV-3)\\n\\nSection Name: Risk Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""RT\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Adverse pathologic features\"", Entity2: \""Systemic therapy\"", Relationship: \""Consideration for treatment\""\\n\\nCausalities:-\\n- **No adverse pathologic features**\\n- **Other risk features**\\n- **Adverse pathologic features**:\\n  - <C> Extranodal extension and/or positive margin </C>\\n  - <A> RT or consider systemic therapy/RT </A>\\n\\nSection Name: Post-Therapy Evaluation\\n====================\\nEntities:-\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nNeck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n2. Entity1: \""RT\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n\\nCausalities:-\\n<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>\\n\\nSection Name: Flowchart Overview\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nSupraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""guides management of\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""healthcare professionals\"", Relationship: \""used by\""\\n\\nCausalities:-\\n<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.\\n\\nSection Name: Assessment and Treatment Decisions\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nComplete Response : The disappearance of all signs of cancer in response to treatment.\\nPartial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Complete Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n2. Entity1: \""Complete Response\"", Entity2: \""Surgery\"", Relationship: \""leads to\""\\n3. Entity1: \""Partial Response\"", Entity2: \""Systemic Therapy\"", Relationship: \""leads to\""\\n4. Entity1: \""Partial Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n\\nCausalities:-\\n<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.\\n\\nSection Name: Adverse Pathologic Features and Follow-up\\n====================\\nEntities:-\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nNeoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nRecurrent Neoplasm : A neoplasm that has returned after treatment.\\nMetastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.\\nMetastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""Treatment decisions\"", Relationship: \""Influence\""\\n2. Entity1: \""Adverse features\"", Entity2: \""Surgical intervention\"", Relationship: \""Recommendation\""\\n3. Entity1: \""Absence of adverse features\"", Entity2: \""Radiation therapy\"", Relationship: \""Pathway\""\\n4. Entity1: \""Follow-up process\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""Detection\""\\n5. Entity1: \""Recurrent or persistent disease\"", Entity2: \""Advanced disease management\"", Relationship: \""Necessity\""\\n\\nCausalities:-\\n<C> The presence of adverse pathologic features \u2014 such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient\\'s disease characteristics.\\n\\nFurthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.\\n'}""",invalid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: Lymph_Node_Biopsy_Results_9
label: Lymph Node Biopsy Examination Results
description: This node represents the results of a biopsy performed on a lymph node to determine the presence or absence of pathological findings, such as cancer cells. It is a critical diagnostic examination used to assess the spread of cancer to the lymphatic system.
type: Examination Result
observability: Observed
states: [{'state_name': 'present', 'state_description': ""The 'present' state indicates that the biopsy results show the presence of pathological findings, such as cancer cells, in the lymph node.""}, {'state_name': 'absent', 'state_description': ""The 'absent' state indicates that the biopsy results do not show any pathological findings in the lymph node, suggesting no presence of cancer cells.""}]

`NODE2`:
id: Extranodal_Extension_5
label: Extranodal Extension
description: Extranodal extension refers to the spread of cancer beyond the lymph node capsule into surrounding tissues. It is a significant factor in cancer staging and prognosis, as it indicates a more advanced disease and may influence treatment decisions.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'present', 'state_description': 'Extranodal extension is present, indicating that cancer has spread beyond the lymph node into surrounding tissues.'}, {'state_name': 'absent', 'state_description': 'Extranodal extension is absent, indicating that cancer is contained within the lymph node and has not spread to surrounding tissues.'}]

`EDGE1`:
{'edges_ids': ['Lymph_Node_Biopsy_Results_9', 'Extranodal_Extension_5'], 'edge': '(Lymph_Node_Biopsy_Results_9) causes (Extranodal_Extension_5)', 'explanation': ['The edge represents the relationship between the results of a lymph node biopsy and the presence of extranodal extension.', 'A positive lymph node biopsy result (presence of cancer cells) is necessary for extranodal extension to occur, as cancer must be present in the lymph node before it can spread beyond it.', 'However, a positive biopsy result is not sufficient to cause extranodal extension, as not all cases with cancer in the lymph node will have extranodal extension.', 'The causal direction is positive because the presence of cancer cells in the lymph node increases the likelihood of extranodal extension.', 'The causal distance is proximal because the presence of cancer cells in the lymph node is directly related to the potential for extranodal extension.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': True, 'sufficient': False}, 'causal_distance': 'Proximal'}

`EDGE2`:
{'edges_ids': ['Extranodal_Extension_5', 'Lymph_Node_Biopsy_Results_9'], 'edge': '(Extranodal_Extension_5) causes (Lymph_Node_Biopsy_Results_9)', 'explanation': ['Extranodal extension indicates that cancer has spread beyond the lymph node capsule into surrounding tissues.', 'If extranodal extension is present, it is likely that a lymph node biopsy would show the presence of cancer cells, as the cancer has spread beyond the lymph node.', 'The edge is valid because extranodal extension can directly influence the results of a lymph node biopsy by indicating the presence of cancer cells.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 49

Section Name: NCCN Guidelines Overview
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Neoplasms : New abnormal growth of tissue that possesses no physiological function and arises from uncontrolled usually rapid cellular proliferation.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Malignant Neoplastic Disease : A disease in which abnormal cells divide uncontrollably and destroy body tissue.
Nccn Guidelines : Clinical practice guidelines developed by the National Comprehensive Cancer Network to ensure that patients receive preventive, diagnostic, treatment, and supportive services that are most likely to lead to optimal outcomes.
National Comprehensive Cancer Network : An alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""National Comprehensive Cancer Network"", Relationship: ""published by""
2. Entity1: ""NCCN Guidelines"", Entity2: ""Clinical Trials"", Relationship: ""recommends""
3. Entity1: ""Clinical Trials"", Entity2: ""Cancer"", Relationship: ""management strategy for""

Causalities:-
<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: SUPRA-1
====================
Entities:-
Tobacco Use Disorder : A disorder characterized by the continued use of tobacco despite significant related problems.
Tobacco Use : The act of using tobacco products.
Tobacco Smoking : The practice of burning tobacco and inhaling the smoke.
Alcohol Drinking : The consumption of beverages containing ethyl alcohol.
Alcohol Use : The act of consuming alcoholic beverages.
Alcohol Consumption : The act of drinking beverages containing ethanol.
Smoking Cessation : The process of discontinuing tobacco smoking.
Depression : A mood disorder characterized by a persistent feeling of sadness and loss of interest.
Depressive Disorder : A mental disorder characterized by persistent low mood and loss of interest.
Depression (Mood) : A state of low mood and aversion to activity.
Distress, Psychological : A state of emotional suffering associated with stressors and demands that are difficult to cope with in daily life.
Psychological Distress : A state of emotional suffering typically characterized by symptoms of depression and anxiety.
Psychological Stress : A feeling of strain and pressure.
Biopsy, Needle : The removal of tissue or cells with a needle for examination under a microscope.
Needle Biopsy : A procedure to extract tissue or fluid samples from the body using a needle.
Neck : The part of the body on many vertebrates that separates the head from the torso or trunk.
Neck Structure : Anatomical structure of the neck.
Biopsy : The removal and examination of tissue, cells, or fluids from the living body.
Core Biopsy : A biopsy procedure that uses a hollow needle to remove a core of tissue for examination.
Core Needle Biopsy : A procedure that uses a hollow needle to remove a sample of tissue for examination.
Genomics : An interdisciplinary field of biology focusing on the structure, function, evolution, mapping, and editing of genomes.
Genomic Testing : Testing that involves the analysis of the genome.

Relationships:-
1. Entity1: ""Tobacco use"", Entity2: ""Smoking cessation"", Relationship: ""advised to quit""
2. Entity1: ""Depression"", Entity2: ""Distress management"", Relationship: ""screening for""
3. Entity1: ""Image-guided needle biopsy"", Entity2: ""Cystic neck nodes"", Relationship: ""used for""
4. Entity1: ""Core biopsy"", Entity2: ""Immune-genomic testing"", Relationship: ""allows for""

Causalities:-
- <A> H&P should include documentation and quantification (pack years smoked) of tobacco use history, as well as alcohol use and counseling </A>. <A> All patients who currently smoke should be advised to quit smoking </A>, and <A> those who formerly smoked should be advised to remain abstinent from smoking </A>. <A> For additional cessation support, refer to the Patient/Provider Smoking Cessation and Treatment Resources in the [NCCN Guidelines for Smoking Cessation](#) </A>.
- <A> Screen for depression ([NCCN Guidelines for Distress Management](#)) </A>.
- <A> Image-guided (US or CT) needle biopsy of cystic neck nodes may offer better diagnostic yield than FNA by palpation alone for initial diagnosis in this setting </A>. <CO> For unresectable or metastatic disease where there is a plan for systemic therapy </CO>, <A> a core biopsy would allow for ancillary immune-genomic testing </A>.

Section Name: WORKUP
====================
Entities:-
Biopsy : The removal and examination of tissue, cells, or fluids from the living body.
Fine Needle Aspiration Biopsy : A type of biopsy procedure that uses a thin, hollow needle to extract cells or fluid from a lump or mass.
Computed Tomography : A medical imaging technique used in radiology to obtain detailed internal images of the body.
Positron-Emission Tomography : An imaging technique that uses radioactive substances to visualize and measure changes in metabolic processes.
Endoscopy : A procedure that uses an endoscope to examine the interior of a hollow organ or cavity of the body.
Laryngectomy : A surgical procedure to remove the larynx and separate the airway from the mouth, nose, and esophagus.

Relationships:-
1. Entity1: ""Biopsy"", Entity2: ""Primary tumor site"", Relationship: ""performed on""
2. Entity1: ""Fine needle aspiration biopsy"", Entity2: ""Cervical lymph nodes"", Relationship: ""samples""
3. Entity1: ""Computed tomography"", Entity2: ""Disease extent"", Relationship: ""assesses""
4. Entity1: ""Positron-Emission Tomography"", Entity2: ""Advanced imaging"", Relationship: ""considered for""
5. Entity1: ""Endoscopy"", Entity2: ""Examination"", Relationship: ""used for""
6. Entity1: ""Laryngectomy"", Entity2: ""Disease stage"", Relationship: ""required for""

Causalities:-
<A> The ""WORKUP"" section details the essential initial assessments and procedures that must be conducted. </A> <A> It begins with a comprehensive history and physical examination, emphasizing the need for an exhaustive evaluation of both the head and neck, including any necessary biopsies of the primary tumor site or fine-needle aspiration (FNA) of cervical lymph nodes. </A> <A> Additional imaging techniques, such as chest CT scans and contrast-enhanced imaging (CT or MRI), are recommended to assess the extent of the disease. </A> <A> The guideline suggests considering advanced imaging methods like FDG-PET/CT and endoscopic examinations when clinically indicated. </A>

<CO> Amenable to larynx-preserving (conservation) surgery (Most T1–2, N0; selected T3) </CO>
<A> Treatment of Primary and Neck (SUPRA-2) </A>
<A> H&P including a complete head and neck exam; mirror and/or fiberoptic examination as clinically indicated </A>
<A> Biopsy of primary site or FNA of the neck </A>
<A> Chest CT (with or without contrast) as clinically indicated </A>
<A> CT with contrast and thin angled cuts through larynx and/or MRI with and without contrast of primary and neck </A>
<A> Consider FDG-PET/CT </A>
<A> EUA with endoscopy </A>
<A> As clinically indicated: Preanesthesia studies, Consider PFTs for conservation surgery candidates, Consider videostrobe for select patients, Dental evaluation, Nutrition, speech and swallowing evaluation/therapy, Audiogram, Smoking cessation counseling, Fertility/reproductive counseling, Screening for hepatitis B </A>
<A> Multidisciplinary consultation as clinically indicated </A>

<CO> Requiring (amenable to) total laryngectomy (T3, N0) </CO>
<CO> T4a, N0 </CO>
<CO> Node-positive disease </CO>
<CO> T4b, N0–3 </CO>
<CO> or Unresectable nodal disease or Unfit for surgery </CO>
<CO> Metastatic (M1) disease at initial presentation </CO>
<A> Treatment of Primary and Neck (SUPRA-3) </A>
<A> Treatment of Primary and Neck (SUPRA-8) </A>
<A> Clinical Staging (SUPRA-4) </A>
<A> Treatment of Very Advanced Head and Neck Cancer (ADV-1) </A>
<A> Treatment of Very Advanced Head and Neck Cancer (ADV-2) </A>

Section Name: Principles
====================
Entities:-
Diagnostic Imaging : The production of diagnostic images, commonly through the use of X-rays, ultrasound, or magnetic resonance imaging (MRI).
Dental Examination : A clinical examination of the teeth and oral cavity.
Nutrition Therapy : The use of specific nutrition services to treat an illness, injury, or condition.
National Comprehensive Cancer Network : An alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.

Relationships:-
1. Entity1: ""Principles of Imaging"", Entity2: ""Diagnostic Imaging"", Relationship: ""is related to""
2. Entity1: ""Principles of Dental Evaluation and Management"", Entity2: ""Dental Examination"", Relationship: ""is related to""
3. Entity1: ""Principles of Nutrition: Management and Supportive Care"", Entity2: ""Nutrition Therapy"", Relationship: ""is related to""
4. Entity1: ""NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology"", Entity2: ""National Comprehensive Cancer Network"", Relationship: ""is related to""

Causalities:-
### Principles

- **Principles of Imaging (IMG-A)**
- **Principles of Dental Evaluation and Management (DENT-A)**
- **Principles of Nutrition: Management and Supportive Care (NUTR-A)**
- **See fertility and reproductive endocrine considerations in the [NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology](#).**
--------------------------------------------------
Page Number: 130

Section Name: Pathological N (pN)
====================
Entities:-
Lymph Nodes : Small, bean-shaped structures that are part of the body's lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.
Lymph Node : An organ of the lymphatic system and the adaptive immune system.

Relationships:-
1. Entity1: ""Lymph Nodes"", Entity2: ""Neoplasm Metastasis"", Relationship: ""involved in""
2. Entity1: ""TNM Staging"", Entity2: ""Lymph Nodes"", Relationship: ""includes""
3. Entity1: ""TNM Staging"", Entity2: ""Neoplasm Metastasis"", Relationship: ""describes""

Causalities:-
<CO> NX: Regional lymph nodes cannot be assessed </CO>
<CO> N0: No regional lymph node metastasis </CO>
<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(–) </CO>
<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> Note: A designation of “U” or “L” may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(−) or ENE(+). </CO>

Section Name: Distant Metastasis (M)
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""M0"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""
2. Entity1: ""M1"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""

Causalities:-
### Distant Metastasis (M)

- **M0**: No distant metastasis
- **M1**: Distant metastasis

Section Name: Histologic Grade (G)
====================
Entities:-
Neoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.
Histologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.

Relationships:-
1. Entity1: ""GX"", Entity2: ""Grade cannot be assessed"", Relationship: ""is described as""
2. Entity1: ""G1"", Entity2: ""Well differentiated"", Relationship: ""is described as""
3. Entity1: ""G2"", Entity2: ""Moderately differentiated"", Relationship: ""is described as""
4. Entity1: ""G3"", Entity2: ""Poorly differentiated"", Relationship: ""is described as""

Causalities:-
<CO>GX</CO>: <E>Grade cannot be assessed</E>
<CO>G1</CO>: <E>Well differentiated</E>
<CO>G2</CO>: <E>Moderately differentiated</E>
<CO>G3</CO>: <E>Poorly differentiated</E>

Section Name: Prognostic Stage Groups
====================
Entities:-
Neoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.
Tumor Staging : A system for describing the size and spread of cancer within the body.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.

Relationships:-
1. Entity1: ""Stage 0"", Entity2: ""Tis N0 M0"", Relationship: ""defined by""
2. Entity1: ""Stage I"", Entity2: ""T1 N0 M0"", Relationship: ""defined by""
3. Entity1: ""Stage II"", Entity2: ""T2 N0 M0"", Relationship: ""defined by""
4. Entity1: ""Stage III"", Entity2: ""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0"", Relationship: ""defined by""
5. Entity1: ""Stage IVA"", Entity2: ""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0"", Relationship: ""defined by""
6. Entity1: ""Stage IVB"", Entity2: ""Any T N3 M0, T4b Any N M0"", Relationship: ""defined by""
7. Entity1: ""Stage IVC"", Entity2: ""Any T Any N M1"", Relationship: ""defined by""
--------------------------------------------------
Page Number: 41

Section Name: Workup
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
History And Physical Examination : A comprehensive assessment of a patient's medical history and physical condition.
Tobacco Smoking : The act of smoking tobacco products, which is a risk factor for many diseases.
Alcohol Drinking : The consumption of beverages containing ethyl alcohol.
Smoking Cessation : The process of discontinuing tobacco smoking.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Laryngoscopy : A procedure to examine the larynx, often using a scope.
Computed Tomography (Ct) : A diagnostic imaging procedure that uses computer-processed combinations of many X-ray measurements taken from different angles to produce cross-sectional images of specific areas of a scanned object.
Magnetic Resonance Imaging (Mri) : A medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body.
Positron-Emission Tomography : A type of nuclear medicine imaging that measures metabolic activity of the cells of body tissues.
Pulmonary Function Test : Tests that measure how well the lungs are working.
Dental Examination : An evaluation of the teeth and gums to assess oral health.
Nutritional Support : Therapies to provide nutrition to patients who cannot obtain nutrition by mouth.
Speech Therapy : Therapy to improve speech and communication skills.
Swallowing Therapy : Therapy to help individuals with swallowing difficulties.
Multidisciplinary Care Team : A group of healthcare professionals from different specialties working together to manage patient care.

Relationships:-
1. Entity1: ""glottic larynx cancer"", Entity2: ""history and physical examination"", Relationship: ""initial diagnostic step""
2. Entity1: ""glottic larynx cancer"", Entity2: ""biopsy"", Relationship: ""required diagnostic procedure""
3. Entity1: ""glottic larynx cancer"", Entity2: ""direct laryngoscopy"", Relationship: ""recommended procedure""
4. Entity1: ""glottic larynx cancer"", Entity2: ""CT scans"", Relationship: ""imaging study""
5. Entity1: ""glottic larynx cancer"", Entity2: ""MRI"", Relationship: ""imaging study""
6. Entity1: ""glottic larynx cancer"", Entity2: ""multidisciplinary consultation"", Relationship: ""advised as clinically indicated""

Causalities:-
The workup section outlines the initial steps for diagnosing <C>glottic larynx cancer</C>. It includes <A>a comprehensive history and physical examination (H&P)</A>, which should document tobacco and alcohol use, and provide counseling for smoking cessation. <A>A biopsy of the primary site is required</A>, and <A>direct laryngoscopy under anesthesia is generally recommended</A>. <A>Imaging studies such as CT scans with contrast and possibly MRI are used to evaluate the larynx and neck</A>. Additional evaluations may include <A>chest CT, FDG-PET/CT, pulmonary function tests, dental evaluation, and nutrition, speech, and swallowing therapy</A>. <A>Multidisciplinary consultation is advised</A> <CO>as clinically indicated</CO>.

Section Name: Clinical Staging
====================
Entities:-
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Carcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Laryngectomy : A surgical procedure to remove the larynx.

Relationships:-
1. Entity1: ""Clinical staging"", Entity2: ""Cancer"", Relationship: ""involves""
2. Entity1: ""Carcinoma in situ"", Entity2: ""Stages T1-T4"", Relationship: ""is a stage of""
3. Entity1: ""Biopsy"", Entity2: ""Cancer"", Relationship: ""used in staging""
4. Entity1: ""Larynx-preserving surgeries"", Entity2: ""Stages T1-T2"", Relationship: ""considered for""
5. Entity1: ""Total laryngectomy"", Entity2: ""Stages T3-T4"", Relationship: ""required for""

Causalities:-
<C> Clinical staging involves categorizing the cancer based on its aggressiveness </C>. It starts with carcinoma in situ, which is non-invasive, and progresses through stages T1-T4. <CO> Staging is based on H&P, biopsy, and imaging studies </CO>. <CO> For T1-T2 </CO>, <A> larynx-preserving surgeries are considered </A>, while <CO> more advanced stages like T3 or T4 </CO> <A> may require total laryngectomy </A>. <A> Additional evaluations such as videostrobe, audiogram, and fertility counseling may be considered </A>.

Section Name: Treatment
====================
Entities:-
Carcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.
Laryngectomy : A surgical procedure to remove the larynx.
Metastasis : The transfer of a disease from one organ or part to another not directly connected with it.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.

Relationships:-
1. Entity1: ""Carcinoma in situ"", Entity2: ""Larynx-preserving surgery"", Relationship: ""treated with""
2. Entity1: ""T1-T2 stages"", Entity2: ""Conservation surgery"", Relationship: ""treated with""
3. Entity1: ""T3 stages"", Entity2: ""Total laryngectomy"", Relationship: ""may require""
4. Entity1: ""T4a disease"", Entity2: ""Complex interventions"", Relationship: ""require""
5. Entity1: ""Guidelines"", Entity2: ""Multidisciplinary consultations"", Relationship: ""emphasize importance of""
6. Entity1: ""Guidelines"", Entity2: ""Clinical trials"", Relationship: ""consider as best option""

Causalities:-
<CO>Treatment recommendations vary by stage</CO>. <CO>Carcinoma in situ</CO> <A>may be treated with larynx-preserving surgery</A>. <CO>T1-T2 stages</CO> <A>may also be amenable to conservation surgery</A>. <CO>T3 stages</CO> <A>may require total laryngectomy</A>, <CO>especially if nodal involvement is present</CO>. <CO>T4a disease and unresectable or metastatic cases</CO> <A>require more complex interventions</A>. <A>The guidelines emphasize the importance of multidisciplinary consultations</A> and <A>consider clinical trials as the best management option</A>.

Section Name: Additional Notes
====================
Entities:-
Biopsy, Needle : A procedure to remove a small sample of tissue for examination under a microscope.
Image-Guided Biopsy : A biopsy procedure that uses imaging techniques to guide the needle to the precise location of the tissue to be sampled.
Biopsy : A medical test involving the extraction of sample cells or tissues for examination.
Diagnostic Techniques And Procedures : Methods and procedures for the diagnosis of disease or dysfunction.
Imaging : The process of producing images of the body for clinical purposes.
Dental Care : The total of dental diagnostic, preventive, and corrective procedures.
Nutritional Physiological Phenomena : The functions and properties of nutrients in living organisms.
Fertility : The capacity to conceive or induce conception.
Reproductive Health : A state of physical, mental, and social well-being in all matters relating to the reproductive system.
Lymphatic Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Glottis : The part of the larynx consisting of the vocal cords and the opening between them.

Relationships:-
1. Entity1: ""image-guided needle biopsy"", Entity2: ""diagnostic yield"", Relationship: ""used for""
2. Entity1: ""nodal disease"", Entity2: ""glottic tumors"", Relationship: ""is rare in""

Causalities:-
<A> use of image-guided needle biopsy </A> for <E> better diagnostic yield </E>, principles of imaging, dental evaluation, and nutrition management. The guidelines also address fertility and reproductive considerations, and note that <CO> nodal disease in glottic tumors is rare </CO>.
--------------------------------------------------
Page Number: 102

Section Name: Head and Neck Cancers - Principles of Surgery
====================
Entities:-
Surgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.
Lymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.
Neoplasms : New abnormal growth of tissue in animals or plants; a tumor.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Neoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Surgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Lymphatic Structure : Anatomical structure that is part of the lymphatic system.
Tumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.
Staging : The process of determining the size and spread of cancer within the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.

Relationships:-
1. Entity1: ""surgical management"", Entity2: ""regional lymphatics"", Relationship: ""dictated by tumor staging""
2. Entity1: ""neck dissections"", Entity2: ""primary tumor"", Relationship: ""part of treatment""
3. Entity1: ""surgery"", Entity2: ""ipsilateral side of the neck"", Relationship: ""risk for metastases""

Causalities:-
<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.

Section Name: Neck Management
====================
Entities:-
Tongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.
Palate : The roof of the mouth, separating the oral and nasal cavities.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.
Hypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.
Nasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Squamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.
Biopsy : The removal of cells or tissues for examination under a microscope.

Relationships:-
1. Entity1: ""Tumor sites"", Entity2: ""Bilateral lymphatic drainage"", Relationship: ""associated with""
2. Entity1: ""Elective neck dissection"", Entity2: ""Risk of occult metastasis"", Relationship: ""based on""
3. Entity1: ""SLN biopsy"", Entity2: ""Elective neck dissection"", Relationship: ""guides decision-making for""

Causalities:-
- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.

- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.

- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.

  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2–4 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.

Section Name: Types of Neck Dissection
====================
Entities:-
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.

Relationships:-
1. Entity1: ""N0"", Entity2: ""Selective neck dissection"", Relationship: ""associated with""
2. Entity1: ""N3"", Entity2: ""Comprehensive neck dissection"", Relationship: ""associated with""
3. Entity1: ""Level VI neck dissection"", Entity2: ""Larynx"", Relationship: ""performed for""
4. Entity1: ""Level VI neck dissection"", Entity2: ""Hypopharynx"", Relationship: ""performed for""

Causalities:-
- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:
  - **N0:** <A> Selective neck dissection </A>
    - Oral cavity at least levels I–III
    - Oropharynx at least levels II–IV
    - Hypopharynx at least levels II–IV and level VI when appropriate
    - Larynx at least levels II–IV and level VI when appropriate
  - **N1–N2a–c:** <A> Selective or comprehensive neck dissection </A> (Discussion)
  - **N3:** <A> Comprehensive neck dissection </A>

- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.

- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.
--------------------------------------------------
Page Number: 55

Section Name: General Information
====================
Entities:-
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Nccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""National Comprehensive Cancer Network"", Relationship: ""produced by""

Section Name: Important Notes
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Neoplasms : New abnormal growth of tissue that can be benign or malignant.
Malignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Clinical Trials"", Entity2: ""Cancer"", Relationship: ""recommended for""
2. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""

Causalities:-
<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles
====================
Entities:-
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Chemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""Both are principles of cancer treatment methods.""
2. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""
3. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""

Causalities:-
### Principles

- **Principles of Surgery (SURG-A)**
- **Principles of Radiation Therapy (SUPRA-A)**
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**

Section Name: Adverse Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Perineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The invasion of cancer cells into blood vessels.
Lymphatic Invasion : The invasion of cancer cells into lymphatic vessels.

Relationships:-
1. Entity1: ""Extranodal extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
2. Entity1: ""Positive margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
3. Entity1: ""Close margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
4. Entity1: ""pT3 or pT4 primary"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
5. Entity1: ""pN2 or pN3 nodal disease"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
6. Entity1: ""Perineural invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
7. Entity1: ""Vascular invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
8. Entity1: ""Lymphatic invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""

Causalities:-
<C> Extranodal extension </C>
<C> Positive margins </C>
<C> Close margins </C>
<C> pT3 or pT4 primary </C>
<C> pN2 or pN3 nodal disease </C>
<C> Perineural invasion </C>
<C> Vascular invasion </C>
<C> Lymphatic invasion </C>

Section Name: Response Assessment
====================
Entities:-
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Primary Site : The original location where a tumor or cancer begins.
Complete Remission : The disappearance of all signs of cancer in response to treatment.
Partial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.

Relationships:-
1. Entity1: ""induction chemotherapy"", Entity2: ""Primary site"", Relationship: ""treatment outcome""
2. Entity1: ""Definitive RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
3. Entity1: ""RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
4. Entity1: ""Surgery"", Entity2: ""unresectable nodal disease"", Relationship: ""treatment option""

Causalities:-
<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.
Follow-Up (Medicine) : The process of monitoring a patient's health over time after treatment or diagnosis.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : A disease that returns after a period of remission.
Recurrence (Medicine) : The return of a disease or condition after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
### Follow-up

- **Follow-up** (FOLL-A, 1 of 2)
- **Recurrent or persistent disease** (ADV-3)

Section Name: Risk Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""RT"", Relationship: ""Consideration for treatment""
2. Entity1: ""Adverse pathologic features"", Entity2: ""Systemic therapy"", Relationship: ""Consideration for treatment""

Causalities:-
- **No adverse pathologic features**
- **Other risk features**
- **Adverse pathologic features**:
  - <C> Extranodal extension and/or positive margin </C>
  - <A> RT or consider systemic therapy/RT </A>

Section Name: Post-Therapy Evaluation
====================
Entities:-
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Neck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""
2. Entity1: ""RT"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""

Causalities:-
<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>

Section Name: Flowchart Overview
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Supraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""guides management of""
2. Entity1: ""NCCN Guidelines"", Entity2: ""healthcare professionals"", Relationship: ""used by""

Causalities:-
<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.

Section Name: Assessment and Treatment Decisions
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Complete Response : The disappearance of all signs of cancer in response to treatment.
Partial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Complete Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""
2. Entity1: ""Complete Response"", Entity2: ""Surgery"", Relationship: ""leads to""
3. Entity1: ""Partial Response"", Entity2: ""Systemic Therapy"", Relationship: ""leads to""
4. Entity1: ""Partial Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""

Causalities:-
<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.

Section Name: Adverse Pathologic Features and Follow-up
====================
Entities:-
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Neoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Recurrent Neoplasm : A neoplasm that has returned after treatment.
Metastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.
Metastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""Treatment decisions"", Relationship: ""Influence""
2. Entity1: ""Adverse features"", Entity2: ""Surgical intervention"", Relationship: ""Recommendation""
3. Entity1: ""Absence of adverse features"", Entity2: ""Radiation therapy"", Relationship: ""Pathway""
4. Entity1: ""Follow-up process"", Entity2: ""Recurrent or persistent disease"", Relationship: ""Detection""
5. Entity1: ""Recurrent or persistent disease"", Entity2: ""Advanced disease management"", Relationship: ""Necessity""

Causalities:-
<C> The presence of adverse pathologic features — such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient's disease characteristics.

Furthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.


Among these two options which one is the most likely true:

(A) `Lymph_Node_Biopsy_Results_9` increases risk `Extranodal_Extension_5`
(B) `Extranodal_Extension_5` `increases risk `Lymph_Node_Biopsy_Results_9`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge (A) suggests that the presence of cancer cells in the lymph node, as indicated by a positive lymph node biopsy result, is necessary for extranodal extension to occur. This is because cancer must be present in the lymph node before it can spread beyond it.
2. The edge (B) suggests that extranodal extension, which indicates cancer spread beyond the lymph node, can influence the results of a lymph node biopsy by indicating the presence of cancer cells.
3. The causal direction for both edges is positive, meaning that the presence of one increases the likelihood of the other.
4. The causal factor for edge (A) is necessary but not sufficient, meaning that while a positive biopsy is required for extranodal extension, it does not guarantee it.
5. The causal factor for edge (B) is neither necessary nor sufficient, meaning that extranodal extension does not guarantee a positive biopsy result, nor is it required for one.
6. The causal distance for both edges is proximal, indicating a direct relationship between the presence of cancer cells in the lymph node and extranodal extension.
7. From the NCCN Guidelines, extranodal extension is considered an adverse pathologic feature, which can influence treatment decisions and prognosis.
8. The presence of extranodal extension is a significant factor in cancer staging and prognosis, as it indicates a more advanced disease.
9. The NCCN Guidelines emphasize the importance of lymph node biopsy in diagnosing and staging cancer, which aligns with the necessity of a positive biopsy result for extranodal extension to occur.
","1. Page Number: 55, Section Name: Adverse Pathologic Features, Entity: Extranodal Extension, Relationship: is a type of Adverse Pathologic Features
2. Page Number: 130, Section Name: Pathological N (pN), Entity: Lymph Nodes, Relationship: involved in Neoplasm Metastasis
3. Page Number: 41, Section Name: Workup, Entity: Biopsy, Relationship: performed on Primary tumor site
",A,"{'A': 100.0, 'B': 0.0}",yes,A,"1. The AI assistant's reasoning for option (A) is based on the explanation that a positive lymph node biopsy result is necessary for extranodal extension to occur. This is because cancer must be present in the lymph node before it can spread beyond it, which aligns with the definition of a necessary causal factor.
2. The assistant correctly identifies that the causal direction is positive, meaning that the presence of cancer cells in the lymph node increases the likelihood of extranodal extension. This is consistent with the explanation provided in the edge description.
3. The assistant also notes that the causal factor is necessary but not sufficient, which is consistent with the explanation that not all cases with cancer in the lymph node will have extranodal extension. This aligns with the definition of a necessary but not sufficient condition.
4. The causal distance is described as proximal, indicating a direct relationship between the presence of cancer cells in the lymph node and extranodal extension. This is consistent with the explanation provided in the edge description.
5. The assistant references the NCCN Guidelines, noting that extranodal extension is considered an adverse pathologic feature, which can influence treatment decisions and prognosis. This supports the reasoning that extranodal extension is a significant factor in cancer staging and prognosis.
6. The assistant's reasoning for option (B) is less supported, as the explanation for this edge suggests that extranodal extension can influence the results of a lymph node biopsy by indicating the presence of cancer cells. However, this does not align with the definition of a necessary or sufficient causal factor, as extranodal extension is not required for a positive biopsy result.
7. Overall, the assistant's reasoning for option (A) is consistent with the explanation provided in the edge description and is supported by the NCCN Guidelines. The reasoning for option (B) is less consistent and lacks support from the guidelines.
"
5,gpt-4o,"N_Staging_1,Number_of_Affected_Lymph_Nodes_2","""{'NODE1': {'id': 'N_Staging_1', 'label': 'Nearby Lymph Nodes Cancer Staging', 'description': 'This node represents the staging of cancer in nearby lymph nodes, which is a critical factor in determining the extent of cancer spread and guiding treatment decisions. The staging helps in assessing the prognosis and planning the appropriate therapeutic approach.', 'type': 'Decision Node', 'observability': 'Needs to be Predicted', 'states': [{'state_name': 'present', 'state_description': 'Cancer is present in the nearby lymph nodes, indicating that the cancer has spread beyond the primary site. This is an important factor in staging and affects treatment decisions and prognosis.'}, {'state_name': 'absent', 'state_description': 'Cancer is absent in the nearby lymph nodes, suggesting that the cancer has not spread to these nodes. This is a favorable sign and influences the staging and treatment plan.'}]}, 'NODE2': {'id': 'Number_of_Affected_Lymph_Nodes_2', 'label': 'Number of Affected Lymph Nodes', 'description': 'This node represents the clinical assessment of whether there are affected lymph nodes in the patient, which is crucial for staging cancer and determining the extent of metastasis.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'present', 'state_description': 'There are affected lymph nodes, indicating potential metastasis and a more advanced stage of cancer.'}, {'state_name': 'absent', 'state_description': 'There are no affected lymph nodes, suggesting no metastasis to the lymphatic system and potentially an earlier stage of cancer.'}]}, 'EDGE1': {'edges_ids': ['N_Staging_1', 'Number_of_Affected_Lymph_Nodes_2'], 'edge': '(N_Staging_1) causes (Number_of_Affected_Lymph_Nodes_2)', 'explanation': ['The edge `(N_Staging_1) causes (Number_of_Affected_Lymph_Nodes_2)` is not valid because the causal relationship is reversed.', 'In reality, the number of affected lymph nodes (Number_of_Affected_Lymph_Nodes_2) influences the staging of cancer in lymph nodes (N_Staging_1).', 'The staging is determined based on the clinical assessment of affected lymph nodes, not the other way around.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}, 'EDGE2': {'edges_ids': ['Number_of_Affected_Lymph_Nodes_2', 'N_Staging_1'], 'edge': '(Number_of_Affected_Lymph_Nodes_2) causes (N_Staging_1)', 'explanation': [\""The 'Number of Affected Lymph Nodes' is a critical factor in determining the 'N Staging' of cancer.\"", 'The presence of affected lymph nodes directly influences the N stage, which is part of the TNM staging system used in oncology.', 'The causal relationship is valid because the N stage is defined based on the involvement of lymph nodes.', 'The causal direction is positive because more affected lymph nodes lead to a higher N stage.', 'The presence of affected lymph nodes is necessary for a higher N stage, but not sufficient on its own as other factors might be involved in staging.', 'The causal distance is proximal because the number of affected lymph nodes directly affects the N stage.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': True, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'ENTITIES_MATCHING_PAGES_INFO': {'130': {'matching_entities': [{'LYMPH NODE STRUCTURE': 0.99134904}, {'LYMPH NODE': 0.98570025}, {'LYMPH NODES': 0.97445965}, {'TUMOR STAGING': 0.9742619}, {'TNM STAGING SYSTEM': 0.9654991}, {'TNM STAGING': 0.946078}, {'NEOPLASM STAGING': 0.9326755}], 'count': 7}, '102': {'matching_entities': [{'STAGING': 0.9886105}, {'CANCER STAGING': 0.9805381}, {'LYMPHATIC SYSTEM': 0.95855314}, {'LYMPHATIC STRUCTURE': 0.9469132}, {'NEOPLASM STAGING': 0.9326755}], 'count': 5}, '51': {'matching_entities': [{'CANCER STAGING': 0.9805381}, {'TNM STAGING SYSTEM': 0.9654991}, {'NEOPLASM STAGING': 0.9326755}, {'MALIGNANT NEOPLASM': 0.9201188}, {'CANCER': 0.92000854}], 'count': 5}, '42': {'matching_entities': [{'CANCER STAGING': 0.9805381}, {'TUMOR STAGING': 0.9742619}, {'NEOPLASM STAGING': 0.9326755}], 'count': 3}, '57': {'matching_entities': [{'CANCER STAGING': 0.9805381}, {'TNM STAGING SYSTEM': 0.9654991}, {'NEOPLASM STAGING': 0.9326755}], 'count': 3}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 130\\n\\nSection Name: Pathological N (pN)\\n====================\\nEntities:-\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nTnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system.\\n\\nRelationships:-\\n1. Entity1: \""Lymph Nodes\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""involved in\""\\n2. Entity1: \""TNM Staging\"", Entity2: \""Lymph Nodes\"", Relationship: \""includes\""\\n3. Entity1: \""TNM Staging\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""describes\""\\n\\nCausalities:-\\n<CO> NX: Regional lymph nodes cannot be assessed </CO>\\n<CO> N0: No regional lymph node metastasis </CO>\\n<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(\u2013) </CO>\\n<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(\u2212); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> Note: A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+). </CO>\\n\\nSection Name: Distant Metastasis (M)\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""M0\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n2. Entity1: \""M1\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n\\nCausalities:-\\n### Distant Metastasis (M)\\n\\n- **M0**: No distant metastasis\\n- **M1**: Distant metastasis\\n\\nSection Name: Histologic Grade (G)\\n====================\\nEntities:-\\nNeoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.\\nHistologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.\\n\\nRelationships:-\\n1. Entity1: \""GX\"", Entity2: \""Grade cannot be assessed\"", Relationship: \""is described as\""\\n2. Entity1: \""G1\"", Entity2: \""Well differentiated\"", Relationship: \""is described as\""\\n3. Entity1: \""G2\"", Entity2: \""Moderately differentiated\"", Relationship: \""is described as\""\\n4. Entity1: \""G3\"", Entity2: \""Poorly differentiated\"", Relationship: \""is described as\""\\n\\nCausalities:-\\n<CO>GX</CO>: <E>Grade cannot be assessed</E>\\n<CO>G1</CO>: <E>Well differentiated</E>\\n<CO>G2</CO>: <E>Moderately differentiated</E>\\n<CO>G3</CO>: <E>Poorly differentiated</E>\\n\\nSection Name: Prognostic Stage Groups\\n====================\\nEntities:-\\nNeoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.\\nTumor Staging : A system for describing the size and spread of cancer within the body.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\n\\nRelationships:-\\n1. Entity1: \""Stage 0\"", Entity2: \""Tis N0 M0\"", Relationship: \""defined by\""\\n2. Entity1: \""Stage I\"", Entity2: \""T1 N0 M0\"", Relationship: \""defined by\""\\n3. Entity1: \""Stage II\"", Entity2: \""T2 N0 M0\"", Relationship: \""defined by\""\\n4. Entity1: \""Stage III\"", Entity2: \""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0\"", Relationship: \""defined by\""\\n5. Entity1: \""Stage IVA\"", Entity2: \""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0\"", Relationship: \""defined by\""\\n6. Entity1: \""Stage IVB\"", Entity2: \""Any T N3 M0, T4b Any N M0\"", Relationship: \""defined by\""\\n7. Entity1: \""Stage IVC\"", Entity2: \""Any T Any N M1\"", Relationship: \""defined by\""\\n--------------------------------------------------\\nPage Number: 102\\n\\nSection Name: Head and Neck Cancers - Principles of Surgery\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.\\nLymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.\\nNeoplasms : New abnormal growth of tissue in animals or plants; a tumor.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nNeoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSurgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nLymphatic Structure : Anatomical structure that is part of the lymphatic system.\\nTumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.\\nStaging : The process of determining the size and spread of cancer within the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.\\n\\nRelationships:-\\n1. Entity1: \""surgical management\"", Entity2: \""regional lymphatics\"", Relationship: \""dictated by tumor staging\""\\n2. Entity1: \""neck dissections\"", Entity2: \""primary tumor\"", Relationship: \""part of treatment\""\\n3. Entity1: \""surgery\"", Entity2: \""ipsilateral side of the neck\"", Relationship: \""risk for metastases\""\\n\\nCausalities:-\\n<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.\\n\\nSection Name: Neck Management\\n====================\\nEntities:-\\nTongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.\\nPalate : The roof of the mouth, separating the oral and nasal cavities.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\nHypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.\\nNasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSquamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.\\nBiopsy : The removal of cells or tissues for examination under a microscope.\\n\\nRelationships:-\\n1. Entity1: \""Tumor sites\"", Entity2: \""Bilateral lymphatic drainage\"", Relationship: \""associated with\""\\n2. Entity1: \""Elective neck dissection\"", Entity2: \""Risk of occult metastasis\"", Relationship: \""based on\""\\n3. Entity1: \""SLN biopsy\"", Entity2: \""Elective neck dissection\"", Relationship: \""guides decision-making for\""\\n\\nCausalities:-\\n- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.\\n\\n- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.\\n\\n- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.\\n\\n  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2\u20134 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.\\n\\nSection Name: Types of Neck Dissection\\n====================\\nEntities:-\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\n\\nRelationships:-\\n1. Entity1: \""N0\"", Entity2: \""Selective neck dissection\"", Relationship: \""associated with\""\\n2. Entity1: \""N3\"", Entity2: \""Comprehensive neck dissection\"", Relationship: \""associated with\""\\n3. Entity1: \""Level VI neck dissection\"", Entity2: \""Larynx\"", Relationship: \""performed for\""\\n4. Entity1: \""Level VI neck dissection\"", Entity2: \""Hypopharynx\"", Relationship: \""performed for\""\\n\\nCausalities:-\\n- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:\\n  - **N0:** <A> Selective neck dissection </A>\\n    - Oral cavity at least levels I\u2013III\\n    - Oropharynx at least levels II\u2013IV\\n    - Hypopharynx at least levels II\u2013IV and level VI when appropriate\\n    - Larynx at least levels II\u2013IV and level VI when appropriate\\n  - **N1\u2013N2a\u2013c:** <A> Selective or comprehensive neck dissection </A> (Discussion)\\n  - **N3:** <A> Comprehensive neck dissection </A>\\n\\n- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.\\n\\n- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.\\n--------------------------------------------------\\nPage Number: 51\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\nSupraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network (NCCN)\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""provides guidelines for\""\\n2. Entity1: \""healthcare professionals\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""manage\""\\n\\nCausalities:-\\nThe provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nTotal Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nCancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.\\nTnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging criteria\"", Entity2: \""Total laryngectomy\"", Relationship: \""determines necessity of\""\\n2. Entity1: \""T3, N0\"", Entity2: \""Clinical staging criteria\"", Relationship: \""is a categorization of\""\\n\\nCausalities:-\\nThe flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.\\n\\nSection Name: Treatment of Primary and Neck\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nLymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""combined with\""\\n2. Entity1: \""Laryngectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n3. Entity1: \""Thyroidectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n4. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n\\nCausalities:-\\n<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.\\n\\nSection Name: Surgical Options\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nLymph Node Excision : Surgical removal of one or more lymph nodes.\\nLymphadenectomy : Surgical removal of one or more groups of lymph nodes.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Laryngectomy\"", Entity2: \""Thyroidectomy\"", Relationship: \""combined with\""\\n2. Entity1: \""Lymph Node Dissection\"", Entity2: \""Surgical Intervention\"", Relationship: \""extent of\""\\n3. Entity1: \""Surgical Intervention\"", Entity2: \""Advanced Cases\"", Relationship: \""management option for\""\\n\\nCausalities:-\\n<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.\\n\\nSection Name: Induction Chemotherapy\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nTherapeutic Approach : A method or strategy used in the treatment of disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Induction Chemotherapy\"", Entity2: \""Surgical Intervention\"", Relationship: \""alternative or sequential treatment option\""\\n\\nCausalities:-\\n<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.\\n\\nSection Name: Adjuvant Treatment\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nNeoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.\\nDisease Progression : The worsening of a disease over time.\\n\\nRelationships:-\\n1. Entity1: \""Primary Treatment\"", Entity2: \""Adjuvant Treatment\"", Relationship: \""followed by\""\\n2. Entity1: \""Adjuvant Treatment\"", Entity2: \""Systemic Therapy\"", Relationship: \""includes\""\\n3. Entity1: \""Adjuvant Treatment\"", Entity2: \""Radiotherapy\"", Relationship: \""includes\""\\n4. Entity1: \""Follow-up Assessments\"", Entity2: \""Treatment Efficacy\"", Relationship: \""used to evaluate\""\\n\\nCausalities:-\\n<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient\\'s response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.\\n\\nSection Name: Risk Features and Response Assessment\\n====================\\nEntities:-\\nNeoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.\\nSurgical Margins : The edge or border of the tissue removed in cancer surgery.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nExtramural Extension : Extension of a tumor beyond the wall of an organ.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nCancer Management : The process of planning and coordinating the treatment of cancer.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Extramural extension\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n2. Entity1: \""Positive surgical margin\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n3. Entity1: \""Ongoing assessment\"", Entity2: \""Response evaluation\"", Relationship: \""leads to\""\\n4. Entity1: \""Response evaluation\"", Entity2: \""Adjustments to treatment\"", Relationship: \""leads to\""\\n5. Entity1: \""Management of cancer\"", Entity2: \""Treatment decisions\"", Relationship: \""involves\""\\n6. Entity1: \""Management of cancer\"", Entity2: \""Ongoing assessment\"", Relationship: \""involves\""\\n7. Entity1: \""Management of cancer\"", Entity2: \""Adjustments to treatment\"", Relationship: \""involves\""\\n\\nCausalities:-\\nThe chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nMalignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""NCCN Guidelines\"", Relationship: \""provides\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""Clinical Trials\"", Relationship: \""recommend\""\\n3. Entity1: \""NCCN Guidelines\"", Entity2: \""Cancer\"", Relationship: \""related to management of\""\\n\\nCausalities:-\\n<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: SUPRA-3\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nClinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""Total laryngectomy\"", Entity2: \""Laryngectomy\"", Relationship: \""is a type of\""\\n2. Entity1: \""Systemic therapy\"", Entity2: \""RT\"", Relationship: \""concurrent treatment option\""\\n3. Entity1: \""Induction chemotherapy\"", Entity2: \""Other treatments\"", Relationship: \""initial treatment option before\""\\n\\nCausalities:-\\n<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>\\n  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>\\n  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>\\n  - or\\n  - <A> Induction chemotherapy </A>\\n  - or\\n  - <A> Clinical trials </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient\\'s condition after initial treatment.\\nFollow-Up : Medical care given to a patient over time after initial treatment.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : The reappearance of a disease after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n- **Follow-up (FOLL-A, 1 of 2)**\\n  - <CO> Recurrent or persistent disease </CO> (ADV-3)\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""pN1\"", Entity2: \""Radiotherapy\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Extranodal extension\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n3. Entity1: \""Extranodal extension\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n4. Entity1: \""Positive surgical margin\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n5. Entity1: \""Positive surgical margin\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n\\nCausalities:-\\n- <CO>pN1 without other risk features</CO>\\n  - <C>Adverse pathologic features</C>\\n  - <A>Consider RT</A>\\n  - <CO>Extranodal extension and/or positive margin</CO>\\n  - <CO>Other risk features</CO>\\n  - <A>Systemic therapy/RT (category 1)</A>\\n  - <A>RT or Consider systemic therapy/RT</A>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nResponse Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.\\nResponse To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.\\n\\nRelationships:-\\n\\nSection Name: Principles of Surgery and Radiation Therapy\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""complementary treatments\""\\n\\nCausalities:-\\n**Principles of Surgery (SURG-A).**\\n\\n**Principles of Radiation Therapy (SUPRA-A).**\\n\\nSection Name: Principles of Systemic Therapy\\n====================\\nEntities:-\\nCisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Cisplatin\"", Entity2: \""Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""preferred agent\""\\n2. Entity1: \""Cisplatin\"", Entity2: \""Concurrent Systemic Therapy/RT\"", Relationship: \""used in\""\\n\\nCausalities:-\\n<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.\\n--------------------------------------------------\\nPage Number: 42\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nCarcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.\\nLarynx : An organ in the neck involved in breathing, sound production, and protecting the trachea against food aspiration.\\nNeoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.\\nTumor Staging : The process of determining the extent of spread of a tumor.\\nCancer Staging : The process of determining the extent to which a cancer has developed by growing and possibly spreading.\\n\\nRelationships:-\\n1. Entity1: \""Carcinoma in situ\"", Entity2: \""larynx-preserving surgery\"", Relationship: \""progression to determine suitability\""\\n2. Entity1: \""nodal disease\"", Entity2: \""glottic tumors\"", Relationship: \""rare occurrence\""\\n\\nCausalities:-\\n<C>Carcinoma in situ</C> and progresses to <A>determine the amenability of the patient to larynx-preserving surgery</A>, specifically <CO>for tumors classified as T1 to T2, N0, or select T3, N0</CO>. This initial assessment is critical as it <E>drives treatment decisions</E>. In SOURCE2, it is noted that <C>nodal disease in such glottic tumors</C> <E>is rare</E>.\\n\\nSection Name: Treatment of Primary and Neck\\n====================\\nEntities:-\\nEndoscopic Surgical Procedures : Surgery performed with the aid of an endoscope, which is a medical device with a light attached. It is used to look inside a body cavity or organ.\\nRadiotherapy : The use of ionizing radiation to treat cancer.\\nLaryngectomy, Partial : Surgical removal of part of the larynx.\\nNeck Dissection : Surgical procedure for control of neck lymph node metastasis.\\nNeoplasms : An abnormal mass of tissue as a result of neoplasia. Neoplasia is the abnormal proliferation of cells.\\n\\nRelationships:-\\n1. Entity1: \""Condition\"", Entity2: \""Endoscopic Resection\"", Relationship: \""preferred treatment\""\\n2. Entity1: \""Condition\"", Entity2: \""Radiation Therapy\"", Relationship: \""alternative treatment\""\\n3. Entity1: \""Condition\"", Entity2: \""Partial Laryngectomy\"", Relationship: \""alternative treatment\""\\n4. Entity1: \""Condition\"", Entity2: \""Neck Dissection\"", Relationship: \""part of extensive treatment\""\\n\\nCausalities:-\\n<CO>If the condition allows for larynx-preserving options</CO>, the <A>preferred treatment is endoscopic resection or radiation therapy (RT)</A>. Alternative <A>options include partial laryngectomy or a more extensive endoscopic/open resection with neck dissection</A>, <CO>depending on the specific characteristics of the tumor</CO>. SOURCE2 specifies that <A>endoscopic resection is preferred</A>, and <A>RT or partial laryngectomy/endoscopic or open resection is indicated as needed</A>.\\n\\nSection Name: Adjuvant Treatment\\n====================\\nEntities:-\\nAdjuvant Therapy : Treatment given in addition to the primary (main) treatment to enhance its effectiveness.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nPathologic Processes : The abnormal mechanisms and forms involved in the dysfunctions of tissues and organs.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margins : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nRadiation Therapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\n\\nRelationships:-\\n1. Entity1: \""Adjuvant Treatment\"", Entity2: \""Surgical Intervention\"", Relationship: \""follows\""\\n2. Entity1: \""Adjuvant Treatment\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""depends on\""\\n3. Entity1: \""Extranodal Extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n4. Entity1: \""Positive Margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n5. Entity1: \""Systemic Therapy\"", Entity2: \""Adjuvant Treatment\"", Relationship: \""is a component of\""\\n6. Entity1: \""Radiation\"", Entity2: \""Adjuvant Treatment\"", Relationship: \""is a component of\""\\n\\nSection Name: Follow-Up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nNeoplasm Recurrence, Local : The return of a tumor at the original site after treatment.\\nDisease Progression : The worsening of a disease over time.\\nObservation : The act of noting and recording an event, characteristic, or behavior.\\nAntineoplastic Agents : Drugs used to treat cancer.\\nRadiotherapy : The use of ionizing radiation to treat cancer.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\n\\nRelationships:-\\n1. Entity1: \""Follow-Up\"", Entity2: \""recurrence\"", Relationship: \""monitoring\""\\n2. Entity1: \""Follow-Up\"", Entity2: \""persistent disease\"", Relationship: \""monitoring\""\\n3. Entity1: \""systemic therapy\"", Entity2: \""recurrent or persistent disease\"", Relationship: \""treatment option\""\\n4. Entity1: \""RT\"", Entity2: \""recurrent or persistent disease\"", Relationship: \""treatment option\""\\n5. Entity1: \""re-resection\"", Entity2: \""recurrent or persistent disease\"", Relationship: \""treatment option\""\\n\\nCausalities:-\\n<C> recurrence or persistent disease </C> <E> monitoring recurrence or persistent disease </E>. <A> follow-up strategies </A> are essential for <E> monitoring recurrence or persistent disease </E>. <A> continual assessment post-treatment </A> to <E> ensure any signs of recurrence are addressed promptly </E>. SOURCE2 mentions <A> observation, systemic therapy/RT, re-resection if feasible, and follow-up </A> for <CO> recurrent or persistent disease </CO>.\\n--------------------------------------------------\\nPage Number: 57\\n\\nSection Name: Definitive Treatment\\n====================\\nEntities:-\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nNeoplasm Staging : Methods used for staging neoplasms, including the TNM staging system.\\nCancer Staging : A system of classifying cancer according to the extent of the disease.\\nTnm Staging System : A cancer staging system that describes the extent of cancer in a patient\\'s body.\\n\\nRelationships:-\\n1. Entity1: \""Radiation Therapy\"", Entity2: \""T1\u20133, N0\u20131\"", Relationship: \""treats\""\\n2. Entity1: \""Conventional RT\"", Entity2: \""Radiation Therapy\"", Relationship: \""is a type of\""\\n3. Entity1: \""66 to 70 Gray (Gy)\"", Entity2: \""Conventional RT\"", Relationship: \""is the dosage for\""\\n\\nCausalities:-\\nThe document begins by defining the definitive radiation therapy (RT) approach for <CO> patients classified as T1\u20133, N0\u20131, with a specific focus on high-risk patients </CO>. It suggests <A> a regimen involving conventional RT, particularly highlighting a total dose of 66 to 70 Gray (Gy) delivered in fractions of 2.0 Gy each </A>. The schedule emphasizes <A> daily treatments, indicating a typical 7-week plan </A>.\\n\\nSection Name: Concurrent Therapy\\n====================\\nEntities:-\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nCisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.\\nChemotherapy : The use of drugs to destroy cancer cells, usually by stopping the cancer cells\u2019 ability to grow and divide.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""used in combination with\""\\n2. Entity1: \""Cisplatin\"", Entity2: \""Systemic Therapy\"", Relationship: \""is a type of\""\\n3. Entity1: \""Cisplatin\"", Entity2: \""Chemotherapy\"", Relationship: \""part of\""\\n\\nCausalities:-\\nIt further elaborates on concurrent systemic therapy in combination with radiation treatment. <CO> High-risk patients </CO> <E> may receive up to 70 Gy </E>, while <CO> those with lower risks </CO> <E> are advised to receive between 44 to 63 Gy </E>, <CO> depending on their specific case </CO>. This section <A> recommends careful consideration of systemic therapies like cisplatin, particularly every three weeks or in combination with pre-existing chemotherapy protocols </A>.\\n\\nSection Name: Additional Techniques and Research\\n====================\\nEntities:-\\nIntensity-Modulated Radiotherapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nIntensity Modulated Radiation Therapy : A type of cancer treatment that uses beams of radiation of varying intensities to deliver a precise dose of radiation to a tumor.\\nIntensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nThree-Dimensional Conformal Radiotherapy : A technique in radiotherapy that allows the radiation beams to be shaped to match the shape of the tumor.\\n3D Conformal Radiation Therapy : A type of radiation therapy that uses computer technology to create a 3-dimensional image of the tumor so that multiple radiation beams can be shaped exactly to the contour of the treatment area.\\nProton Therapy : The use of a beam of protons to irradiate diseased tissue, most often in the treatment of cancer.\\nToxicity : The degree to which a chemical substance or a particular mixture of substances can damage an organism.\\nRadiotherapy : The use of ionizing radiation to treat cancer and other diseases.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\n\\nRelationships:-\\n1. Entity1: \""Intensity-Modulated Radiation Therapy (IMRT)\"", Entity2: \""3D-Conformal Radiation Therapy (3D-CRT)\"", Relationship: \""preferred treatment modalities\""\\n2. Entity1: \""Proton therapy\"", Entity2: \""specific conditions\"", Relationship: \""could be beneficial\""\\n3. Entity1: \""treatment toxicity\"", Entity2: \""radiation techniques\"", Relationship: \""minimizing\""\\n4. Entity1: \""ongoing research\"", Entity2: \""radiation techniques\"", Relationship: \""efficacy and safety\""\\n\\nCausalities:-\\n<A> The document suggests employing either Intensity-Modulated Radiation Therapy (IMRT) or 3D-Conformal Radiation Therapy (3D-CRT) as preferred treatment modalities </A>. It mentions that <A> proton therapy could be beneficial </A> <CO> under specific conditions </CO> and <A> stresses the importance of minimizing treatment toxicity </A>. <CO> This part indicates ongoing research into the efficacy and safety of various radiation techniques </CO>.\\n\\nSection Name: Practical Recommendations\\n====================\\nEntities:-\\nTreatment Protocols : Treatment protocols are standardized procedures or plans of treatment for specific diseases or conditions.\\nMultidisciplinary Care : Multidisciplinary care involves the collaboration of professionals from various disciplines to provide comprehensive care.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Treatment Protocols\"", Entity2: \""Individual Patient Circumstances\"", Relationship: \""tailored based on\""\\n2. Entity1: \""Multidisciplinary Care\"", Entity2: \""Treatment Planning\"", Relationship: \""important for\""\\n3. Entity1: \""Patient Management\"", Entity2: \""Systemic Therapy\"", Relationship: \""necessary due to complexity and risks\""\\n\\nCausalities:-\\n<A> practical recommendations for treatment sequencing </A>, emphasizing <A> a tailored approach </A> <CO> based on individual patient circumstances </CO>, and highlights <A> the importance of multi-disciplinary collaboration in treatment planning </A>. There\u2019s an implicit suggestion for <A> careful patient management </A> <C> due to the complexity and risks of concurrent systemic therapies </C>.\\n\\nSection Name: NCCN Guidelines Index\\n====================\\nEntities:-\\n\\nRelationships:-\\n\\nCausalities:-\\n- **Table of Contents**\\n- **Discussion**\\n\\nSection Name: SUPRA-A 1 OF 2\\n====================\\nEntities:-\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nCisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.\\nCarboplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers, similar to cisplatin but with a different toxicity profile.\\nFluorouracil : A pyrimidine analog used as an antineoplastic agent, often in the treatment of cancers.\\nChemotherapy, Adjuvant : Treatment given in addition to the primary (main) treatment to enhance its effectiveness, often used in cancer therapy.\\nFractionation, Radiation : The division of the total dose of radiation into smaller doses delivered over a period of time.\\n\\nRelationships:-\\n1. Entity1: \""Cisplatin\"", Entity2: \""Concurrent Systemic Therapy/RT\"", Relationship: \""used in\""\\n2. Entity1: \""Carboplatin\"", Entity2: \""5-FU\"", Relationship: \""used with\""\\n3. Entity1: \""Concurrent Systemic Therapy/RT\"", Entity2: \""Non-Nasopharyngeal Cancers\"", Relationship: \""treatment for\""\\n\\nCausalities:-\\n1. **See Principles of Radiation Techniques (RAD-A) and Discussion.**\\n2. <CO>For select T1\u20132, N0 tumors</CO>, <A>accelerated fractionation may be used</A>.\\n3. <CO>For doses >70 Gy</CO>, <A>some clinicians feel that the fractionation should be slightly modified (e.g., <2.0 Gy/fraction for at least some of the treatment)</A> <E>to minimize toxicity</E>. An additional 2\u20133 doses can be added depending on clinical circumstances.\\n4. <A>Suggest 44\u201350 Gy in 3D-CRT and sequentially planned IMRT or 54\u201363 Gy with IMRT dose painting technique</A> <CO>(dependent on dose per fraction)</CO>.\\n5. **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A).**\\n6. <C>Based on published data</C>, <A>concurrent systemic therapy/RT most commonly uses conventional fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks with single-agent cisplatin given every 3 weeks at 100 mg/m\u00b2</A>; <CO>2\u20133 cycles of chemotherapy are used depending on the radiation fractionation scheme (RTOG)</CO>. <CO>When carboplatin and 5-FU are used</CO>, <A>the recommended regimen is standard fractionation plus 3 cycles of chemotherapy</A>. <A>Other fraction sizes, multiagent chemotherapy, other dosing schedules of cisplatin, or altered fractionation with chemotherapy are efficacious</A>, and <CO>there is no consensus on the optimal approach</CO>. <C>In general, the use of concurrent systemic therapy/RT</C> <E>carries a high toxicity burden</E>; <C>multiagent chemotherapy</C> <E>will likely further increase the toxicity burden</E>. <A>For any systemic therapy/RT approach, close attention should be paid to published reports for the specific chemotherapy agent, dose, and schedule of administration</A>. <A>Systemic therapy/RT should be performed by an experienced team and should include substantial supportive care</A>.\\n\\nSection Name: PRINCIPLES OF RADIATION THERAPY\\n====================\\nEntities:-\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nPlanning Target Volume : A volume that includes the gross tumor volume and a margin to account for tumor motion and setup variations.\\nIntensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nProton Therapy : The use of a beam of protons to irradiate diseased tissue, most often in the treatment of cancer.\\n\\nRelationships:-\\n1. Entity1: \""RT Alone\"", Entity2: \""PTV\"", Relationship: \""involves\""\\n2. Entity1: \""Concurrent Systemic Therapy/RT\"", Entity2: \""IMRT\"", Relationship: \""involves\""\\n3. Entity1: \""Proton Therapy\"", Entity2: \""Photon-based Therapy\"", Relationship: \""alternative to\""\\n\\nCausalities:-\\n1. **DEFINITIVE: RT Alone**\\n   - T1\u20133, N0\u20131: 66\u201370 Gy conventional (2.0 Gy/fraction)\\n   - **PTV**\\n     - <CO> High risk </CO>: <A> Primary tumor and involved lymph nodes [this includes possible local subclinical infiltration at the primary site and at the high-risk level lymph node(s)] </A>\\n       - <A> Fractionation: 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction); daily Monday\u2013Friday in 6\u20137 weeks </A>\\n     - <A> Concomitant boost accelerated RT: </A>\\n       - <A> 72 Gy/6 weeks (1.8 Gy/fraction, large field; 1.5 Gy boost as second daily fraction during last 12 treatment days) </A>\\n       - <A> 66\u201370 Gy (2.0 Gy/fraction; 6 fractions/wk accelerated) </A>\\n     - <A> Hyperfractionation: 79.2\u201381.6 Gy/7 weeks (1.2 Gy/fraction twice daily) </A>\\n     - <CO> Low to intermediate risk </CO>: <A> Sites of suspected subclinical spread </A>\\n       - <A> 44\u201350 Gy (2.0 Gy/fraction) to 54\u201363 Gy (1.6\u20131.8 Gy/fraction) </A>\\n\\n2. **CONCURRENT SYSTEMIC THERAPY/RT:**\\n   - **PTV**\\n     - <CO> High risk </CO>: <A> Typically 70 Gy (2.0 Gy/fraction) </A>\\n     - <CO> Low to intermediate and low risk </CO>: <A> 44\u201350 Gy (2.0 Gy/fraction) to 54\u201363 Gy (1.6\u20131.8 Gy/fraction) </A>\\n   - <A> Either IMRT (preferred) or 3D-CRT is recommended. </A> <CO> Use of proton therapy is an area of active investigation. </CO> <A> Proton therapy may be considered </A> <CO> when normal tissue constraints cannot be met by photon-based therapy, or when photon-based therapy causes compromise of standard radiation dosing to tumor or postoperative volumes. </CO>\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: N_Staging_1
label: Nearby Lymph Nodes Cancer Staging
description: This node represents the staging of cancer in nearby lymph nodes, which is a critical factor in determining the extent of cancer spread and guiding treatment decisions. The staging helps in assessing the prognosis and planning the appropriate therapeutic approach.
type: Decision Node
observability: Needs to be Predicted
states: [{'state_name': 'present', 'state_description': 'Cancer is present in the nearby lymph nodes, indicating that the cancer has spread beyond the primary site. This is an important factor in staging and affects treatment decisions and prognosis.'}, {'state_name': 'absent', 'state_description': 'Cancer is absent in the nearby lymph nodes, suggesting that the cancer has not spread to these nodes. This is a favorable sign and influences the staging and treatment plan.'}]

`NODE2`:
id: Number_of_Affected_Lymph_Nodes_2
label: Number of Affected Lymph Nodes
description: This node represents the clinical assessment of whether there are affected lymph nodes in the patient, which is crucial for staging cancer and determining the extent of metastasis.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'present', 'state_description': 'There are affected lymph nodes, indicating potential metastasis and a more advanced stage of cancer.'}, {'state_name': 'absent', 'state_description': 'There are no affected lymph nodes, suggesting no metastasis to the lymphatic system and potentially an earlier stage of cancer.'}]

`EDGE1`:
{'edges_ids': ['N_Staging_1', 'Number_of_Affected_Lymph_Nodes_2'], 'edge': '(N_Staging_1) causes (Number_of_Affected_Lymph_Nodes_2)', 'explanation': ['The edge `(N_Staging_1) causes (Number_of_Affected_Lymph_Nodes_2)` is not valid because the causal relationship is reversed.', 'In reality, the number of affected lymph nodes (Number_of_Affected_Lymph_Nodes_2) influences the staging of cancer in lymph nodes (N_Staging_1).', 'The staging is determined based on the clinical assessment of affected lymph nodes, not the other way around.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}

`EDGE2`:
{'edges_ids': ['Number_of_Affected_Lymph_Nodes_2', 'N_Staging_1'], 'edge': '(Number_of_Affected_Lymph_Nodes_2) causes (N_Staging_1)', 'explanation': ['The `Number of Affected Lymph Nodes` is a critical factor in determining the `N Staging` of cancer.', 'The presence of affected lymph nodes directly influences the N stage, which is part of the TNM staging system used in oncology.', 'The causal relationship is valid because the N stage is defined based on the involvement of lymph nodes.', 'The causal direction is positive because more affected lymph nodes lead to a higher N stage.', 'The presence of affected lymph nodes is necessary for a higher N stage, but not sufficient on its own as other factors might be involved in staging.', 'The causal distance is proximal because the number of affected lymph nodes directly affects the N stage.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': True, 'sufficient': False}, 'causal_distance': 'Proximal'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 130

Section Name: Pathological N (pN)
====================
Entities:-
Lymph Nodes : Small, bean-shaped structures that are part of the body's lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.
Lymph Node : An organ of the lymphatic system and the adaptive immune system.

Relationships:-
1. Entity1: ""Lymph Nodes"", Entity2: ""Neoplasm Metastasis"", Relationship: ""involved in""
2. Entity1: ""TNM Staging"", Entity2: ""Lymph Nodes"", Relationship: ""includes""
3. Entity1: ""TNM Staging"", Entity2: ""Neoplasm Metastasis"", Relationship: ""describes""

Causalities:-
<CO> NX: Regional lymph nodes cannot be assessed </CO>
<CO> N0: No regional lymph node metastasis </CO>
<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(–) </CO>
<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> Note: A designation of “U” or “L” may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(−) or ENE(+). </CO>

Section Name: Distant Metastasis (M)
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""M0"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""
2. Entity1: ""M1"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""

Causalities:-
### Distant Metastasis (M)

- **M0**: No distant metastasis
- **M1**: Distant metastasis

Section Name: Histologic Grade (G)
====================
Entities:-
Neoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.
Histologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.

Relationships:-
1. Entity1: ""GX"", Entity2: ""Grade cannot be assessed"", Relationship: ""is described as""
2. Entity1: ""G1"", Entity2: ""Well differentiated"", Relationship: ""is described as""
3. Entity1: ""G2"", Entity2: ""Moderately differentiated"", Relationship: ""is described as""
4. Entity1: ""G3"", Entity2: ""Poorly differentiated"", Relationship: ""is described as""

Causalities:-
<CO>GX</CO>: <E>Grade cannot be assessed</E>
<CO>G1</CO>: <E>Well differentiated</E>
<CO>G2</CO>: <E>Moderately differentiated</E>
<CO>G3</CO>: <E>Poorly differentiated</E>

Section Name: Prognostic Stage Groups
====================
Entities:-
Neoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.
Tumor Staging : A system for describing the size and spread of cancer within the body.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.

Relationships:-
1. Entity1: ""Stage 0"", Entity2: ""Tis N0 M0"", Relationship: ""defined by""
2. Entity1: ""Stage I"", Entity2: ""T1 N0 M0"", Relationship: ""defined by""
3. Entity1: ""Stage II"", Entity2: ""T2 N0 M0"", Relationship: ""defined by""
4. Entity1: ""Stage III"", Entity2: ""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0"", Relationship: ""defined by""
5. Entity1: ""Stage IVA"", Entity2: ""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0"", Relationship: ""defined by""
6. Entity1: ""Stage IVB"", Entity2: ""Any T N3 M0, T4b Any N M0"", Relationship: ""defined by""
7. Entity1: ""Stage IVC"", Entity2: ""Any T Any N M1"", Relationship: ""defined by""
--------------------------------------------------
Page Number: 102

Section Name: Head and Neck Cancers - Principles of Surgery
====================
Entities:-
Surgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.
Lymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.
Neoplasms : New abnormal growth of tissue in animals or plants; a tumor.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Neoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Surgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Lymphatic Structure : Anatomical structure that is part of the lymphatic system.
Tumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.
Staging : The process of determining the size and spread of cancer within the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.

Relationships:-
1. Entity1: ""surgical management"", Entity2: ""regional lymphatics"", Relationship: ""dictated by tumor staging""
2. Entity1: ""neck dissections"", Entity2: ""primary tumor"", Relationship: ""part of treatment""
3. Entity1: ""surgery"", Entity2: ""ipsilateral side of the neck"", Relationship: ""risk for metastases""

Causalities:-
<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.

Section Name: Neck Management
====================
Entities:-
Tongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.
Palate : The roof of the mouth, separating the oral and nasal cavities.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.
Hypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.
Nasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Squamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.
Biopsy : The removal of cells or tissues for examination under a microscope.

Relationships:-
1. Entity1: ""Tumor sites"", Entity2: ""Bilateral lymphatic drainage"", Relationship: ""associated with""
2. Entity1: ""Elective neck dissection"", Entity2: ""Risk of occult metastasis"", Relationship: ""based on""
3. Entity1: ""SLN biopsy"", Entity2: ""Elective neck dissection"", Relationship: ""guides decision-making for""

Causalities:-
- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.

- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.

- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.

  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2–4 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.

Section Name: Types of Neck Dissection
====================
Entities:-
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.

Relationships:-
1. Entity1: ""N0"", Entity2: ""Selective neck dissection"", Relationship: ""associated with""
2. Entity1: ""N3"", Entity2: ""Comprehensive neck dissection"", Relationship: ""associated with""
3. Entity1: ""Level VI neck dissection"", Entity2: ""Larynx"", Relationship: ""performed for""
4. Entity1: ""Level VI neck dissection"", Entity2: ""Hypopharynx"", Relationship: ""performed for""

Causalities:-
- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:
  - **N0:** <A> Selective neck dissection </A>
    - Oral cavity at least levels I–III
    - Oropharynx at least levels II–IV
    - Hypopharynx at least levels II–IV and level VI when appropriate
    - Larynx at least levels II–IV and level VI when appropriate
  - **N1–N2a–c:** <A> Selective or comprehensive neck dissection </A> (Discussion)
  - **N3:** <A> Comprehensive neck dissection </A>

- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.

- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.
--------------------------------------------------
Page Number: 51

Section Name: Introduction
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.
Supraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network (NCCN)"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""provides guidelines for""
2. Entity1: ""healthcare professionals"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""manage""

Causalities:-
The provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.

Section Name: Clinical Staging
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Total Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Cancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.
Tnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).

Relationships:-
1. Entity1: ""Clinical staging criteria"", Entity2: ""Total laryngectomy"", Relationship: ""determines necessity of""
2. Entity1: ""T3, N0"", Entity2: ""Clinical staging criteria"", Relationship: ""is a categorization of""

Causalities:-
The flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.

Section Name: Treatment of Primary and Neck
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Lymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Radiation Therapy"", Relationship: ""combined with""
2. Entity1: ""Laryngectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
3. Entity1: ""Thyroidectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
4. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""

Causalities:-
<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.

Section Name: Surgical Options
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Lymph Node Excision : Surgical removal of one or more lymph nodes.
Lymphadenectomy : Surgical removal of one or more groups of lymph nodes.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.

Relationships:-
1. Entity1: ""Laryngectomy"", Entity2: ""Thyroidectomy"", Relationship: ""combined with""
2. Entity1: ""Lymph Node Dissection"", Entity2: ""Surgical Intervention"", Relationship: ""extent of""
3. Entity1: ""Surgical Intervention"", Entity2: ""Advanced Cases"", Relationship: ""management option for""

Causalities:-
<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.

Section Name: Induction Chemotherapy
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Therapeutic Approach : A method or strategy used in the treatment of disease or injury.

Relationships:-
1. Entity1: ""Induction Chemotherapy"", Entity2: ""Surgical Intervention"", Relationship: ""alternative or sequential treatment option""

Causalities:-
<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.

Section Name: Adjuvant Treatment
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Neoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.
Disease Progression : The worsening of a disease over time.

Relationships:-
1. Entity1: ""Primary Treatment"", Entity2: ""Adjuvant Treatment"", Relationship: ""followed by""
2. Entity1: ""Adjuvant Treatment"", Entity2: ""Systemic Therapy"", Relationship: ""includes""
3. Entity1: ""Adjuvant Treatment"", Entity2: ""Radiotherapy"", Relationship: ""includes""
4. Entity1: ""Follow-up Assessments"", Entity2: ""Treatment Efficacy"", Relationship: ""used to evaluate""

Causalities:-
<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient's response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.

Section Name: Risk Features and Response Assessment
====================
Entities:-
Neoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.
Surgical Margins : The edge or border of the tissue removed in cancer surgery.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Extramural Extension : Extension of a tumor beyond the wall of an organ.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Cancer Management : The process of planning and coordinating the treatment of cancer.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Extramural extension"", Entity2: ""Treatment decisions"", Relationship: ""influences""
2. Entity1: ""Positive surgical margin"", Entity2: ""Treatment decisions"", Relationship: ""influences""
3. Entity1: ""Ongoing assessment"", Entity2: ""Response evaluation"", Relationship: ""leads to""
4. Entity1: ""Response evaluation"", Entity2: ""Adjustments to treatment"", Relationship: ""leads to""
5. Entity1: ""Management of cancer"", Entity2: ""Treatment decisions"", Relationship: ""involves""
6. Entity1: ""Management of cancer"", Entity2: ""Ongoing assessment"", Relationship: ""involves""
7. Entity1: ""Management of cancer"", Entity2: ""Adjustments to treatment"", Relationship: ""involves""

Causalities:-
The chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Malignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""NCCN Guidelines"", Relationship: ""provides""
2. Entity1: ""NCCN Guidelines"", Entity2: ""Clinical Trials"", Relationship: ""recommend""
3. Entity1: ""NCCN Guidelines"", Entity2: ""Cancer"", Relationship: ""related to management of""

Causalities:-
<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: SUPRA-3
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Clinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""Total laryngectomy"", Entity2: ""Laryngectomy"", Relationship: ""is a type of""
2. Entity1: ""Systemic therapy"", Entity2: ""RT"", Relationship: ""concurrent treatment option""
3. Entity1: ""Induction chemotherapy"", Entity2: ""Other treatments"", Relationship: ""initial treatment option before""

Causalities:-
<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>
  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>
  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>
  - or
  - <A> Induction chemotherapy </A>
  - or
  - <A> Clinical trials </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient's condition after initial treatment.
Follow-Up : Medical care given to a patient over time after initial treatment.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : The reappearance of a disease after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
- **Follow-up (FOLL-A, 1 of 2)**
  - <CO> Recurrent or persistent disease </CO> (ADV-3)

Section Name: Adverse Pathologic Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer beyond the lymph node capsule.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""pN1"", Entity2: ""Radiotherapy"", Relationship: ""Consideration for treatment""
2. Entity1: ""Extranodal extension"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
3. Entity1: ""Extranodal extension"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""
4. Entity1: ""Positive surgical margin"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
5. Entity1: ""Positive surgical margin"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""

Causalities:-
- <CO>pN1 without other risk features</CO>
  - <C>Adverse pathologic features</C>
  - <A>Consider RT</A>
  - <CO>Extranodal extension and/or positive margin</CO>
  - <CO>Other risk features</CO>
  - <A>Systemic therapy/RT (category 1)</A>
  - <A>RT or Consider systemic therapy/RT</A>

Section Name: Response Assessment
====================
Entities:-
Response Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.
Response To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.

Relationships:-

Section Name: Principles of Surgery and Radiation Therapy
====================
Entities:-
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""complementary treatments""

Causalities:-
**Principles of Surgery (SURG-A).**

**Principles of Radiation Therapy (SUPRA-A).**

Section Name: Principles of Systemic Therapy
====================
Entities:-
Cisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Cisplatin"", Entity2: ""Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""preferred agent""
2. Entity1: ""Cisplatin"", Entity2: ""Concurrent Systemic Therapy/RT"", Relationship: ""used in""

Causalities:-
<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.
--------------------------------------------------
Page Number: 42

Section Name: Clinical Staging
====================
Entities:-
Carcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.
Larynx : An organ in the neck involved in breathing, sound production, and protecting the trachea against food aspiration.
Neoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Tumor Staging : The process of determining the extent of spread of a tumor.
Cancer Staging : The process of determining the extent to which a cancer has developed by growing and possibly spreading.

Relationships:-
1. Entity1: ""Carcinoma in situ"", Entity2: ""larynx-preserving surgery"", Relationship: ""progression to determine suitability""
2. Entity1: ""nodal disease"", Entity2: ""glottic tumors"", Relationship: ""rare occurrence""

Causalities:-
<C>Carcinoma in situ</C> and progresses to <A>determine the amenability of the patient to larynx-preserving surgery</A>, specifically <CO>for tumors classified as T1 to T2, N0, or select T3, N0</CO>. This initial assessment is critical as it <E>drives treatment decisions</E>. In SOURCE2, it is noted that <C>nodal disease in such glottic tumors</C> <E>is rare</E>.

Section Name: Treatment of Primary and Neck
====================
Entities:-
Endoscopic Surgical Procedures : Surgery performed with the aid of an endoscope, which is a medical device with a light attached. It is used to look inside a body cavity or organ.
Radiotherapy : The use of ionizing radiation to treat cancer.
Laryngectomy, Partial : Surgical removal of part of the larynx.
Neck Dissection : Surgical procedure for control of neck lymph node metastasis.
Neoplasms : An abnormal mass of tissue as a result of neoplasia. Neoplasia is the abnormal proliferation of cells.

Relationships:-
1. Entity1: ""Condition"", Entity2: ""Endoscopic Resection"", Relationship: ""preferred treatment""
2. Entity1: ""Condition"", Entity2: ""Radiation Therapy"", Relationship: ""alternative treatment""
3. Entity1: ""Condition"", Entity2: ""Partial Laryngectomy"", Relationship: ""alternative treatment""
4. Entity1: ""Condition"", Entity2: ""Neck Dissection"", Relationship: ""part of extensive treatment""

Causalities:-
<CO>If the condition allows for larynx-preserving options</CO>, the <A>preferred treatment is endoscopic resection or radiation therapy (RT)</A>. Alternative <A>options include partial laryngectomy or a more extensive endoscopic/open resection with neck dissection</A>, <CO>depending on the specific characteristics of the tumor</CO>. SOURCE2 specifies that <A>endoscopic resection is preferred</A>, and <A>RT or partial laryngectomy/endoscopic or open resection is indicated as needed</A>.

Section Name: Adjuvant Treatment
====================
Entities:-
Adjuvant Therapy : Treatment given in addition to the primary (main) treatment to enhance its effectiveness.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Pathologic Processes : The abnormal mechanisms and forms involved in the dysfunctions of tissues and organs.
Extranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margins : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Radiation Therapy : The use of high-energy radiation to kill cancer cells and shrink tumors.

Relationships:-
1. Entity1: ""Adjuvant Treatment"", Entity2: ""Surgical Intervention"", Relationship: ""follows""
2. Entity1: ""Adjuvant Treatment"", Entity2: ""Adverse Pathologic Features"", Relationship: ""depends on""
3. Entity1: ""Extranodal Extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
4. Entity1: ""Positive Margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
5. Entity1: ""Systemic Therapy"", Entity2: ""Adjuvant Treatment"", Relationship: ""is a component of""
6. Entity1: ""Radiation"", Entity2: ""Adjuvant Treatment"", Relationship: ""is a component of""

Section Name: Follow-Up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Neoplasm Recurrence, Local : The return of a tumor at the original site after treatment.
Disease Progression : The worsening of a disease over time.
Observation : The act of noting and recording an event, characteristic, or behavior.
Antineoplastic Agents : Drugs used to treat cancer.
Radiotherapy : The use of ionizing radiation to treat cancer.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.

Relationships:-
1. Entity1: ""Follow-Up"", Entity2: ""recurrence"", Relationship: ""monitoring""
2. Entity1: ""Follow-Up"", Entity2: ""persistent disease"", Relationship: ""monitoring""
3. Entity1: ""systemic therapy"", Entity2: ""recurrent or persistent disease"", Relationship: ""treatment option""
4. Entity1: ""RT"", Entity2: ""recurrent or persistent disease"", Relationship: ""treatment option""
5. Entity1: ""re-resection"", Entity2: ""recurrent or persistent disease"", Relationship: ""treatment option""

Causalities:-
<C> recurrence or persistent disease </C> <E> monitoring recurrence or persistent disease </E>. <A> follow-up strategies </A> are essential for <E> monitoring recurrence or persistent disease </E>. <A> continual assessment post-treatment </A> to <E> ensure any signs of recurrence are addressed promptly </E>. SOURCE2 mentions <A> observation, systemic therapy/RT, re-resection if feasible, and follow-up </A> for <CO> recurrent or persistent disease </CO>.
--------------------------------------------------
Page Number: 57

Section Name: Definitive Treatment
====================
Entities:-
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Neoplasm Staging : Methods used for staging neoplasms, including the TNM staging system.
Cancer Staging : A system of classifying cancer according to the extent of the disease.
Tnm Staging System : A cancer staging system that describes the extent of cancer in a patient's body.

Relationships:-
1. Entity1: ""Radiation Therapy"", Entity2: ""T1–3, N0–1"", Relationship: ""treats""
2. Entity1: ""Conventional RT"", Entity2: ""Radiation Therapy"", Relationship: ""is a type of""
3. Entity1: ""66 to 70 Gray (Gy)"", Entity2: ""Conventional RT"", Relationship: ""is the dosage for""

Causalities:-
The document begins by defining the definitive radiation therapy (RT) approach for <CO> patients classified as T1–3, N0–1, with a specific focus on high-risk patients </CO>. It suggests <A> a regimen involving conventional RT, particularly highlighting a total dose of 66 to 70 Gray (Gy) delivered in fractions of 2.0 Gy each </A>. The schedule emphasizes <A> daily treatments, indicating a typical 7-week plan </A>.

Section Name: Concurrent Therapy
====================
Entities:-
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Cisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.
Chemotherapy : The use of drugs to destroy cancer cells, usually by stopping the cancer cells’ ability to grow and divide.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Radiation Therapy"", Relationship: ""used in combination with""
2. Entity1: ""Cisplatin"", Entity2: ""Systemic Therapy"", Relationship: ""is a type of""
3. Entity1: ""Cisplatin"", Entity2: ""Chemotherapy"", Relationship: ""part of""

Causalities:-
It further elaborates on concurrent systemic therapy in combination with radiation treatment. <CO> High-risk patients </CO> <E> may receive up to 70 Gy </E>, while <CO> those with lower risks </CO> <E> are advised to receive between 44 to 63 Gy </E>, <CO> depending on their specific case </CO>. This section <A> recommends careful consideration of systemic therapies like cisplatin, particularly every three weeks or in combination with pre-existing chemotherapy protocols </A>.

Section Name: Additional Techniques and Research
====================
Entities:-
Intensity-Modulated Radiotherapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Intensity Modulated Radiation Therapy : A type of cancer treatment that uses beams of radiation of varying intensities to deliver a precise dose of radiation to a tumor.
Intensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Three-Dimensional Conformal Radiotherapy : A technique in radiotherapy that allows the radiation beams to be shaped to match the shape of the tumor.
3D Conformal Radiation Therapy : A type of radiation therapy that uses computer technology to create a 3-dimensional image of the tumor so that multiple radiation beams can be shaped exactly to the contour of the treatment area.
Proton Therapy : The use of a beam of protons to irradiate diseased tissue, most often in the treatment of cancer.
Toxicity : The degree to which a chemical substance or a particular mixture of substances can damage an organism.
Radiotherapy : The use of ionizing radiation to treat cancer and other diseases.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.

Relationships:-
1. Entity1: ""Intensity-Modulated Radiation Therapy (IMRT)"", Entity2: ""3D-Conformal Radiation Therapy (3D-CRT)"", Relationship: ""preferred treatment modalities""
2. Entity1: ""Proton therapy"", Entity2: ""specific conditions"", Relationship: ""could be beneficial""
3. Entity1: ""treatment toxicity"", Entity2: ""radiation techniques"", Relationship: ""minimizing""
4. Entity1: ""ongoing research"", Entity2: ""radiation techniques"", Relationship: ""efficacy and safety""

Causalities:-
<A> The document suggests employing either Intensity-Modulated Radiation Therapy (IMRT) or 3D-Conformal Radiation Therapy (3D-CRT) as preferred treatment modalities </A>. It mentions that <A> proton therapy could be beneficial </A> <CO> under specific conditions </CO> and <A> stresses the importance of minimizing treatment toxicity </A>. <CO> This part indicates ongoing research into the efficacy and safety of various radiation techniques </CO>.

Section Name: Practical Recommendations
====================
Entities:-
Treatment Protocols : Treatment protocols are standardized procedures or plans of treatment for specific diseases or conditions.
Multidisciplinary Care : Multidisciplinary care involves the collaboration of professionals from various disciplines to provide comprehensive care.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Treatment Protocols"", Entity2: ""Individual Patient Circumstances"", Relationship: ""tailored based on""
2. Entity1: ""Multidisciplinary Care"", Entity2: ""Treatment Planning"", Relationship: ""important for""
3. Entity1: ""Patient Management"", Entity2: ""Systemic Therapy"", Relationship: ""necessary due to complexity and risks""

Causalities:-
<A> practical recommendations for treatment sequencing </A>, emphasizing <A> a tailored approach </A> <CO> based on individual patient circumstances </CO>, and highlights <A> the importance of multi-disciplinary collaboration in treatment planning </A>. There’s an implicit suggestion for <A> careful patient management </A> <C> due to the complexity and risks of concurrent systemic therapies </C>.

Section Name: NCCN Guidelines Index
====================
Entities:-

Relationships:-

Causalities:-
- **Table of Contents**
- **Discussion**

Section Name: SUPRA-A 1 OF 2
====================
Entities:-
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Cisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.
Carboplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers, similar to cisplatin but with a different toxicity profile.
Fluorouracil : A pyrimidine analog used as an antineoplastic agent, often in the treatment of cancers.
Chemotherapy, Adjuvant : Treatment given in addition to the primary (main) treatment to enhance its effectiveness, often used in cancer therapy.
Fractionation, Radiation : The division of the total dose of radiation into smaller doses delivered over a period of time.

Relationships:-
1. Entity1: ""Cisplatin"", Entity2: ""Concurrent Systemic Therapy/RT"", Relationship: ""used in""
2. Entity1: ""Carboplatin"", Entity2: ""5-FU"", Relationship: ""used with""
3. Entity1: ""Concurrent Systemic Therapy/RT"", Entity2: ""Non-Nasopharyngeal Cancers"", Relationship: ""treatment for""

Causalities:-
1. **See Principles of Radiation Techniques (RAD-A) and Discussion.**
2. <CO>For select T1–2, N0 tumors</CO>, <A>accelerated fractionation may be used</A>.
3. <CO>For doses >70 Gy</CO>, <A>some clinicians feel that the fractionation should be slightly modified (e.g., <2.0 Gy/fraction for at least some of the treatment)</A> <E>to minimize toxicity</E>. An additional 2–3 doses can be added depending on clinical circumstances.
4. <A>Suggest 44–50 Gy in 3D-CRT and sequentially planned IMRT or 54–63 Gy with IMRT dose painting technique</A> <CO>(dependent on dose per fraction)</CO>.
5. **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A).**
6. <C>Based on published data</C>, <A>concurrent systemic therapy/RT most commonly uses conventional fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks with single-agent cisplatin given every 3 weeks at 100 mg/m²</A>; <CO>2–3 cycles of chemotherapy are used depending on the radiation fractionation scheme (RTOG)</CO>. <CO>When carboplatin and 5-FU are used</CO>, <A>the recommended regimen is standard fractionation plus 3 cycles of chemotherapy</A>. <A>Other fraction sizes, multiagent chemotherapy, other dosing schedules of cisplatin, or altered fractionation with chemotherapy are efficacious</A>, and <CO>there is no consensus on the optimal approach</CO>. <C>In general, the use of concurrent systemic therapy/RT</C> <E>carries a high toxicity burden</E>; <C>multiagent chemotherapy</C> <E>will likely further increase the toxicity burden</E>. <A>For any systemic therapy/RT approach, close attention should be paid to published reports for the specific chemotherapy agent, dose, and schedule of administration</A>. <A>Systemic therapy/RT should be performed by an experienced team and should include substantial supportive care</A>.

Section Name: PRINCIPLES OF RADIATION THERAPY
====================
Entities:-
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Planning Target Volume : A volume that includes the gross tumor volume and a margin to account for tumor motion and setup variations.
Intensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Proton Therapy : The use of a beam of protons to irradiate diseased tissue, most often in the treatment of cancer.

Relationships:-
1. Entity1: ""RT Alone"", Entity2: ""PTV"", Relationship: ""involves""
2. Entity1: ""Concurrent Systemic Therapy/RT"", Entity2: ""IMRT"", Relationship: ""involves""
3. Entity1: ""Proton Therapy"", Entity2: ""Photon-based Therapy"", Relationship: ""alternative to""

Causalities:-
1. **DEFINITIVE: RT Alone**
   - T1–3, N0–1: 66–70 Gy conventional (2.0 Gy/fraction)
   - **PTV**
     - <CO> High risk </CO>: <A> Primary tumor and involved lymph nodes [this includes possible local subclinical infiltration at the primary site and at the high-risk level lymph node(s)] </A>
       - <A> Fractionation: 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction); daily Monday–Friday in 6–7 weeks </A>
     - <A> Concomitant boost accelerated RT: </A>
       - <A> 72 Gy/6 weeks (1.8 Gy/fraction, large field; 1.5 Gy boost as second daily fraction during last 12 treatment days) </A>
       - <A> 66–70 Gy (2.0 Gy/fraction; 6 fractions/wk accelerated) </A>
     - <A> Hyperfractionation: 79.2–81.6 Gy/7 weeks (1.2 Gy/fraction twice daily) </A>
     - <CO> Low to intermediate risk </CO>: <A> Sites of suspected subclinical spread </A>
       - <A> 44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </A>

2. **CONCURRENT SYSTEMIC THERAPY/RT:**
   - **PTV**
     - <CO> High risk </CO>: <A> Typically 70 Gy (2.0 Gy/fraction) </A>
     - <CO> Low to intermediate and low risk </CO>: <A> 44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </A>
   - <A> Either IMRT (preferred) or 3D-CRT is recommended. </A> <CO> Use of proton therapy is an area of active investigation. </CO> <A> Proton therapy may be considered </A> <CO> when normal tissue constraints cannot be met by photon-based therapy, or when photon-based therapy causes compromise of standard radiation dosing to tumor or postoperative volumes. </CO>


Among these two options which one is the most likely true:

(A) `N_Staging_1` increases risk `Number_of_Affected_Lymph_Nodes_2`
(B) `Number_of_Affected_Lymph_Nodes_2` `increases risk `N_Staging_1`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge in question is between 'N_Staging_1' and 'Number_of_Affected_Lymph_Nodes_2'.
2. The explanation for EDGE1 suggests that the causal relationship is reversed, meaning 'Number_of_Affected_Lymph_Nodes_2' should influence 'N_Staging_1'.
3. EDGE2 supports this by stating that the number of affected lymph nodes is a critical factor in determining the N stage of cancer.
4. The TNM staging system, as described in the knowledge base, includes lymph node involvement as a key component in staging cancer.
5. The causal direction for EDGE2 is positive, indicating that more affected lymph nodes lead to a higher N stage.
6. The causal distance is proximal, meaning the number of affected lymph nodes directly affects the N stage.
7. The knowledge base on page 130, under the section 'Pathological N (pN)', describes the involvement of lymph nodes in the TNM staging system.
8. The relationship between 'TNM Staging' and 'Lymph Nodes' is described as 'includes', supporting the idea that lymph node involvement is part of the staging process.
","1. Page Number: 130
2. Section Name: Pathological N (pN)
3. Entities: Lymph Nodes, TNM Staging
4. Relationships: TNM Staging includes Lymph Nodes
5. Causalities: N stage is defined based on lymph node involvement
",B,"{'A': 0.0, 'B': 100.0}",yes,B,"1. The AI assistant's reasoning begins by identifying the edge in question, which is between 'N_Staging_1' and 'Number_of_Affected_Lymph_Nodes_2'.
2. The assistant correctly identifies that the explanation for EDGE1 suggests the causal relationship is reversed, meaning 'Number_of_Affected_Lymph_Nodes_2' should influence 'N_Staging_1'.
3. EDGE2 supports this by stating that the number of affected lymph nodes is a critical factor in determining the N stage of cancer, which aligns with the TNM staging system.
4. The assistant references the TNM staging system, which includes lymph node involvement as a key component in staging cancer, supporting the causal relationship described in EDGE2.
5. The causal direction for EDGE2 is positive, indicating that more affected lymph nodes lead to a higher N stage, which is consistent with the explanation provided.
6. The causal distance is proximal, meaning the number of affected lymph nodes directly affects the N stage, further supporting the validity of EDGE2.
7. The assistant references the knowledge base on page 130, under the section 'Pathological N (pN)', which describes the involvement of lymph nodes in the TNM staging system.
8. The relationship between 'TNM Staging' and 'Lymph Nodes' is described as 'includes', supporting the idea that lymph node involvement is part of the staging process.
9. The assistant's reasoning is consistent with the information provided in the knowledge base and the explanation for EDGE2, supporting the validity of option (B).
"
6,gpt-4o,"N_Staging_1,Number_of_Lymph_Nodes_Metastasis_3","""{'NODE1': {'id': 'N_Staging_1', 'label': 'Nearby Lymph Nodes Cancer Staging', 'description': 'This node represents the staging of cancer in nearby lymph nodes, which is a critical factor in determining the extent of cancer spread and guiding treatment decisions. The staging helps in assessing the prognosis and planning the appropriate therapeutic approach.', 'type': 'Decision Node', 'observability': 'Needs to be Predicted', 'states': [{'state_name': 'present', 'state_description': 'Cancer is present in the nearby lymph nodes, indicating that the cancer has spread beyond the primary site. This is an important factor in staging and affects treatment decisions and prognosis.'}, {'state_name': 'absent', 'state_description': 'Cancer is absent in the nearby lymph nodes, suggesting that the cancer has not spread to these nodes. This is a favorable sign and influences the staging and treatment plan.'}]}, 'NODE2': {'id': 'Number_of_Lymph_Nodes_Metastasis_3', 'label': 'Assessment of Lymph Node Metastasis', 'description': 'This node represents the assessment of whether metastasis is present in the lymph nodes. It is crucial for staging cancer and determining the extent of its spread, which impacts treatment decisions and prognosis.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'present', 'state_description': 'Metastasis is present in the lymph nodes, indicating that cancer has spread to these nodes.'}, {'state_name': 'absent', 'state_description': 'Metastasis is absent in the lymph nodes, indicating that cancer has not spread to these nodes.'}]}, 'EDGE1': {'edges_ids': ['N_Staging_1', 'Number_of_Lymph_Nodes_Metastasis_3'], 'edge': '(N_Staging_1) causes (Number_of_Lymph_Nodes_Metastasis_3)', 'explanation': ['The edge represents the causal relationship between the staging of cancer in nearby lymph nodes (N_Staging_1) and the assessment of metastasis in lymph nodes (Number_of_Lymph_Nodes_Metastasis_3).', 'N_Staging_1 being `present` indicates that cancer is present in the lymph nodes, which directly implies that metastasis is present in the lymph nodes (Number_of_Lymph_Nodes_Metastasis_3).', 'This relationship is valid because the staging of cancer in lymph nodes is a critical factor in determining the presence of metastasis in those nodes.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': True, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'EDGE2': {'edges_ids': ['Number_of_Lymph_Nodes_Metastasis_3', 'N_Staging_1'], 'edge': '(Number_of_Lymph_Nodes_Metastasis_3) causes (N_Staging_1)', 'explanation': [\""The edge represents the causal relationship where the assessment of lymph node metastasis ('Number_of_Lymph_Nodes_Metastasis_3') influences the N staging ('N_Staging_1').\"", 'The presence of metastasis in lymph nodes is a critical factor in determining the N stage of cancer, which reflects the extent of cancer spread.', 'This relationship is valid because the staging process directly considers the presence or absence of metastasis in lymph nodes.', 'The causal direction is positive because the presence of metastasis leads to a higher N stage, indicating more advanced cancer.', 'The presence of metastasis is necessary for a higher N stage, but not sufficient alone, as other factors may also play a role in staging.', 'The causal distance is proximal because the assessment of metastasis directly impacts the staging decision.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': True, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'ENTITIES_MATCHING_PAGES_INFO': {'130': {'matching_entities': [{'NEOPLASM METASTASIS': 1.0}, {'LYMPH NODE STRUCTURE': 0.99134904}, {'LYMPH NODE': 0.98570025}, {'LYMPH NODES': 0.97445965}, {'TUMOR STAGING': 0.9742619}, {'TNM STAGING SYSTEM': 0.9654991}, {'METASTASIS': 0.9630129}, {'TNM STAGING': 0.946078}, {'NEOPLASM STAGING': 0.9326755}], 'count': 9}, '102': {'matching_entities': [{'STAGING': 0.9886105}, {'CANCER STAGING': 0.9805381}, {'METASTASIS': 0.9630129}, {'LYMPHATIC SYSTEM': 0.95855314}, {'LYMPHATIC STRUCTURE': 0.9469132}, {'NEOPLASM STAGING': 0.9326755}], 'count': 6}, '51': {'matching_entities': [{'CANCER STAGING': 0.9805381}, {'LYMPHATIC METASTASIS': 0.97019297}, {'TNM STAGING SYSTEM': 0.9654991}, {'MALIGNANT NEOPLASM': 0.9448747}, {'NEOPLASM STAGING': 0.9326755}, {'CANCER': 0.92851335}], 'count': 6}, '55': {'matching_entities': [{'NEOPLASM METASTASIS': 1.0}, {'METASTASIS': 0.9630129}, {'METASTATIC NEOPLASM': 0.96172774}, {'MALIGNANT NEOPLASTIC DISEASE': 0.9424237}, {'CANCER': 0.92851335}, {'PARTIAL RESPONSE': 0.9250841}], 'count': 6}, '44': {'matching_entities': [{'LYMPHATIC METASTASIS': 0.97019297}, {'MALIGNANT NEOPLASTIC DISEASE': 0.9424237}, {'NEOPLASM STAGING': 0.9326755}, {'CANCER': 0.92851335}], 'count': 4}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 130\\n\\nSection Name: Pathological N (pN)\\n====================\\nEntities:-\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nTnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system.\\n\\nRelationships:-\\n1. Entity1: \""Lymph Nodes\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""involved in\""\\n2. Entity1: \""TNM Staging\"", Entity2: \""Lymph Nodes\"", Relationship: \""includes\""\\n3. Entity1: \""TNM Staging\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""describes\""\\n\\nCausalities:-\\n<CO> NX: Regional lymph nodes cannot be assessed </CO>\\n<CO> N0: No regional lymph node metastasis </CO>\\n<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(\u2013) </CO>\\n<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(\u2212); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> Note: A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+). </CO>\\n\\nSection Name: Distant Metastasis (M)\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""M0\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n2. Entity1: \""M1\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n\\nCausalities:-\\n### Distant Metastasis (M)\\n\\n- **M0**: No distant metastasis\\n- **M1**: Distant metastasis\\n\\nSection Name: Histologic Grade (G)\\n====================\\nEntities:-\\nNeoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.\\nHistologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.\\n\\nRelationships:-\\n1. Entity1: \""GX\"", Entity2: \""Grade cannot be assessed\"", Relationship: \""is described as\""\\n2. Entity1: \""G1\"", Entity2: \""Well differentiated\"", Relationship: \""is described as\""\\n3. Entity1: \""G2\"", Entity2: \""Moderately differentiated\"", Relationship: \""is described as\""\\n4. Entity1: \""G3\"", Entity2: \""Poorly differentiated\"", Relationship: \""is described as\""\\n\\nCausalities:-\\n<CO>GX</CO>: <E>Grade cannot be assessed</E>\\n<CO>G1</CO>: <E>Well differentiated</E>\\n<CO>G2</CO>: <E>Moderately differentiated</E>\\n<CO>G3</CO>: <E>Poorly differentiated</E>\\n\\nSection Name: Prognostic Stage Groups\\n====================\\nEntities:-\\nNeoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.\\nTumor Staging : A system for describing the size and spread of cancer within the body.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\n\\nRelationships:-\\n1. Entity1: \""Stage 0\"", Entity2: \""Tis N0 M0\"", Relationship: \""defined by\""\\n2. Entity1: \""Stage I\"", Entity2: \""T1 N0 M0\"", Relationship: \""defined by\""\\n3. Entity1: \""Stage II\"", Entity2: \""T2 N0 M0\"", Relationship: \""defined by\""\\n4. Entity1: \""Stage III\"", Entity2: \""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0\"", Relationship: \""defined by\""\\n5. Entity1: \""Stage IVA\"", Entity2: \""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0\"", Relationship: \""defined by\""\\n6. Entity1: \""Stage IVB\"", Entity2: \""Any T N3 M0, T4b Any N M0\"", Relationship: \""defined by\""\\n7. Entity1: \""Stage IVC\"", Entity2: \""Any T Any N M1\"", Relationship: \""defined by\""\\n--------------------------------------------------\\nPage Number: 102\\n\\nSection Name: Head and Neck Cancers - Principles of Surgery\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.\\nLymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.\\nNeoplasms : New abnormal growth of tissue in animals or plants; a tumor.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nNeoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSurgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nLymphatic Structure : Anatomical structure that is part of the lymphatic system.\\nTumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.\\nStaging : The process of determining the size and spread of cancer within the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.\\n\\nRelationships:-\\n1. Entity1: \""surgical management\"", Entity2: \""regional lymphatics\"", Relationship: \""dictated by tumor staging\""\\n2. Entity1: \""neck dissections\"", Entity2: \""primary tumor\"", Relationship: \""part of treatment\""\\n3. Entity1: \""surgery\"", Entity2: \""ipsilateral side of the neck\"", Relationship: \""risk for metastases\""\\n\\nCausalities:-\\n<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.\\n\\nSection Name: Neck Management\\n====================\\nEntities:-\\nTongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.\\nPalate : The roof of the mouth, separating the oral and nasal cavities.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\nHypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.\\nNasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSquamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.\\nBiopsy : The removal of cells or tissues for examination under a microscope.\\n\\nRelationships:-\\n1. Entity1: \""Tumor sites\"", Entity2: \""Bilateral lymphatic drainage\"", Relationship: \""associated with\""\\n2. Entity1: \""Elective neck dissection\"", Entity2: \""Risk of occult metastasis\"", Relationship: \""based on\""\\n3. Entity1: \""SLN biopsy\"", Entity2: \""Elective neck dissection\"", Relationship: \""guides decision-making for\""\\n\\nCausalities:-\\n- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.\\n\\n- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.\\n\\n- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.\\n\\n  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2\u20134 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.\\n\\nSection Name: Types of Neck Dissection\\n====================\\nEntities:-\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\n\\nRelationships:-\\n1. Entity1: \""N0\"", Entity2: \""Selective neck dissection\"", Relationship: \""associated with\""\\n2. Entity1: \""N3\"", Entity2: \""Comprehensive neck dissection\"", Relationship: \""associated with\""\\n3. Entity1: \""Level VI neck dissection\"", Entity2: \""Larynx\"", Relationship: \""performed for\""\\n4. Entity1: \""Level VI neck dissection\"", Entity2: \""Hypopharynx\"", Relationship: \""performed for\""\\n\\nCausalities:-\\n- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:\\n  - **N0:** <A> Selective neck dissection </A>\\n    - Oral cavity at least levels I\u2013III\\n    - Oropharynx at least levels II\u2013IV\\n    - Hypopharynx at least levels II\u2013IV and level VI when appropriate\\n    - Larynx at least levels II\u2013IV and level VI when appropriate\\n  - **N1\u2013N2a\u2013c:** <A> Selective or comprehensive neck dissection </A> (Discussion)\\n  - **N3:** <A> Comprehensive neck dissection </A>\\n\\n- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.\\n\\n- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.\\n--------------------------------------------------\\nPage Number: 51\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\nSupraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network (NCCN)\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""provides guidelines for\""\\n2. Entity1: \""healthcare professionals\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""manage\""\\n\\nCausalities:-\\nThe provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nTotal Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nCancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.\\nTnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging criteria\"", Entity2: \""Total laryngectomy\"", Relationship: \""determines necessity of\""\\n2. Entity1: \""T3, N0\"", Entity2: \""Clinical staging criteria\"", Relationship: \""is a categorization of\""\\n\\nCausalities:-\\nThe flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.\\n\\nSection Name: Treatment of Primary and Neck\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nLymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""combined with\""\\n2. Entity1: \""Laryngectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n3. Entity1: \""Thyroidectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n4. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n\\nCausalities:-\\n<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.\\n\\nSection Name: Surgical Options\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nLymph Node Excision : Surgical removal of one or more lymph nodes.\\nLymphadenectomy : Surgical removal of one or more groups of lymph nodes.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Laryngectomy\"", Entity2: \""Thyroidectomy\"", Relationship: \""combined with\""\\n2. Entity1: \""Lymph Node Dissection\"", Entity2: \""Surgical Intervention\"", Relationship: \""extent of\""\\n3. Entity1: \""Surgical Intervention\"", Entity2: \""Advanced Cases\"", Relationship: \""management option for\""\\n\\nCausalities:-\\n<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.\\n\\nSection Name: Induction Chemotherapy\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nTherapeutic Approach : A method or strategy used in the treatment of disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Induction Chemotherapy\"", Entity2: \""Surgical Intervention\"", Relationship: \""alternative or sequential treatment option\""\\n\\nCausalities:-\\n<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.\\n\\nSection Name: Adjuvant Treatment\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nNeoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.\\nDisease Progression : The worsening of a disease over time.\\n\\nRelationships:-\\n1. Entity1: \""Primary Treatment\"", Entity2: \""Adjuvant Treatment\"", Relationship: \""followed by\""\\n2. Entity1: \""Adjuvant Treatment\"", Entity2: \""Systemic Therapy\"", Relationship: \""includes\""\\n3. Entity1: \""Adjuvant Treatment\"", Entity2: \""Radiotherapy\"", Relationship: \""includes\""\\n4. Entity1: \""Follow-up Assessments\"", Entity2: \""Treatment Efficacy\"", Relationship: \""used to evaluate\""\\n\\nCausalities:-\\n<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient\\'s response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.\\n\\nSection Name: Risk Features and Response Assessment\\n====================\\nEntities:-\\nNeoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.\\nSurgical Margins : The edge or border of the tissue removed in cancer surgery.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nExtramural Extension : Extension of a tumor beyond the wall of an organ.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nCancer Management : The process of planning and coordinating the treatment of cancer.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Extramural extension\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n2. Entity1: \""Positive surgical margin\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n3. Entity1: \""Ongoing assessment\"", Entity2: \""Response evaluation\"", Relationship: \""leads to\""\\n4. Entity1: \""Response evaluation\"", Entity2: \""Adjustments to treatment\"", Relationship: \""leads to\""\\n5. Entity1: \""Management of cancer\"", Entity2: \""Treatment decisions\"", Relationship: \""involves\""\\n6. Entity1: \""Management of cancer\"", Entity2: \""Ongoing assessment\"", Relationship: \""involves\""\\n7. Entity1: \""Management of cancer\"", Entity2: \""Adjustments to treatment\"", Relationship: \""involves\""\\n\\nCausalities:-\\nThe chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nMalignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""NCCN Guidelines\"", Relationship: \""provides\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""Clinical Trials\"", Relationship: \""recommend\""\\n3. Entity1: \""NCCN Guidelines\"", Entity2: \""Cancer\"", Relationship: \""related to management of\""\\n\\nCausalities:-\\n<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: SUPRA-3\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nClinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""Total laryngectomy\"", Entity2: \""Laryngectomy\"", Relationship: \""is a type of\""\\n2. Entity1: \""Systemic therapy\"", Entity2: \""RT\"", Relationship: \""concurrent treatment option\""\\n3. Entity1: \""Induction chemotherapy\"", Entity2: \""Other treatments\"", Relationship: \""initial treatment option before\""\\n\\nCausalities:-\\n<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>\\n  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>\\n  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>\\n  - or\\n  - <A> Induction chemotherapy </A>\\n  - or\\n  - <A> Clinical trials </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient\\'s condition after initial treatment.\\nFollow-Up : Medical care given to a patient over time after initial treatment.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : The reappearance of a disease after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n- **Follow-up (FOLL-A, 1 of 2)**\\n  - <CO> Recurrent or persistent disease </CO> (ADV-3)\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""pN1\"", Entity2: \""Radiotherapy\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Extranodal extension\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n3. Entity1: \""Extranodal extension\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n4. Entity1: \""Positive surgical margin\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n5. Entity1: \""Positive surgical margin\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n\\nCausalities:-\\n- <CO>pN1 without other risk features</CO>\\n  - <C>Adverse pathologic features</C>\\n  - <A>Consider RT</A>\\n  - <CO>Extranodal extension and/or positive margin</CO>\\n  - <CO>Other risk features</CO>\\n  - <A>Systemic therapy/RT (category 1)</A>\\n  - <A>RT or Consider systemic therapy/RT</A>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nResponse Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.\\nResponse To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.\\n\\nRelationships:-\\n\\nSection Name: Principles of Surgery and Radiation Therapy\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""complementary treatments\""\\n\\nCausalities:-\\n**Principles of Surgery (SURG-A).**\\n\\n**Principles of Radiation Therapy (SUPRA-A).**\\n\\nSection Name: Principles of Systemic Therapy\\n====================\\nEntities:-\\nCisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Cisplatin\"", Entity2: \""Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""preferred agent\""\\n2. Entity1: \""Cisplatin\"", Entity2: \""Concurrent Systemic Therapy/RT\"", Relationship: \""used in\""\\n\\nCausalities:-\\n<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.\\n--------------------------------------------------\\nPage Number: 55\\n\\nSection Name: General Information\\n====================\\nEntities:-\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""National Comprehensive Cancer Network\"", Relationship: \""produced by\""\\n\\nSection Name: Important Notes\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNeoplasms : New abnormal growth of tissue that can be benign or malignant.\\nMalignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Trials\"", Entity2: \""Cancer\"", Relationship: \""recommended for\""\\n2. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n\\nCausalities:-\\n<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nChemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n2. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n3. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n\\nCausalities:-\\n### Principles\\n\\n- **Principles of Surgery (SURG-A)**\\n- **Principles of Radiation Therapy (SUPRA-A)**\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nPerineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The invasion of cancer cells into blood vessels.\\nLymphatic Invasion : The invasion of cancer cells into lymphatic vessels.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n2. Entity1: \""Positive margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n3. Entity1: \""Close margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n4. Entity1: \""pT3 or pT4 primary\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n5. Entity1: \""pN2 or pN3 nodal disease\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n6. Entity1: \""Perineural invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n7. Entity1: \""Vascular invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n8. Entity1: \""Lymphatic invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n\\nCausalities:-\\n<C> Extranodal extension </C>\\n<C> Positive margins </C>\\n<C> Close margins </C>\\n<C> pT3 or pT4 primary </C>\\n<C> pN2 or pN3 nodal disease </C>\\n<C> Perineural invasion </C>\\n<C> Vascular invasion </C>\\n<C> Lymphatic invasion </C>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nPrimary Site : The original location where a tumor or cancer begins.\\nComplete Remission : The disappearance of all signs of cancer in response to treatment.\\nPartial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""induction chemotherapy\"", Entity2: \""Primary site\"", Relationship: \""treatment outcome\""\\n2. Entity1: \""Definitive RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n3. Entity1: \""RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n4. Entity1: \""Surgery\"", Entity2: \""unresectable nodal disease\"", Relationship: \""treatment option\""\\n\\nCausalities:-\\n<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.\\nFollow-Up (Medicine) : The process of monitoring a patient\\'s health over time after treatment or diagnosis.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : A disease that returns after a period of remission.\\nRecurrence (Medicine) : The return of a disease or condition after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n### Follow-up\\n\\n- **Follow-up** (FOLL-A, 1 of 2)\\n- **Recurrent or persistent disease** (ADV-3)\\n\\nSection Name: Risk Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""RT\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Adverse pathologic features\"", Entity2: \""Systemic therapy\"", Relationship: \""Consideration for treatment\""\\n\\nCausalities:-\\n- **No adverse pathologic features**\\n- **Other risk features**\\n- **Adverse pathologic features**:\\n  - <C> Extranodal extension and/or positive margin </C>\\n  - <A> RT or consider systemic therapy/RT </A>\\n\\nSection Name: Post-Therapy Evaluation\\n====================\\nEntities:-\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nNeck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n2. Entity1: \""RT\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n\\nCausalities:-\\n<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>\\n\\nSection Name: Flowchart Overview\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nSupraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""guides management of\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""healthcare professionals\"", Relationship: \""used by\""\\n\\nCausalities:-\\n<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.\\n\\nSection Name: Assessment and Treatment Decisions\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nComplete Response : The disappearance of all signs of cancer in response to treatment.\\nPartial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Complete Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n2. Entity1: \""Complete Response\"", Entity2: \""Surgery\"", Relationship: \""leads to\""\\n3. Entity1: \""Partial Response\"", Entity2: \""Systemic Therapy\"", Relationship: \""leads to\""\\n4. Entity1: \""Partial Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n\\nCausalities:-\\n<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.\\n\\nSection Name: Adverse Pathologic Features and Follow-up\\n====================\\nEntities:-\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nNeoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nRecurrent Neoplasm : A neoplasm that has returned after treatment.\\nMetastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.\\nMetastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""Treatment decisions\"", Relationship: \""Influence\""\\n2. Entity1: \""Adverse features\"", Entity2: \""Surgical intervention\"", Relationship: \""Recommendation\""\\n3. Entity1: \""Absence of adverse features\"", Entity2: \""Radiation therapy\"", Relationship: \""Pathway\""\\n4. Entity1: \""Follow-up process\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""Detection\""\\n5. Entity1: \""Recurrent or persistent disease\"", Entity2: \""Advanced disease management\"", Relationship: \""Necessity\""\\n\\nCausalities:-\\n<C> The presence of adverse pathologic features \u2014 such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient\\'s disease characteristics.\\n\\nFurthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.\\n--------------------------------------------------\\nPage Number: 44\\n\\nSection Name: Flowchart Structure\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms based on extent of tumor spread according to standardized criteria.\\nLaryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.\\nChemotherapy, Adjuvant : Drug therapy given in addition to the primary treatment to enhance its effectiveness.\\nRadiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nNeoplasm Recurrence, Local : The return of a tumor at the original site after treatment.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Staging\"", Entity2: \""T3 tumors\"", Relationship: \""determines treatment approach\""\\n2. Entity1: \""Adverse Pathologic Features\"", Entity2: \""Systemic Therapy\"", Relationship: \""directs to\""\\n3. Entity1: \""Adverse Pathologic Features\"", Entity2: \""Radiation Treatment\"", Relationship: \""directs to\""\\n4. Entity1: \""Induction Chemotherapy\"", Entity2: \""Imaging (CT or MRI)\"", Relationship: \""leads to\""\\n\\nCausalities:-\\n1. <A> The flow begins with the clinical staging of T3 tumors </A> <C> that require total laryngectomy (N2\u20133) </C>. <CO> This staging </CO> <E> is crucial for determining the appropriate therapeutic approach </E>.\\n\\n2. The flowchart provides multiple pathways for treatment, indicating that <CO> patients </CO> <A> may undergo either \""Concurrent systemic therapy/RT\"" or \""Surgery\"" </A>. There is also an <A> option for \""Induction chemotherapy,\"" leading to further imaging (CT or MRI) to assess the primary site and neck status </A>.\\n\\n3. For <CO> patients who have surgery </CO>, the flowchart distinguishes between those with adverse pathologic features and those without. <CO> Patients with adverse features\u2014such as extranodal extension or positive margins </CO>\u2014are <A> directed toward systemic therapy or radiation treatment </A>, while those without may follow a different management path.\\n\\n4. The flowchart concludes by <A> outlining follow-up procedures for recurrent or persistent disease </A>, suggesting additional assessments and treatments based on the risk features identified during earlier stages.\\n\\nSection Name: Detailed Explanation\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.\\nAdverse Pathological Feature : A pathological feature that indicates a worse prognosis or outcome.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\n\\nRelationships:-\\n1. Entity1: \""Systemic therapy\"", Entity2: \""Radiation\"", Relationship: \""Concurrent treatment\""\\n2. Entity1: \""Clinical trials\"", Entity2: \""Personalized treatment plans\"", Relationship: \""Development of\""\\n\\nCausalities:-\\n<A> The flowchart is designed to provide healthcare professionals with a systematic pathway for managing glottic larynx cancer </A>. Each step is meticulously organized to ensure that important factors are considered, such as <C> the presence of adverse pathological features </C>, which <E> strongly influence treatment decisions </E>.\\n\\n<A> The emphasis on concurrent treatments, such as systemic therapy combined with radiation </A>, reflects current best practices in oncology, where multimodal approaches are often necessary to achieve better outcomes. <A> The inclusion of clinical trials </A> indicates an emphasis on maintaining up-to-date practices and personalized treatment plans as part of patient management strategies.\\n\\nFurthermore, <A> the chart\\'s organization into treatment and follow-up segments </A> allows for a straightforward interpretation, guiding oncologists through complex decisions in a logical manner. This can <E> improve consistency in care and enhance patient safety through meticulous monitoring and responses to treatment efficacy or disease progression </E>.\\n\\nIn summary, <E> this flowchart serves as an essential resource for oncologists, facilitating a better understanding of treatment protocols for glottic larynx cancer while promoting a patient-centered approach to oncological care </E>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nNeoplasms : New abnormal growth of tissue that may be benign or malignant.\\nMalignant Neoplastic Disease : A disease in which abnormal cells divide uncontrollably and destroy body tissue.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\nNational Comprehensive Cancer Network : An alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""NCCN Guidelines\"", Relationship: \""publishes\""\\n2. Entity1: \""Clinical trial\"", Entity2: \""Cancer\"", Relationship: \""manages\""\\n\\nCausalities:-\\n<C> any patient with cancer </C> <E> the best management is in a clinical trial </E>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles of Treatment\\n====================\\nEntities:-\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margins : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.\\nPerineural Invasion : Cancer cells are found surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The presence of cancer cells within blood vessels.\\nLymphatic Metastasis : The spread of cancer cells through the lymphatic system to distant sites.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Extranodal Extension\"", Relationship: \""management of\""\\n2. Entity1: \""Principles of Surgery\"", Entity2: \""Positive Surgical Margins\"", Relationship: \""concerned with avoiding\""\\n3. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Perineural Invasion\"", Relationship: \""consideration in treatment planning\""\\n\\nCausalities:-\\n<C> Extranodal extension </C> <C> Positive margins </C> <C> Close margins </C> <C> pT4 primary </C> <C> pN2 or pN3 nodal disease </C> <C> Perineural invasion </C> <C> Vascular invasion </C> <C> Lymphatic invasion </C> <C> Subglottic extension </C>\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to enhance its effectiveness.\\nAdjuvant Therapy : A therapy given in addition to the primary or initial therapy to maximize its effectiveness.\\nFollow-Up Studies : Studies that continue to monitor patients after treatment to assess long-term outcomes.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient after initial treatment.\\nFollow-Up : The act of monitoring a patient\\'s health over time after treatment.\\nNeoplasm Recurrence, Local : The return of a tumor at the original site after treatment.\\nRecurrent Disease : A disease that has returned after a period of remission.\\n\\nRelationships:-\\n1. Entity1: \""Adjuvant Treatment\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""prevention\""\\n2. Entity1: \""Follow-up\"", Entity2: \""Recurrent or Persistent Disease\"", Relationship: \""monitoring\""\\n\\nSection Name: Treatment Options\\n====================\\nEntities:-\\nLaryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.\\nTotal Laryngectomy : A surgical procedure to remove the entire larynx.\\nChemotherapy, Adjuvant : Drug therapy given in addition to the primary treatment to enhance its effectiveness.\\nInduction Chemotherapy : Chemotherapy given as a first step to shrink a tumor before the main treatment.\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.\\nClinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""T3 requiring total laryngectomy\"", Entity2: \""Concurrent systemic therapy/RT\"", Relationship: \""treatment option\""\\n2. Entity1: \""T3 requiring total laryngectomy\"", Entity2: \""Induction chemotherapy\"", Relationship: \""treatment option\""\\n3. Entity1: \""T3 requiring total laryngectomy\"", Entity2: \""Clinical trials\"", Relationship: \""research option\""\\n\\nCausalities:-\\n<CO> T3 requiring (amenable to) total laryngectomy (N2\u20133) </CO> <A> Concurrent systemic therapy/RT </A> <A> Surgery </A> <A> Induction chemotherapy </A> <A> Clinical trials </A>\\n\\nSection Name: Surgical Considerations\\n====================\\nEntities:-\\nLaryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.\\nThyroidectomy : Surgical removal of all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue in the neck.\\nLymph Node Excision : Surgical removal of one or more lymph nodes.\\nLymph Node Dissection : A surgical procedure to remove lymph nodes.\\nLymphadenectomy : Surgical removal of one or more groups of lymph nodes.\\n\\nRelationships:-\\n1. Entity1: \""Laryngectomy\"", Entity2: \""Thyroidectomy\"", Relationship: \""performed with\""\\n2. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Excision\"", Relationship: \""includes\""\\n3. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Excision\"", Relationship: \""includes specific types\""\\n\\nCausalities:-\\n<A> Laryngectomy with thyroidectomy as indicated, ipsilateral or bilateral neck dissection, and pretracheal and ipsilateral paratracheal lymph node dissection </A>\\n\\nSection Name: Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margins : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.\\nPositive Margin : A surgical margin that contains residual tumor cells.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""Extranodal extension\"", Relationship: \""includes\""\\n2. Entity1: \""Adverse pathologic features\"", Entity2: \""Positive margin\"", Relationship: \""includes\""\\n\\nCausalities:-\\n- **No adverse pathologic features**\\n- **Adverse pathologic features**\\n  - <C> Extranodal extension and/or positive margin </C>\\n  - Other risk features\\n\\nSection Name: Systemic Therapy\\n====================\\nEntities:-\\nAntineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.\\nSystemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\n\\nRelationships:-\\n1. Entity1: \""Systemic therapy\"", Entity2: \""RT\"", Relationship: \""Consideration\""\\n\\nCausalities:-\\n<A> Systemic therapy/RT (category 1) </A>\\n<A> RT </A>\\n<A> Consider systemic therapy/RT </A>\\n\\nSection Name: Imaging\\n====================\\nEntities:-\\nTomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.\\nMagnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body\\'s soft tissue and bones.\\nNeck : Part of the body, on many terrestrial or secondarily aquatic vertebrates, that distinguishes the head from the torso or trunk.\\nComputed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images (often called slices), both horizontally and vertically, of the body.\\nNeck Structure : The anatomical structure that connects the head to the torso.\\n\\nRelationships:-\\n1. Entity1: \""CT\"", Entity2: \""Neck\"", Relationship: \""imaging of\""\\n2. Entity1: \""MRI\"", Entity2: \""Neck\"", Relationship: \""imaging of\""\\n\\nCausalities:-\\n<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>\\n\\nSection Name: Post-Treatment Evaluation\\n====================\\nEntities:-\\nRadiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.\\nPn1 Category : A pathological classification indicating regional lymph node metastasis in cancer staging.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\n\\nRelationships:-\\n1. Entity1: \""Post Systemic Therapy/RT or RT Neck Evaluation\"", Entity2: \""pN1\"", Relationship: \""evaluation of cancer staging\""\\n2. Entity1: \""pN1\"", Entity2: \""Consider RT\"", Relationship: \""treatment recommendation\""\\n\\nCausalities:-\\n<CO> pN1 without other risk features </CO> <A> Consider RT </A>\\n\\nSection Name: Additional Notes\\n====================\\nEntities:-\\nAntineoplastic Combined Chemotherapy Protocols : Protocols for the administration of more than one antineoplastic agent in combination to treat malignant neoplasms.\\nCisplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Non-Nasopharyngeal Cancers\"", Relationship: \""used for\""\\n2. Entity1: \""Cisplatin\"", Entity2: \""Systemic Therapy\"", Relationship: \""preferred agent in\""\\n3. Entity1: \""Induction Chemotherapy\"", Entity2: \""Systemic Therapy\"", Relationship: \""discussed in context of\""\\n\\nCausalities:-\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n- **<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>. See Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A).**\\n- **<A> See Discussion on induction chemotherapy. </A>**\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: N_Staging_1
label: Nearby Lymph Nodes Cancer Staging
description: This node represents the staging of cancer in nearby lymph nodes, which is a critical factor in determining the extent of cancer spread and guiding treatment decisions. The staging helps in assessing the prognosis and planning the appropriate therapeutic approach.
type: Decision Node
observability: Needs to be Predicted
states: [{'state_name': 'present', 'state_description': 'Cancer is present in the nearby lymph nodes, indicating that the cancer has spread beyond the primary site. This is an important factor in staging and affects treatment decisions and prognosis.'}, {'state_name': 'absent', 'state_description': 'Cancer is absent in the nearby lymph nodes, suggesting that the cancer has not spread to these nodes. This is a favorable sign and influences the staging and treatment plan.'}]

`NODE2`:
id: Number_of_Lymph_Nodes_Metastasis_3
label: Assessment of Lymph Node Metastasis
description: This node represents the assessment of whether metastasis is present in the lymph nodes. It is crucial for staging cancer and determining the extent of its spread, which impacts treatment decisions and prognosis.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'present', 'state_description': 'Metastasis is present in the lymph nodes, indicating that cancer has spread to these nodes.'}, {'state_name': 'absent', 'state_description': 'Metastasis is absent in the lymph nodes, indicating that cancer has not spread to these nodes.'}]

`EDGE1`:
{'edges_ids': ['N_Staging_1', 'Number_of_Lymph_Nodes_Metastasis_3'], 'edge': '(N_Staging_1) causes (Number_of_Lymph_Nodes_Metastasis_3)', 'explanation': ['The edge represents the causal relationship between the staging of cancer in nearby lymph nodes (N_Staging_1) and the assessment of metastasis in lymph nodes (Number_of_Lymph_Nodes_Metastasis_3).', 'N_Staging_1 being `present` indicates that cancer is present in the lymph nodes, which directly implies that metastasis is present in the lymph nodes (Number_of_Lymph_Nodes_Metastasis_3).', 'This relationship is valid because the staging of cancer in lymph nodes is a critical factor in determining the presence of metastasis in those nodes.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': True, 'sufficient': False}, 'causal_distance': 'Proximal'}

`EDGE2`:
{'edges_ids': ['Number_of_Lymph_Nodes_Metastasis_3', 'N_Staging_1'], 'edge': '(Number_of_Lymph_Nodes_Metastasis_3) causes (N_Staging_1)', 'explanation': ['The edge represents the causal relationship where the assessment of lymph node metastasis (Number_of_Lymph_Nodes_Metastasis_3) influences the N staging (N_Staging_1).', 'The presence of metastasis in lymph nodes is a critical factor in determining the N stage of cancer, which reflects the extent of cancer spread.', 'This relationship is valid because the staging process directly considers the presence or absence of metastasis in lymph nodes.', 'The causal direction is positive because the presence of metastasis leads to a higher N stage, indicating more advanced cancer.', 'The presence of metastasis is necessary for a higher N stage, but not sufficient alone, as other factors may also play a role in staging.', 'The causal distance is proximal because the assessment of metastasis directly impacts the staging decision.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': True, 'sufficient': False}, 'causal_distance': 'Proximal'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 130

Section Name: Pathological N (pN)
====================
Entities:-
Lymph Nodes : Small, bean-shaped structures that are part of the body's lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.
Lymph Node : An organ of the lymphatic system and the adaptive immune system.

Relationships:-
1. Entity1: ""Lymph Nodes"", Entity2: ""Neoplasm Metastasis"", Relationship: ""involved in""
2. Entity1: ""TNM Staging"", Entity2: ""Lymph Nodes"", Relationship: ""includes""
3. Entity1: ""TNM Staging"", Entity2: ""Neoplasm Metastasis"", Relationship: ""describes""

Causalities:-
<CO> NX: Regional lymph nodes cannot be assessed </CO>
<CO> N0: No regional lymph node metastasis </CO>
<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(–) </CO>
<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> Note: A designation of “U” or “L” may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(−) or ENE(+). </CO>

Section Name: Distant Metastasis (M)
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""M0"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""
2. Entity1: ""M1"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""

Causalities:-
### Distant Metastasis (M)

- **M0**: No distant metastasis
- **M1**: Distant metastasis

Section Name: Histologic Grade (G)
====================
Entities:-
Neoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.
Histologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.

Relationships:-
1. Entity1: ""GX"", Entity2: ""Grade cannot be assessed"", Relationship: ""is described as""
2. Entity1: ""G1"", Entity2: ""Well differentiated"", Relationship: ""is described as""
3. Entity1: ""G2"", Entity2: ""Moderately differentiated"", Relationship: ""is described as""
4. Entity1: ""G3"", Entity2: ""Poorly differentiated"", Relationship: ""is described as""

Causalities:-
<CO>GX</CO>: <E>Grade cannot be assessed</E>
<CO>G1</CO>: <E>Well differentiated</E>
<CO>G2</CO>: <E>Moderately differentiated</E>
<CO>G3</CO>: <E>Poorly differentiated</E>

Section Name: Prognostic Stage Groups
====================
Entities:-
Neoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.
Tumor Staging : A system for describing the size and spread of cancer within the body.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.

Relationships:-
1. Entity1: ""Stage 0"", Entity2: ""Tis N0 M0"", Relationship: ""defined by""
2. Entity1: ""Stage I"", Entity2: ""T1 N0 M0"", Relationship: ""defined by""
3. Entity1: ""Stage II"", Entity2: ""T2 N0 M0"", Relationship: ""defined by""
4. Entity1: ""Stage III"", Entity2: ""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0"", Relationship: ""defined by""
5. Entity1: ""Stage IVA"", Entity2: ""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0"", Relationship: ""defined by""
6. Entity1: ""Stage IVB"", Entity2: ""Any T N3 M0, T4b Any N M0"", Relationship: ""defined by""
7. Entity1: ""Stage IVC"", Entity2: ""Any T Any N M1"", Relationship: ""defined by""
--------------------------------------------------
Page Number: 102

Section Name: Head and Neck Cancers - Principles of Surgery
====================
Entities:-
Surgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.
Lymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.
Neoplasms : New abnormal growth of tissue in animals or plants; a tumor.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Neoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Surgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Lymphatic Structure : Anatomical structure that is part of the lymphatic system.
Tumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.
Staging : The process of determining the size and spread of cancer within the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.

Relationships:-
1. Entity1: ""surgical management"", Entity2: ""regional lymphatics"", Relationship: ""dictated by tumor staging""
2. Entity1: ""neck dissections"", Entity2: ""primary tumor"", Relationship: ""part of treatment""
3. Entity1: ""surgery"", Entity2: ""ipsilateral side of the neck"", Relationship: ""risk for metastases""

Causalities:-
<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.

Section Name: Neck Management
====================
Entities:-
Tongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.
Palate : The roof of the mouth, separating the oral and nasal cavities.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.
Hypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.
Nasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Squamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.
Biopsy : The removal of cells or tissues for examination under a microscope.

Relationships:-
1. Entity1: ""Tumor sites"", Entity2: ""Bilateral lymphatic drainage"", Relationship: ""associated with""
2. Entity1: ""Elective neck dissection"", Entity2: ""Risk of occult metastasis"", Relationship: ""based on""
3. Entity1: ""SLN biopsy"", Entity2: ""Elective neck dissection"", Relationship: ""guides decision-making for""

Causalities:-
- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.

- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.

- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.

  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2–4 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.

Section Name: Types of Neck Dissection
====================
Entities:-
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.

Relationships:-
1. Entity1: ""N0"", Entity2: ""Selective neck dissection"", Relationship: ""associated with""
2. Entity1: ""N3"", Entity2: ""Comprehensive neck dissection"", Relationship: ""associated with""
3. Entity1: ""Level VI neck dissection"", Entity2: ""Larynx"", Relationship: ""performed for""
4. Entity1: ""Level VI neck dissection"", Entity2: ""Hypopharynx"", Relationship: ""performed for""

Causalities:-
- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:
  - **N0:** <A> Selective neck dissection </A>
    - Oral cavity at least levels I–III
    - Oropharynx at least levels II–IV
    - Hypopharynx at least levels II–IV and level VI when appropriate
    - Larynx at least levels II–IV and level VI when appropriate
  - **N1–N2a–c:** <A> Selective or comprehensive neck dissection </A> (Discussion)
  - **N3:** <A> Comprehensive neck dissection </A>

- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.

- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.
--------------------------------------------------
Page Number: 51

Section Name: Introduction
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.
Supraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network (NCCN)"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""provides guidelines for""
2. Entity1: ""healthcare professionals"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""manage""

Causalities:-
The provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.

Section Name: Clinical Staging
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Total Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Cancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.
Tnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).

Relationships:-
1. Entity1: ""Clinical staging criteria"", Entity2: ""Total laryngectomy"", Relationship: ""determines necessity of""
2. Entity1: ""T3, N0"", Entity2: ""Clinical staging criteria"", Relationship: ""is a categorization of""

Causalities:-
The flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.

Section Name: Treatment of Primary and Neck
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Lymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Radiation Therapy"", Relationship: ""combined with""
2. Entity1: ""Laryngectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
3. Entity1: ""Thyroidectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
4. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""

Causalities:-
<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.

Section Name: Surgical Options
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Lymph Node Excision : Surgical removal of one or more lymph nodes.
Lymphadenectomy : Surgical removal of one or more groups of lymph nodes.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.

Relationships:-
1. Entity1: ""Laryngectomy"", Entity2: ""Thyroidectomy"", Relationship: ""combined with""
2. Entity1: ""Lymph Node Dissection"", Entity2: ""Surgical Intervention"", Relationship: ""extent of""
3. Entity1: ""Surgical Intervention"", Entity2: ""Advanced Cases"", Relationship: ""management option for""

Causalities:-
<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.

Section Name: Induction Chemotherapy
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Therapeutic Approach : A method or strategy used in the treatment of disease or injury.

Relationships:-
1. Entity1: ""Induction Chemotherapy"", Entity2: ""Surgical Intervention"", Relationship: ""alternative or sequential treatment option""

Causalities:-
<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.

Section Name: Adjuvant Treatment
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Neoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.
Disease Progression : The worsening of a disease over time.

Relationships:-
1. Entity1: ""Primary Treatment"", Entity2: ""Adjuvant Treatment"", Relationship: ""followed by""
2. Entity1: ""Adjuvant Treatment"", Entity2: ""Systemic Therapy"", Relationship: ""includes""
3. Entity1: ""Adjuvant Treatment"", Entity2: ""Radiotherapy"", Relationship: ""includes""
4. Entity1: ""Follow-up Assessments"", Entity2: ""Treatment Efficacy"", Relationship: ""used to evaluate""

Causalities:-
<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient's response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.

Section Name: Risk Features and Response Assessment
====================
Entities:-
Neoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.
Surgical Margins : The edge or border of the tissue removed in cancer surgery.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Extramural Extension : Extension of a tumor beyond the wall of an organ.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Cancer Management : The process of planning and coordinating the treatment of cancer.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Extramural extension"", Entity2: ""Treatment decisions"", Relationship: ""influences""
2. Entity1: ""Positive surgical margin"", Entity2: ""Treatment decisions"", Relationship: ""influences""
3. Entity1: ""Ongoing assessment"", Entity2: ""Response evaluation"", Relationship: ""leads to""
4. Entity1: ""Response evaluation"", Entity2: ""Adjustments to treatment"", Relationship: ""leads to""
5. Entity1: ""Management of cancer"", Entity2: ""Treatment decisions"", Relationship: ""involves""
6. Entity1: ""Management of cancer"", Entity2: ""Ongoing assessment"", Relationship: ""involves""
7. Entity1: ""Management of cancer"", Entity2: ""Adjustments to treatment"", Relationship: ""involves""

Causalities:-
The chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Malignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""NCCN Guidelines"", Relationship: ""provides""
2. Entity1: ""NCCN Guidelines"", Entity2: ""Clinical Trials"", Relationship: ""recommend""
3. Entity1: ""NCCN Guidelines"", Entity2: ""Cancer"", Relationship: ""related to management of""

Causalities:-
<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: SUPRA-3
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Clinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""Total laryngectomy"", Entity2: ""Laryngectomy"", Relationship: ""is a type of""
2. Entity1: ""Systemic therapy"", Entity2: ""RT"", Relationship: ""concurrent treatment option""
3. Entity1: ""Induction chemotherapy"", Entity2: ""Other treatments"", Relationship: ""initial treatment option before""

Causalities:-
<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>
  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>
  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>
  - or
  - <A> Induction chemotherapy </A>
  - or
  - <A> Clinical trials </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient's condition after initial treatment.
Follow-Up : Medical care given to a patient over time after initial treatment.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : The reappearance of a disease after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
- **Follow-up (FOLL-A, 1 of 2)**
  - <CO> Recurrent or persistent disease </CO> (ADV-3)

Section Name: Adverse Pathologic Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer beyond the lymph node capsule.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""pN1"", Entity2: ""Radiotherapy"", Relationship: ""Consideration for treatment""
2. Entity1: ""Extranodal extension"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
3. Entity1: ""Extranodal extension"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""
4. Entity1: ""Positive surgical margin"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
5. Entity1: ""Positive surgical margin"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""

Causalities:-
- <CO>pN1 without other risk features</CO>
  - <C>Adverse pathologic features</C>
  - <A>Consider RT</A>
  - <CO>Extranodal extension and/or positive margin</CO>
  - <CO>Other risk features</CO>
  - <A>Systemic therapy/RT (category 1)</A>
  - <A>RT or Consider systemic therapy/RT</A>

Section Name: Response Assessment
====================
Entities:-
Response Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.
Response To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.

Relationships:-

Section Name: Principles of Surgery and Radiation Therapy
====================
Entities:-
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""complementary treatments""

Causalities:-
**Principles of Surgery (SURG-A).**

**Principles of Radiation Therapy (SUPRA-A).**

Section Name: Principles of Systemic Therapy
====================
Entities:-
Cisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Cisplatin"", Entity2: ""Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""preferred agent""
2. Entity1: ""Cisplatin"", Entity2: ""Concurrent Systemic Therapy/RT"", Relationship: ""used in""

Causalities:-
<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.
--------------------------------------------------
Page Number: 55

Section Name: General Information
====================
Entities:-
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Nccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""National Comprehensive Cancer Network"", Relationship: ""produced by""

Section Name: Important Notes
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Neoplasms : New abnormal growth of tissue that can be benign or malignant.
Malignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Clinical Trials"", Entity2: ""Cancer"", Relationship: ""recommended for""
2. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""

Causalities:-
<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles
====================
Entities:-
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Chemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""Both are principles of cancer treatment methods.""
2. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""
3. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""

Causalities:-
### Principles

- **Principles of Surgery (SURG-A)**
- **Principles of Radiation Therapy (SUPRA-A)**
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**

Section Name: Adverse Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Perineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The invasion of cancer cells into blood vessels.
Lymphatic Invasion : The invasion of cancer cells into lymphatic vessels.

Relationships:-
1. Entity1: ""Extranodal extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
2. Entity1: ""Positive margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
3. Entity1: ""Close margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
4. Entity1: ""pT3 or pT4 primary"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
5. Entity1: ""pN2 or pN3 nodal disease"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
6. Entity1: ""Perineural invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
7. Entity1: ""Vascular invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
8. Entity1: ""Lymphatic invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""

Causalities:-
<C> Extranodal extension </C>
<C> Positive margins </C>
<C> Close margins </C>
<C> pT3 or pT4 primary </C>
<C> pN2 or pN3 nodal disease </C>
<C> Perineural invasion </C>
<C> Vascular invasion </C>
<C> Lymphatic invasion </C>

Section Name: Response Assessment
====================
Entities:-
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Primary Site : The original location where a tumor or cancer begins.
Complete Remission : The disappearance of all signs of cancer in response to treatment.
Partial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.

Relationships:-
1. Entity1: ""induction chemotherapy"", Entity2: ""Primary site"", Relationship: ""treatment outcome""
2. Entity1: ""Definitive RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
3. Entity1: ""RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
4. Entity1: ""Surgery"", Entity2: ""unresectable nodal disease"", Relationship: ""treatment option""

Causalities:-
<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.
Follow-Up (Medicine) : The process of monitoring a patient's health over time after treatment or diagnosis.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : A disease that returns after a period of remission.
Recurrence (Medicine) : The return of a disease or condition after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
### Follow-up

- **Follow-up** (FOLL-A, 1 of 2)
- **Recurrent or persistent disease** (ADV-3)

Section Name: Risk Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""RT"", Relationship: ""Consideration for treatment""
2. Entity1: ""Adverse pathologic features"", Entity2: ""Systemic therapy"", Relationship: ""Consideration for treatment""

Causalities:-
- **No adverse pathologic features**
- **Other risk features**
- **Adverse pathologic features**:
  - <C> Extranodal extension and/or positive margin </C>
  - <A> RT or consider systemic therapy/RT </A>

Section Name: Post-Therapy Evaluation
====================
Entities:-
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Neck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""
2. Entity1: ""RT"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""

Causalities:-
<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>

Section Name: Flowchart Overview
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Supraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""guides management of""
2. Entity1: ""NCCN Guidelines"", Entity2: ""healthcare professionals"", Relationship: ""used by""

Causalities:-
<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.

Section Name: Assessment and Treatment Decisions
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Complete Response : The disappearance of all signs of cancer in response to treatment.
Partial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Complete Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""
2. Entity1: ""Complete Response"", Entity2: ""Surgery"", Relationship: ""leads to""
3. Entity1: ""Partial Response"", Entity2: ""Systemic Therapy"", Relationship: ""leads to""
4. Entity1: ""Partial Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""

Causalities:-
<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.

Section Name: Adverse Pathologic Features and Follow-up
====================
Entities:-
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Neoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Recurrent Neoplasm : A neoplasm that has returned after treatment.
Metastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.
Metastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""Treatment decisions"", Relationship: ""Influence""
2. Entity1: ""Adverse features"", Entity2: ""Surgical intervention"", Relationship: ""Recommendation""
3. Entity1: ""Absence of adverse features"", Entity2: ""Radiation therapy"", Relationship: ""Pathway""
4. Entity1: ""Follow-up process"", Entity2: ""Recurrent or persistent disease"", Relationship: ""Detection""
5. Entity1: ""Recurrent or persistent disease"", Entity2: ""Advanced disease management"", Relationship: ""Necessity""

Causalities:-
<C> The presence of adverse pathologic features — such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient's disease characteristics.

Furthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.
--------------------------------------------------
Page Number: 44

Section Name: Flowchart Structure
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms based on extent of tumor spread according to standardized criteria.
Laryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.
Chemotherapy, Adjuvant : Drug therapy given in addition to the primary treatment to enhance its effectiveness.
Radiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Neoplasm Recurrence, Local : The return of a tumor at the original site after treatment.

Relationships:-
1. Entity1: ""Clinical Staging"", Entity2: ""T3 tumors"", Relationship: ""determines treatment approach""
2. Entity1: ""Adverse Pathologic Features"", Entity2: ""Systemic Therapy"", Relationship: ""directs to""
3. Entity1: ""Adverse Pathologic Features"", Entity2: ""Radiation Treatment"", Relationship: ""directs to""
4. Entity1: ""Induction Chemotherapy"", Entity2: ""Imaging (CT or MRI)"", Relationship: ""leads to""

Causalities:-
1. <A> The flow begins with the clinical staging of T3 tumors </A> <C> that require total laryngectomy (N2–3) </C>. <CO> This staging </CO> <E> is crucial for determining the appropriate therapeutic approach </E>.

2. The flowchart provides multiple pathways for treatment, indicating that <CO> patients </CO> <A> may undergo either ""Concurrent systemic therapy/RT"" or ""Surgery"" </A>. There is also an <A> option for ""Induction chemotherapy,"" leading to further imaging (CT or MRI) to assess the primary site and neck status </A>.

3. For <CO> patients who have surgery </CO>, the flowchart distinguishes between those with adverse pathologic features and those without. <CO> Patients with adverse features—such as extranodal extension or positive margins </CO>—are <A> directed toward systemic therapy or radiation treatment </A>, while those without may follow a different management path.

4. The flowchart concludes by <A> outlining follow-up procedures for recurrent or persistent disease </A>, suggesting additional assessments and treatments based on the risk features identified during earlier stages.

Section Name: Detailed Explanation
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the glottis, supraglottis, or subglottis.
Adverse Pathological Feature : A pathological feature that indicates a worse prognosis or outcome.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.

Relationships:-
1. Entity1: ""Systemic therapy"", Entity2: ""Radiation"", Relationship: ""Concurrent treatment""
2. Entity1: ""Clinical trials"", Entity2: ""Personalized treatment plans"", Relationship: ""Development of""

Causalities:-
<A> The flowchart is designed to provide healthcare professionals with a systematic pathway for managing glottic larynx cancer </A>. Each step is meticulously organized to ensure that important factors are considered, such as <C> the presence of adverse pathological features </C>, which <E> strongly influence treatment decisions </E>.

<A> The emphasis on concurrent treatments, such as systemic therapy combined with radiation </A>, reflects current best practices in oncology, where multimodal approaches are often necessary to achieve better outcomes. <A> The inclusion of clinical trials </A> indicates an emphasis on maintaining up-to-date practices and personalized treatment plans as part of patient management strategies.

Furthermore, <A> the chart's organization into treatment and follow-up segments </A> allows for a straightforward interpretation, guiding oncologists through complex decisions in a logical manner. This can <E> improve consistency in care and enhance patient safety through meticulous monitoring and responses to treatment efficacy or disease progression </E>.

In summary, <E> this flowchart serves as an essential resource for oncologists, facilitating a better understanding of treatment protocols for glottic larynx cancer while promoting a patient-centered approach to oncological care </E>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Neoplasms : New abnormal growth of tissue that may be benign or malignant.
Malignant Neoplastic Disease : A disease in which abnormal cells divide uncontrollably and destroy body tissue.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
National Comprehensive Cancer Network : An alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""NCCN Guidelines"", Relationship: ""publishes""
2. Entity1: ""Clinical trial"", Entity2: ""Cancer"", Relationship: ""manages""

Causalities:-
<C> any patient with cancer </C> <E> the best management is in a clinical trial </E>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles of Treatment
====================
Entities:-
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Extranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margins : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.
Perineural Invasion : Cancer cells are found surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The presence of cancer cells within blood vessels.
Lymphatic Metastasis : The spread of cancer cells through the lymphatic system to distant sites.

Relationships:-
1. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Extranodal Extension"", Relationship: ""management of""
2. Entity1: ""Principles of Surgery"", Entity2: ""Positive Surgical Margins"", Relationship: ""concerned with avoiding""
3. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Perineural Invasion"", Relationship: ""consideration in treatment planning""

Causalities:-
<C> Extranodal extension </C> <C> Positive margins </C> <C> Close margins </C> <C> pT4 primary </C> <C> pN2 or pN3 nodal disease </C> <C> Perineural invasion </C> <C> Vascular invasion </C> <C> Lymphatic invasion </C> <C> Subglottic extension </C>

Section Name: Clinical Staging
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to enhance its effectiveness.
Adjuvant Therapy : A therapy given in addition to the primary or initial therapy to maximize its effectiveness.
Follow-Up Studies : Studies that continue to monitor patients after treatment to assess long-term outcomes.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient after initial treatment.
Follow-Up : The act of monitoring a patient's health over time after treatment.
Neoplasm Recurrence, Local : The return of a tumor at the original site after treatment.
Recurrent Disease : A disease that has returned after a period of remission.

Relationships:-
1. Entity1: ""Adjuvant Treatment"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""prevention""
2. Entity1: ""Follow-up"", Entity2: ""Recurrent or Persistent Disease"", Relationship: ""monitoring""

Section Name: Treatment Options
====================
Entities:-
Laryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.
Total Laryngectomy : A surgical procedure to remove the entire larynx.
Chemotherapy, Adjuvant : Drug therapy given in addition to the primary treatment to enhance its effectiveness.
Induction Chemotherapy : Chemotherapy given as a first step to shrink a tumor before the main treatment.
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medications or medical devices by monitoring their effects on large groups of people.
Clinical Trial : A research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""T3 requiring total laryngectomy"", Entity2: ""Concurrent systemic therapy/RT"", Relationship: ""treatment option""
2. Entity1: ""T3 requiring total laryngectomy"", Entity2: ""Induction chemotherapy"", Relationship: ""treatment option""
3. Entity1: ""T3 requiring total laryngectomy"", Entity2: ""Clinical trials"", Relationship: ""research option""

Causalities:-
<CO> T3 requiring (amenable to) total laryngectomy (N2–3) </CO> <A> Concurrent systemic therapy/RT </A> <A> Surgery </A> <A> Induction chemotherapy </A> <A> Clinical trials </A>

Section Name: Surgical Considerations
====================
Entities:-
Laryngectomy : Surgical procedure to remove the larynx, often used to treat laryngeal cancer.
Thyroidectomy : Surgical removal of all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue in the neck.
Lymph Node Excision : Surgical removal of one or more lymph nodes.
Lymph Node Dissection : A surgical procedure to remove lymph nodes.
Lymphadenectomy : Surgical removal of one or more groups of lymph nodes.

Relationships:-
1. Entity1: ""Laryngectomy"", Entity2: ""Thyroidectomy"", Relationship: ""performed with""
2. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Excision"", Relationship: ""includes""
3. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Excision"", Relationship: ""includes specific types""

Causalities:-
<A> Laryngectomy with thyroidectomy as indicated, ipsilateral or bilateral neck dissection, and pretracheal and ipsilateral paratracheal lymph node dissection </A>

Section Name: Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margins : Cancer cells are found at the edge of the material removed during surgery, indicating that some cancer may have been left behind.
Positive Margin : A surgical margin that contains residual tumor cells.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""Extranodal extension"", Relationship: ""includes""
2. Entity1: ""Adverse pathologic features"", Entity2: ""Positive margin"", Relationship: ""includes""

Causalities:-
- **No adverse pathologic features**
- **Adverse pathologic features**
  - <C> Extranodal extension and/or positive margin </C>
  - Other risk features

Section Name: Systemic Therapy
====================
Entities:-
Antineoplastic Agents : Drugs used to treat cancer by inhibiting the growth of cancerous cells.
Systemic Therapy : A treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.

Relationships:-
1. Entity1: ""Systemic therapy"", Entity2: ""RT"", Relationship: ""Consideration""

Causalities:-
<A> Systemic therapy/RT (category 1) </A>
<A> RT </A>
<A> Consider systemic therapy/RT </A>

Section Name: Imaging
====================
Entities:-
Tomography, X-Ray Computed : An imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body.
Magnetic Resonance Imaging : A noninvasive diagnostic technique that uses magnetic fields and radio waves to produce a detailed image of the body's soft tissue and bones.
Neck : Part of the body, on many terrestrial or secondarily aquatic vertebrates, that distinguishes the head from the torso or trunk.
Computed Tomography : A diagnostic imaging procedure that uses a combination of X-rays and computer technology to produce cross-sectional images (often called slices), both horizontally and vertically, of the body.
Neck Structure : The anatomical structure that connects the head to the torso.

Relationships:-
1. Entity1: ""CT"", Entity2: ""Neck"", Relationship: ""imaging of""
2. Entity1: ""MRI"", Entity2: ""Neck"", Relationship: ""imaging of""

Causalities:-
<A> CT (with contrast) or MRI (with and without contrast) of primary and neck </A>

Section Name: Post-Treatment Evaluation
====================
Entities:-
Radiotherapy : The use of radiation, usually high-energy X-rays, to damage cancer cells and treat cancer.
Pn1 Category : A pathological classification indicating regional lymph node metastasis in cancer staging.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.

Relationships:-
1. Entity1: ""Post Systemic Therapy/RT or RT Neck Evaluation"", Entity2: ""pN1"", Relationship: ""evaluation of cancer staging""
2. Entity1: ""pN1"", Entity2: ""Consider RT"", Relationship: ""treatment recommendation""

Causalities:-
<CO> pN1 without other risk features </CO> <A> Consider RT </A>

Section Name: Additional Notes
====================
Entities:-
Antineoplastic Combined Chemotherapy Protocols : Protocols for the administration of more than one antineoplastic agent in combination to treat malignant neoplasms.
Cisplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Non-Nasopharyngeal Cancers"", Relationship: ""used for""
2. Entity1: ""Cisplatin"", Entity2: ""Systemic Therapy"", Relationship: ""preferred agent in""
3. Entity1: ""Induction Chemotherapy"", Entity2: ""Systemic Therapy"", Relationship: ""discussed in context of""

Causalities:-
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**
- **<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>. See Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A).**
- **<A> See Discussion on induction chemotherapy. </A>**


Among these two options which one is the most likely true:

(A) `N_Staging_1` increases risk `Number_of_Lymph_Nodes_Metastasis_3`
(B) `Number_of_Lymph_Nodes_Metastasis_3` `increases risk `N_Staging_1`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge in question involves two nodes: `N_Staging_1` and `Number_of_Lymph_Nodes_Metastasis_3`.
2. `N_Staging_1` refers to the staging of cancer in nearby lymph nodes, which is a decision node that needs to be predicted.
3. `Number_of_Lymph_Nodes_Metastasis_3` refers to the assessment of lymph node metastasis, a patient situation that is unobserved.
4. The causal direction for `EDGE1` is positive, indicating that the presence of cancer in lymph nodes (`N_Staging_1`) implies metastasis (`Number_of_Lymph_Nodes_Metastasis_3`).
5. The causal direction for `EDGE2` is also positive, indicating that the presence of metastasis (`Number_of_Lymph_Nodes_Metastasis_3`) influences the N staging (`N_Staging_1`).
6. Both edges suggest a proximal causal distance, meaning the factors are closely related in the causal chain.
7. The NCCN guidelines and knowledge base information emphasize the role of lymph node metastasis in determining cancer staging.
8. The TNM staging system includes lymph node involvement as a critical factor in cancer staging, supporting the idea that metastasis assessment influences staging.
9. The knowledge base (Page 130, Section: Pathological N (pN)) describes the TNM staging system, where lymph node involvement is a key component.
10. The causalities in the knowledge base indicate that lymph node metastasis is a necessary condition for higher N staging, but not sufficient alone.
","1. Page 130, Section: Pathological N (pN) - TNM Staging includes lymph node involvement as a critical factor.
2. Causalities: Lymph node metastasis is necessary for higher N staging, but not sufficient alone.
3. The presence of metastasis in lymph nodes directly impacts the N stage of cancer, reflecting the extent of cancer spread.
",B,"{'A': 0.05, 'B': 99.95}",yes,B,"1. The AI assistant's reasoning involves analyzing the causal relationship between two nodes: `N_Staging_1` and `Number_of_Lymph_Nodes_Metastasis_3`.
2. `N_Staging_1` is described as a decision node that represents the staging of cancer in nearby lymph nodes, which is crucial for determining the extent of cancer spread and guiding treatment decisions.
3. `Number_of_Lymph_Nodes_Metastasis_3` is a patient situation node that assesses whether metastasis is present in the lymph nodes, impacting cancer staging and treatment.
4. The AI assistant identifies two edges: `EDGE1` and `EDGE2`, both with a positive causal direction, indicating a direct relationship between the presence of cancer in lymph nodes and metastasis.
5. The assistant's reasoning suggests that the presence of metastasis in lymph nodes (`Number_of_Lymph_Nodes_Metastasis_3`) influences the N staging (`N_Staging_1`), which aligns with the TNM staging system described in the knowledge base.
6. The knowledge base information supports the idea that lymph node metastasis is a necessary condition for higher N staging, but not sufficient alone, indicating that metastasis assessment influences staging.
7. The AI assistant concludes that option (B) is more likely true, as the presence of metastasis in lymph nodes directly impacts the N stage of cancer, reflecting the extent of cancer spread.
"
7,gpt-4o,"N_Staging_1,Largest_Diameter_of_Positive_Lymph_Node_4","""{'NODE1': {'id': 'N_Staging_1', 'label': 'Nearby Lymph Nodes Cancer Staging', 'description': 'This node represents the staging of cancer in nearby lymph nodes, which is a critical factor in determining the extent of cancer spread and guiding treatment decisions. The staging helps in assessing the prognosis and planning the appropriate therapeutic approach.', 'type': 'Decision Node', 'observability': 'Needs to be Predicted', 'states': [{'state_name': 'present', 'state_description': 'Cancer is present in the nearby lymph nodes, indicating that the cancer has spread beyond the primary site. This is an important factor in staging and affects treatment decisions and prognosis.'}, {'state_name': 'absent', 'state_description': 'Cancer is absent in the nearby lymph nodes, suggesting that the cancer has not spread to these nodes. This is a favorable sign and influences the staging and treatment plan.'}]}, 'NODE2': {'id': 'Largest_Diameter_of_Positive_Lymph_Node_4', 'label': 'Largest Diameter of Positive Lymph Node', 'description': 'This node represents the measurement of the largest diameter of a positive lymph node, specifically the fourth one in a clinical context. The size of lymph nodes is crucial in assessing the extent of cancer spread and is used in staging and prognosis.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'present', 'state_description': 'The largest diameter of the positive lymph node is measurable, indicating potential lymph node involvement in cancer.'}, {'state_name': 'absent', 'state_description': 'There is no measurable largest diameter for the positive lymph node, suggesting no significant lymph node involvement or the absence of detectable cancer spread in the lymph nodes.'}]}, 'EDGE1': {'edges_ids': ['N_Staging_1', 'Largest_Diameter_of_Positive_Lymph_Node_4'], 'edge': '(N_Staging_1) causes (Largest_Diameter_of_Positive_Lymph_Node_4)', 'explanation': ['The edge `(N_Staging_1) causes (Largest_Diameter_of_Positive_Lymph_Node_4)` is not valid because the staging of cancer in nearby lymph nodes (N_Staging_1) does not cause the size of the lymph node (Largest_Diameter_of_Positive_Lymph_Node_4).', 'In clinical practice, the size of the lymph node is used to help determine the staging, not the other way around.', 'Therefore, the causal direction is likely incorrect, and the relationship is not supported by typical clinical understanding.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}, 'EDGE2': {'edges_ids': ['Largest_Diameter_of_Positive_Lymph_Node_4', 'N_Staging_1'], 'edge': '(Largest_Diameter_of_Positive_Lymph_Node_4) causes (N_Staging_1)', 'explanation': ['The `Largest Diameter of Positive Lymph Node 4` is a measure of the size of a lymph node, which is used in cancer staging.', 'The `N Staging 1` node represents the staging of cancer in nearby lymph nodes, which is influenced by the size of the lymph nodes.', 'In cancer staging, larger lymph nodes often indicate more advanced disease and a higher N stage.', 'Therefore, the size of the largest positive lymph node can influence the N staging, making this a valid causal relationship.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'ENTITIES_MATCHING_PAGES_INFO': {'130': {'matching_entities': [{'LYMPH NODE STRUCTURE': 0.99134904}, {'LYMPH NODE': 0.98570025}, {'LYMPH NODES': 0.97445965}, {'TUMOR STAGING': 0.9742619}, {'TNM STAGING SYSTEM': 0.9654991}, {'TNM STAGING': 0.946078}, {'NEOPLASM STAGING': 0.9326755}], 'count': 7}, '102': {'matching_entities': [{'STAGING': 0.9886105}, {'CANCER STAGING': 0.9805381}, {'LYMPHATIC SYSTEM': 0.95855314}, {'LYMPHATIC STRUCTURE': 0.9469132}, {'NEOPLASM STAGING': 0.9326755}], 'count': 5}, '51': {'matching_entities': [{'CANCER STAGING': 0.9805381}, {'TNM STAGING SYSTEM': 0.9654991}, {'NEOPLASM STAGING': 0.9326755}, {'MALIGNANT NEOPLASM': 0.9201188}, {'CANCER': 0.92000854}], 'count': 5}, '42': {'matching_entities': [{'CANCER STAGING': 0.9805381}, {'TUMOR STAGING': 0.9742619}, {'NEOPLASM STAGING': 0.9326755}], 'count': 3}, '57': {'matching_entities': [{'CANCER STAGING': 0.9805381}, {'TNM STAGING SYSTEM': 0.9654991}, {'NEOPLASM STAGING': 0.9326755}], 'count': 3}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 130\\n\\nSection Name: Pathological N (pN)\\n====================\\nEntities:-\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nTnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system.\\n\\nRelationships:-\\n1. Entity1: \""Lymph Nodes\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""involved in\""\\n2. Entity1: \""TNM Staging\"", Entity2: \""Lymph Nodes\"", Relationship: \""includes\""\\n3. Entity1: \""TNM Staging\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""describes\""\\n\\nCausalities:-\\n<CO> NX: Regional lymph nodes cannot be assessed </CO>\\n<CO> N0: No regional lymph node metastasis </CO>\\n<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(\u2013) </CO>\\n<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(\u2212); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> Note: A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+). </CO>\\n\\nSection Name: Distant Metastasis (M)\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""M0\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n2. Entity1: \""M1\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n\\nCausalities:-\\n### Distant Metastasis (M)\\n\\n- **M0**: No distant metastasis\\n- **M1**: Distant metastasis\\n\\nSection Name: Histologic Grade (G)\\n====================\\nEntities:-\\nNeoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.\\nHistologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.\\n\\nRelationships:-\\n1. Entity1: \""GX\"", Entity2: \""Grade cannot be assessed\"", Relationship: \""is described as\""\\n2. Entity1: \""G1\"", Entity2: \""Well differentiated\"", Relationship: \""is described as\""\\n3. Entity1: \""G2\"", Entity2: \""Moderately differentiated\"", Relationship: \""is described as\""\\n4. Entity1: \""G3\"", Entity2: \""Poorly differentiated\"", Relationship: \""is described as\""\\n\\nCausalities:-\\n<CO>GX</CO>: <E>Grade cannot be assessed</E>\\n<CO>G1</CO>: <E>Well differentiated</E>\\n<CO>G2</CO>: <E>Moderately differentiated</E>\\n<CO>G3</CO>: <E>Poorly differentiated</E>\\n\\nSection Name: Prognostic Stage Groups\\n====================\\nEntities:-\\nNeoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.\\nTumor Staging : A system for describing the size and spread of cancer within the body.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\n\\nRelationships:-\\n1. Entity1: \""Stage 0\"", Entity2: \""Tis N0 M0\"", Relationship: \""defined by\""\\n2. Entity1: \""Stage I\"", Entity2: \""T1 N0 M0\"", Relationship: \""defined by\""\\n3. Entity1: \""Stage II\"", Entity2: \""T2 N0 M0\"", Relationship: \""defined by\""\\n4. Entity1: \""Stage III\"", Entity2: \""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0\"", Relationship: \""defined by\""\\n5. Entity1: \""Stage IVA\"", Entity2: \""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0\"", Relationship: \""defined by\""\\n6. Entity1: \""Stage IVB\"", Entity2: \""Any T N3 M0, T4b Any N M0\"", Relationship: \""defined by\""\\n7. Entity1: \""Stage IVC\"", Entity2: \""Any T Any N M1\"", Relationship: \""defined by\""\\n--------------------------------------------------\\nPage Number: 102\\n\\nSection Name: Head and Neck Cancers - Principles of Surgery\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.\\nLymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.\\nNeoplasms : New abnormal growth of tissue in animals or plants; a tumor.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nNeoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSurgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nLymphatic Structure : Anatomical structure that is part of the lymphatic system.\\nTumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.\\nStaging : The process of determining the size and spread of cancer within the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.\\n\\nRelationships:-\\n1. Entity1: \""surgical management\"", Entity2: \""regional lymphatics\"", Relationship: \""dictated by tumor staging\""\\n2. Entity1: \""neck dissections\"", Entity2: \""primary tumor\"", Relationship: \""part of treatment\""\\n3. Entity1: \""surgery\"", Entity2: \""ipsilateral side of the neck\"", Relationship: \""risk for metastases\""\\n\\nCausalities:-\\n<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.\\n\\nSection Name: Neck Management\\n====================\\nEntities:-\\nTongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.\\nPalate : The roof of the mouth, separating the oral and nasal cavities.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\nHypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.\\nNasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSquamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.\\nBiopsy : The removal of cells or tissues for examination under a microscope.\\n\\nRelationships:-\\n1. Entity1: \""Tumor sites\"", Entity2: \""Bilateral lymphatic drainage\"", Relationship: \""associated with\""\\n2. Entity1: \""Elective neck dissection\"", Entity2: \""Risk of occult metastasis\"", Relationship: \""based on\""\\n3. Entity1: \""SLN biopsy\"", Entity2: \""Elective neck dissection\"", Relationship: \""guides decision-making for\""\\n\\nCausalities:-\\n- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.\\n\\n- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.\\n\\n- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.\\n\\n  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2\u20134 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.\\n\\nSection Name: Types of Neck Dissection\\n====================\\nEntities:-\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\n\\nRelationships:-\\n1. Entity1: \""N0\"", Entity2: \""Selective neck dissection\"", Relationship: \""associated with\""\\n2. Entity1: \""N3\"", Entity2: \""Comprehensive neck dissection\"", Relationship: \""associated with\""\\n3. Entity1: \""Level VI neck dissection\"", Entity2: \""Larynx\"", Relationship: \""performed for\""\\n4. Entity1: \""Level VI neck dissection\"", Entity2: \""Hypopharynx\"", Relationship: \""performed for\""\\n\\nCausalities:-\\n- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:\\n  - **N0:** <A> Selective neck dissection </A>\\n    - Oral cavity at least levels I\u2013III\\n    - Oropharynx at least levels II\u2013IV\\n    - Hypopharynx at least levels II\u2013IV and level VI when appropriate\\n    - Larynx at least levels II\u2013IV and level VI when appropriate\\n  - **N1\u2013N2a\u2013c:** <A> Selective or comprehensive neck dissection </A> (Discussion)\\n  - **N3:** <A> Comprehensive neck dissection </A>\\n\\n- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.\\n\\n- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.\\n--------------------------------------------------\\nPage Number: 51\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\nSupraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network (NCCN)\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""provides guidelines for\""\\n2. Entity1: \""healthcare professionals\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""manage\""\\n\\nCausalities:-\\nThe provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nTotal Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nCancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.\\nTnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging criteria\"", Entity2: \""Total laryngectomy\"", Relationship: \""determines necessity of\""\\n2. Entity1: \""T3, N0\"", Entity2: \""Clinical staging criteria\"", Relationship: \""is a categorization of\""\\n\\nCausalities:-\\nThe flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.\\n\\nSection Name: Treatment of Primary and Neck\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nLymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""combined with\""\\n2. Entity1: \""Laryngectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n3. Entity1: \""Thyroidectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n4. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n\\nCausalities:-\\n<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.\\n\\nSection Name: Surgical Options\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nLymph Node Excision : Surgical removal of one or more lymph nodes.\\nLymphadenectomy : Surgical removal of one or more groups of lymph nodes.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Laryngectomy\"", Entity2: \""Thyroidectomy\"", Relationship: \""combined with\""\\n2. Entity1: \""Lymph Node Dissection\"", Entity2: \""Surgical Intervention\"", Relationship: \""extent of\""\\n3. Entity1: \""Surgical Intervention\"", Entity2: \""Advanced Cases\"", Relationship: \""management option for\""\\n\\nCausalities:-\\n<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.\\n\\nSection Name: Induction Chemotherapy\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nTherapeutic Approach : A method or strategy used in the treatment of disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Induction Chemotherapy\"", Entity2: \""Surgical Intervention\"", Relationship: \""alternative or sequential treatment option\""\\n\\nCausalities:-\\n<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.\\n\\nSection Name: Adjuvant Treatment\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nNeoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.\\nDisease Progression : The worsening of a disease over time.\\n\\nRelationships:-\\n1. Entity1: \""Primary Treatment\"", Entity2: \""Adjuvant Treatment\"", Relationship: \""followed by\""\\n2. Entity1: \""Adjuvant Treatment\"", Entity2: \""Systemic Therapy\"", Relationship: \""includes\""\\n3. Entity1: \""Adjuvant Treatment\"", Entity2: \""Radiotherapy\"", Relationship: \""includes\""\\n4. Entity1: \""Follow-up Assessments\"", Entity2: \""Treatment Efficacy\"", Relationship: \""used to evaluate\""\\n\\nCausalities:-\\n<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient\\'s response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.\\n\\nSection Name: Risk Features and Response Assessment\\n====================\\nEntities:-\\nNeoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.\\nSurgical Margins : The edge or border of the tissue removed in cancer surgery.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nExtramural Extension : Extension of a tumor beyond the wall of an organ.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nCancer Management : The process of planning and coordinating the treatment of cancer.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Extramural extension\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n2. Entity1: \""Positive surgical margin\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n3. Entity1: \""Ongoing assessment\"", Entity2: \""Response evaluation\"", Relationship: \""leads to\""\\n4. Entity1: \""Response evaluation\"", Entity2: \""Adjustments to treatment\"", Relationship: \""leads to\""\\n5. Entity1: \""Management of cancer\"", Entity2: \""Treatment decisions\"", Relationship: \""involves\""\\n6. Entity1: \""Management of cancer\"", Entity2: \""Ongoing assessment\"", Relationship: \""involves\""\\n7. Entity1: \""Management of cancer\"", Entity2: \""Adjustments to treatment\"", Relationship: \""involves\""\\n\\nCausalities:-\\nThe chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nMalignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""NCCN Guidelines\"", Relationship: \""provides\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""Clinical Trials\"", Relationship: \""recommend\""\\n3. Entity1: \""NCCN Guidelines\"", Entity2: \""Cancer\"", Relationship: \""related to management of\""\\n\\nCausalities:-\\n<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: SUPRA-3\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nClinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""Total laryngectomy\"", Entity2: \""Laryngectomy\"", Relationship: \""is a type of\""\\n2. Entity1: \""Systemic therapy\"", Entity2: \""RT\"", Relationship: \""concurrent treatment option\""\\n3. Entity1: \""Induction chemotherapy\"", Entity2: \""Other treatments\"", Relationship: \""initial treatment option before\""\\n\\nCausalities:-\\n<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>\\n  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>\\n  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>\\n  - or\\n  - <A> Induction chemotherapy </A>\\n  - or\\n  - <A> Clinical trials </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient\\'s condition after initial treatment.\\nFollow-Up : Medical care given to a patient over time after initial treatment.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : The reappearance of a disease after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n- **Follow-up (FOLL-A, 1 of 2)**\\n  - <CO> Recurrent or persistent disease </CO> (ADV-3)\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""pN1\"", Entity2: \""Radiotherapy\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Extranodal extension\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n3. Entity1: \""Extranodal extension\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n4. Entity1: \""Positive surgical margin\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n5. Entity1: \""Positive surgical margin\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n\\nCausalities:-\\n- <CO>pN1 without other risk features</CO>\\n  - <C>Adverse pathologic features</C>\\n  - <A>Consider RT</A>\\n  - <CO>Extranodal extension and/or positive margin</CO>\\n  - <CO>Other risk features</CO>\\n  - <A>Systemic therapy/RT (category 1)</A>\\n  - <A>RT or Consider systemic therapy/RT</A>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nResponse Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.\\nResponse To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.\\n\\nRelationships:-\\n\\nSection Name: Principles of Surgery and Radiation Therapy\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""complementary treatments\""\\n\\nCausalities:-\\n**Principles of Surgery (SURG-A).**\\n\\n**Principles of Radiation Therapy (SUPRA-A).**\\n\\nSection Name: Principles of Systemic Therapy\\n====================\\nEntities:-\\nCisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Cisplatin\"", Entity2: \""Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""preferred agent\""\\n2. Entity1: \""Cisplatin\"", Entity2: \""Concurrent Systemic Therapy/RT\"", Relationship: \""used in\""\\n\\nCausalities:-\\n<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.\\n--------------------------------------------------\\nPage Number: 42\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nCarcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.\\nLarynx : An organ in the neck involved in breathing, sound production, and protecting the trachea against food aspiration.\\nNeoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.\\nTumor Staging : The process of determining the extent of spread of a tumor.\\nCancer Staging : The process of determining the extent to which a cancer has developed by growing and possibly spreading.\\n\\nRelationships:-\\n1. Entity1: \""Carcinoma in situ\"", Entity2: \""larynx-preserving surgery\"", Relationship: \""progression to determine suitability\""\\n2. Entity1: \""nodal disease\"", Entity2: \""glottic tumors\"", Relationship: \""rare occurrence\""\\n\\nCausalities:-\\n<C>Carcinoma in situ</C> and progresses to <A>determine the amenability of the patient to larynx-preserving surgery</A>, specifically <CO>for tumors classified as T1 to T2, N0, or select T3, N0</CO>. This initial assessment is critical as it <E>drives treatment decisions</E>. In SOURCE2, it is noted that <C>nodal disease in such glottic tumors</C> <E>is rare</E>.\\n\\nSection Name: Treatment of Primary and Neck\\n====================\\nEntities:-\\nEndoscopic Surgical Procedures : Surgery performed with the aid of an endoscope, which is a medical device with a light attached. It is used to look inside a body cavity or organ.\\nRadiotherapy : The use of ionizing radiation to treat cancer.\\nLaryngectomy, Partial : Surgical removal of part of the larynx.\\nNeck Dissection : Surgical procedure for control of neck lymph node metastasis.\\nNeoplasms : An abnormal mass of tissue as a result of neoplasia. Neoplasia is the abnormal proliferation of cells.\\n\\nRelationships:-\\n1. Entity1: \""Condition\"", Entity2: \""Endoscopic Resection\"", Relationship: \""preferred treatment\""\\n2. Entity1: \""Condition\"", Entity2: \""Radiation Therapy\"", Relationship: \""alternative treatment\""\\n3. Entity1: \""Condition\"", Entity2: \""Partial Laryngectomy\"", Relationship: \""alternative treatment\""\\n4. Entity1: \""Condition\"", Entity2: \""Neck Dissection\"", Relationship: \""part of extensive treatment\""\\n\\nCausalities:-\\n<CO>If the condition allows for larynx-preserving options</CO>, the <A>preferred treatment is endoscopic resection or radiation therapy (RT)</A>. Alternative <A>options include partial laryngectomy or a more extensive endoscopic/open resection with neck dissection</A>, <CO>depending on the specific characteristics of the tumor</CO>. SOURCE2 specifies that <A>endoscopic resection is preferred</A>, and <A>RT or partial laryngectomy/endoscopic or open resection is indicated as needed</A>.\\n\\nSection Name: Adjuvant Treatment\\n====================\\nEntities:-\\nAdjuvant Therapy : Treatment given in addition to the primary (main) treatment to enhance its effectiveness.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nPathologic Processes : The abnormal mechanisms and forms involved in the dysfunctions of tissues and organs.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margins : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nRadiation Therapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\n\\nRelationships:-\\n1. Entity1: \""Adjuvant Treatment\"", Entity2: \""Surgical Intervention\"", Relationship: \""follows\""\\n2. Entity1: \""Adjuvant Treatment\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""depends on\""\\n3. Entity1: \""Extranodal Extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n4. Entity1: \""Positive Margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n5. Entity1: \""Systemic Therapy\"", Entity2: \""Adjuvant Treatment\"", Relationship: \""is a component of\""\\n6. Entity1: \""Radiation\"", Entity2: \""Adjuvant Treatment\"", Relationship: \""is a component of\""\\n\\nSection Name: Follow-Up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nNeoplasm Recurrence, Local : The return of a tumor at the original site after treatment.\\nDisease Progression : The worsening of a disease over time.\\nObservation : The act of noting and recording an event, characteristic, or behavior.\\nAntineoplastic Agents : Drugs used to treat cancer.\\nRadiotherapy : The use of ionizing radiation to treat cancer.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\n\\nRelationships:-\\n1. Entity1: \""Follow-Up\"", Entity2: \""recurrence\"", Relationship: \""monitoring\""\\n2. Entity1: \""Follow-Up\"", Entity2: \""persistent disease\"", Relationship: \""monitoring\""\\n3. Entity1: \""systemic therapy\"", Entity2: \""recurrent or persistent disease\"", Relationship: \""treatment option\""\\n4. Entity1: \""RT\"", Entity2: \""recurrent or persistent disease\"", Relationship: \""treatment option\""\\n5. Entity1: \""re-resection\"", Entity2: \""recurrent or persistent disease\"", Relationship: \""treatment option\""\\n\\nCausalities:-\\n<C> recurrence or persistent disease </C> <E> monitoring recurrence or persistent disease </E>. <A> follow-up strategies </A> are essential for <E> monitoring recurrence or persistent disease </E>. <A> continual assessment post-treatment </A> to <E> ensure any signs of recurrence are addressed promptly </E>. SOURCE2 mentions <A> observation, systemic therapy/RT, re-resection if feasible, and follow-up </A> for <CO> recurrent or persistent disease </CO>.\\n--------------------------------------------------\\nPage Number: 57\\n\\nSection Name: Definitive Treatment\\n====================\\nEntities:-\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nNeoplasm Staging : Methods used for staging neoplasms, including the TNM staging system.\\nCancer Staging : A system of classifying cancer according to the extent of the disease.\\nTnm Staging System : A cancer staging system that describes the extent of cancer in a patient\\'s body.\\n\\nRelationships:-\\n1. Entity1: \""Radiation Therapy\"", Entity2: \""T1\u20133, N0\u20131\"", Relationship: \""treats\""\\n2. Entity1: \""Conventional RT\"", Entity2: \""Radiation Therapy\"", Relationship: \""is a type of\""\\n3. Entity1: \""66 to 70 Gray (Gy)\"", Entity2: \""Conventional RT\"", Relationship: \""is the dosage for\""\\n\\nCausalities:-\\nThe document begins by defining the definitive radiation therapy (RT) approach for <CO> patients classified as T1\u20133, N0\u20131, with a specific focus on high-risk patients </CO>. It suggests <A> a regimen involving conventional RT, particularly highlighting a total dose of 66 to 70 Gray (Gy) delivered in fractions of 2.0 Gy each </A>. The schedule emphasizes <A> daily treatments, indicating a typical 7-week plan </A>.\\n\\nSection Name: Concurrent Therapy\\n====================\\nEntities:-\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nCisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.\\nChemotherapy : The use of drugs to destroy cancer cells, usually by stopping the cancer cells\u2019 ability to grow and divide.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""used in combination with\""\\n2. Entity1: \""Cisplatin\"", Entity2: \""Systemic Therapy\"", Relationship: \""is a type of\""\\n3. Entity1: \""Cisplatin\"", Entity2: \""Chemotherapy\"", Relationship: \""part of\""\\n\\nCausalities:-\\nIt further elaborates on concurrent systemic therapy in combination with radiation treatment. <CO> High-risk patients </CO> <E> may receive up to 70 Gy </E>, while <CO> those with lower risks </CO> <E> are advised to receive between 44 to 63 Gy </E>, <CO> depending on their specific case </CO>. This section <A> recommends careful consideration of systemic therapies like cisplatin, particularly every three weeks or in combination with pre-existing chemotherapy protocols </A>.\\n\\nSection Name: Additional Techniques and Research\\n====================\\nEntities:-\\nIntensity-Modulated Radiotherapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nIntensity Modulated Radiation Therapy : A type of cancer treatment that uses beams of radiation of varying intensities to deliver a precise dose of radiation to a tumor.\\nIntensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nThree-Dimensional Conformal Radiotherapy : A technique in radiotherapy that allows the radiation beams to be shaped to match the shape of the tumor.\\n3D Conformal Radiation Therapy : A type of radiation therapy that uses computer technology to create a 3-dimensional image of the tumor so that multiple radiation beams can be shaped exactly to the contour of the treatment area.\\nProton Therapy : The use of a beam of protons to irradiate diseased tissue, most often in the treatment of cancer.\\nToxicity : The degree to which a chemical substance or a particular mixture of substances can damage an organism.\\nRadiotherapy : The use of ionizing radiation to treat cancer and other diseases.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\n\\nRelationships:-\\n1. Entity1: \""Intensity-Modulated Radiation Therapy (IMRT)\"", Entity2: \""3D-Conformal Radiation Therapy (3D-CRT)\"", Relationship: \""preferred treatment modalities\""\\n2. Entity1: \""Proton therapy\"", Entity2: \""specific conditions\"", Relationship: \""could be beneficial\""\\n3. Entity1: \""treatment toxicity\"", Entity2: \""radiation techniques\"", Relationship: \""minimizing\""\\n4. Entity1: \""ongoing research\"", Entity2: \""radiation techniques\"", Relationship: \""efficacy and safety\""\\n\\nCausalities:-\\n<A> The document suggests employing either Intensity-Modulated Radiation Therapy (IMRT) or 3D-Conformal Radiation Therapy (3D-CRT) as preferred treatment modalities </A>. It mentions that <A> proton therapy could be beneficial </A> <CO> under specific conditions </CO> and <A> stresses the importance of minimizing treatment toxicity </A>. <CO> This part indicates ongoing research into the efficacy and safety of various radiation techniques </CO>.\\n\\nSection Name: Practical Recommendations\\n====================\\nEntities:-\\nTreatment Protocols : Treatment protocols are standardized procedures or plans of treatment for specific diseases or conditions.\\nMultidisciplinary Care : Multidisciplinary care involves the collaboration of professionals from various disciplines to provide comprehensive care.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Treatment Protocols\"", Entity2: \""Individual Patient Circumstances\"", Relationship: \""tailored based on\""\\n2. Entity1: \""Multidisciplinary Care\"", Entity2: \""Treatment Planning\"", Relationship: \""important for\""\\n3. Entity1: \""Patient Management\"", Entity2: \""Systemic Therapy\"", Relationship: \""necessary due to complexity and risks\""\\n\\nCausalities:-\\n<A> practical recommendations for treatment sequencing </A>, emphasizing <A> a tailored approach </A> <CO> based on individual patient circumstances </CO>, and highlights <A> the importance of multi-disciplinary collaboration in treatment planning </A>. There\u2019s an implicit suggestion for <A> careful patient management </A> <C> due to the complexity and risks of concurrent systemic therapies </C>.\\n\\nSection Name: NCCN Guidelines Index\\n====================\\nEntities:-\\n\\nRelationships:-\\n\\nCausalities:-\\n- **Table of Contents**\\n- **Discussion**\\n\\nSection Name: SUPRA-A 1 OF 2\\n====================\\nEntities:-\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nCisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.\\nCarboplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers, similar to cisplatin but with a different toxicity profile.\\nFluorouracil : A pyrimidine analog used as an antineoplastic agent, often in the treatment of cancers.\\nChemotherapy, Adjuvant : Treatment given in addition to the primary (main) treatment to enhance its effectiveness, often used in cancer therapy.\\nFractionation, Radiation : The division of the total dose of radiation into smaller doses delivered over a period of time.\\n\\nRelationships:-\\n1. Entity1: \""Cisplatin\"", Entity2: \""Concurrent Systemic Therapy/RT\"", Relationship: \""used in\""\\n2. Entity1: \""Carboplatin\"", Entity2: \""5-FU\"", Relationship: \""used with\""\\n3. Entity1: \""Concurrent Systemic Therapy/RT\"", Entity2: \""Non-Nasopharyngeal Cancers\"", Relationship: \""treatment for\""\\n\\nCausalities:-\\n1. **See Principles of Radiation Techniques (RAD-A) and Discussion.**\\n2. <CO>For select T1\u20132, N0 tumors</CO>, <A>accelerated fractionation may be used</A>.\\n3. <CO>For doses >70 Gy</CO>, <A>some clinicians feel that the fractionation should be slightly modified (e.g., <2.0 Gy/fraction for at least some of the treatment)</A> <E>to minimize toxicity</E>. An additional 2\u20133 doses can be added depending on clinical circumstances.\\n4. <A>Suggest 44\u201350 Gy in 3D-CRT and sequentially planned IMRT or 54\u201363 Gy with IMRT dose painting technique</A> <CO>(dependent on dose per fraction)</CO>.\\n5. **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A).**\\n6. <C>Based on published data</C>, <A>concurrent systemic therapy/RT most commonly uses conventional fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks with single-agent cisplatin given every 3 weeks at 100 mg/m\u00b2</A>; <CO>2\u20133 cycles of chemotherapy are used depending on the radiation fractionation scheme (RTOG)</CO>. <CO>When carboplatin and 5-FU are used</CO>, <A>the recommended regimen is standard fractionation plus 3 cycles of chemotherapy</A>. <A>Other fraction sizes, multiagent chemotherapy, other dosing schedules of cisplatin, or altered fractionation with chemotherapy are efficacious</A>, and <CO>there is no consensus on the optimal approach</CO>. <C>In general, the use of concurrent systemic therapy/RT</C> <E>carries a high toxicity burden</E>; <C>multiagent chemotherapy</C> <E>will likely further increase the toxicity burden</E>. <A>For any systemic therapy/RT approach, close attention should be paid to published reports for the specific chemotherapy agent, dose, and schedule of administration</A>. <A>Systemic therapy/RT should be performed by an experienced team and should include substantial supportive care</A>.\\n\\nSection Name: PRINCIPLES OF RADIATION THERAPY\\n====================\\nEntities:-\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nPlanning Target Volume : A volume that includes the gross tumor volume and a margin to account for tumor motion and setup variations.\\nIntensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nProton Therapy : The use of a beam of protons to irradiate diseased tissue, most often in the treatment of cancer.\\n\\nRelationships:-\\n1. Entity1: \""RT Alone\"", Entity2: \""PTV\"", Relationship: \""involves\""\\n2. Entity1: \""Concurrent Systemic Therapy/RT\"", Entity2: \""IMRT\"", Relationship: \""involves\""\\n3. Entity1: \""Proton Therapy\"", Entity2: \""Photon-based Therapy\"", Relationship: \""alternative to\""\\n\\nCausalities:-\\n1. **DEFINITIVE: RT Alone**\\n   - T1\u20133, N0\u20131: 66\u201370 Gy conventional (2.0 Gy/fraction)\\n   - **PTV**\\n     - <CO> High risk </CO>: <A> Primary tumor and involved lymph nodes [this includes possible local subclinical infiltration at the primary site and at the high-risk level lymph node(s)] </A>\\n       - <A> Fractionation: 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction); daily Monday\u2013Friday in 6\u20137 weeks </A>\\n     - <A> Concomitant boost accelerated RT: </A>\\n       - <A> 72 Gy/6 weeks (1.8 Gy/fraction, large field; 1.5 Gy boost as second daily fraction during last 12 treatment days) </A>\\n       - <A> 66\u201370 Gy (2.0 Gy/fraction; 6 fractions/wk accelerated) </A>\\n     - <A> Hyperfractionation: 79.2\u201381.6 Gy/7 weeks (1.2 Gy/fraction twice daily) </A>\\n     - <CO> Low to intermediate risk </CO>: <A> Sites of suspected subclinical spread </A>\\n       - <A> 44\u201350 Gy (2.0 Gy/fraction) to 54\u201363 Gy (1.6\u20131.8 Gy/fraction) </A>\\n\\n2. **CONCURRENT SYSTEMIC THERAPY/RT:**\\n   - **PTV**\\n     - <CO> High risk </CO>: <A> Typically 70 Gy (2.0 Gy/fraction) </A>\\n     - <CO> Low to intermediate and low risk </CO>: <A> 44\u201350 Gy (2.0 Gy/fraction) to 54\u201363 Gy (1.6\u20131.8 Gy/fraction) </A>\\n   - <A> Either IMRT (preferred) or 3D-CRT is recommended. </A> <CO> Use of proton therapy is an area of active investigation. </CO> <A> Proton therapy may be considered </A> <CO> when normal tissue constraints cannot be met by photon-based therapy, or when photon-based therapy causes compromise of standard radiation dosing to tumor or postoperative volumes. </CO>\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: N_Staging_1
label: Nearby Lymph Nodes Cancer Staging
description: This node represents the staging of cancer in nearby lymph nodes, which is a critical factor in determining the extent of cancer spread and guiding treatment decisions. The staging helps in assessing the prognosis and planning the appropriate therapeutic approach.
type: Decision Node
observability: Needs to be Predicted
states: [{'state_name': 'present', 'state_description': 'Cancer is present in the nearby lymph nodes, indicating that the cancer has spread beyond the primary site. This is an important factor in staging and affects treatment decisions and prognosis.'}, {'state_name': 'absent', 'state_description': 'Cancer is absent in the nearby lymph nodes, suggesting that the cancer has not spread to these nodes. This is a favorable sign and influences the staging and treatment plan.'}]

`NODE2`:
id: Largest_Diameter_of_Positive_Lymph_Node_4
label: Largest Diameter of Positive Lymph Node
description: This node represents the measurement of the largest diameter of a positive lymph node, specifically the fourth one in a clinical context. The size of lymph nodes is crucial in assessing the extent of cancer spread and is used in staging and prognosis.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'present', 'state_description': 'The largest diameter of the positive lymph node is measurable, indicating potential lymph node involvement in cancer.'}, {'state_name': 'absent', 'state_description': 'There is no measurable largest diameter for the positive lymph node, suggesting no significant lymph node involvement or the absence of detectable cancer spread in the lymph nodes.'}]

`EDGE1`:
{'edges_ids': ['N_Staging_1', 'Largest_Diameter_of_Positive_Lymph_Node_4'], 'edge': '(N_Staging_1) causes (Largest_Diameter_of_Positive_Lymph_Node_4)', 'explanation': ['The edge `(N_Staging_1) causes (Largest_Diameter_of_Positive_Lymph_Node_4)` is not valid because the staging of cancer in nearby lymph nodes (N_Staging_1) does not cause the size of the lymph node (Largest_Diameter_of_Positive_Lymph_Node_4).', 'In clinical practice, the size of the lymph node is used to help determine the staging, not the other way around.', 'Therefore, the causal direction is likely incorrect, and the relationship is not supported by typical clinical understanding.'], 'causal_direction': 'Unknown', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Unknown'}

`EDGE2`:
{'edges_ids': ['Largest_Diameter_of_Positive_Lymph_Node_4', 'N_Staging_1'], 'edge': '(Largest_Diameter_of_Positive_Lymph_Node_4) causes (N_Staging_1)', 'explanation': ['The `Largest Diameter of Positive Lymph Node 4` is a measure of the size of a lymph node, which is used in cancer staging.', 'The `N Staging 1` node represents the staging of cancer in nearby lymph nodes, which is influenced by the size of the lymph nodes.', 'In cancer staging, larger lymph nodes often indicate more advanced disease and a higher N stage.', 'Therefore, the size of the largest positive lymph node can influence the N staging, making this a valid causal relationship.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 130

Section Name: Pathological N (pN)
====================
Entities:-
Lymph Nodes : Small, bean-shaped structures that are part of the body's lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.
Lymph Node : An organ of the lymphatic system and the adaptive immune system.

Relationships:-
1. Entity1: ""Lymph Nodes"", Entity2: ""Neoplasm Metastasis"", Relationship: ""involved in""
2. Entity1: ""TNM Staging"", Entity2: ""Lymph Nodes"", Relationship: ""includes""
3. Entity1: ""TNM Staging"", Entity2: ""Neoplasm Metastasis"", Relationship: ""describes""

Causalities:-
<CO> NX: Regional lymph nodes cannot be assessed </CO>
<CO> N0: No regional lymph node metastasis </CO>
<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(–) </CO>
<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> Note: A designation of “U” or “L” may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(−) or ENE(+). </CO>

Section Name: Distant Metastasis (M)
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""M0"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""
2. Entity1: ""M1"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""

Causalities:-
### Distant Metastasis (M)

- **M0**: No distant metastasis
- **M1**: Distant metastasis

Section Name: Histologic Grade (G)
====================
Entities:-
Neoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.
Histologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.

Relationships:-
1. Entity1: ""GX"", Entity2: ""Grade cannot be assessed"", Relationship: ""is described as""
2. Entity1: ""G1"", Entity2: ""Well differentiated"", Relationship: ""is described as""
3. Entity1: ""G2"", Entity2: ""Moderately differentiated"", Relationship: ""is described as""
4. Entity1: ""G3"", Entity2: ""Poorly differentiated"", Relationship: ""is described as""

Causalities:-
<CO>GX</CO>: <E>Grade cannot be assessed</E>
<CO>G1</CO>: <E>Well differentiated</E>
<CO>G2</CO>: <E>Moderately differentiated</E>
<CO>G3</CO>: <E>Poorly differentiated</E>

Section Name: Prognostic Stage Groups
====================
Entities:-
Neoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.
Tumor Staging : A system for describing the size and spread of cancer within the body.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.

Relationships:-
1. Entity1: ""Stage 0"", Entity2: ""Tis N0 M0"", Relationship: ""defined by""
2. Entity1: ""Stage I"", Entity2: ""T1 N0 M0"", Relationship: ""defined by""
3. Entity1: ""Stage II"", Entity2: ""T2 N0 M0"", Relationship: ""defined by""
4. Entity1: ""Stage III"", Entity2: ""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0"", Relationship: ""defined by""
5. Entity1: ""Stage IVA"", Entity2: ""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0"", Relationship: ""defined by""
6. Entity1: ""Stage IVB"", Entity2: ""Any T N3 M0, T4b Any N M0"", Relationship: ""defined by""
7. Entity1: ""Stage IVC"", Entity2: ""Any T Any N M1"", Relationship: ""defined by""
--------------------------------------------------
Page Number: 102

Section Name: Head and Neck Cancers - Principles of Surgery
====================
Entities:-
Surgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.
Lymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.
Neoplasms : New abnormal growth of tissue in animals or plants; a tumor.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Neoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Surgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Lymphatic Structure : Anatomical structure that is part of the lymphatic system.
Tumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.
Staging : The process of determining the size and spread of cancer within the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.

Relationships:-
1. Entity1: ""surgical management"", Entity2: ""regional lymphatics"", Relationship: ""dictated by tumor staging""
2. Entity1: ""neck dissections"", Entity2: ""primary tumor"", Relationship: ""part of treatment""
3. Entity1: ""surgery"", Entity2: ""ipsilateral side of the neck"", Relationship: ""risk for metastases""

Causalities:-
<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.

Section Name: Neck Management
====================
Entities:-
Tongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.
Palate : The roof of the mouth, separating the oral and nasal cavities.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.
Hypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.
Nasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Squamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.
Biopsy : The removal of cells or tissues for examination under a microscope.

Relationships:-
1. Entity1: ""Tumor sites"", Entity2: ""Bilateral lymphatic drainage"", Relationship: ""associated with""
2. Entity1: ""Elective neck dissection"", Entity2: ""Risk of occult metastasis"", Relationship: ""based on""
3. Entity1: ""SLN biopsy"", Entity2: ""Elective neck dissection"", Relationship: ""guides decision-making for""

Causalities:-
- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.

- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.

- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.

  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2–4 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.

Section Name: Types of Neck Dissection
====================
Entities:-
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.

Relationships:-
1. Entity1: ""N0"", Entity2: ""Selective neck dissection"", Relationship: ""associated with""
2. Entity1: ""N3"", Entity2: ""Comprehensive neck dissection"", Relationship: ""associated with""
3. Entity1: ""Level VI neck dissection"", Entity2: ""Larynx"", Relationship: ""performed for""
4. Entity1: ""Level VI neck dissection"", Entity2: ""Hypopharynx"", Relationship: ""performed for""

Causalities:-
- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:
  - **N0:** <A> Selective neck dissection </A>
    - Oral cavity at least levels I–III
    - Oropharynx at least levels II–IV
    - Hypopharynx at least levels II–IV and level VI when appropriate
    - Larynx at least levels II–IV and level VI when appropriate
  - **N1–N2a–c:** <A> Selective or comprehensive neck dissection </A> (Discussion)
  - **N3:** <A> Comprehensive neck dissection </A>

- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.

- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.
--------------------------------------------------
Page Number: 51

Section Name: Introduction
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.
Supraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network (NCCN)"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""provides guidelines for""
2. Entity1: ""healthcare professionals"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""manage""

Causalities:-
The provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.

Section Name: Clinical Staging
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Total Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Cancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.
Tnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).

Relationships:-
1. Entity1: ""Clinical staging criteria"", Entity2: ""Total laryngectomy"", Relationship: ""determines necessity of""
2. Entity1: ""T3, N0"", Entity2: ""Clinical staging criteria"", Relationship: ""is a categorization of""

Causalities:-
The flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.

Section Name: Treatment of Primary and Neck
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Lymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Radiation Therapy"", Relationship: ""combined with""
2. Entity1: ""Laryngectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
3. Entity1: ""Thyroidectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
4. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""

Causalities:-
<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.

Section Name: Surgical Options
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Lymph Node Excision : Surgical removal of one or more lymph nodes.
Lymphadenectomy : Surgical removal of one or more groups of lymph nodes.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.

Relationships:-
1. Entity1: ""Laryngectomy"", Entity2: ""Thyroidectomy"", Relationship: ""combined with""
2. Entity1: ""Lymph Node Dissection"", Entity2: ""Surgical Intervention"", Relationship: ""extent of""
3. Entity1: ""Surgical Intervention"", Entity2: ""Advanced Cases"", Relationship: ""management option for""

Causalities:-
<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.

Section Name: Induction Chemotherapy
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Therapeutic Approach : A method or strategy used in the treatment of disease or injury.

Relationships:-
1. Entity1: ""Induction Chemotherapy"", Entity2: ""Surgical Intervention"", Relationship: ""alternative or sequential treatment option""

Causalities:-
<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.

Section Name: Adjuvant Treatment
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Neoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.
Disease Progression : The worsening of a disease over time.

Relationships:-
1. Entity1: ""Primary Treatment"", Entity2: ""Adjuvant Treatment"", Relationship: ""followed by""
2. Entity1: ""Adjuvant Treatment"", Entity2: ""Systemic Therapy"", Relationship: ""includes""
3. Entity1: ""Adjuvant Treatment"", Entity2: ""Radiotherapy"", Relationship: ""includes""
4. Entity1: ""Follow-up Assessments"", Entity2: ""Treatment Efficacy"", Relationship: ""used to evaluate""

Causalities:-
<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient's response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.

Section Name: Risk Features and Response Assessment
====================
Entities:-
Neoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.
Surgical Margins : The edge or border of the tissue removed in cancer surgery.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Extramural Extension : Extension of a tumor beyond the wall of an organ.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Cancer Management : The process of planning and coordinating the treatment of cancer.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Extramural extension"", Entity2: ""Treatment decisions"", Relationship: ""influences""
2. Entity1: ""Positive surgical margin"", Entity2: ""Treatment decisions"", Relationship: ""influences""
3. Entity1: ""Ongoing assessment"", Entity2: ""Response evaluation"", Relationship: ""leads to""
4. Entity1: ""Response evaluation"", Entity2: ""Adjustments to treatment"", Relationship: ""leads to""
5. Entity1: ""Management of cancer"", Entity2: ""Treatment decisions"", Relationship: ""involves""
6. Entity1: ""Management of cancer"", Entity2: ""Ongoing assessment"", Relationship: ""involves""
7. Entity1: ""Management of cancer"", Entity2: ""Adjustments to treatment"", Relationship: ""involves""

Causalities:-
The chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Malignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""NCCN Guidelines"", Relationship: ""provides""
2. Entity1: ""NCCN Guidelines"", Entity2: ""Clinical Trials"", Relationship: ""recommend""
3. Entity1: ""NCCN Guidelines"", Entity2: ""Cancer"", Relationship: ""related to management of""

Causalities:-
<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: SUPRA-3
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Clinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""Total laryngectomy"", Entity2: ""Laryngectomy"", Relationship: ""is a type of""
2. Entity1: ""Systemic therapy"", Entity2: ""RT"", Relationship: ""concurrent treatment option""
3. Entity1: ""Induction chemotherapy"", Entity2: ""Other treatments"", Relationship: ""initial treatment option before""

Causalities:-
<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>
  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>
  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>
  - or
  - <A> Induction chemotherapy </A>
  - or
  - <A> Clinical trials </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient's condition after initial treatment.
Follow-Up : Medical care given to a patient over time after initial treatment.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : The reappearance of a disease after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
- **Follow-up (FOLL-A, 1 of 2)**
  - <CO> Recurrent or persistent disease </CO> (ADV-3)

Section Name: Adverse Pathologic Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer beyond the lymph node capsule.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""pN1"", Entity2: ""Radiotherapy"", Relationship: ""Consideration for treatment""
2. Entity1: ""Extranodal extension"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
3. Entity1: ""Extranodal extension"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""
4. Entity1: ""Positive surgical margin"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
5. Entity1: ""Positive surgical margin"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""

Causalities:-
- <CO>pN1 without other risk features</CO>
  - <C>Adverse pathologic features</C>
  - <A>Consider RT</A>
  - <CO>Extranodal extension and/or positive margin</CO>
  - <CO>Other risk features</CO>
  - <A>Systemic therapy/RT (category 1)</A>
  - <A>RT or Consider systemic therapy/RT</A>

Section Name: Response Assessment
====================
Entities:-
Response Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.
Response To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.

Relationships:-

Section Name: Principles of Surgery and Radiation Therapy
====================
Entities:-
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""complementary treatments""

Causalities:-
**Principles of Surgery (SURG-A).**

**Principles of Radiation Therapy (SUPRA-A).**

Section Name: Principles of Systemic Therapy
====================
Entities:-
Cisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Cisplatin"", Entity2: ""Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""preferred agent""
2. Entity1: ""Cisplatin"", Entity2: ""Concurrent Systemic Therapy/RT"", Relationship: ""used in""

Causalities:-
<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.
--------------------------------------------------
Page Number: 42

Section Name: Clinical Staging
====================
Entities:-
Carcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.
Larynx : An organ in the neck involved in breathing, sound production, and protecting the trachea against food aspiration.
Neoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Tumor Staging : The process of determining the extent of spread of a tumor.
Cancer Staging : The process of determining the extent to which a cancer has developed by growing and possibly spreading.

Relationships:-
1. Entity1: ""Carcinoma in situ"", Entity2: ""larynx-preserving surgery"", Relationship: ""progression to determine suitability""
2. Entity1: ""nodal disease"", Entity2: ""glottic tumors"", Relationship: ""rare occurrence""

Causalities:-
<C>Carcinoma in situ</C> and progresses to <A>determine the amenability of the patient to larynx-preserving surgery</A>, specifically <CO>for tumors classified as T1 to T2, N0, or select T3, N0</CO>. This initial assessment is critical as it <E>drives treatment decisions</E>. In SOURCE2, it is noted that <C>nodal disease in such glottic tumors</C> <E>is rare</E>.

Section Name: Treatment of Primary and Neck
====================
Entities:-
Endoscopic Surgical Procedures : Surgery performed with the aid of an endoscope, which is a medical device with a light attached. It is used to look inside a body cavity or organ.
Radiotherapy : The use of ionizing radiation to treat cancer.
Laryngectomy, Partial : Surgical removal of part of the larynx.
Neck Dissection : Surgical procedure for control of neck lymph node metastasis.
Neoplasms : An abnormal mass of tissue as a result of neoplasia. Neoplasia is the abnormal proliferation of cells.

Relationships:-
1. Entity1: ""Condition"", Entity2: ""Endoscopic Resection"", Relationship: ""preferred treatment""
2. Entity1: ""Condition"", Entity2: ""Radiation Therapy"", Relationship: ""alternative treatment""
3. Entity1: ""Condition"", Entity2: ""Partial Laryngectomy"", Relationship: ""alternative treatment""
4. Entity1: ""Condition"", Entity2: ""Neck Dissection"", Relationship: ""part of extensive treatment""

Causalities:-
<CO>If the condition allows for larynx-preserving options</CO>, the <A>preferred treatment is endoscopic resection or radiation therapy (RT)</A>. Alternative <A>options include partial laryngectomy or a more extensive endoscopic/open resection with neck dissection</A>, <CO>depending on the specific characteristics of the tumor</CO>. SOURCE2 specifies that <A>endoscopic resection is preferred</A>, and <A>RT or partial laryngectomy/endoscopic or open resection is indicated as needed</A>.

Section Name: Adjuvant Treatment
====================
Entities:-
Adjuvant Therapy : Treatment given in addition to the primary (main) treatment to enhance its effectiveness.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Pathologic Processes : The abnormal mechanisms and forms involved in the dysfunctions of tissues and organs.
Extranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margins : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Radiation Therapy : The use of high-energy radiation to kill cancer cells and shrink tumors.

Relationships:-
1. Entity1: ""Adjuvant Treatment"", Entity2: ""Surgical Intervention"", Relationship: ""follows""
2. Entity1: ""Adjuvant Treatment"", Entity2: ""Adverse Pathologic Features"", Relationship: ""depends on""
3. Entity1: ""Extranodal Extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
4. Entity1: ""Positive Margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
5. Entity1: ""Systemic Therapy"", Entity2: ""Adjuvant Treatment"", Relationship: ""is a component of""
6. Entity1: ""Radiation"", Entity2: ""Adjuvant Treatment"", Relationship: ""is a component of""

Section Name: Follow-Up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Neoplasm Recurrence, Local : The return of a tumor at the original site after treatment.
Disease Progression : The worsening of a disease over time.
Observation : The act of noting and recording an event, characteristic, or behavior.
Antineoplastic Agents : Drugs used to treat cancer.
Radiotherapy : The use of ionizing radiation to treat cancer.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.

Relationships:-
1. Entity1: ""Follow-Up"", Entity2: ""recurrence"", Relationship: ""monitoring""
2. Entity1: ""Follow-Up"", Entity2: ""persistent disease"", Relationship: ""monitoring""
3. Entity1: ""systemic therapy"", Entity2: ""recurrent or persistent disease"", Relationship: ""treatment option""
4. Entity1: ""RT"", Entity2: ""recurrent or persistent disease"", Relationship: ""treatment option""
5. Entity1: ""re-resection"", Entity2: ""recurrent or persistent disease"", Relationship: ""treatment option""

Causalities:-
<C> recurrence or persistent disease </C> <E> monitoring recurrence or persistent disease </E>. <A> follow-up strategies </A> are essential for <E> monitoring recurrence or persistent disease </E>. <A> continual assessment post-treatment </A> to <E> ensure any signs of recurrence are addressed promptly </E>. SOURCE2 mentions <A> observation, systemic therapy/RT, re-resection if feasible, and follow-up </A> for <CO> recurrent or persistent disease </CO>.
--------------------------------------------------
Page Number: 57

Section Name: Definitive Treatment
====================
Entities:-
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Neoplasm Staging : Methods used for staging neoplasms, including the TNM staging system.
Cancer Staging : A system of classifying cancer according to the extent of the disease.
Tnm Staging System : A cancer staging system that describes the extent of cancer in a patient's body.

Relationships:-
1. Entity1: ""Radiation Therapy"", Entity2: ""T1–3, N0–1"", Relationship: ""treats""
2. Entity1: ""Conventional RT"", Entity2: ""Radiation Therapy"", Relationship: ""is a type of""
3. Entity1: ""66 to 70 Gray (Gy)"", Entity2: ""Conventional RT"", Relationship: ""is the dosage for""

Causalities:-
The document begins by defining the definitive radiation therapy (RT) approach for <CO> patients classified as T1–3, N0–1, with a specific focus on high-risk patients </CO>. It suggests <A> a regimen involving conventional RT, particularly highlighting a total dose of 66 to 70 Gray (Gy) delivered in fractions of 2.0 Gy each </A>. The schedule emphasizes <A> daily treatments, indicating a typical 7-week plan </A>.

Section Name: Concurrent Therapy
====================
Entities:-
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Cisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.
Chemotherapy : The use of drugs to destroy cancer cells, usually by stopping the cancer cells’ ability to grow and divide.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Radiation Therapy"", Relationship: ""used in combination with""
2. Entity1: ""Cisplatin"", Entity2: ""Systemic Therapy"", Relationship: ""is a type of""
3. Entity1: ""Cisplatin"", Entity2: ""Chemotherapy"", Relationship: ""part of""

Causalities:-
It further elaborates on concurrent systemic therapy in combination with radiation treatment. <CO> High-risk patients </CO> <E> may receive up to 70 Gy </E>, while <CO> those with lower risks </CO> <E> are advised to receive between 44 to 63 Gy </E>, <CO> depending on their specific case </CO>. This section <A> recommends careful consideration of systemic therapies like cisplatin, particularly every three weeks or in combination with pre-existing chemotherapy protocols </A>.

Section Name: Additional Techniques and Research
====================
Entities:-
Intensity-Modulated Radiotherapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Intensity Modulated Radiation Therapy : A type of cancer treatment that uses beams of radiation of varying intensities to deliver a precise dose of radiation to a tumor.
Intensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Three-Dimensional Conformal Radiotherapy : A technique in radiotherapy that allows the radiation beams to be shaped to match the shape of the tumor.
3D Conformal Radiation Therapy : A type of radiation therapy that uses computer technology to create a 3-dimensional image of the tumor so that multiple radiation beams can be shaped exactly to the contour of the treatment area.
Proton Therapy : The use of a beam of protons to irradiate diseased tissue, most often in the treatment of cancer.
Toxicity : The degree to which a chemical substance or a particular mixture of substances can damage an organism.
Radiotherapy : The use of ionizing radiation to treat cancer and other diseases.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.

Relationships:-
1. Entity1: ""Intensity-Modulated Radiation Therapy (IMRT)"", Entity2: ""3D-Conformal Radiation Therapy (3D-CRT)"", Relationship: ""preferred treatment modalities""
2. Entity1: ""Proton therapy"", Entity2: ""specific conditions"", Relationship: ""could be beneficial""
3. Entity1: ""treatment toxicity"", Entity2: ""radiation techniques"", Relationship: ""minimizing""
4. Entity1: ""ongoing research"", Entity2: ""radiation techniques"", Relationship: ""efficacy and safety""

Causalities:-
<A> The document suggests employing either Intensity-Modulated Radiation Therapy (IMRT) or 3D-Conformal Radiation Therapy (3D-CRT) as preferred treatment modalities </A>. It mentions that <A> proton therapy could be beneficial </A> <CO> under specific conditions </CO> and <A> stresses the importance of minimizing treatment toxicity </A>. <CO> This part indicates ongoing research into the efficacy and safety of various radiation techniques </CO>.

Section Name: Practical Recommendations
====================
Entities:-
Treatment Protocols : Treatment protocols are standardized procedures or plans of treatment for specific diseases or conditions.
Multidisciplinary Care : Multidisciplinary care involves the collaboration of professionals from various disciplines to provide comprehensive care.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Treatment Protocols"", Entity2: ""Individual Patient Circumstances"", Relationship: ""tailored based on""
2. Entity1: ""Multidisciplinary Care"", Entity2: ""Treatment Planning"", Relationship: ""important for""
3. Entity1: ""Patient Management"", Entity2: ""Systemic Therapy"", Relationship: ""necessary due to complexity and risks""

Causalities:-
<A> practical recommendations for treatment sequencing </A>, emphasizing <A> a tailored approach </A> <CO> based on individual patient circumstances </CO>, and highlights <A> the importance of multi-disciplinary collaboration in treatment planning </A>. There’s an implicit suggestion for <A> careful patient management </A> <C> due to the complexity and risks of concurrent systemic therapies </C>.

Section Name: NCCN Guidelines Index
====================
Entities:-

Relationships:-

Causalities:-
- **Table of Contents**
- **Discussion**

Section Name: SUPRA-A 1 OF 2
====================
Entities:-
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Cisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.
Carboplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers, similar to cisplatin but with a different toxicity profile.
Fluorouracil : A pyrimidine analog used as an antineoplastic agent, often in the treatment of cancers.
Chemotherapy, Adjuvant : Treatment given in addition to the primary (main) treatment to enhance its effectiveness, often used in cancer therapy.
Fractionation, Radiation : The division of the total dose of radiation into smaller doses delivered over a period of time.

Relationships:-
1. Entity1: ""Cisplatin"", Entity2: ""Concurrent Systemic Therapy/RT"", Relationship: ""used in""
2. Entity1: ""Carboplatin"", Entity2: ""5-FU"", Relationship: ""used with""
3. Entity1: ""Concurrent Systemic Therapy/RT"", Entity2: ""Non-Nasopharyngeal Cancers"", Relationship: ""treatment for""

Causalities:-
1. **See Principles of Radiation Techniques (RAD-A) and Discussion.**
2. <CO>For select T1–2, N0 tumors</CO>, <A>accelerated fractionation may be used</A>.
3. <CO>For doses >70 Gy</CO>, <A>some clinicians feel that the fractionation should be slightly modified (e.g., <2.0 Gy/fraction for at least some of the treatment)</A> <E>to minimize toxicity</E>. An additional 2–3 doses can be added depending on clinical circumstances.
4. <A>Suggest 44–50 Gy in 3D-CRT and sequentially planned IMRT or 54–63 Gy with IMRT dose painting technique</A> <CO>(dependent on dose per fraction)</CO>.
5. **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A).**
6. <C>Based on published data</C>, <A>concurrent systemic therapy/RT most commonly uses conventional fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks with single-agent cisplatin given every 3 weeks at 100 mg/m²</A>; <CO>2–3 cycles of chemotherapy are used depending on the radiation fractionation scheme (RTOG)</CO>. <CO>When carboplatin and 5-FU are used</CO>, <A>the recommended regimen is standard fractionation plus 3 cycles of chemotherapy</A>. <A>Other fraction sizes, multiagent chemotherapy, other dosing schedules of cisplatin, or altered fractionation with chemotherapy are efficacious</A>, and <CO>there is no consensus on the optimal approach</CO>. <C>In general, the use of concurrent systemic therapy/RT</C> <E>carries a high toxicity burden</E>; <C>multiagent chemotherapy</C> <E>will likely further increase the toxicity burden</E>. <A>For any systemic therapy/RT approach, close attention should be paid to published reports for the specific chemotherapy agent, dose, and schedule of administration</A>. <A>Systemic therapy/RT should be performed by an experienced team and should include substantial supportive care</A>.

Section Name: PRINCIPLES OF RADIATION THERAPY
====================
Entities:-
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Planning Target Volume : A volume that includes the gross tumor volume and a margin to account for tumor motion and setup variations.
Intensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Proton Therapy : The use of a beam of protons to irradiate diseased tissue, most often in the treatment of cancer.

Relationships:-
1. Entity1: ""RT Alone"", Entity2: ""PTV"", Relationship: ""involves""
2. Entity1: ""Concurrent Systemic Therapy/RT"", Entity2: ""IMRT"", Relationship: ""involves""
3. Entity1: ""Proton Therapy"", Entity2: ""Photon-based Therapy"", Relationship: ""alternative to""

Causalities:-
1. **DEFINITIVE: RT Alone**
   - T1–3, N0–1: 66–70 Gy conventional (2.0 Gy/fraction)
   - **PTV**
     - <CO> High risk </CO>: <A> Primary tumor and involved lymph nodes [this includes possible local subclinical infiltration at the primary site and at the high-risk level lymph node(s)] </A>
       - <A> Fractionation: 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction); daily Monday–Friday in 6–7 weeks </A>
     - <A> Concomitant boost accelerated RT: </A>
       - <A> 72 Gy/6 weeks (1.8 Gy/fraction, large field; 1.5 Gy boost as second daily fraction during last 12 treatment days) </A>
       - <A> 66–70 Gy (2.0 Gy/fraction; 6 fractions/wk accelerated) </A>
     - <A> Hyperfractionation: 79.2–81.6 Gy/7 weeks (1.2 Gy/fraction twice daily) </A>
     - <CO> Low to intermediate risk </CO>: <A> Sites of suspected subclinical spread </A>
       - <A> 44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </A>

2. **CONCURRENT SYSTEMIC THERAPY/RT:**
   - **PTV**
     - <CO> High risk </CO>: <A> Typically 70 Gy (2.0 Gy/fraction) </A>
     - <CO> Low to intermediate and low risk </CO>: <A> 44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </A>
   - <A> Either IMRT (preferred) or 3D-CRT is recommended. </A> <CO> Use of proton therapy is an area of active investigation. </CO> <A> Proton therapy may be considered </A> <CO> when normal tissue constraints cannot be met by photon-based therapy, or when photon-based therapy causes compromise of standard radiation dosing to tumor or postoperative volumes. </CO>


Among these two options which one is the most likely true:

(A) `N_Staging_1` increases risk `Largest_Diameter_of_Positive_Lymph_Node_4`
(B) `Largest_Diameter_of_Positive_Lymph_Node_4` `increases risk `N_Staging_1`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge in question is between 'N_Staging_1' and 'Largest_Diameter_of_Positive_Lymph_Node_4'.
2. Option (A) suggests that the staging of cancer in nearby lymph nodes ('N_Staging_1') increases the risk of having a larger diameter of a positive lymph node ('Largest_Diameter_of_Positive_Lymph_Node_4').
3. Option (B) suggests that the size of the largest positive lymph node ('Largest_Diameter_of_Positive_Lymph_Node_4') influences the staging of cancer in nearby lymph nodes ('N_Staging_1').
4. From the explanation provided for EDGE1, it is stated that the staging of cancer does not cause the size of the lymph node, indicating that option (A) is not valid.
5. For EDGE2, it is explained that the size of the lymph node is used in cancer staging, supporting option (B).
6. The TNM staging system, as described in the knowledge base, includes the size and involvement of lymph nodes as part of the staging criteria, supporting the idea that the size of the lymph node influences the staging.
7. The causal direction for EDGE2 is positive, indicating that an increase in the size of the lymph node is associated with a higher stage, aligning with option (B).
8. The knowledge base information on page 130, under the section 'Pathological N (pN)', describes the involvement of lymph nodes in the TNM staging system, supporting the causal relationship in option (B).
","1. Page Number: 130
2. Section Name: Pathological N (pN)
3. Entities: Lymph Nodes, TNM Staging
4. Relationships: TNM Staging includes Lymph Nodes
5. Causalities: TNM Staging describes the extent of cancer, including lymph node involvement
",B,"{'A': 0.0, 'B': 100.0}",yes,B,"1. The AI assistant is tasked with analyzing the causal relationship between two nodes: 'N_Staging_1' and 'Largest_Diameter_of_Positive_Lymph_Node_4'.
2. The assistant is given two options: (A) 'N_Staging_1' increases the risk of 'Largest_Diameter_of_Positive_Lymph_Node_4', and (B) 'Largest_Diameter_of_Positive_Lymph_Node_4' increases the risk of 'N_Staging_1'.
3. The assistant's reasoning for option (A) is that the staging of cancer does not cause the size of the lymph node, which aligns with the explanation provided for EDGE1.
4. For option (B), the assistant notes that the size of the lymph node is used in cancer staging, which is supported by the explanation for EDGE2 and the TNM staging system described in the knowledge base.
5. The assistant correctly identifies that the causal direction for EDGE2 is positive, indicating that an increase in the size of the lymph node is associated with a higher stage, supporting option (B).
6. The assistant references the knowledge base information on page 130, under the section 'Pathological N (pN)', which describes the involvement of lymph nodes in the TNM staging system, supporting the causal relationship in option (B).
7. The assistant's final answer is option (B), which is consistent with the reasoning provided and the evidence from the knowledge base.
"
8,gpt-4o,"N_Staging_1,Extranodal_Extension_5","""{'NODE1': {'id': 'N_Staging_1', 'label': 'Nearby Lymph Nodes Cancer Staging', 'description': 'This node represents the staging of cancer in nearby lymph nodes, which is a critical factor in determining the extent of cancer spread and guiding treatment decisions. The staging helps in assessing the prognosis and planning the appropriate therapeutic approach.', 'type': 'Decision Node', 'observability': 'Needs to be Predicted', 'states': [{'state_name': 'present', 'state_description': 'Cancer is present in the nearby lymph nodes, indicating that the cancer has spread beyond the primary site. This is an important factor in staging and affects treatment decisions and prognosis.'}, {'state_name': 'absent', 'state_description': 'Cancer is absent in the nearby lymph nodes, suggesting that the cancer has not spread to these nodes. This is a favorable sign and influences the staging and treatment plan.'}]}, 'NODE2': {'id': 'Extranodal_Extension_5', 'label': 'Extranodal Extension', 'description': 'Extranodal extension refers to the spread of cancer beyond the lymph node capsule into surrounding tissues. It is a significant factor in cancer staging and prognosis, as it indicates a more advanced disease and may influence treatment decisions.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'present', 'state_description': 'Extranodal extension is present, indicating that cancer has spread beyond the lymph node into surrounding tissues.'}, {'state_name': 'absent', 'state_description': 'Extranodal extension is absent, indicating that cancer is contained within the lymph node and has not spread to surrounding tissues.'}]}, 'EDGE1': {'edges_ids': ['N_Staging_1', 'Extranodal_Extension_5'], 'edge': '(N_Staging_1) causes (Extranodal_Extension_5)', 'explanation': ['The edge `(N_Staging_1) causes (Extranodal_Extension_5)` is valid because the presence of cancer in nearby lymph nodes (N_Staging_1) is a necessary condition for extranodal extension (Extranodal_Extension_5).', 'Extranodal extension occurs when cancer spreads beyond the lymph node capsule, which can only happen if cancer is present in the lymph nodes.', 'Therefore, the presence of cancer in lymph nodes is a necessary precursor to extranodal extension, making the causal relationship valid.', 'The causal direction is positive because the presence of cancer in lymph nodes increases the likelihood of extranodal extension.', 'The causal distance is proximal because the presence of cancer in lymph nodes directly affects the likelihood of extranodal extension.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': True, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'EDGE2': {'edges_ids': ['Extranodal_Extension_5', 'N_Staging_1'], 'edge': '(Extranodal_Extension_5) causes (N_Staging_1)', 'explanation': ['Extranodal extension indicates that cancer has spread beyond the lymph node capsule into surrounding tissues, which is a significant factor in cancer staging.', 'N staging assesses the presence of cancer in nearby lymph nodes, which is critical for determining the extent of cancer spread and guiding treatment decisions.', 'The presence of extranodal extension typically suggests a more advanced stage of cancer, which would likely affect the N staging by indicating that cancer has spread to nearby lymph nodes.', 'Therefore, the edge `(Extranodal_Extension_5) causes (N_Staging_1)` is valid because extranodal extension directly influences the staging of cancer in nearby lymph nodes.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'ENTITIES_MATCHING_PAGES_INFO': {'130': {'matching_entities': [{'LYMPH NODE STRUCTURE': 0.99134904}, {'LYMPH NODE': 0.98570025}, {'LYMPH NODES': 0.97445965}, {'TUMOR STAGING': 0.9742619}, {'TNM STAGING SYSTEM': 0.9654991}, {'NEOPLASM METASTASIS': 0.95823944}, {'TNM STAGING': 0.946078}, {'NEOPLASM STAGING': 0.9326755}, {'METASTASIS': 0.9265935}], 'count': 9}, '51': {'matching_entities': [{'CANCER STAGING': 0.9805381}, {'EXTRANODAL EXTENSION': 0.97547734}, {'TNM STAGING SYSTEM': 0.9654991}, {'LYMPHATIC METASTASIS': 0.94701207}, {'EXTRAMURAL EXTENSION': 0.94649863}, {'NEOPLASM STAGING': 0.9326755}, {'MALIGNANT NEOPLASM': 0.9201188}, {'CANCER': 0.92000854}], 'count': 8}, '102': {'matching_entities': [{'STAGING': 0.9886105}, {'CANCER STAGING': 0.9805381}, {'LYMPHATIC SYSTEM': 0.95855314}, {'LYMPHATIC STRUCTURE': 0.9469132}, {'NEOPLASM STAGING': 0.9326755}, {'METASTASIS': 0.9265935}], 'count': 6}, '55': {'matching_entities': [{'EXTRANODAL EXTENSION': 0.97547734}, {'NEOPLASM METASTASIS': 0.95823944}, {'METASTATIC NEOPLASM': 0.9350836}, {'METASTASIS': 0.9265935}, {'PARTIAL RESPONSE': 0.9250841}, {'CANCER': 0.92000854}], 'count': 6}, '42': {'matching_entities': [{'CANCER STAGING': 0.9805381}, {'EXTRANODAL EXTENSION': 0.97547734}, {'TUMOR STAGING': 0.9742619}, {'NEOPLASM STAGING': 0.9326755}], 'count': 4}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 130\\n\\nSection Name: Pathological N (pN)\\n====================\\nEntities:-\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nTnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system.\\n\\nRelationships:-\\n1. Entity1: \""Lymph Nodes\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""involved in\""\\n2. Entity1: \""TNM Staging\"", Entity2: \""Lymph Nodes\"", Relationship: \""includes\""\\n3. Entity1: \""TNM Staging\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""describes\""\\n\\nCausalities:-\\n<CO> NX: Regional lymph nodes cannot be assessed </CO>\\n<CO> N0: No regional lymph node metastasis </CO>\\n<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(\u2013) </CO>\\n<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(\u2212); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> Note: A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+). </CO>\\n\\nSection Name: Distant Metastasis (M)\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""M0\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n2. Entity1: \""M1\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n\\nCausalities:-\\n### Distant Metastasis (M)\\n\\n- **M0**: No distant metastasis\\n- **M1**: Distant metastasis\\n\\nSection Name: Histologic Grade (G)\\n====================\\nEntities:-\\nNeoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.\\nHistologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.\\n\\nRelationships:-\\n1. Entity1: \""GX\"", Entity2: \""Grade cannot be assessed\"", Relationship: \""is described as\""\\n2. Entity1: \""G1\"", Entity2: \""Well differentiated\"", Relationship: \""is described as\""\\n3. Entity1: \""G2\"", Entity2: \""Moderately differentiated\"", Relationship: \""is described as\""\\n4. Entity1: \""G3\"", Entity2: \""Poorly differentiated\"", Relationship: \""is described as\""\\n\\nCausalities:-\\n<CO>GX</CO>: <E>Grade cannot be assessed</E>\\n<CO>G1</CO>: <E>Well differentiated</E>\\n<CO>G2</CO>: <E>Moderately differentiated</E>\\n<CO>G3</CO>: <E>Poorly differentiated</E>\\n\\nSection Name: Prognostic Stage Groups\\n====================\\nEntities:-\\nNeoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.\\nTumor Staging : A system for describing the size and spread of cancer within the body.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\n\\nRelationships:-\\n1. Entity1: \""Stage 0\"", Entity2: \""Tis N0 M0\"", Relationship: \""defined by\""\\n2. Entity1: \""Stage I\"", Entity2: \""T1 N0 M0\"", Relationship: \""defined by\""\\n3. Entity1: \""Stage II\"", Entity2: \""T2 N0 M0\"", Relationship: \""defined by\""\\n4. Entity1: \""Stage III\"", Entity2: \""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0\"", Relationship: \""defined by\""\\n5. Entity1: \""Stage IVA\"", Entity2: \""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0\"", Relationship: \""defined by\""\\n6. Entity1: \""Stage IVB\"", Entity2: \""Any T N3 M0, T4b Any N M0\"", Relationship: \""defined by\""\\n7. Entity1: \""Stage IVC\"", Entity2: \""Any T Any N M1\"", Relationship: \""defined by\""\\n--------------------------------------------------\\nPage Number: 51\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\nSupraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network (NCCN)\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""provides guidelines for\""\\n2. Entity1: \""healthcare professionals\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""manage\""\\n\\nCausalities:-\\nThe provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nTotal Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nCancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.\\nTnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging criteria\"", Entity2: \""Total laryngectomy\"", Relationship: \""determines necessity of\""\\n2. Entity1: \""T3, N0\"", Entity2: \""Clinical staging criteria\"", Relationship: \""is a categorization of\""\\n\\nCausalities:-\\nThe flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.\\n\\nSection Name: Treatment of Primary and Neck\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nLymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""combined with\""\\n2. Entity1: \""Laryngectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n3. Entity1: \""Thyroidectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n4. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n\\nCausalities:-\\n<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.\\n\\nSection Name: Surgical Options\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nLymph Node Excision : Surgical removal of one or more lymph nodes.\\nLymphadenectomy : Surgical removal of one or more groups of lymph nodes.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Laryngectomy\"", Entity2: \""Thyroidectomy\"", Relationship: \""combined with\""\\n2. Entity1: \""Lymph Node Dissection\"", Entity2: \""Surgical Intervention\"", Relationship: \""extent of\""\\n3. Entity1: \""Surgical Intervention\"", Entity2: \""Advanced Cases\"", Relationship: \""management option for\""\\n\\nCausalities:-\\n<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.\\n\\nSection Name: Induction Chemotherapy\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nTherapeutic Approach : A method or strategy used in the treatment of disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Induction Chemotherapy\"", Entity2: \""Surgical Intervention\"", Relationship: \""alternative or sequential treatment option\""\\n\\nCausalities:-\\n<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.\\n\\nSection Name: Adjuvant Treatment\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nNeoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.\\nDisease Progression : The worsening of a disease over time.\\n\\nRelationships:-\\n1. Entity1: \""Primary Treatment\"", Entity2: \""Adjuvant Treatment\"", Relationship: \""followed by\""\\n2. Entity1: \""Adjuvant Treatment\"", Entity2: \""Systemic Therapy\"", Relationship: \""includes\""\\n3. Entity1: \""Adjuvant Treatment\"", Entity2: \""Radiotherapy\"", Relationship: \""includes\""\\n4. Entity1: \""Follow-up Assessments\"", Entity2: \""Treatment Efficacy\"", Relationship: \""used to evaluate\""\\n\\nCausalities:-\\n<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient\\'s response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.\\n\\nSection Name: Risk Features and Response Assessment\\n====================\\nEntities:-\\nNeoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.\\nSurgical Margins : The edge or border of the tissue removed in cancer surgery.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nExtramural Extension : Extension of a tumor beyond the wall of an organ.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nCancer Management : The process of planning and coordinating the treatment of cancer.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Extramural extension\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n2. Entity1: \""Positive surgical margin\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n3. Entity1: \""Ongoing assessment\"", Entity2: \""Response evaluation\"", Relationship: \""leads to\""\\n4. Entity1: \""Response evaluation\"", Entity2: \""Adjustments to treatment\"", Relationship: \""leads to\""\\n5. Entity1: \""Management of cancer\"", Entity2: \""Treatment decisions\"", Relationship: \""involves\""\\n6. Entity1: \""Management of cancer\"", Entity2: \""Ongoing assessment\"", Relationship: \""involves\""\\n7. Entity1: \""Management of cancer\"", Entity2: \""Adjustments to treatment\"", Relationship: \""involves\""\\n\\nCausalities:-\\nThe chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nMalignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""NCCN Guidelines\"", Relationship: \""provides\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""Clinical Trials\"", Relationship: \""recommend\""\\n3. Entity1: \""NCCN Guidelines\"", Entity2: \""Cancer\"", Relationship: \""related to management of\""\\n\\nCausalities:-\\n<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: SUPRA-3\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nClinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""Total laryngectomy\"", Entity2: \""Laryngectomy\"", Relationship: \""is a type of\""\\n2. Entity1: \""Systemic therapy\"", Entity2: \""RT\"", Relationship: \""concurrent treatment option\""\\n3. Entity1: \""Induction chemotherapy\"", Entity2: \""Other treatments\"", Relationship: \""initial treatment option before\""\\n\\nCausalities:-\\n<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>\\n  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>\\n  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>\\n  - or\\n  - <A> Induction chemotherapy </A>\\n  - or\\n  - <A> Clinical trials </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient\\'s condition after initial treatment.\\nFollow-Up : Medical care given to a patient over time after initial treatment.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : The reappearance of a disease after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n- **Follow-up (FOLL-A, 1 of 2)**\\n  - <CO> Recurrent or persistent disease </CO> (ADV-3)\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""pN1\"", Entity2: \""Radiotherapy\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Extranodal extension\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n3. Entity1: \""Extranodal extension\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n4. Entity1: \""Positive surgical margin\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n5. Entity1: \""Positive surgical margin\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n\\nCausalities:-\\n- <CO>pN1 without other risk features</CO>\\n  - <C>Adverse pathologic features</C>\\n  - <A>Consider RT</A>\\n  - <CO>Extranodal extension and/or positive margin</CO>\\n  - <CO>Other risk features</CO>\\n  - <A>Systemic therapy/RT (category 1)</A>\\n  - <A>RT or Consider systemic therapy/RT</A>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nResponse Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.\\nResponse To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.\\n\\nRelationships:-\\n\\nSection Name: Principles of Surgery and Radiation Therapy\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""complementary treatments\""\\n\\nCausalities:-\\n**Principles of Surgery (SURG-A).**\\n\\n**Principles of Radiation Therapy (SUPRA-A).**\\n\\nSection Name: Principles of Systemic Therapy\\n====================\\nEntities:-\\nCisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Cisplatin\"", Entity2: \""Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""preferred agent\""\\n2. Entity1: \""Cisplatin\"", Entity2: \""Concurrent Systemic Therapy/RT\"", Relationship: \""used in\""\\n\\nCausalities:-\\n<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.\\n--------------------------------------------------\\nPage Number: 102\\n\\nSection Name: Head and Neck Cancers - Principles of Surgery\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.\\nLymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.\\nNeoplasms : New abnormal growth of tissue in animals or plants; a tumor.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nNeoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSurgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nLymphatic Structure : Anatomical structure that is part of the lymphatic system.\\nTumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.\\nStaging : The process of determining the size and spread of cancer within the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.\\n\\nRelationships:-\\n1. Entity1: \""surgical management\"", Entity2: \""regional lymphatics\"", Relationship: \""dictated by tumor staging\""\\n2. Entity1: \""neck dissections\"", Entity2: \""primary tumor\"", Relationship: \""part of treatment\""\\n3. Entity1: \""surgery\"", Entity2: \""ipsilateral side of the neck\"", Relationship: \""risk for metastases\""\\n\\nCausalities:-\\n<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.\\n\\nSection Name: Neck Management\\n====================\\nEntities:-\\nTongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.\\nPalate : The roof of the mouth, separating the oral and nasal cavities.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\nHypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.\\nNasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSquamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.\\nBiopsy : The removal of cells or tissues for examination under a microscope.\\n\\nRelationships:-\\n1. Entity1: \""Tumor sites\"", Entity2: \""Bilateral lymphatic drainage\"", Relationship: \""associated with\""\\n2. Entity1: \""Elective neck dissection\"", Entity2: \""Risk of occult metastasis\"", Relationship: \""based on\""\\n3. Entity1: \""SLN biopsy\"", Entity2: \""Elective neck dissection\"", Relationship: \""guides decision-making for\""\\n\\nCausalities:-\\n- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.\\n\\n- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.\\n\\n- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.\\n\\n  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2\u20134 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.\\n\\nSection Name: Types of Neck Dissection\\n====================\\nEntities:-\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\n\\nRelationships:-\\n1. Entity1: \""N0\"", Entity2: \""Selective neck dissection\"", Relationship: \""associated with\""\\n2. Entity1: \""N3\"", Entity2: \""Comprehensive neck dissection\"", Relationship: \""associated with\""\\n3. Entity1: \""Level VI neck dissection\"", Entity2: \""Larynx\"", Relationship: \""performed for\""\\n4. Entity1: \""Level VI neck dissection\"", Entity2: \""Hypopharynx\"", Relationship: \""performed for\""\\n\\nCausalities:-\\n- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:\\n  - **N0:** <A> Selective neck dissection </A>\\n    - Oral cavity at least levels I\u2013III\\n    - Oropharynx at least levels II\u2013IV\\n    - Hypopharynx at least levels II\u2013IV and level VI when appropriate\\n    - Larynx at least levels II\u2013IV and level VI when appropriate\\n  - **N1\u2013N2a\u2013c:** <A> Selective or comprehensive neck dissection </A> (Discussion)\\n  - **N3:** <A> Comprehensive neck dissection </A>\\n\\n- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.\\n\\n- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.\\n--------------------------------------------------\\nPage Number: 55\\n\\nSection Name: General Information\\n====================\\nEntities:-\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""National Comprehensive Cancer Network\"", Relationship: \""produced by\""\\n\\nSection Name: Important Notes\\n====================\\nEntities:-\\nClinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.\\nClinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nNeoplasms : New abnormal growth of tissue that can be benign or malignant.\\nMalignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.\\nCancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Clinical Trials\"", Entity2: \""Cancer\"", Relationship: \""recommended for\""\\n2. Entity1: \""NCCN\"", Entity2: \""Clinical Trials\"", Relationship: \""encourages participation in\""\\n\\nCausalities:-\\n<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: Principles\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nChemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n2. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n3. Entity1: \""Principles of Radiation Therapy\"", Entity2: \""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""Both are principles of cancer treatment methods.\""\\n\\nCausalities:-\\n### Principles\\n\\n- **Principles of Surgery (SURG-A)**\\n- **Principles of Radiation Therapy (SUPRA-A)**\\n- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nPerineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.\\nVascular Invasion : The invasion of cancer cells into blood vessels.\\nLymphatic Invasion : The invasion of cancer cells into lymphatic vessels.\\n\\nRelationships:-\\n1. Entity1: \""Extranodal extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n2. Entity1: \""Positive margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n3. Entity1: \""Close margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n4. Entity1: \""pT3 or pT4 primary\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n5. Entity1: \""pN2 or pN3 nodal disease\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n6. Entity1: \""Perineural invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n7. Entity1: \""Vascular invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n8. Entity1: \""Lymphatic invasion\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n\\nCausalities:-\\n<C> Extranodal extension </C>\\n<C> Positive margins </C>\\n<C> Close margins </C>\\n<C> pT3 or pT4 primary </C>\\n<C> pN2 or pN3 nodal disease </C>\\n<C> Perineural invasion </C>\\n<C> Vascular invasion </C>\\n<C> Lymphatic invasion </C>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nPrimary Site : The original location where a tumor or cancer begins.\\nComplete Remission : The disappearance of all signs of cancer in response to treatment.\\nPartial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""induction chemotherapy\"", Entity2: \""Primary site\"", Relationship: \""treatment outcome\""\\n2. Entity1: \""Definitive RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n3. Entity1: \""RT\"", Entity2: \""Primary site\"", Relationship: \""treatment option\""\\n4. Entity1: \""Surgery\"", Entity2: \""unresectable nodal disease\"", Relationship: \""treatment option\""\\n\\nCausalities:-\\n<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.\\nFollow-Up (Medicine) : The process of monitoring a patient\\'s health over time after treatment or diagnosis.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : A disease that returns after a period of remission.\\nRecurrence (Medicine) : The return of a disease or condition after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n### Follow-up\\n\\n- **Follow-up** (FOLL-A, 1 of 2)\\n- **Recurrent or persistent disease** (ADV-3)\\n\\nSection Name: Risk Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""RT\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Adverse pathologic features\"", Entity2: \""Systemic therapy\"", Relationship: \""Consideration for treatment\""\\n\\nCausalities:-\\n- **No adverse pathologic features**\\n- **Other risk features**\\n- **Adverse pathologic features**:\\n  - <C> Extranodal extension and/or positive margin </C>\\n  - <A> RT or consider systemic therapy/RT </A>\\n\\nSection Name: Post-Therapy Evaluation\\n====================\\nEntities:-\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nNeck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n2. Entity1: \""RT\"", Entity2: \""Neck Evaluation\"", Relationship: \""evaluated in\""\\n\\nCausalities:-\\n<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>\\n\\nSection Name: Flowchart Overview\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nSupraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.\\nNational Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\n\\nRelationships:-\\n1. Entity1: \""NCCN Guidelines\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""guides management of\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""healthcare professionals\"", Relationship: \""used by\""\\n\\nCausalities:-\\n<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.\\n\\nSection Name: Assessment and Treatment Decisions\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nComplete Response : The disappearance of all signs of cancer in response to treatment.\\nPartial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Complete Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n2. Entity1: \""Complete Response\"", Entity2: \""Surgery\"", Relationship: \""leads to\""\\n3. Entity1: \""Partial Response\"", Entity2: \""Systemic Therapy\"", Relationship: \""leads to\""\\n4. Entity1: \""Partial Response\"", Entity2: \""Radiation Therapy\"", Relationship: \""leads to\""\\n\\nCausalities:-\\n<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.\\n\\nSection Name: Adverse Pathologic Features and Follow-up\\n====================\\nEntities:-\\nRadiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\nSurgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nNeoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nRecurrent Neoplasm : A neoplasm that has returned after treatment.\\nMetastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.\\nMetastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""Adverse pathologic features\"", Entity2: \""Treatment decisions\"", Relationship: \""Influence\""\\n2. Entity1: \""Adverse features\"", Entity2: \""Surgical intervention\"", Relationship: \""Recommendation\""\\n3. Entity1: \""Absence of adverse features\"", Entity2: \""Radiation therapy\"", Relationship: \""Pathway\""\\n4. Entity1: \""Follow-up process\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""Detection\""\\n5. Entity1: \""Recurrent or persistent disease\"", Entity2: \""Advanced disease management\"", Relationship: \""Necessity\""\\n\\nCausalities:-\\n<C> The presence of adverse pathologic features \u2014 such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient\\'s disease characteristics.\\n\\nFurthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.\\n--------------------------------------------------\\nPage Number: 42\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nCarcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.\\nLarynx : An organ in the neck involved in breathing, sound production, and protecting the trachea against food aspiration.\\nNeoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.\\nTumor Staging : The process of determining the extent of spread of a tumor.\\nCancer Staging : The process of determining the extent to which a cancer has developed by growing and possibly spreading.\\n\\nRelationships:-\\n1. Entity1: \""Carcinoma in situ\"", Entity2: \""larynx-preserving surgery\"", Relationship: \""progression to determine suitability\""\\n2. Entity1: \""nodal disease\"", Entity2: \""glottic tumors\"", Relationship: \""rare occurrence\""\\n\\nCausalities:-\\n<C>Carcinoma in situ</C> and progresses to <A>determine the amenability of the patient to larynx-preserving surgery</A>, specifically <CO>for tumors classified as T1 to T2, N0, or select T3, N0</CO>. This initial assessment is critical as it <E>drives treatment decisions</E>. In SOURCE2, it is noted that <C>nodal disease in such glottic tumors</C> <E>is rare</E>.\\n\\nSection Name: Treatment of Primary and Neck\\n====================\\nEntities:-\\nEndoscopic Surgical Procedures : Surgery performed with the aid of an endoscope, which is a medical device with a light attached. It is used to look inside a body cavity or organ.\\nRadiotherapy : The use of ionizing radiation to treat cancer.\\nLaryngectomy, Partial : Surgical removal of part of the larynx.\\nNeck Dissection : Surgical procedure for control of neck lymph node metastasis.\\nNeoplasms : An abnormal mass of tissue as a result of neoplasia. Neoplasia is the abnormal proliferation of cells.\\n\\nRelationships:-\\n1. Entity1: \""Condition\"", Entity2: \""Endoscopic Resection\"", Relationship: \""preferred treatment\""\\n2. Entity1: \""Condition\"", Entity2: \""Radiation Therapy\"", Relationship: \""alternative treatment\""\\n3. Entity1: \""Condition\"", Entity2: \""Partial Laryngectomy\"", Relationship: \""alternative treatment\""\\n4. Entity1: \""Condition\"", Entity2: \""Neck Dissection\"", Relationship: \""part of extensive treatment\""\\n\\nCausalities:-\\n<CO>If the condition allows for larynx-preserving options</CO>, the <A>preferred treatment is endoscopic resection or radiation therapy (RT)</A>. Alternative <A>options include partial laryngectomy or a more extensive endoscopic/open resection with neck dissection</A>, <CO>depending on the specific characteristics of the tumor</CO>. SOURCE2 specifies that <A>endoscopic resection is preferred</A>, and <A>RT or partial laryngectomy/endoscopic or open resection is indicated as needed</A>.\\n\\nSection Name: Adjuvant Treatment\\n====================\\nEntities:-\\nAdjuvant Therapy : Treatment given in addition to the primary (main) treatment to enhance its effectiveness.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nPathologic Processes : The abnormal mechanisms and forms involved in the dysfunctions of tissues and organs.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margins : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nRadiation Therapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\n\\nRelationships:-\\n1. Entity1: \""Adjuvant Treatment\"", Entity2: \""Surgical Intervention\"", Relationship: \""follows\""\\n2. Entity1: \""Adjuvant Treatment\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""depends on\""\\n3. Entity1: \""Extranodal Extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n4. Entity1: \""Positive Margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n5. Entity1: \""Systemic Therapy\"", Entity2: \""Adjuvant Treatment\"", Relationship: \""is a component of\""\\n6. Entity1: \""Radiation\"", Entity2: \""Adjuvant Treatment\"", Relationship: \""is a component of\""\\n\\nSection Name: Follow-Up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nNeoplasm Recurrence, Local : The return of a tumor at the original site after treatment.\\nDisease Progression : The worsening of a disease over time.\\nObservation : The act of noting and recording an event, characteristic, or behavior.\\nAntineoplastic Agents : Drugs used to treat cancer.\\nRadiotherapy : The use of ionizing radiation to treat cancer.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\n\\nRelationships:-\\n1. Entity1: \""Follow-Up\"", Entity2: \""recurrence\"", Relationship: \""monitoring\""\\n2. Entity1: \""Follow-Up\"", Entity2: \""persistent disease\"", Relationship: \""monitoring\""\\n3. Entity1: \""systemic therapy\"", Entity2: \""recurrent or persistent disease\"", Relationship: \""treatment option\""\\n4. Entity1: \""RT\"", Entity2: \""recurrent or persistent disease\"", Relationship: \""treatment option\""\\n5. Entity1: \""re-resection\"", Entity2: \""recurrent or persistent disease\"", Relationship: \""treatment option\""\\n\\nCausalities:-\\n<C> recurrence or persistent disease </C> <E> monitoring recurrence or persistent disease </E>. <A> follow-up strategies </A> are essential for <E> monitoring recurrence or persistent disease </E>. <A> continual assessment post-treatment </A> to <E> ensure any signs of recurrence are addressed promptly </E>. SOURCE2 mentions <A> observation, systemic therapy/RT, re-resection if feasible, and follow-up </A> for <CO> recurrent or persistent disease </CO>.\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: N_Staging_1
label: Nearby Lymph Nodes Cancer Staging
description: This node represents the staging of cancer in nearby lymph nodes, which is a critical factor in determining the extent of cancer spread and guiding treatment decisions. The staging helps in assessing the prognosis and planning the appropriate therapeutic approach.
type: Decision Node
observability: Needs to be Predicted
states: [{'state_name': 'present', 'state_description': 'Cancer is present in the nearby lymph nodes, indicating that the cancer has spread beyond the primary site. This is an important factor in staging and affects treatment decisions and prognosis.'}, {'state_name': 'absent', 'state_description': 'Cancer is absent in the nearby lymph nodes, suggesting that the cancer has not spread to these nodes. This is a favorable sign and influences the staging and treatment plan.'}]

`NODE2`:
id: Extranodal_Extension_5
label: Extranodal Extension
description: Extranodal extension refers to the spread of cancer beyond the lymph node capsule into surrounding tissues. It is a significant factor in cancer staging and prognosis, as it indicates a more advanced disease and may influence treatment decisions.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'present', 'state_description': 'Extranodal extension is present, indicating that cancer has spread beyond the lymph node into surrounding tissues.'}, {'state_name': 'absent', 'state_description': 'Extranodal extension is absent, indicating that cancer is contained within the lymph node and has not spread to surrounding tissues.'}]

`EDGE1`:
{'edges_ids': ['N_Staging_1', 'Extranodal_Extension_5'], 'edge': '(N_Staging_1) causes (Extranodal_Extension_5)', 'explanation': ['The edge `(N_Staging_1) causes (Extranodal_Extension_5)` is valid because the presence of cancer in nearby lymph nodes (N_Staging_1) is a necessary condition for extranodal extension (Extranodal_Extension_5).', 'Extranodal extension occurs when cancer spreads beyond the lymph node capsule, which can only happen if cancer is present in the lymph nodes.', 'Therefore, the presence of cancer in lymph nodes is a necessary precursor to extranodal extension, making the causal relationship valid.', 'The causal direction is positive because the presence of cancer in lymph nodes increases the likelihood of extranodal extension.', 'The causal distance is proximal because the presence of cancer in lymph nodes directly affects the likelihood of extranodal extension.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': True, 'sufficient': False}, 'causal_distance': 'Proximal'}

`EDGE2`:
{'edges_ids': ['Extranodal_Extension_5', 'N_Staging_1'], 'edge': '(Extranodal_Extension_5) causes (N_Staging_1)', 'explanation': ['Extranodal extension indicates that cancer has spread beyond the lymph node capsule into surrounding tissues, which is a significant factor in cancer staging.', 'N staging assesses the presence of cancer in nearby lymph nodes, which is critical for determining the extent of cancer spread and guiding treatment decisions.', 'The presence of extranodal extension typically suggests a more advanced stage of cancer, which would likely affect the N staging by indicating that cancer has spread to nearby lymph nodes.', 'Therefore, the edge `(Extranodal_Extension_5) causes (N_Staging_1)` is valid because extranodal extension directly influences the staging of cancer in nearby lymph nodes.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 130

Section Name: Pathological N (pN)
====================
Entities:-
Lymph Nodes : Small, bean-shaped structures that are part of the body's lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.
Lymph Node : An organ of the lymphatic system and the adaptive immune system.

Relationships:-
1. Entity1: ""Lymph Nodes"", Entity2: ""Neoplasm Metastasis"", Relationship: ""involved in""
2. Entity1: ""TNM Staging"", Entity2: ""Lymph Nodes"", Relationship: ""includes""
3. Entity1: ""TNM Staging"", Entity2: ""Neoplasm Metastasis"", Relationship: ""describes""

Causalities:-
<CO> NX: Regional lymph nodes cannot be assessed </CO>
<CO> N0: No regional lymph node metastasis </CO>
<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(–) </CO>
<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> Note: A designation of “U” or “L” may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(−) or ENE(+). </CO>

Section Name: Distant Metastasis (M)
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""M0"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""
2. Entity1: ""M1"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""

Causalities:-
### Distant Metastasis (M)

- **M0**: No distant metastasis
- **M1**: Distant metastasis

Section Name: Histologic Grade (G)
====================
Entities:-
Neoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.
Histologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.

Relationships:-
1. Entity1: ""GX"", Entity2: ""Grade cannot be assessed"", Relationship: ""is described as""
2. Entity1: ""G1"", Entity2: ""Well differentiated"", Relationship: ""is described as""
3. Entity1: ""G2"", Entity2: ""Moderately differentiated"", Relationship: ""is described as""
4. Entity1: ""G3"", Entity2: ""Poorly differentiated"", Relationship: ""is described as""

Causalities:-
<CO>GX</CO>: <E>Grade cannot be assessed</E>
<CO>G1</CO>: <E>Well differentiated</E>
<CO>G2</CO>: <E>Moderately differentiated</E>
<CO>G3</CO>: <E>Poorly differentiated</E>

Section Name: Prognostic Stage Groups
====================
Entities:-
Neoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.
Tumor Staging : A system for describing the size and spread of cancer within the body.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.

Relationships:-
1. Entity1: ""Stage 0"", Entity2: ""Tis N0 M0"", Relationship: ""defined by""
2. Entity1: ""Stage I"", Entity2: ""T1 N0 M0"", Relationship: ""defined by""
3. Entity1: ""Stage II"", Entity2: ""T2 N0 M0"", Relationship: ""defined by""
4. Entity1: ""Stage III"", Entity2: ""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0"", Relationship: ""defined by""
5. Entity1: ""Stage IVA"", Entity2: ""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0"", Relationship: ""defined by""
6. Entity1: ""Stage IVB"", Entity2: ""Any T N3 M0, T4b Any N M0"", Relationship: ""defined by""
7. Entity1: ""Stage IVC"", Entity2: ""Any T Any N M1"", Relationship: ""defined by""
--------------------------------------------------
Page Number: 51

Section Name: Introduction
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.
Supraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network (NCCN)"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""provides guidelines for""
2. Entity1: ""healthcare professionals"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""manage""

Causalities:-
The provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.

Section Name: Clinical Staging
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Total Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Cancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.
Tnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).

Relationships:-
1. Entity1: ""Clinical staging criteria"", Entity2: ""Total laryngectomy"", Relationship: ""determines necessity of""
2. Entity1: ""T3, N0"", Entity2: ""Clinical staging criteria"", Relationship: ""is a categorization of""

Causalities:-
The flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.

Section Name: Treatment of Primary and Neck
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Lymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Radiation Therapy"", Relationship: ""combined with""
2. Entity1: ""Laryngectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
3. Entity1: ""Thyroidectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
4. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""

Causalities:-
<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.

Section Name: Surgical Options
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Lymph Node Excision : Surgical removal of one or more lymph nodes.
Lymphadenectomy : Surgical removal of one or more groups of lymph nodes.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.

Relationships:-
1. Entity1: ""Laryngectomy"", Entity2: ""Thyroidectomy"", Relationship: ""combined with""
2. Entity1: ""Lymph Node Dissection"", Entity2: ""Surgical Intervention"", Relationship: ""extent of""
3. Entity1: ""Surgical Intervention"", Entity2: ""Advanced Cases"", Relationship: ""management option for""

Causalities:-
<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.

Section Name: Induction Chemotherapy
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Therapeutic Approach : A method or strategy used in the treatment of disease or injury.

Relationships:-
1. Entity1: ""Induction Chemotherapy"", Entity2: ""Surgical Intervention"", Relationship: ""alternative or sequential treatment option""

Causalities:-
<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.

Section Name: Adjuvant Treatment
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Neoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.
Disease Progression : The worsening of a disease over time.

Relationships:-
1. Entity1: ""Primary Treatment"", Entity2: ""Adjuvant Treatment"", Relationship: ""followed by""
2. Entity1: ""Adjuvant Treatment"", Entity2: ""Systemic Therapy"", Relationship: ""includes""
3. Entity1: ""Adjuvant Treatment"", Entity2: ""Radiotherapy"", Relationship: ""includes""
4. Entity1: ""Follow-up Assessments"", Entity2: ""Treatment Efficacy"", Relationship: ""used to evaluate""

Causalities:-
<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient's response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.

Section Name: Risk Features and Response Assessment
====================
Entities:-
Neoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.
Surgical Margins : The edge or border of the tissue removed in cancer surgery.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Extramural Extension : Extension of a tumor beyond the wall of an organ.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Cancer Management : The process of planning and coordinating the treatment of cancer.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Extramural extension"", Entity2: ""Treatment decisions"", Relationship: ""influences""
2. Entity1: ""Positive surgical margin"", Entity2: ""Treatment decisions"", Relationship: ""influences""
3. Entity1: ""Ongoing assessment"", Entity2: ""Response evaluation"", Relationship: ""leads to""
4. Entity1: ""Response evaluation"", Entity2: ""Adjustments to treatment"", Relationship: ""leads to""
5. Entity1: ""Management of cancer"", Entity2: ""Treatment decisions"", Relationship: ""involves""
6. Entity1: ""Management of cancer"", Entity2: ""Ongoing assessment"", Relationship: ""involves""
7. Entity1: ""Management of cancer"", Entity2: ""Adjustments to treatment"", Relationship: ""involves""

Causalities:-
The chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Malignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""NCCN Guidelines"", Relationship: ""provides""
2. Entity1: ""NCCN Guidelines"", Entity2: ""Clinical Trials"", Relationship: ""recommend""
3. Entity1: ""NCCN Guidelines"", Entity2: ""Cancer"", Relationship: ""related to management of""

Causalities:-
<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: SUPRA-3
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Clinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""Total laryngectomy"", Entity2: ""Laryngectomy"", Relationship: ""is a type of""
2. Entity1: ""Systemic therapy"", Entity2: ""RT"", Relationship: ""concurrent treatment option""
3. Entity1: ""Induction chemotherapy"", Entity2: ""Other treatments"", Relationship: ""initial treatment option before""

Causalities:-
<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>
  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>
  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>
  - or
  - <A> Induction chemotherapy </A>
  - or
  - <A> Clinical trials </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient's condition after initial treatment.
Follow-Up : Medical care given to a patient over time after initial treatment.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : The reappearance of a disease after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
- **Follow-up (FOLL-A, 1 of 2)**
  - <CO> Recurrent or persistent disease </CO> (ADV-3)

Section Name: Adverse Pathologic Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer beyond the lymph node capsule.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""pN1"", Entity2: ""Radiotherapy"", Relationship: ""Consideration for treatment""
2. Entity1: ""Extranodal extension"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
3. Entity1: ""Extranodal extension"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""
4. Entity1: ""Positive surgical margin"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
5. Entity1: ""Positive surgical margin"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""

Causalities:-
- <CO>pN1 without other risk features</CO>
  - <C>Adverse pathologic features</C>
  - <A>Consider RT</A>
  - <CO>Extranodal extension and/or positive margin</CO>
  - <CO>Other risk features</CO>
  - <A>Systemic therapy/RT (category 1)</A>
  - <A>RT or Consider systemic therapy/RT</A>

Section Name: Response Assessment
====================
Entities:-
Response Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.
Response To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.

Relationships:-

Section Name: Principles of Surgery and Radiation Therapy
====================
Entities:-
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""complementary treatments""

Causalities:-
**Principles of Surgery (SURG-A).**

**Principles of Radiation Therapy (SUPRA-A).**

Section Name: Principles of Systemic Therapy
====================
Entities:-
Cisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Cisplatin"", Entity2: ""Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""preferred agent""
2. Entity1: ""Cisplatin"", Entity2: ""Concurrent Systemic Therapy/RT"", Relationship: ""used in""

Causalities:-
<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.
--------------------------------------------------
Page Number: 102

Section Name: Head and Neck Cancers - Principles of Surgery
====================
Entities:-
Surgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.
Lymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.
Neoplasms : New abnormal growth of tissue in animals or plants; a tumor.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Neoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Surgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Lymphatic Structure : Anatomical structure that is part of the lymphatic system.
Tumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.
Staging : The process of determining the size and spread of cancer within the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.

Relationships:-
1. Entity1: ""surgical management"", Entity2: ""regional lymphatics"", Relationship: ""dictated by tumor staging""
2. Entity1: ""neck dissections"", Entity2: ""primary tumor"", Relationship: ""part of treatment""
3. Entity1: ""surgery"", Entity2: ""ipsilateral side of the neck"", Relationship: ""risk for metastases""

Causalities:-
<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.

Section Name: Neck Management
====================
Entities:-
Tongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.
Palate : The roof of the mouth, separating the oral and nasal cavities.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.
Hypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.
Nasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Squamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.
Biopsy : The removal of cells or tissues for examination under a microscope.

Relationships:-
1. Entity1: ""Tumor sites"", Entity2: ""Bilateral lymphatic drainage"", Relationship: ""associated with""
2. Entity1: ""Elective neck dissection"", Entity2: ""Risk of occult metastasis"", Relationship: ""based on""
3. Entity1: ""SLN biopsy"", Entity2: ""Elective neck dissection"", Relationship: ""guides decision-making for""

Causalities:-
- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.

- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.

- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.

  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2–4 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.

Section Name: Types of Neck Dissection
====================
Entities:-
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.

Relationships:-
1. Entity1: ""N0"", Entity2: ""Selective neck dissection"", Relationship: ""associated with""
2. Entity1: ""N3"", Entity2: ""Comprehensive neck dissection"", Relationship: ""associated with""
3. Entity1: ""Level VI neck dissection"", Entity2: ""Larynx"", Relationship: ""performed for""
4. Entity1: ""Level VI neck dissection"", Entity2: ""Hypopharynx"", Relationship: ""performed for""

Causalities:-
- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:
  - **N0:** <A> Selective neck dissection </A>
    - Oral cavity at least levels I–III
    - Oropharynx at least levels II–IV
    - Hypopharynx at least levels II–IV and level VI when appropriate
    - Larynx at least levels II–IV and level VI when appropriate
  - **N1–N2a–c:** <A> Selective or comprehensive neck dissection </A> (Discussion)
  - **N3:** <A> Comprehensive neck dissection </A>

- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.

- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.
--------------------------------------------------
Page Number: 55

Section Name: General Information
====================
Entities:-
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Nccn Guidelines : Clinical practice guidelines in oncology developed by the National Comprehensive Cancer Network.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""National Comprehensive Cancer Network"", Relationship: ""produced by""

Section Name: Important Notes
====================
Entities:-
Clinical Trials As Topic : Works about research studies that evaluate the effectiveness and safety of medical, surgical, or behavioral interventions.
Clinical Trial : A type of research that studies new tests and treatments and evaluates their effects on human health outcomes.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Neoplasms : New abnormal growth of tissue that can be benign or malignant.
Malignant Neoplastic Disease : A disease resulting from the growth of malignant neoplasms.
Cancer : A group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Clinical Trials"", Entity2: ""Cancer"", Relationship: ""recommended for""
2. Entity1: ""NCCN"", Entity2: ""Clinical Trials"", Relationship: ""encourages participation in""

Causalities:-
<C> NCCN believes that the best management of any patient with cancer is in a clinical trial </C>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: Principles
====================
Entities:-
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Chemotherapy : A type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""Both are principles of cancer treatment methods.""
2. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""
3. Entity1: ""Principles of Radiation Therapy"", Entity2: ""Principles of Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""Both are principles of cancer treatment methods.""

Causalities:-
### Principles

- **Principles of Surgery (SURG-A)**
- **Principles of Radiation Therapy (SUPRA-A)**
- **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)**

Section Name: Adverse Pathologic Features
====================
Entities:-
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Perineural Invasion : The presence of cancer cells surrounding or tracking along a nerve within the perineural space.
Vascular Invasion : The invasion of cancer cells into blood vessels.
Lymphatic Invasion : The invasion of cancer cells into lymphatic vessels.

Relationships:-
1. Entity1: ""Extranodal extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
2. Entity1: ""Positive margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
3. Entity1: ""Close margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
4. Entity1: ""pT3 or pT4 primary"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
5. Entity1: ""pN2 or pN3 nodal disease"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
6. Entity1: ""Perineural invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
7. Entity1: ""Vascular invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
8. Entity1: ""Lymphatic invasion"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""

Causalities:-
<C> Extranodal extension </C>
<C> Positive margins </C>
<C> Close margins </C>
<C> pT3 or pT4 primary </C>
<C> pN2 or pN3 nodal disease </C>
<C> Perineural invasion </C>
<C> Vascular invasion </C>
<C> Lymphatic invasion </C>

Section Name: Response Assessment
====================
Entities:-
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Primary Site : The original location where a tumor or cancer begins.
Complete Remission : The disappearance of all signs of cancer in response to treatment.
Partial Remission : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.

Relationships:-
1. Entity1: ""induction chemotherapy"", Entity2: ""Primary site"", Relationship: ""treatment outcome""
2. Entity1: ""Definitive RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
3. Entity1: ""RT"", Entity2: ""Primary site"", Relationship: ""treatment option""
4. Entity1: ""Surgery"", Entity2: ""unresectable nodal disease"", Relationship: ""treatment option""

Causalities:-
<C> Response after induction chemotherapy </C>: <E> Primary site: CR </E> <E> Primary site: PR </E> <E> Primary site: < PR </E> <A> Definitive RT </A> (category 1) <A> RT </A> (category 1) or <A> systemic therapy/RT </A> (category 2B) <A> Surgery </A> or <A> unresectable nodal disease </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure where a patient is monitored over time to assess the progress of a condition or the effects of treatment.
Follow-Up (Medicine) : The process of monitoring a patient's health over time after treatment or diagnosis.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : A disease that returns after a period of remission.
Recurrence (Medicine) : The return of a disease or condition after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
### Follow-up

- **Follow-up** (FOLL-A, 1 of 2)
- **Recurrent or persistent disease** (ADV-3)

Section Name: Risk Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer cells beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margin : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""RT"", Relationship: ""Consideration for treatment""
2. Entity1: ""Adverse pathologic features"", Entity2: ""Systemic therapy"", Relationship: ""Consideration for treatment""

Causalities:-
- **No adverse pathologic features**
- **Other risk features**
- **Adverse pathologic features**:
  - <C> Extranodal extension and/or positive margin </C>
  - <A> RT or consider systemic therapy/RT </A>

Section Name: Post-Therapy Evaluation
====================
Entities:-
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Neck : The neck is the part of the body that separates the head from the torso and provides the mobility and movements of the head.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""
2. Entity1: ""RT"", Entity2: ""Neck Evaluation"", Relationship: ""evaluated in""

Causalities:-
<CO> Post Systemic Therapy/RT or RT Neck </CO> <A> Evaluation </A>

Section Name: Flowchart Overview
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Supraglottic Larynx : The part of the larynx located above the vocal cords, including the epiglottis and aryepiglottic folds.
National Comprehensive Cancer Network : An alliance of 32 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.

Relationships:-
1. Entity1: ""NCCN Guidelines"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""guides management of""
2. Entity1: ""NCCN Guidelines"", Entity2: ""healthcare professionals"", Relationship: ""used by""

Causalities:-
<C> cancer of the supraglottic larynx </C> <E> evaluate patient responses following treatment </E> <CO> based on observed outcomes </CO> <A> evaluation of the primary site and determining subsequent steps </A>.

Section Name: Assessment and Treatment Decisions
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Complete Response : The disappearance of all signs of cancer in response to treatment.
Partial Response : A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Complete Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""
2. Entity1: ""Complete Response"", Entity2: ""Surgery"", Relationship: ""leads to""
3. Entity1: ""Partial Response"", Entity2: ""Systemic Therapy"", Relationship: ""leads to""
4. Entity1: ""Partial Response"", Entity2: ""Radiation Therapy"", Relationship: ""leads to""

Causalities:-
<C> responses to initial treatments such as induction chemotherapy </C> <E> Three main response categories are recognized: Complete Response (CR), Partial Response (PR), and less than Partial Response (< PR) </E>. These categories are pivotal in determining the next steps. <C> CR </C> <E> indicates full resolution of the disease at the primary site </E>, <A> leading to the consideration of definitive radiation therapy or the likelihood of surgery </A>. Conversely, <C> PR </C> <E> suggests that the disease has improved but not completely resolved </E>, <A> which directs the pathway towards either systemic therapy or continued radiation therapy </A>, <A> with further evaluation necessary </A>.

Section Name: Adverse Pathologic Features and Follow-up
====================
Entities:-
Radiation Therapy : Therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.
Surgical Procedures, Operative : Surgical procedures involve the use of operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Neoplasm Recurrence, Local : The return of a tumor or cancer, at the original site, after it has been treated.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Recurrent Neoplasm : A neoplasm that has returned after treatment.
Metastatic Neoplasm : A neoplasm that has spread from its original site to one or more other places in the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Recurrence : The return of cancer after treatment and after a period of time during which the cancer was undetectable.
Metastasis : Spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""Adverse pathologic features"", Entity2: ""Treatment decisions"", Relationship: ""Influence""
2. Entity1: ""Adverse features"", Entity2: ""Surgical intervention"", Relationship: ""Recommendation""
3. Entity1: ""Absence of adverse features"", Entity2: ""Radiation therapy"", Relationship: ""Pathway""
4. Entity1: ""Follow-up process"", Entity2: ""Recurrent or persistent disease"", Relationship: ""Detection""
5. Entity1: ""Recurrent or persistent disease"", Entity2: ""Advanced disease management"", Relationship: ""Necessity""

Causalities:-
<C> The presence of adverse pathologic features — such as extranodal extension or positive margins </C> <E> can directly influence treatment decisions </E>. <CO> If adverse features are found </CO>, <A> surgical intervention is recommended </A>. <CO> In cases where there are no adverse features </CO>, the patient may proceed directly to radiation therapy or continued systemic treatment, emphasizing the tailored approach based on the individual patient's disease characteristics.

Furthermore, the chart includes a section addressing the follow-up process after initial treatment. <CO> If there are signs of recurrent or persistent disease </CO>, <A> additional evaluations and treatment modalities may be necessary </A>. These evaluations <E> lead to specific recommendations for advanced disease management, denoted as ADV-3 on the chart </E>, emphasizing the importance of continuous monitoring and assessment in cancer care.
--------------------------------------------------
Page Number: 42

Section Name: Clinical Staging
====================
Entities:-
Carcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.
Larynx : An organ in the neck involved in breathing, sound production, and protecting the trachea against food aspiration.
Neoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Tumor Staging : The process of determining the extent of spread of a tumor.
Cancer Staging : The process of determining the extent to which a cancer has developed by growing and possibly spreading.

Relationships:-
1. Entity1: ""Carcinoma in situ"", Entity2: ""larynx-preserving surgery"", Relationship: ""progression to determine suitability""
2. Entity1: ""nodal disease"", Entity2: ""glottic tumors"", Relationship: ""rare occurrence""

Causalities:-
<C>Carcinoma in situ</C> and progresses to <A>determine the amenability of the patient to larynx-preserving surgery</A>, specifically <CO>for tumors classified as T1 to T2, N0, or select T3, N0</CO>. This initial assessment is critical as it <E>drives treatment decisions</E>. In SOURCE2, it is noted that <C>nodal disease in such glottic tumors</C> <E>is rare</E>.

Section Name: Treatment of Primary and Neck
====================
Entities:-
Endoscopic Surgical Procedures : Surgery performed with the aid of an endoscope, which is a medical device with a light attached. It is used to look inside a body cavity or organ.
Radiotherapy : The use of ionizing radiation to treat cancer.
Laryngectomy, Partial : Surgical removal of part of the larynx.
Neck Dissection : Surgical procedure for control of neck lymph node metastasis.
Neoplasms : An abnormal mass of tissue as a result of neoplasia. Neoplasia is the abnormal proliferation of cells.

Relationships:-
1. Entity1: ""Condition"", Entity2: ""Endoscopic Resection"", Relationship: ""preferred treatment""
2. Entity1: ""Condition"", Entity2: ""Radiation Therapy"", Relationship: ""alternative treatment""
3. Entity1: ""Condition"", Entity2: ""Partial Laryngectomy"", Relationship: ""alternative treatment""
4. Entity1: ""Condition"", Entity2: ""Neck Dissection"", Relationship: ""part of extensive treatment""

Causalities:-
<CO>If the condition allows for larynx-preserving options</CO>, the <A>preferred treatment is endoscopic resection or radiation therapy (RT)</A>. Alternative <A>options include partial laryngectomy or a more extensive endoscopic/open resection with neck dissection</A>, <CO>depending on the specific characteristics of the tumor</CO>. SOURCE2 specifies that <A>endoscopic resection is preferred</A>, and <A>RT or partial laryngectomy/endoscopic or open resection is indicated as needed</A>.

Section Name: Adjuvant Treatment
====================
Entities:-
Adjuvant Therapy : Treatment given in addition to the primary (main) treatment to enhance its effectiveness.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Pathologic Processes : The abnormal mechanisms and forms involved in the dysfunctions of tissues and organs.
Extranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margins : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Radiation Therapy : The use of high-energy radiation to kill cancer cells and shrink tumors.

Relationships:-
1. Entity1: ""Adjuvant Treatment"", Entity2: ""Surgical Intervention"", Relationship: ""follows""
2. Entity1: ""Adjuvant Treatment"", Entity2: ""Adverse Pathologic Features"", Relationship: ""depends on""
3. Entity1: ""Extranodal Extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
4. Entity1: ""Positive Margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
5. Entity1: ""Systemic Therapy"", Entity2: ""Adjuvant Treatment"", Relationship: ""is a component of""
6. Entity1: ""Radiation"", Entity2: ""Adjuvant Treatment"", Relationship: ""is a component of""

Section Name: Follow-Up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Neoplasm Recurrence, Local : The return of a tumor at the original site after treatment.
Disease Progression : The worsening of a disease over time.
Observation : The act of noting and recording an event, characteristic, or behavior.
Antineoplastic Agents : Drugs used to treat cancer.
Radiotherapy : The use of ionizing radiation to treat cancer.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.

Relationships:-
1. Entity1: ""Follow-Up"", Entity2: ""recurrence"", Relationship: ""monitoring""
2. Entity1: ""Follow-Up"", Entity2: ""persistent disease"", Relationship: ""monitoring""
3. Entity1: ""systemic therapy"", Entity2: ""recurrent or persistent disease"", Relationship: ""treatment option""
4. Entity1: ""RT"", Entity2: ""recurrent or persistent disease"", Relationship: ""treatment option""
5. Entity1: ""re-resection"", Entity2: ""recurrent or persistent disease"", Relationship: ""treatment option""

Causalities:-
<C> recurrence or persistent disease </C> <E> monitoring recurrence or persistent disease </E>. <A> follow-up strategies </A> are essential for <E> monitoring recurrence or persistent disease </E>. <A> continual assessment post-treatment </A> to <E> ensure any signs of recurrence are addressed promptly </E>. SOURCE2 mentions <A> observation, systemic therapy/RT, re-resection if feasible, and follow-up </A> for <CO> recurrent or persistent disease </CO>.


Among these two options which one is the most likely true:

(A) `N_Staging_1` increases risk `Extranodal_Extension_5`
(B) `Extranodal_Extension_5` `increases risk `N_Staging_1`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge '(N_Staging_1) causes (Extranodal_Extension_5)' suggests that the presence of cancer in nearby lymph nodes is a necessary condition for extranodal extension. This is because extranodal extension can only occur if cancer is present in the lymph nodes, making the causal relationship valid.
2. The causal direction is positive because the presence of cancer in lymph nodes increases the likelihood of extranodal extension. The causal distance is proximal because the presence of cancer in lymph nodes directly affects the likelihood of extranodal extension.
3. The edge '(Extranodal_Extension_5) causes (N_Staging_1)' suggests that extranodal extension influences the staging of cancer in nearby lymph nodes. Extranodal extension indicates a more advanced stage of cancer, which would likely affect the N staging by indicating that cancer has spread to nearby lymph nodes.
4. The causal direction is positive because extranodal extension suggests a more advanced stage of cancer, affecting the N staging. However, extranodal extension is not a necessary or sufficient condition for N staging, as N staging can occur without extranodal extension.
5. From the NCCN Guidelines, extranodal extension is considered an adverse pathologic feature that influences treatment decisions, but it does not directly cause changes in N staging. Instead, N staging is based on the presence and extent of cancer in lymph nodes, which can occur independently of extranodal extension.
","1. Page Number: 130, Section Name: Pathological N (pN), Entities: Lymph Nodes, Neoplasm Metastasis, TNM Staging, Relationships: TNM Staging includes Lymph Nodes, Causalities: N1, N2, N3 categories describe lymph node involvement.
2. Page Number: 51, Section Name: Adverse Pathologic Features, Entities: Extranodal Extension, Positive Surgical Margin, Relationships: Extranodal extension is a type of Adverse Pathologic Features, Causalities: Extranodal extension influences treatment decisions.
",A,"{'A': 99.99, 'B': 0.01}",yes,A,"1. The AI assistant's reasoning for option (A) is based on the idea that the presence of cancer in nearby lymph nodes is a necessary condition for extranodal extension. This is supported by the explanation that extranodal extension can only occur if cancer is present in the lymph nodes, making the causal relationship valid.
2. The assistant also mentions that the causal direction is positive because the presence of cancer in lymph nodes increases the likelihood of extranodal extension, and the causal distance is proximal because the presence of cancer in lymph nodes directly affects the likelihood of extranodal extension.
3. For option (B), the assistant suggests that extranodal extension influences the staging of cancer in nearby lymph nodes. However, it notes that extranodal extension is not a necessary or sufficient condition for N staging, as N staging can occur without extranodal extension.
4. The assistant references the NCCN Guidelines, stating that extranodal extension is considered an adverse pathologic feature that influences treatment decisions but does not directly cause changes in N staging. Instead, N staging is based on the presence and extent of cancer in lymph nodes, which can occur independently of extranodal extension.
5. The evidence provided from the knowledge base supports the assistant's reasoning for option (A) by highlighting the role of lymph nodes in TNM staging and the influence of extranodal extension as an adverse pathologic feature.
"
9,gpt-4o,"N_Staging_1,Lymph_Node_Ratio_6","""{'NODE1': {'id': 'N_Staging_1', 'label': 'Nearby Lymph Nodes Cancer Staging', 'description': 'This node represents the staging of cancer in nearby lymph nodes, which is a critical factor in determining the extent of cancer spread and guiding treatment decisions. The staging helps in assessing the prognosis and planning the appropriate therapeutic approach.', 'type': 'Decision Node', 'observability': 'Needs to be Predicted', 'states': [{'state_name': 'present', 'state_description': 'Cancer is present in the nearby lymph nodes, indicating that the cancer has spread beyond the primary site. This is an important factor in staging and affects treatment decisions and prognosis.'}, {'state_name': 'absent', 'state_description': 'Cancer is absent in the nearby lymph nodes, suggesting that the cancer has not spread to these nodes. This is a favorable sign and influences the staging and treatment plan.'}]}, 'NODE2': {'id': 'Lymph_Node_Ratio_6', 'label': 'Lymph Node Ratio Category', 'description': 'This node represents a specific category or threshold of the ratio of affected lymph nodes in a patient, which is used to assess the extent of lymphatic involvement in a disease process.', 'type': 'Patient Situation', 'observability': 'Unobserved', 'states': [{'state_name': 'present', 'state_description': \""The 'present' state indicates that the lymph node ratio falls within category 6, suggesting a significant level of lymphatic involvement.\""}, {'state_name': 'absent', 'state_description': \""The 'absent' state indicates that the lymph node ratio does not fall within category 6, suggesting a lower level of lymphatic involvement.\""}]}, 'EDGE1': {'edges_ids': ['N_Staging_1', 'Lymph_Node_Ratio_6'], 'edge': '(N_Staging_1) causes (Lymph_Node_Ratio_6)', 'explanation': ['The edge `(N_Staging_1) causes (Lymph_Node_Ratio_6)` is valid because the staging of cancer in nearby lymph nodes (N_Staging_1) is directly related to the lymph node ratio (Lymph_Node_Ratio_6).', 'If cancer is present in the nearby lymph nodes, it indicates a higher level of lymphatic involvement, which would likely result in a higher lymph node ratio, thus falling into category 6.', 'The causal direction is positive because the presence of cancer in lymph nodes would increase the lymph node ratio.', 'The causal factor is neither necessary nor sufficient because other factors can influence the lymph node ratio, and the presence of cancer does not guarantee a specific ratio category.', 'The causal distance is proximal because the staging of cancer in lymph nodes is directly related to the lymph node ratio.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}, 'EDGE2': {'edges_ids': ['Lymph_Node_Ratio_6', 'N_Staging_1'], 'edge': '(Lymph_Node_Ratio_6) causes (N_Staging_1)', 'explanation': [\""The edge '(Lymph_Node_Ratio_6) causes (N_Staging_1)' is valid because the lymph node ratio is a direct measure of lymphatic involvement, which is a key factor in cancer staging.\"", 'Lymph_Node_Ratio_6 represents a significant level of lymphatic involvement, which would directly influence the N staging of cancer in nearby lymph nodes.', 'The causal direction is positive because an increase in lymph node ratio (more involvement) would likely lead to a higher N stage (more advanced cancer spread).', 'The causal factor is not necessary because other factors can influence N staging, but it might be sufficient if a high lymph node ratio guarantees a certain N stage.', 'The causal distance is proximal because the lymph node ratio directly affects the staging of cancer in the lymph nodes.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': True}, 'causal_distance': 'Proximal'}, 'ENTITIES_MATCHING_PAGES_INFO': {'130': {'matching_entities': [{'LYMPH NODE STRUCTURE': 0.99134904}, {'LYMPH NODE': 0.98570025}, {'LYMPH NODES': 0.97445965}, {'TUMOR STAGING': 0.9742619}, {'TNM STAGING SYSTEM': 0.9654991}, {'TNM STAGING': 0.946078}, {'NEOPLASM STAGING': 0.9326755}], 'count': 7}, '102': {'matching_entities': [{'STAGING': 0.9886105}, {'CANCER STAGING': 0.9805381}, {'LYMPHATIC SYSTEM': 0.95855314}, {'LYMPHATIC STRUCTURE': 0.9469132}, {'NEOPLASM STAGING': 0.9326755}], 'count': 5}, '51': {'matching_entities': [{'CANCER STAGING': 0.9805381}, {'TNM STAGING SYSTEM': 0.9654991}, {'NEOPLASM STAGING': 0.9326755}, {'MALIGNANT NEOPLASM': 0.9201188}, {'CANCER': 0.92000854}], 'count': 5}, '42': {'matching_entities': [{'CANCER STAGING': 0.9805381}, {'TUMOR STAGING': 0.9742619}, {'NEOPLASM STAGING': 0.9326755}], 'count': 3}, '57': {'matching_entities': [{'CANCER STAGING': 0.9805381}, {'TNM STAGING SYSTEM': 0.9654991}, {'NEOPLASM STAGING': 0.9326755}], 'count': 3}}, 'GUIDELINE_PAGES_INFO': '--------------------------------------------------\\nPage Number: 130\\n\\nSection Name: Pathological N (pN)\\n====================\\nEntities:-\\nLymph Nodes : Small, bean-shaped structures that are part of the body\\'s lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nTnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.\\nLymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\nLymph Node : An organ of the lymphatic system and the adaptive immune system.\\n\\nRelationships:-\\n1. Entity1: \""Lymph Nodes\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""involved in\""\\n2. Entity1: \""TNM Staging\"", Entity2: \""Lymph Nodes\"", Relationship: \""includes\""\\n3. Entity1: \""TNM Staging\"", Entity2: \""Neoplasm Metastasis\"", Relationship: \""describes\""\\n\\nCausalities:-\\n<CO> NX: Regional lymph nodes cannot be assessed </CO>\\n<CO> N0: No regional lymph node metastasis </CO>\\n<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(\u2013) </CO>\\n<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(\u2212); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(\u2212) </CO>\\n<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>\\n<CO> Note: A designation of \u201cU\u201d or \u201cL\u201d may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(\u2212) or ENE(+). </CO>\\n\\nSection Name: Distant Metastasis (M)\\n====================\\nEntities:-\\nNeoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\nMetastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.\\n\\nRelationships:-\\n1. Entity1: \""M0\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n2. Entity1: \""M1\"", Entity2: \""Distant Metastasis\"", Relationship: \""is a category of\""\\n\\nCausalities:-\\n### Distant Metastasis (M)\\n\\n- **M0**: No distant metastasis\\n- **M1**: Distant metastasis\\n\\nSection Name: Histologic Grade (G)\\n====================\\nEntities:-\\nNeoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.\\nHistologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.\\n\\nRelationships:-\\n1. Entity1: \""GX\"", Entity2: \""Grade cannot be assessed\"", Relationship: \""is described as\""\\n2. Entity1: \""G1\"", Entity2: \""Well differentiated\"", Relationship: \""is described as\""\\n3. Entity1: \""G2\"", Entity2: \""Moderately differentiated\"", Relationship: \""is described as\""\\n4. Entity1: \""G3\"", Entity2: \""Poorly differentiated\"", Relationship: \""is described as\""\\n\\nCausalities:-\\n<CO>GX</CO>: <E>Grade cannot be assessed</E>\\n<CO>G1</CO>: <E>Well differentiated</E>\\n<CO>G2</CO>: <E>Moderately differentiated</E>\\n<CO>G3</CO>: <E>Poorly differentiated</E>\\n\\nSection Name: Prognostic Stage Groups\\n====================\\nEntities:-\\nNeoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.\\nTumor Staging : A system for describing the size and spread of cancer within the body.\\nTnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient\\'s body.\\n\\nRelationships:-\\n1. Entity1: \""Stage 0\"", Entity2: \""Tis N0 M0\"", Relationship: \""defined by\""\\n2. Entity1: \""Stage I\"", Entity2: \""T1 N0 M0\"", Relationship: \""defined by\""\\n3. Entity1: \""Stage II\"", Entity2: \""T2 N0 M0\"", Relationship: \""defined by\""\\n4. Entity1: \""Stage III\"", Entity2: \""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0\"", Relationship: \""defined by\""\\n5. Entity1: \""Stage IVA\"", Entity2: \""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0\"", Relationship: \""defined by\""\\n6. Entity1: \""Stage IVB\"", Entity2: \""Any T N3 M0, T4b Any N M0\"", Relationship: \""defined by\""\\n7. Entity1: \""Stage IVC\"", Entity2: \""Any T Any N M1\"", Relationship: \""defined by\""\\n--------------------------------------------------\\nPage Number: 102\\n\\nSection Name: Head and Neck Cancers - Principles of Surgery\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.\\nLymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.\\nNeoplasms : New abnormal growth of tissue in animals or plants; a tumor.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nNeoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSurgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nLymphatic Structure : Anatomical structure that is part of the lymphatic system.\\nTumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.\\nStaging : The process of determining the size and spread of cancer within the body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.\\nCancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.\\n\\nRelationships:-\\n1. Entity1: \""surgical management\"", Entity2: \""regional lymphatics\"", Relationship: \""dictated by tumor staging\""\\n2. Entity1: \""neck dissections\"", Entity2: \""primary tumor\"", Relationship: \""part of treatment\""\\n3. Entity1: \""surgery\"", Entity2: \""ipsilateral side of the neck\"", Relationship: \""risk for metastases\""\\n\\nCausalities:-\\n<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.\\n\\nSection Name: Neck Management\\n====================\\nEntities:-\\nTongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.\\nPalate : The roof of the mouth, separating the oral and nasal cavities.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\nHypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.\\nNasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nMetastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.\\nSquamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.\\nBiopsy : The removal of cells or tissues for examination under a microscope.\\n\\nRelationships:-\\n1. Entity1: \""Tumor sites\"", Entity2: \""Bilateral lymphatic drainage\"", Relationship: \""associated with\""\\n2. Entity1: \""Elective neck dissection\"", Entity2: \""Risk of occult metastasis\"", Relationship: \""based on\""\\n3. Entity1: \""SLN biopsy\"", Entity2: \""Elective neck dissection\"", Relationship: \""guides decision-making for\""\\n\\nCausalities:-\\n- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.\\n\\n- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.\\n\\n- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.\\n\\n  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2\u20134 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.\\n\\nSection Name: Types of Neck Dissection\\n====================\\nEntities:-\\nNeck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.\\nLarynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.\\n\\nRelationships:-\\n1. Entity1: \""N0\"", Entity2: \""Selective neck dissection\"", Relationship: \""associated with\""\\n2. Entity1: \""N3\"", Entity2: \""Comprehensive neck dissection\"", Relationship: \""associated with\""\\n3. Entity1: \""Level VI neck dissection\"", Entity2: \""Larynx\"", Relationship: \""performed for\""\\n4. Entity1: \""Level VI neck dissection\"", Entity2: \""Hypopharynx\"", Relationship: \""performed for\""\\n\\nCausalities:-\\n- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:\\n  - **N0:** <A> Selective neck dissection </A>\\n    - Oral cavity at least levels I\u2013III\\n    - Oropharynx at least levels II\u2013IV\\n    - Hypopharynx at least levels II\u2013IV and level VI when appropriate\\n    - Larynx at least levels II\u2013IV and level VI when appropriate\\n  - **N1\u2013N2a\u2013c:** <A> Selective or comprehensive neck dissection </A> (Discussion)\\n  - **N3:** <A> Comprehensive neck dissection </A>\\n\\n- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.\\n\\n- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.\\n--------------------------------------------------\\nPage Number: 51\\n\\nSection Name: Introduction\\n====================\\nEntities:-\\nLaryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.\\nMalignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.\\nSupraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network (NCCN)\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""provides guidelines for\""\\n2. Entity1: \""healthcare professionals\"", Entity2: \""cancer of the supraglottic larynx\"", Relationship: \""manage\""\\n\\nCausalities:-\\nThe provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nTotal Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nCancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.\\nTnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).\\n\\nRelationships:-\\n1. Entity1: \""Clinical staging criteria\"", Entity2: \""Total laryngectomy\"", Relationship: \""determines necessity of\""\\n2. Entity1: \""T3, N0\"", Entity2: \""Clinical staging criteria\"", Relationship: \""is a categorization of\""\\n\\nCausalities:-\\nThe flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.\\n\\nSection Name: Treatment of Primary and Neck\\n====================\\nEntities:-\\nNeoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nLymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""combined with\""\\n2. Entity1: \""Laryngectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n3. Entity1: \""Thyroidectomy\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n4. Entity1: \""Neck Dissection\"", Entity2: \""Lymph Node Involvement\"", Relationship: \""considered based on\""\\n\\nCausalities:-\\n<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.\\n\\nSection Name: Surgical Options\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nLymph Node Excision : Surgical removal of one or more lymph nodes.\\nLymphadenectomy : Surgical removal of one or more groups of lymph nodes.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Laryngectomy\"", Entity2: \""Thyroidectomy\"", Relationship: \""combined with\""\\n2. Entity1: \""Lymph Node Dissection\"", Entity2: \""Surgical Intervention\"", Relationship: \""extent of\""\\n3. Entity1: \""Surgical Intervention\"", Entity2: \""Advanced Cases\"", Relationship: \""management option for\""\\n\\nCausalities:-\\n<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.\\n\\nSection Name: Induction Chemotherapy\\n====================\\nEntities:-\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nTherapeutic Approach : A method or strategy used in the treatment of disease or injury.\\n\\nRelationships:-\\n1. Entity1: \""Induction Chemotherapy\"", Entity2: \""Surgical Intervention\"", Relationship: \""alternative or sequential treatment option\""\\n\\nCausalities:-\\n<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.\\n\\nSection Name: Adjuvant Treatment\\n====================\\nEntities:-\\nAdjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nNeoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.\\nDisease Progression : The worsening of a disease over time.\\n\\nRelationships:-\\n1. Entity1: \""Primary Treatment\"", Entity2: \""Adjuvant Treatment\"", Relationship: \""followed by\""\\n2. Entity1: \""Adjuvant Treatment\"", Entity2: \""Systemic Therapy\"", Relationship: \""includes\""\\n3. Entity1: \""Adjuvant Treatment\"", Entity2: \""Radiotherapy\"", Relationship: \""includes\""\\n4. Entity1: \""Follow-up Assessments\"", Entity2: \""Treatment Efficacy\"", Relationship: \""used to evaluate\""\\n\\nCausalities:-\\n<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient\\'s response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.\\n\\nSection Name: Risk Features and Response Assessment\\n====================\\nEntities:-\\nNeoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.\\nSurgical Margins : The edge or border of the tissue removed in cancer surgery.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nExtramural Extension : Extension of a tumor beyond the wall of an organ.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nCancer Management : The process of planning and coordinating the treatment of cancer.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""Extramural extension\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n2. Entity1: \""Positive surgical margin\"", Entity2: \""Treatment decisions\"", Relationship: \""influences\""\\n3. Entity1: \""Ongoing assessment\"", Entity2: \""Response evaluation\"", Relationship: \""leads to\""\\n4. Entity1: \""Response evaluation\"", Entity2: \""Adjustments to treatment\"", Relationship: \""leads to\""\\n5. Entity1: \""Management of cancer\"", Entity2: \""Treatment decisions\"", Relationship: \""involves\""\\n6. Entity1: \""Management of cancer\"", Entity2: \""Ongoing assessment\"", Relationship: \""involves\""\\n7. Entity1: \""Management of cancer\"", Entity2: \""Adjustments to treatment\"", Relationship: \""involves\""\\n\\nCausalities:-\\nThe chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.\\n\\nSection Name: NCCN Guidelines Version 4.2024\\n====================\\nEntities:-\\nClinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.\\nNeoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nMalignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.\\nNational Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.\\nCancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.\\n\\nRelationships:-\\n1. Entity1: \""National Comprehensive Cancer Network\"", Entity2: \""NCCN Guidelines\"", Relationship: \""provides\""\\n2. Entity1: \""NCCN Guidelines\"", Entity2: \""Clinical Trials\"", Relationship: \""recommend\""\\n3. Entity1: \""NCCN Guidelines\"", Entity2: \""Cancer\"", Relationship: \""related to management of\""\\n\\nCausalities:-\\n<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.\\n\\nSection Name: SUPRA-3\\n====================\\nEntities:-\\nLaryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.\\nThyroidectomy : A surgical procedure to remove all or part of the thyroid gland.\\nNeck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.\\nChemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.\\nClinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\nInduction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.\\nClinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.\\n\\nRelationships:-\\n1. Entity1: \""Total laryngectomy\"", Entity2: \""Laryngectomy\"", Relationship: \""is a type of\""\\n2. Entity1: \""Systemic therapy\"", Entity2: \""RT\"", Relationship: \""concurrent treatment option\""\\n3. Entity1: \""Induction chemotherapy\"", Entity2: \""Other treatments\"", Relationship: \""initial treatment option before\""\\n\\nCausalities:-\\n<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>\\n  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>\\n  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>\\n  - or\\n  - <A> Induction chemotherapy </A>\\n  - or\\n  - <A> Clinical trials </A>\\n\\nSection Name: Follow-up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nFollow-Up Procedure : A procedure performed to monitor the progress of a patient\\'s condition after initial treatment.\\nFollow-Up : Medical care given to a patient over time after initial treatment.\\nDisease Recurrence : The return of a sign, symptom, or disease after a remission.\\nRecurrent Disease : The reappearance of a disease after a period of improvement.\\n\\nRelationships:-\\n1. Entity1: \""Follow-up\"", Entity2: \""Recurrent or persistent disease\"", Relationship: \""monitoring\""\\n\\nCausalities:-\\n- **Follow-up (FOLL-A, 1 of 2)**\\n  - <CO> Recurrent or persistent disease </CO> (ADV-3)\\n\\nSection Name: Adverse Pathologic Features\\n====================\\nEntities:-\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule.\\nPositive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.\\nSystemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""pN1\"", Entity2: \""Radiotherapy\"", Relationship: \""Consideration for treatment\""\\n2. Entity1: \""Extranodal extension\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n3. Entity1: \""Extranodal extension\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n4. Entity1: \""Positive surgical margin\"", Entity2: \""Systemic Therapy\"", Relationship: \""Treatment option\""\\n5. Entity1: \""Positive surgical margin\"", Entity2: \""Radiotherapy\"", Relationship: \""Treatment option\""\\n\\nCausalities:-\\n- <CO>pN1 without other risk features</CO>\\n  - <C>Adverse pathologic features</C>\\n  - <A>Consider RT</A>\\n  - <CO>Extranodal extension and/or positive margin</CO>\\n  - <CO>Other risk features</CO>\\n  - <A>Systemic therapy/RT (category 1)</A>\\n  - <A>RT or Consider systemic therapy/RT</A>\\n\\nSection Name: Response Assessment\\n====================\\nEntities:-\\nResponse Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.\\nResponse To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.\\n\\nRelationships:-\\n\\nSection Name: Principles of Surgery and Radiation Therapy\\n====================\\nEntities:-\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nSurgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.\\nSurgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Principles of Surgery\"", Entity2: \""Principles of Radiation Therapy\"", Relationship: \""complementary treatments\""\\n\\nCausalities:-\\n**Principles of Surgery (SURG-A).**\\n\\n**Principles of Radiation Therapy (SUPRA-A).**\\n\\nSection Name: Principles of Systemic Therapy\\n====================\\nEntities:-\\nCisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.\\nRadiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nRadiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.\\n\\nRelationships:-\\n1. Entity1: \""Cisplatin\"", Entity2: \""Systemic Therapy for Non-Nasopharyngeal Cancers\"", Relationship: \""preferred agent\""\\n2. Entity1: \""Cisplatin\"", Entity2: \""Concurrent Systemic Therapy/RT\"", Relationship: \""used in\""\\n\\nCausalities:-\\n<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.\\n--------------------------------------------------\\nPage Number: 42\\n\\nSection Name: Clinical Staging\\n====================\\nEntities:-\\nCarcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.\\nLarynx : An organ in the neck involved in breathing, sound production, and protecting the trachea against food aspiration.\\nNeoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.\\nTumor Staging : The process of determining the extent of spread of a tumor.\\nCancer Staging : The process of determining the extent to which a cancer has developed by growing and possibly spreading.\\n\\nRelationships:-\\n1. Entity1: \""Carcinoma in situ\"", Entity2: \""larynx-preserving surgery\"", Relationship: \""progression to determine suitability\""\\n2. Entity1: \""nodal disease\"", Entity2: \""glottic tumors\"", Relationship: \""rare occurrence\""\\n\\nCausalities:-\\n<C>Carcinoma in situ</C> and progresses to <A>determine the amenability of the patient to larynx-preserving surgery</A>, specifically <CO>for tumors classified as T1 to T2, N0, or select T3, N0</CO>. This initial assessment is critical as it <E>drives treatment decisions</E>. In SOURCE2, it is noted that <C>nodal disease in such glottic tumors</C> <E>is rare</E>.\\n\\nSection Name: Treatment of Primary and Neck\\n====================\\nEntities:-\\nEndoscopic Surgical Procedures : Surgery performed with the aid of an endoscope, which is a medical device with a light attached. It is used to look inside a body cavity or organ.\\nRadiotherapy : The use of ionizing radiation to treat cancer.\\nLaryngectomy, Partial : Surgical removal of part of the larynx.\\nNeck Dissection : Surgical procedure for control of neck lymph node metastasis.\\nNeoplasms : An abnormal mass of tissue as a result of neoplasia. Neoplasia is the abnormal proliferation of cells.\\n\\nRelationships:-\\n1. Entity1: \""Condition\"", Entity2: \""Endoscopic Resection\"", Relationship: \""preferred treatment\""\\n2. Entity1: \""Condition\"", Entity2: \""Radiation Therapy\"", Relationship: \""alternative treatment\""\\n3. Entity1: \""Condition\"", Entity2: \""Partial Laryngectomy\"", Relationship: \""alternative treatment\""\\n4. Entity1: \""Condition\"", Entity2: \""Neck Dissection\"", Relationship: \""part of extensive treatment\""\\n\\nCausalities:-\\n<CO>If the condition allows for larynx-preserving options</CO>, the <A>preferred treatment is endoscopic resection or radiation therapy (RT)</A>. Alternative <A>options include partial laryngectomy or a more extensive endoscopic/open resection with neck dissection</A>, <CO>depending on the specific characteristics of the tumor</CO>. SOURCE2 specifies that <A>endoscopic resection is preferred</A>, and <A>RT or partial laryngectomy/endoscopic or open resection is indicated as needed</A>.\\n\\nSection Name: Adjuvant Treatment\\n====================\\nEntities:-\\nAdjuvant Therapy : Treatment given in addition to the primary (main) treatment to enhance its effectiveness.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\nPathologic Processes : The abnormal mechanisms and forms involved in the dysfunctions of tissues and organs.\\nExtranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.\\nPositive Surgical Margins : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.\\nRadiation Therapy : The use of high-energy radiation to kill cancer cells and shrink tumors.\\n\\nRelationships:-\\n1. Entity1: \""Adjuvant Treatment\"", Entity2: \""Surgical Intervention\"", Relationship: \""follows\""\\n2. Entity1: \""Adjuvant Treatment\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""depends on\""\\n3. Entity1: \""Extranodal Extension\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n4. Entity1: \""Positive Margins\"", Entity2: \""Adverse Pathologic Features\"", Relationship: \""is a type of\""\\n5. Entity1: \""Systemic Therapy\"", Entity2: \""Adjuvant Treatment\"", Relationship: \""is a component of\""\\n6. Entity1: \""Radiation\"", Entity2: \""Adjuvant Treatment\"", Relationship: \""is a component of\""\\n\\nSection Name: Follow-Up\\n====================\\nEntities:-\\nFollow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.\\nNeoplasm Recurrence, Local : The return of a tumor at the original site after treatment.\\nDisease Progression : The worsening of a disease over time.\\nObservation : The act of noting and recording an event, characteristic, or behavior.\\nAntineoplastic Agents : Drugs used to treat cancer.\\nRadiotherapy : The use of ionizing radiation to treat cancer.\\nSurgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.\\n\\nRelationships:-\\n1. Entity1: \""Follow-Up\"", Entity2: \""recurrence\"", Relationship: \""monitoring\""\\n2. Entity1: \""Follow-Up\"", Entity2: \""persistent disease\"", Relationship: \""monitoring\""\\n3. Entity1: \""systemic therapy\"", Entity2: \""recurrent or persistent disease\"", Relationship: \""treatment option\""\\n4. Entity1: \""RT\"", Entity2: \""recurrent or persistent disease\"", Relationship: \""treatment option\""\\n5. Entity1: \""re-resection\"", Entity2: \""recurrent or persistent disease\"", Relationship: \""treatment option\""\\n\\nCausalities:-\\n<C> recurrence or persistent disease </C> <E> monitoring recurrence or persistent disease </E>. <A> follow-up strategies </A> are essential for <E> monitoring recurrence or persistent disease </E>. <A> continual assessment post-treatment </A> to <E> ensure any signs of recurrence are addressed promptly </E>. SOURCE2 mentions <A> observation, systemic therapy/RT, re-resection if feasible, and follow-up </A> for <CO> recurrent or persistent disease </CO>.\\n--------------------------------------------------\\nPage Number: 57\\n\\nSection Name: Definitive Treatment\\n====================\\nEntities:-\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nNeoplasm Staging : Methods used for staging neoplasms, including the TNM staging system.\\nCancer Staging : A system of classifying cancer according to the extent of the disease.\\nTnm Staging System : A cancer staging system that describes the extent of cancer in a patient\\'s body.\\n\\nRelationships:-\\n1. Entity1: \""Radiation Therapy\"", Entity2: \""T1\u20133, N0\u20131\"", Relationship: \""treats\""\\n2. Entity1: \""Conventional RT\"", Entity2: \""Radiation Therapy\"", Relationship: \""is a type of\""\\n3. Entity1: \""66 to 70 Gray (Gy)\"", Entity2: \""Conventional RT\"", Relationship: \""is the dosage for\""\\n\\nCausalities:-\\nThe document begins by defining the definitive radiation therapy (RT) approach for <CO> patients classified as T1\u20133, N0\u20131, with a specific focus on high-risk patients </CO>. It suggests <A> a regimen involving conventional RT, particularly highlighting a total dose of 66 to 70 Gray (Gy) delivered in fractions of 2.0 Gy each </A>. The schedule emphasizes <A> daily treatments, indicating a typical 7-week plan </A>.\\n\\nSection Name: Concurrent Therapy\\n====================\\nEntities:-\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nCisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.\\nChemotherapy : The use of drugs to destroy cancer cells, usually by stopping the cancer cells\u2019 ability to grow and divide.\\n\\nRelationships:-\\n1. Entity1: \""Systemic Therapy\"", Entity2: \""Radiation Therapy\"", Relationship: \""used in combination with\""\\n2. Entity1: \""Cisplatin\"", Entity2: \""Systemic Therapy\"", Relationship: \""is a type of\""\\n3. Entity1: \""Cisplatin\"", Entity2: \""Chemotherapy\"", Relationship: \""part of\""\\n\\nCausalities:-\\nIt further elaborates on concurrent systemic therapy in combination with radiation treatment. <CO> High-risk patients </CO> <E> may receive up to 70 Gy </E>, while <CO> those with lower risks </CO> <E> are advised to receive between 44 to 63 Gy </E>, <CO> depending on their specific case </CO>. This section <A> recommends careful consideration of systemic therapies like cisplatin, particularly every three weeks or in combination with pre-existing chemotherapy protocols </A>.\\n\\nSection Name: Additional Techniques and Research\\n====================\\nEntities:-\\nIntensity-Modulated Radiotherapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nIntensity Modulated Radiation Therapy : A type of cancer treatment that uses beams of radiation of varying intensities to deliver a precise dose of radiation to a tumor.\\nIntensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nThree-Dimensional Conformal Radiotherapy : A technique in radiotherapy that allows the radiation beams to be shaped to match the shape of the tumor.\\n3D Conformal Radiation Therapy : A type of radiation therapy that uses computer technology to create a 3-dimensional image of the tumor so that multiple radiation beams can be shaped exactly to the contour of the treatment area.\\nProton Therapy : The use of a beam of protons to irradiate diseased tissue, most often in the treatment of cancer.\\nToxicity : The degree to which a chemical substance or a particular mixture of substances can damage an organism.\\nRadiotherapy : The use of ionizing radiation to treat cancer and other diseases.\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\n\\nRelationships:-\\n1. Entity1: \""Intensity-Modulated Radiation Therapy (IMRT)\"", Entity2: \""3D-Conformal Radiation Therapy (3D-CRT)\"", Relationship: \""preferred treatment modalities\""\\n2. Entity1: \""Proton therapy\"", Entity2: \""specific conditions\"", Relationship: \""could be beneficial\""\\n3. Entity1: \""treatment toxicity\"", Entity2: \""radiation techniques\"", Relationship: \""minimizing\""\\n4. Entity1: \""ongoing research\"", Entity2: \""radiation techniques\"", Relationship: \""efficacy and safety\""\\n\\nCausalities:-\\n<A> The document suggests employing either Intensity-Modulated Radiation Therapy (IMRT) or 3D-Conformal Radiation Therapy (3D-CRT) as preferred treatment modalities </A>. It mentions that <A> proton therapy could be beneficial </A> <CO> under specific conditions </CO> and <A> stresses the importance of minimizing treatment toxicity </A>. <CO> This part indicates ongoing research into the efficacy and safety of various radiation techniques </CO>.\\n\\nSection Name: Practical Recommendations\\n====================\\nEntities:-\\nTreatment Protocols : Treatment protocols are standardized procedures or plans of treatment for specific diseases or conditions.\\nMultidisciplinary Care : Multidisciplinary care involves the collaboration of professionals from various disciplines to provide comprehensive care.\\nSystemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.\\n\\nRelationships:-\\n1. Entity1: \""Treatment Protocols\"", Entity2: \""Individual Patient Circumstances\"", Relationship: \""tailored based on\""\\n2. Entity1: \""Multidisciplinary Care\"", Entity2: \""Treatment Planning\"", Relationship: \""important for\""\\n3. Entity1: \""Patient Management\"", Entity2: \""Systemic Therapy\"", Relationship: \""necessary due to complexity and risks\""\\n\\nCausalities:-\\n<A> practical recommendations for treatment sequencing </A>, emphasizing <A> a tailored approach </A> <CO> based on individual patient circumstances </CO>, and highlights <A> the importance of multi-disciplinary collaboration in treatment planning </A>. There\u2019s an implicit suggestion for <A> careful patient management </A> <C> due to the complexity and risks of concurrent systemic therapies </C>.\\n\\nSection Name: NCCN Guidelines Index\\n====================\\nEntities:-\\n\\nRelationships:-\\n\\nCausalities:-\\n- **Table of Contents**\\n- **Discussion**\\n\\nSection Name: SUPRA-A 1 OF 2\\n====================\\nEntities:-\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nCisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.\\nCarboplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers, similar to cisplatin but with a different toxicity profile.\\nFluorouracil : A pyrimidine analog used as an antineoplastic agent, often in the treatment of cancers.\\nChemotherapy, Adjuvant : Treatment given in addition to the primary (main) treatment to enhance its effectiveness, often used in cancer therapy.\\nFractionation, Radiation : The division of the total dose of radiation into smaller doses delivered over a period of time.\\n\\nRelationships:-\\n1. Entity1: \""Cisplatin\"", Entity2: \""Concurrent Systemic Therapy/RT\"", Relationship: \""used in\""\\n2. Entity1: \""Carboplatin\"", Entity2: \""5-FU\"", Relationship: \""used with\""\\n3. Entity1: \""Concurrent Systemic Therapy/RT\"", Entity2: \""Non-Nasopharyngeal Cancers\"", Relationship: \""treatment for\""\\n\\nCausalities:-\\n1. **See Principles of Radiation Techniques (RAD-A) and Discussion.**\\n2. <CO>For select T1\u20132, N0 tumors</CO>, <A>accelerated fractionation may be used</A>.\\n3. <CO>For doses >70 Gy</CO>, <A>some clinicians feel that the fractionation should be slightly modified (e.g., <2.0 Gy/fraction for at least some of the treatment)</A> <E>to minimize toxicity</E>. An additional 2\u20133 doses can be added depending on clinical circumstances.\\n4. <A>Suggest 44\u201350 Gy in 3D-CRT and sequentially planned IMRT or 54\u201363 Gy with IMRT dose painting technique</A> <CO>(dependent on dose per fraction)</CO>.\\n5. **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A).**\\n6. <C>Based on published data</C>, <A>concurrent systemic therapy/RT most commonly uses conventional fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks with single-agent cisplatin given every 3 weeks at 100 mg/m\u00b2</A>; <CO>2\u20133 cycles of chemotherapy are used depending on the radiation fractionation scheme (RTOG)</CO>. <CO>When carboplatin and 5-FU are used</CO>, <A>the recommended regimen is standard fractionation plus 3 cycles of chemotherapy</A>. <A>Other fraction sizes, multiagent chemotherapy, other dosing schedules of cisplatin, or altered fractionation with chemotherapy are efficacious</A>, and <CO>there is no consensus on the optimal approach</CO>. <C>In general, the use of concurrent systemic therapy/RT</C> <E>carries a high toxicity burden</E>; <C>multiagent chemotherapy</C> <E>will likely further increase the toxicity burden</E>. <A>For any systemic therapy/RT approach, close attention should be paid to published reports for the specific chemotherapy agent, dose, and schedule of administration</A>. <A>Systemic therapy/RT should be performed by an experienced team and should include substantial supportive care</A>.\\n\\nSection Name: PRINCIPLES OF RADIATION THERAPY\\n====================\\nEntities:-\\nRadiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.\\nPlanning Target Volume : A volume that includes the gross tumor volume and a margin to account for tumor motion and setup variations.\\nIntensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.\\nProton Therapy : The use of a beam of protons to irradiate diseased tissue, most often in the treatment of cancer.\\n\\nRelationships:-\\n1. Entity1: \""RT Alone\"", Entity2: \""PTV\"", Relationship: \""involves\""\\n2. Entity1: \""Concurrent Systemic Therapy/RT\"", Entity2: \""IMRT\"", Relationship: \""involves\""\\n3. Entity1: \""Proton Therapy\"", Entity2: \""Photon-based Therapy\"", Relationship: \""alternative to\""\\n\\nCausalities:-\\n1. **DEFINITIVE: RT Alone**\\n   - T1\u20133, N0\u20131: 66\u201370 Gy conventional (2.0 Gy/fraction)\\n   - **PTV**\\n     - <CO> High risk </CO>: <A> Primary tumor and involved lymph nodes [this includes possible local subclinical infiltration at the primary site and at the high-risk level lymph node(s)] </A>\\n       - <A> Fractionation: 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction); daily Monday\u2013Friday in 6\u20137 weeks </A>\\n     - <A> Concomitant boost accelerated RT: </A>\\n       - <A> 72 Gy/6 weeks (1.8 Gy/fraction, large field; 1.5 Gy boost as second daily fraction during last 12 treatment days) </A>\\n       - <A> 66\u201370 Gy (2.0 Gy/fraction; 6 fractions/wk accelerated) </A>\\n     - <A> Hyperfractionation: 79.2\u201381.6 Gy/7 weeks (1.2 Gy/fraction twice daily) </A>\\n     - <CO> Low to intermediate risk </CO>: <A> Sites of suspected subclinical spread </A>\\n       - <A> 44\u201350 Gy (2.0 Gy/fraction) to 54\u201363 Gy (1.6\u20131.8 Gy/fraction) </A>\\n\\n2. **CONCURRENT SYSTEMIC THERAPY/RT:**\\n   - **PTV**\\n     - <CO> High risk </CO>: <A> Typically 70 Gy (2.0 Gy/fraction) </A>\\n     - <CO> Low to intermediate and low risk </CO>: <A> 44\u201350 Gy (2.0 Gy/fraction) to 54\u201363 Gy (1.6\u20131.8 Gy/fraction) </A>\\n   - <A> Either IMRT (preferred) or 3D-CRT is recommended. </A> <CO> Use of proton therapy is an area of active investigation. </CO> <A> Proton therapy may be considered </A> <CO> when normal tissue constraints cannot be met by photon-based therapy, or when photon-based therapy causes compromise of standard radiation dosing to tumor or postoperative volumes. </CO>\\n'}""",valid,increases risk,2,B,"edge - The edge which needs to be verified.
explanation - Explanation of what the edge represents and its validity.
causal_direction - Either Positive or Negative or Unknown. A positive influence direction indicates that both factors change in the same direction (e.g. an increase causes an increase effect). A negative influence direction indicates the opposite changes (e.g. an increase causes a decrease effect).
causal_factor - Is necessary or sufficient condition for an effect to occur. Exposure is a term commonly used in epidemiology to denote any condition that is considered as a possible cause of disease. Exposure is considered necessary when it always precedes the effects (e.g. symptoms) and always presents when the effects occur. A sufficient cause is a causal factor whose presence or occurrence guarantees the occurrence of symptom.
causal_distance - Either Distal or Proximal or Unknown. The distal factors lie towards the beginning of causal chain (i.e. indirect causal factors). The the proximal factors lie towards the end of the chain (i.e. cause directly or almost directly the effect).

Causality Tags:
<A> for action, <C> for cause, <CO> for condition and <E> for effect.
Cause (C): The reason or origin that leads to an effect. Causes often involve disease conditions, risk factors, or underlying mechanisms.
Effect (E): The outcome or result of a cause. Effects usually represent clinical outcomes, complications, or results of a specific cause.
Condition (CO): The circumstance or prerequisite required for an action or effect to occur. Conditions may include patient characteristics, clinical scenarios, or specific diagnostic criteria.
Action (A): The recommended or described response or activity to address a cause or condition. Actions typically involve clinical interventions, diagnostic procedures, or treatment recommendations.


`NODE1`:
id: N_Staging_1
label: Nearby Lymph Nodes Cancer Staging
description: This node represents the staging of cancer in nearby lymph nodes, which is a critical factor in determining the extent of cancer spread and guiding treatment decisions. The staging helps in assessing the prognosis and planning the appropriate therapeutic approach.
type: Decision Node
observability: Needs to be Predicted
states: [{'state_name': 'present', 'state_description': 'Cancer is present in the nearby lymph nodes, indicating that the cancer has spread beyond the primary site. This is an important factor in staging and affects treatment decisions and prognosis.'}, {'state_name': 'absent', 'state_description': 'Cancer is absent in the nearby lymph nodes, suggesting that the cancer has not spread to these nodes. This is a favorable sign and influences the staging and treatment plan.'}]

`NODE2`:
id: Lymph_Node_Ratio_6
label: Lymph Node Ratio Category
description: This node represents a specific category or threshold of the ratio of affected lymph nodes in a patient, which is used to assess the extent of lymphatic involvement in a disease process.
type: Patient Situation
observability: Unobserved
states: [{'state_name': 'present', 'state_description': ""The 'present' state indicates that the lymph node ratio falls within category 6, suggesting a significant level of lymphatic involvement.""}, {'state_name': 'absent', 'state_description': ""The 'absent' state indicates that the lymph node ratio does not fall within category 6, suggesting a lower level of lymphatic involvement.""}]

`EDGE1`:
{'edges_ids': ['N_Staging_1', 'Lymph_Node_Ratio_6'], 'edge': '(N_Staging_1) causes (Lymph_Node_Ratio_6)', 'explanation': ['The edge `(N_Staging_1) causes (Lymph_Node_Ratio_6)` is valid because the staging of cancer in nearby lymph nodes (N_Staging_1) is directly related to the lymph node ratio (Lymph_Node_Ratio_6).', 'If cancer is present in the nearby lymph nodes, it indicates a higher level of lymphatic involvement, which would likely result in a higher lymph node ratio, thus falling into category 6.', 'The causal direction is positive because the presence of cancer in lymph nodes would increase the lymph node ratio.', 'The causal factor is neither necessary nor sufficient because other factors can influence the lymph node ratio, and the presence of cancer does not guarantee a specific ratio category.', 'The causal distance is proximal because the staging of cancer in lymph nodes is directly related to the lymph node ratio.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': False}, 'causal_distance': 'Proximal'}

`EDGE2`:
{'edges_ids': ['Lymph_Node_Ratio_6', 'N_Staging_1'], 'edge': '(Lymph_Node_Ratio_6) causes (N_Staging_1)', 'explanation': ['The edge `(Lymph_Node_Ratio_6) causes (N_Staging_1)` is valid because the lymph node ratio is a direct measure of lymphatic involvement, which is a key factor in cancer staging.', 'Lymph_Node_Ratio_6 represents a significant level of lymphatic involvement, which would directly influence the N staging of cancer in nearby lymph nodes.', 'The causal direction is positive because an increase in lymph node ratio (more involvement) would likely lead to a higher N stage (more advanced cancer spread).', 'The causal factor is not necessary because other factors can influence N staging, but it might be sufficient if a high lymph node ratio guarantees a certain N stage.', 'The causal distance is proximal because the lymph node ratio directly affects the staging of cancer in the lymph nodes.'], 'causal_direction': 'positive', 'causal_factor': {'necessary': False, 'sufficient': True}, 'causal_distance': 'Proximal'}

`INFORMATION FROM KNOWLEDGE BASE`:
--------------------------------------------------
Page Number: 130

Section Name: Pathological N (pN)
====================
Entities:-
Lymph Nodes : Small, bean-shaped structures that are part of the body's lymphatic system. They filter lymph fluid and store white blood cells that help fight infection.
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Tnm Staging : A system used to describe the size and spread of cancer in a standardized way. T refers to the size of the tumor, N to the involvement of lymph nodes, and M to metastasis.
Lymph Node Structure : A structure that is part of the lymphatic system, involved in the immune response.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.
Lymph Node : An organ of the lymphatic system and the adaptive immune system.

Relationships:-
1. Entity1: ""Lymph Nodes"", Entity2: ""Neoplasm Metastasis"", Relationship: ""involved in""
2. Entity1: ""TNM Staging"", Entity2: ""Lymph Nodes"", Relationship: ""includes""
3. Entity1: ""TNM Staging"", Entity2: ""Neoplasm Metastasis"", Relationship: ""describes""

Causalities:-
<CO> NX: Regional lymph nodes cannot be assessed </CO>
<CO> N0: No regional lymph node metastasis </CO>
<CO> N1: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(–) </CO>
<CO> N2: Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2a: Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2b: Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N2c: Metastases in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−); or metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> N3a: Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−) </CO>
<CO> N3b: Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral lymph nodes any with ENE(+); or a single contralateral node of any size and ENE(+) </CO>
<CO> Note: A designation of “U” or “L” may be used for any N category to indicate metastasis above the lower border of the cricoid (U) or below the lower border of the cricoid (L). Similarly, clinical and pathological ENE should be recorded as ENE(−) or ENE(+). </CO>

Section Name: Distant Metastasis (M)
====================
Entities:-
Neoplasm Metastasis : The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Metastasis : The spread of a cancer or other disease from one organ or part to another not directly connected with it.

Relationships:-
1. Entity1: ""M0"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""
2. Entity1: ""M1"", Entity2: ""Distant Metastasis"", Relationship: ""is a category of""

Causalities:-
### Distant Metastasis (M)

- **M0**: No distant metastasis
- **M1**: Distant metastasis

Section Name: Histologic Grade (G)
====================
Entities:-
Neoplasm Grading : A system of classifying cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread.
Histologic Grade : A measure of how much tumor cells differ from healthy cells, used to assess the aggressiveness of cancer.

Relationships:-
1. Entity1: ""GX"", Entity2: ""Grade cannot be assessed"", Relationship: ""is described as""
2. Entity1: ""G1"", Entity2: ""Well differentiated"", Relationship: ""is described as""
3. Entity1: ""G2"", Entity2: ""Moderately differentiated"", Relationship: ""is described as""
4. Entity1: ""G3"", Entity2: ""Poorly differentiated"", Relationship: ""is described as""

Causalities:-
<CO>GX</CO>: <E>Grade cannot be assessed</E>
<CO>G1</CO>: <E>Well differentiated</E>
<CO>G2</CO>: <E>Moderately differentiated</E>
<CO>G3</CO>: <E>Poorly differentiated</E>

Section Name: Prognostic Stage Groups
====================
Entities:-
Neoplasm Staging : Methods and systems of classifying neoplasms according to extent of disease.
Tumor Staging : A system for describing the size and spread of cancer within the body.
Tnm Staging System : A cancer staging notation system that describes the extent of cancer in a patient's body.

Relationships:-
1. Entity1: ""Stage 0"", Entity2: ""Tis N0 M0"", Relationship: ""defined by""
2. Entity1: ""Stage I"", Entity2: ""T1 N0 M0"", Relationship: ""defined by""
3. Entity1: ""Stage II"", Entity2: ""T2 N0 M0"", Relationship: ""defined by""
4. Entity1: ""Stage III"", Entity2: ""T3 N0 M0, T1 N1 M0, T2 N1 M0, T3 N1 M0"", Relationship: ""defined by""
5. Entity1: ""Stage IVA"", Entity2: ""T1 N2 M0, T2 N2 M0, T3 N2 M0, T4a N0,N1,N2 M0"", Relationship: ""defined by""
6. Entity1: ""Stage IVB"", Entity2: ""Any T N3 M0, T4b Any N M0"", Relationship: ""defined by""
7. Entity1: ""Stage IVC"", Entity2: ""Any T Any N M1"", Relationship: ""defined by""
--------------------------------------------------
Page Number: 102

Section Name: Head and Neck Cancers - Principles of Surgery
====================
Entities:-
Surgical Procedures, Operative : Manual or operative procedures used in the treatment of disease, injuries, or deformities.
Lymphatic System : Part of the circulatory system and a vital part of the immune system, comprising a network of lymphatic vessels that carry a clear fluid called lymph.
Neoplasms : New abnormal growth of tissue in animals or plants; a tumor.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Neoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Surgical Procedure : A procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Lymphatic Structure : Anatomical structure that is part of the lymphatic system.
Tumor : An abnormal mass of tissue that results when cells divide more than they should or do not die when they should.
Staging : The process of determining the size and spread of cancer within the body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as disease or injury.
Cancer Staging : The process of determining the extent to which a cancer has developed by growing and spreading.

Relationships:-
1. Entity1: ""surgical management"", Entity2: ""regional lymphatics"", Relationship: ""dictated by tumor staging""
2. Entity1: ""neck dissections"", Entity2: ""primary tumor"", Relationship: ""part of treatment""
3. Entity1: ""surgery"", Entity2: ""ipsilateral side of the neck"", Relationship: ""risk for metastases""

Causalities:-
<C> The extent of the tumor at initial tumor staging </C> <E> dictates the surgical management of regional lymphatics </E>. These guidelines apply to the performance of neck dissections as part of treatment of the primary tumor. <CO> Patients undergoing surgery for resection of the primary tumor </CO> <A> will undergo dissection of the ipsilateral side of the neck that is at greatest risk for metastases </A>.

Section Name: Neck Management
====================
Entities:-
Tongue : A muscular organ in the mouth that is involved in tasting, swallowing, and speech.
Palate : The roof of the mouth, separating the oral and nasal cavities.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.
Hypopharynx : The bottom part of the pharynx, which is the cavity behind the nose and mouth.
Nasopharynx : The upper part of the pharynx, connecting with the nasal cavity above the soft palate.
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Metastasis : The spread of a cancer or other disease from one organ or part of the body to another not directly connected with it.
Squamous Cell Carcinoma : A type of cancer that begins in the squamous cells, which are thin, flat cells that look like fish scales.
Biopsy : The removal of cells or tissues for examination under a microscope.

Relationships:-
1. Entity1: ""Tumor sites"", Entity2: ""Bilateral lymphatic drainage"", Relationship: ""associated with""
2. Entity1: ""Elective neck dissection"", Entity2: ""Risk of occult metastasis"", Relationship: ""based on""
3. Entity1: ""SLN biopsy"", Entity2: ""Elective neck dissection"", Relationship: ""guides decision-making for""

Causalities:-
- **<C> Tumor sites that frequently have bilateral lymphatic drainage </C>** (e.g., base of tongue, palate, supraglottic larynx, hypopharynx, nasopharynx, deep pre-epiglottic space involvement) <E> often should have both sides of the neck dissected </E> with the extent of dissection determined as suggested below. For those patients with tumors at or approaching the midline, <CO> both sides of the neck are at risk for metastases </CO>, and <A> bilateral neck dissections should be performed </A>.

- <CO> Patients with advanced lesions involving the anterior tongue, floor of the mouth, or alveolus that approximate or cross the midline </CO> <A> should undergo contralateral selective/modified neck dissection </A> as necessary to achieve adequate tumor resection.

- **<C> Elective neck dissection </C>** <A> should be based on risk of occult metastasis in the appropriate nodal basin </A>. For oral cavity squamous cell carcinoma, <C> SLN biopsy or the primary tumor depth of invasion </C> is currently <E> the best predictor of occult metastatic disease </E> and <A> should be used to guide decision-making </A>. <CO> For tumors with a depth greater than 3 mm </CO>, <A> elective dissection should be strongly considered if RT is not already planned </A>. Recent randomized trial evidence supports the effectiveness of elective neck dissection in patients with oral cavity cancers greater than 3 mm in depth of invasion.

  - <CO> For a depth less than 2 mm </CO>, <A> elective dissection is only indicated in highly selective situations </A>. <CO> For a depth of 2–4 mm </CO>, <A> clinical judgment (as to reliability of follow-up, clinical suspicion, and other factors) must be utilized to determine appropriateness of elective dissection </A>. Elective dissections are generally selective, preserving all major structures, unless operative findings dictate otherwise.

Section Name: Types of Neck Dissection
====================
Entities:-
Neck Dissection : A surgical procedure for control of neck lymph node metastasis from squamous cell carcinoma of the head and neck.
Larynx : An organ in the top of the neck involved in breathing, producing sound, and protecting the trachea.

Relationships:-
1. Entity1: ""N0"", Entity2: ""Selective neck dissection"", Relationship: ""associated with""
2. Entity1: ""N3"", Entity2: ""Comprehensive neck dissection"", Relationship: ""associated with""
3. Entity1: ""Level VI neck dissection"", Entity2: ""Larynx"", Relationship: ""performed for""
4. Entity1: ""Level VI neck dissection"", Entity2: ""Hypopharynx"", Relationship: ""performed for""

Causalities:-
- **The type of neck dissection (comprehensive or selective)** is defined according to <CO> preoperative clinical staging </CO>, is determined at the discretion of the surgeon, and is based on the initial preoperative staging as follows:
  - **N0:** <A> Selective neck dissection </A>
    - Oral cavity at least levels I–III
    - Oropharynx at least levels II–IV
    - Hypopharynx at least levels II–IV and level VI when appropriate
    - Larynx at least levels II–IV and level VI when appropriate
  - **N1–N2a–c:** <A> Selective or comprehensive neck dissection </A> (Discussion)
  - **N3:** <A> Comprehensive neck dissection </A>

- <C> Level VI neck dissections are performed for certain primary sites (such as the larynx and hypopharynx) </C> <E> as required to resect the primary tumor and any clinically evident neck nodes </E>. <CO> Elective dissection depends on primary tumor extent and site </CO>. <CO> For advanced glottic and hypopharyngeal cancers treated with primary surgery </CO>, <A> a level VI dissection (including pretracheal lymph nodes, the Delphian lymph node, and unilateral or bilateral paratracheal lymph nodes) and hemithyroidectomy to total thyroidectomy are appropriate </A>.

- <CO> For primary subglottic tumors or glottic cancers with significant subglottic extension </CO>, <A> a level VI dissection with unilateral or total thyroidectomy is considered appropriate </A> based on the extent of the primary tumor. <CO> For example, a T4a glottic tumor with extension through the cricothyroid membrane and subglottic extension </CO> <A> should include thyroidectomy and pretracheal and bilateral paratracheal lymph node dissection </A>. <A> Parathyroid glands should be preserved in situ or auto transplanted as indicated </A>.
--------------------------------------------------
Page Number: 51

Section Name: Introduction
====================
Entities:-
Laryngeal Neoplasms : Tumors or cancer of the larynx, which may affect the supraglottic, glottic, or subglottic regions.
Malignant Neoplasm Of Supraglottis : A malignant tumor located in the supraglottic region of the larynx.
Supraglottic Laryngeal Cancer : A type of cancer that occurs in the supraglottic region of the larynx, which is above the vocal cords.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network (NCCN)"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""provides guidelines for""
2. Entity1: ""healthcare professionals"", Entity2: ""cancer of the supraglottic larynx"", Relationship: ""manage""

Causalities:-
The provided image is a detailed flowchart from the National Comprehensive Cancer Network (NCCN) guidelines regarding the <C> clinical staging and treatment protocols for cancer of the supraglottic larynx </C>. This flowchart is structured to <A> guide healthcare professionals through the stages of treatment </A> based on <CO> clinical findings </CO>, emphasizing the <E> complexity and systematic approach required in managing this type of cancer </E>.

Section Name: Clinical Staging
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Total Laryngectomy : A surgical procedure to remove the entire larynx, often used in the treatment of advanced laryngeal cancer.
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Cancer Staging : The process of determining the extent of cancer in the body, often using the TNM system.
Tnm Staging System : A cancer staging system that describes the extent of cancer using Tumor size (T), Node involvement (N), and Metastasis (M).

Relationships:-
1. Entity1: ""Clinical staging criteria"", Entity2: ""Total laryngectomy"", Relationship: ""determines necessity of""
2. Entity1: ""T3, N0"", Entity2: ""Clinical staging criteria"", Relationship: ""is a categorization of""

Causalities:-
The flowchart begins with the <C> clinical staging criteria </C>, specifically focusing on <CO> cases that require total laryngectomy, denoted as requiring (amenable to) total laryngectomy (T3, N0) </CO>. This <A> categorization </A> is crucial as it <E> forms the basis for determining the appropriate treatment strategy </E>.

Section Name: Treatment of Primary and Neck
====================
Entities:-
Neoplasm Staging : Methods used for staging neoplasms, including clinical and pathological staging.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Lymphatic Metastasis : Transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Radiation Therapy"", Relationship: ""combined with""
2. Entity1: ""Laryngectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
3. Entity1: ""Thyroidectomy"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""
4. Entity1: ""Neck Dissection"", Entity2: ""Lymph Node Involvement"", Relationship: ""considered based on""

Causalities:-
<CO> Once clinical staging is established </CO>, the chart outlines various treatment options. <A> The initial step may involve either concurrent systemic therapy combined with radiation therapy (RT) or opting for RT alone </A>, <CO> especially if the patient is not a medical candidate for both therapies </CO>. <A> Laryngectomy, thyroidectomy, and neck dissection are considered </A> <CO> based on the extent of lymph node involvement </CO>.

Section Name: Surgical Options
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Lymph Node Excision : Surgical removal of one or more lymph nodes.
Lymphadenectomy : Surgical removal of one or more groups of lymph nodes.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.

Relationships:-
1. Entity1: ""Laryngectomy"", Entity2: ""Thyroidectomy"", Relationship: ""combined with""
2. Entity1: ""Lymph Node Dissection"", Entity2: ""Surgical Intervention"", Relationship: ""extent of""
3. Entity1: ""Surgical Intervention"", Entity2: ""Advanced Cases"", Relationship: ""management option for""

Causalities:-
<CO> If concurrent therapies are not suitable </CO>, <A> the chart presents laryngectomy combined with thyroidectomy </A>, <CO> depending on the extent of lymph node dissection required </CO>. <E> This highlights surgical intervention as a viable option in the management of advanced cases </E>.

Section Name: Induction Chemotherapy
====================
Entities:-
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Therapeutic Approach : A method or strategy used in the treatment of disease or injury.

Relationships:-
1. Entity1: ""Induction Chemotherapy"", Entity2: ""Surgical Intervention"", Relationship: ""alternative or sequential treatment option""

Causalities:-
<C> immediate surgical intervention is either not feasible or considered insufficient </C> <E> The flowchart also considers the option of induction chemotherapy </E> <CO> in cases where immediate surgical intervention is either not feasible or considered insufficient </CO>. <A> tailoring therapeutic approaches tailored to individual patient needs </A>.

Section Name: Adjuvant Treatment
====================
Entities:-
Adjuvant Chemotherapy : Chemotherapy given in addition to the primary treatment to maximize its effectiveness.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Neoplasm Recurrence, Local : The return of a cancer, at the same site, after it has been treated.
Disease Progression : The worsening of a disease over time.

Relationships:-
1. Entity1: ""Primary Treatment"", Entity2: ""Adjuvant Treatment"", Relationship: ""followed by""
2. Entity1: ""Adjuvant Treatment"", Entity2: ""Systemic Therapy"", Relationship: ""includes""
3. Entity1: ""Adjuvant Treatment"", Entity2: ""Radiotherapy"", Relationship: ""includes""
4. Entity1: ""Follow-up Assessments"", Entity2: ""Treatment Efficacy"", Relationship: ""used to evaluate""

Causalities:-
<C> Following primary treatment </C>, <E> the flowchart addresses the potential for adjuvant treatment pathways </E>. This may include systemic therapy, RT, or further evaluations based on <CO> the patient's response and any recurrence or persistent disease </CO>. It emphasizes <A> the need for follow-up assessments to evaluate treatment efficacy </A>.

Section Name: Risk Features and Response Assessment
====================
Entities:-
Neoplasm Invasiveness : The property of a neoplasm to infiltrate and destroy surrounding tissue.
Surgical Margins : The edge or border of the tissue removed in cancer surgery.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Extramural Extension : Extension of a tumor beyond the wall of an organ.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Cancer Management : The process of planning and coordinating the treatment of cancer.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""Extramural extension"", Entity2: ""Treatment decisions"", Relationship: ""influences""
2. Entity1: ""Positive surgical margin"", Entity2: ""Treatment decisions"", Relationship: ""influences""
3. Entity1: ""Ongoing assessment"", Entity2: ""Response evaluation"", Relationship: ""leads to""
4. Entity1: ""Response evaluation"", Entity2: ""Adjustments to treatment"", Relationship: ""leads to""
5. Entity1: ""Management of cancer"", Entity2: ""Treatment decisions"", Relationship: ""involves""
6. Entity1: ""Management of cancer"", Entity2: ""Ongoing assessment"", Relationship: ""involves""
7. Entity1: ""Management of cancer"", Entity2: ""Adjustments to treatment"", Relationship: ""involves""

Causalities:-
The chart incorporates a segment that takes into account <CO> adverse pathologic features, such as extramural extension or positive margins </CO>, <E> which could influence subsequent treatment decisions </E>. This highlights the importance of <A> ongoing assessment in the management of cancer, leading to response evaluation and adjustments to treatment as necessary </A>.

Section Name: NCCN Guidelines Version 4.2024
====================
Entities:-
Clinical Trials : Clinical trials are research studies performed in people that are aimed at evaluating a medical, surgical, or behavioral intervention.
Neoplasms : Neoplasms are abnormal growths of tissue, which can be cancerous or non-cancerous.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Malignant Neoplasm : A malignant neoplasm is a cancerous growth that has the potential to invade and destroy nearby tissue and spread to other parts of the body.
National Comprehensive Cancer Network : The National Comprehensive Cancer Network (NCCN) is an alliance of 31 cancer centers in the United States, dedicated to improving the quality, effectiveness, and efficiency of cancer care.
Cancer : Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.

Relationships:-
1. Entity1: ""National Comprehensive Cancer Network"", Entity2: ""NCCN Guidelines"", Relationship: ""provides""
2. Entity1: ""NCCN Guidelines"", Entity2: ""Clinical Trials"", Relationship: ""recommend""
3. Entity1: ""NCCN Guidelines"", Entity2: ""Cancer"", Relationship: ""related to management of""

Causalities:-
<CO> any patient with cancer </CO> <A> the best management is in a clinical trial </A>. <A> Participation in clinical trials is especially encouraged </A>.

Section Name: SUPRA-3
====================
Entities:-
Laryngectomy : A surgical procedure involving the removal of the larynx, usually to treat cancer of the larynx.
Thyroidectomy : A surgical procedure to remove all or part of the thyroid gland.
Neck Dissection : Surgical procedure to remove lymph nodes and surrounding tissue to treat or prevent cancer spread.
Chemotherapy, Induction : Initial chemotherapy treatment to shrink a tumor before the main treatment.
Clinical Trials As Topic : Research studies that prospectively assign human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.
Induction Chemotherapy : Initial chemotherapy treatment used to shrink a tumor before the main treatment, which is usually surgery.
Clinical Trial : A clinical trial is a research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.

Relationships:-
1. Entity1: ""Total laryngectomy"", Entity2: ""Laryngectomy"", Relationship: ""is a type of""
2. Entity1: ""Systemic therapy"", Entity2: ""RT"", Relationship: ""concurrent treatment option""
3. Entity1: ""Induction chemotherapy"", Entity2: ""Other treatments"", Relationship: ""initial treatment option before""

Causalities:-
<CO> Requiring (amenable to) total laryngectomy (T3,N0) </CO>
  - <A> Concurrent systemic therapy/RT </A> or <A> RT if patient not medical candidate for concurrent systemic therapy/RT </A>
  - <A> Laryngectomy, thyroidectomy and with ipsilateral, central, or bilateral neck dissection </A>
  - or
  - <A> Induction chemotherapy </A>
  - or
  - <A> Clinical trials </A>

Section Name: Follow-up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Follow-Up Procedure : A procedure performed to monitor the progress of a patient's condition after initial treatment.
Follow-Up : Medical care given to a patient over time after initial treatment.
Disease Recurrence : The return of a sign, symptom, or disease after a remission.
Recurrent Disease : The reappearance of a disease after a period of improvement.

Relationships:-
1. Entity1: ""Follow-up"", Entity2: ""Recurrent or persistent disease"", Relationship: ""monitoring""

Causalities:-
- **Follow-up (FOLL-A, 1 of 2)**
  - <CO> Recurrent or persistent disease </CO> (ADV-3)

Section Name: Adverse Pathologic Features
====================
Entities:-
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Extranodal Extension : The spread of cancer beyond the lymph node capsule.
Positive Surgical Margin : Cancer cells are present at the edge of the tissue removed during surgery.
Systemic Therapy : Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""pN1"", Entity2: ""Radiotherapy"", Relationship: ""Consideration for treatment""
2. Entity1: ""Extranodal extension"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
3. Entity1: ""Extranodal extension"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""
4. Entity1: ""Positive surgical margin"", Entity2: ""Systemic Therapy"", Relationship: ""Treatment option""
5. Entity1: ""Positive surgical margin"", Entity2: ""Radiotherapy"", Relationship: ""Treatment option""

Causalities:-
- <CO>pN1 without other risk features</CO>
  - <C>Adverse pathologic features</C>
  - <A>Consider RT</A>
  - <CO>Extranodal extension and/or positive margin</CO>
  - <CO>Other risk features</CO>
  - <A>Systemic therapy/RT (category 1)</A>
  - <A>RT or Consider systemic therapy/RT</A>

Section Name: Response Assessment
====================
Entities:-
Response Evaluation : The process of assessing the response of a disease to treatment, often used in clinical trials to determine the effectiveness of a therapy.
Response To Treatment : A clinical finding indicating the response of a condition to a therapeutic intervention.

Relationships:-

Section Name: Principles of Surgery and Radiation Therapy
====================
Entities:-
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Surgical Procedure : A medical procedure involving an incision with instruments; performed to repair damage or arrest disease in a living body.
Surgery : Medical specialty that uses operative manual and instrumental techniques on a patient to investigate or treat a pathological condition such as a disease or injury.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Principles of Surgery"", Entity2: ""Principles of Radiation Therapy"", Relationship: ""complementary treatments""

Causalities:-
**Principles of Surgery (SURG-A).**

**Principles of Radiation Therapy (SUPRA-A).**

Section Name: Principles of Systemic Therapy
====================
Entities:-
Cisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.
Radiotherapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Radiation Therapy : Radiation therapy is a therapy using ionizing radiation, generally as part of cancer treatment to control or kill malignant cells.

Relationships:-
1. Entity1: ""Cisplatin"", Entity2: ""Systemic Therapy for Non-Nasopharyngeal Cancers"", Relationship: ""preferred agent""
2. Entity1: ""Cisplatin"", Entity2: ""Concurrent Systemic Therapy/RT"", Relationship: ""used in""

Causalities:-
<CO> When using concurrent systemic therapy/RT </CO>, <A> the preferred agent is cisplatin (category 1) </A>.
--------------------------------------------------
Page Number: 42

Section Name: Clinical Staging
====================
Entities:-
Carcinoma In Situ : A lesion with cytological characteristics of cancer but which has not invaded the basement membrane.
Larynx : An organ in the neck involved in breathing, sound production, and protecting the trachea against food aspiration.
Neoplasm Staging : Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Tumor Staging : The process of determining the extent of spread of a tumor.
Cancer Staging : The process of determining the extent to which a cancer has developed by growing and possibly spreading.

Relationships:-
1. Entity1: ""Carcinoma in situ"", Entity2: ""larynx-preserving surgery"", Relationship: ""progression to determine suitability""
2. Entity1: ""nodal disease"", Entity2: ""glottic tumors"", Relationship: ""rare occurrence""

Causalities:-
<C>Carcinoma in situ</C> and progresses to <A>determine the amenability of the patient to larynx-preserving surgery</A>, specifically <CO>for tumors classified as T1 to T2, N0, or select T3, N0</CO>. This initial assessment is critical as it <E>drives treatment decisions</E>. In SOURCE2, it is noted that <C>nodal disease in such glottic tumors</C> <E>is rare</E>.

Section Name: Treatment of Primary and Neck
====================
Entities:-
Endoscopic Surgical Procedures : Surgery performed with the aid of an endoscope, which is a medical device with a light attached. It is used to look inside a body cavity or organ.
Radiotherapy : The use of ionizing radiation to treat cancer.
Laryngectomy, Partial : Surgical removal of part of the larynx.
Neck Dissection : Surgical procedure for control of neck lymph node metastasis.
Neoplasms : An abnormal mass of tissue as a result of neoplasia. Neoplasia is the abnormal proliferation of cells.

Relationships:-
1. Entity1: ""Condition"", Entity2: ""Endoscopic Resection"", Relationship: ""preferred treatment""
2. Entity1: ""Condition"", Entity2: ""Radiation Therapy"", Relationship: ""alternative treatment""
3. Entity1: ""Condition"", Entity2: ""Partial Laryngectomy"", Relationship: ""alternative treatment""
4. Entity1: ""Condition"", Entity2: ""Neck Dissection"", Relationship: ""part of extensive treatment""

Causalities:-
<CO>If the condition allows for larynx-preserving options</CO>, the <A>preferred treatment is endoscopic resection or radiation therapy (RT)</A>. Alternative <A>options include partial laryngectomy or a more extensive endoscopic/open resection with neck dissection</A>, <CO>depending on the specific characteristics of the tumor</CO>. SOURCE2 specifies that <A>endoscopic resection is preferred</A>, and <A>RT or partial laryngectomy/endoscopic or open resection is indicated as needed</A>.

Section Name: Adjuvant Treatment
====================
Entities:-
Adjuvant Therapy : Treatment given in addition to the primary (main) treatment to enhance its effectiveness.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.
Pathologic Processes : The abnormal mechanisms and forms involved in the dysfunctions of tissues and organs.
Extranodal Extension : The spread of cancer beyond the lymph node capsule into the surrounding tissues.
Positive Surgical Margins : The presence of cancer cells at the edge of the tissue removed during surgery, indicating that some cancer may have been left behind.
Radiation Therapy : The use of high-energy radiation to kill cancer cells and shrink tumors.

Relationships:-
1. Entity1: ""Adjuvant Treatment"", Entity2: ""Surgical Intervention"", Relationship: ""follows""
2. Entity1: ""Adjuvant Treatment"", Entity2: ""Adverse Pathologic Features"", Relationship: ""depends on""
3. Entity1: ""Extranodal Extension"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
4. Entity1: ""Positive Margins"", Entity2: ""Adverse Pathologic Features"", Relationship: ""is a type of""
5. Entity1: ""Systemic Therapy"", Entity2: ""Adjuvant Treatment"", Relationship: ""is a component of""
6. Entity1: ""Radiation"", Entity2: ""Adjuvant Treatment"", Relationship: ""is a component of""

Section Name: Follow-Up
====================
Entities:-
Follow-Up Studies : Studies in which individuals are followed over time to determine the outcome of exposures, treatments, or interventions.
Neoplasm Recurrence, Local : The return of a tumor at the original site after treatment.
Disease Progression : The worsening of a disease over time.
Observation : The act of noting and recording an event, characteristic, or behavior.
Antineoplastic Agents : Drugs used to treat cancer.
Radiotherapy : The use of ionizing radiation to treat cancer.
Surgical Procedures, Operative : Operations carried out for the correction of deformities and defects, repair of injuries, and diagnosis and cure of certain diseases.

Relationships:-
1. Entity1: ""Follow-Up"", Entity2: ""recurrence"", Relationship: ""monitoring""
2. Entity1: ""Follow-Up"", Entity2: ""persistent disease"", Relationship: ""monitoring""
3. Entity1: ""systemic therapy"", Entity2: ""recurrent or persistent disease"", Relationship: ""treatment option""
4. Entity1: ""RT"", Entity2: ""recurrent or persistent disease"", Relationship: ""treatment option""
5. Entity1: ""re-resection"", Entity2: ""recurrent or persistent disease"", Relationship: ""treatment option""

Causalities:-
<C> recurrence or persistent disease </C> <E> monitoring recurrence or persistent disease </E>. <A> follow-up strategies </A> are essential for <E> monitoring recurrence or persistent disease </E>. <A> continual assessment post-treatment </A> to <E> ensure any signs of recurrence are addressed promptly </E>. SOURCE2 mentions <A> observation, systemic therapy/RT, re-resection if feasible, and follow-up </A> for <CO> recurrent or persistent disease </CO>.
--------------------------------------------------
Page Number: 57

Section Name: Definitive Treatment
====================
Entities:-
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Neoplasm Staging : Methods used for staging neoplasms, including the TNM staging system.
Cancer Staging : A system of classifying cancer according to the extent of the disease.
Tnm Staging System : A cancer staging system that describes the extent of cancer in a patient's body.

Relationships:-
1. Entity1: ""Radiation Therapy"", Entity2: ""T1–3, N0–1"", Relationship: ""treats""
2. Entity1: ""Conventional RT"", Entity2: ""Radiation Therapy"", Relationship: ""is a type of""
3. Entity1: ""66 to 70 Gray (Gy)"", Entity2: ""Conventional RT"", Relationship: ""is the dosage for""

Causalities:-
The document begins by defining the definitive radiation therapy (RT) approach for <CO> patients classified as T1–3, N0–1, with a specific focus on high-risk patients </CO>. It suggests <A> a regimen involving conventional RT, particularly highlighting a total dose of 66 to 70 Gray (Gy) delivered in fractions of 2.0 Gy each </A>. The schedule emphasizes <A> daily treatments, indicating a typical 7-week plan </A>.

Section Name: Concurrent Therapy
====================
Entities:-
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Cisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.
Chemotherapy : The use of drugs to destroy cancer cells, usually by stopping the cancer cells’ ability to grow and divide.

Relationships:-
1. Entity1: ""Systemic Therapy"", Entity2: ""Radiation Therapy"", Relationship: ""used in combination with""
2. Entity1: ""Cisplatin"", Entity2: ""Systemic Therapy"", Relationship: ""is a type of""
3. Entity1: ""Cisplatin"", Entity2: ""Chemotherapy"", Relationship: ""part of""

Causalities:-
It further elaborates on concurrent systemic therapy in combination with radiation treatment. <CO> High-risk patients </CO> <E> may receive up to 70 Gy </E>, while <CO> those with lower risks </CO> <E> are advised to receive between 44 to 63 Gy </E>, <CO> depending on their specific case </CO>. This section <A> recommends careful consideration of systemic therapies like cisplatin, particularly every three weeks or in combination with pre-existing chemotherapy protocols </A>.

Section Name: Additional Techniques and Research
====================
Entities:-
Intensity-Modulated Radiotherapy : A type of conformal radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Intensity Modulated Radiation Therapy : A type of cancer treatment that uses beams of radiation of varying intensities to deliver a precise dose of radiation to a tumor.
Intensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Three-Dimensional Conformal Radiotherapy : A technique in radiotherapy that allows the radiation beams to be shaped to match the shape of the tumor.
3D Conformal Radiation Therapy : A type of radiation therapy that uses computer technology to create a 3-dimensional image of the tumor so that multiple radiation beams can be shaped exactly to the contour of the treatment area.
Proton Therapy : The use of a beam of protons to irradiate diseased tissue, most often in the treatment of cancer.
Toxicity : The degree to which a chemical substance or a particular mixture of substances can damage an organism.
Radiotherapy : The use of ionizing radiation to treat cancer and other diseases.
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.

Relationships:-
1. Entity1: ""Intensity-Modulated Radiation Therapy (IMRT)"", Entity2: ""3D-Conformal Radiation Therapy (3D-CRT)"", Relationship: ""preferred treatment modalities""
2. Entity1: ""Proton therapy"", Entity2: ""specific conditions"", Relationship: ""could be beneficial""
3. Entity1: ""treatment toxicity"", Entity2: ""radiation techniques"", Relationship: ""minimizing""
4. Entity1: ""ongoing research"", Entity2: ""radiation techniques"", Relationship: ""efficacy and safety""

Causalities:-
<A> The document suggests employing either Intensity-Modulated Radiation Therapy (IMRT) or 3D-Conformal Radiation Therapy (3D-CRT) as preferred treatment modalities </A>. It mentions that <A> proton therapy could be beneficial </A> <CO> under specific conditions </CO> and <A> stresses the importance of minimizing treatment toxicity </A>. <CO> This part indicates ongoing research into the efficacy and safety of various radiation techniques </CO>.

Section Name: Practical Recommendations
====================
Entities:-
Treatment Protocols : Treatment protocols are standardized procedures or plans of treatment for specific diseases or conditions.
Multidisciplinary Care : Multidisciplinary care involves the collaboration of professionals from various disciplines to provide comprehensive care.
Systemic Therapy : Systemic therapy refers to treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.

Relationships:-
1. Entity1: ""Treatment Protocols"", Entity2: ""Individual Patient Circumstances"", Relationship: ""tailored based on""
2. Entity1: ""Multidisciplinary Care"", Entity2: ""Treatment Planning"", Relationship: ""important for""
3. Entity1: ""Patient Management"", Entity2: ""Systemic Therapy"", Relationship: ""necessary due to complexity and risks""

Causalities:-
<A> practical recommendations for treatment sequencing </A>, emphasizing <A> a tailored approach </A> <CO> based on individual patient circumstances </CO>, and highlights <A> the importance of multi-disciplinary collaboration in treatment planning </A>. There’s an implicit suggestion for <A> careful patient management </A> <C> due to the complexity and risks of concurrent systemic therapies </C>.

Section Name: NCCN Guidelines Index
====================
Entities:-

Relationships:-

Causalities:-
- **Table of Contents**
- **Discussion**

Section Name: SUPRA-A 1 OF 2
====================
Entities:-
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Cisplatin : An inorganic and water-soluble platinum complex, cisplatin is an antineoplastic agent that is used in the treatment of various cancers.
Carboplatin : A platinum-containing antineoplastic agent used in the treatment of various cancers, similar to cisplatin but with a different toxicity profile.
Fluorouracil : A pyrimidine analog used as an antineoplastic agent, often in the treatment of cancers.
Chemotherapy, Adjuvant : Treatment given in addition to the primary (main) treatment to enhance its effectiveness, often used in cancer therapy.
Fractionation, Radiation : The division of the total dose of radiation into smaller doses delivered over a period of time.

Relationships:-
1. Entity1: ""Cisplatin"", Entity2: ""Concurrent Systemic Therapy/RT"", Relationship: ""used in""
2. Entity1: ""Carboplatin"", Entity2: ""5-FU"", Relationship: ""used with""
3. Entity1: ""Concurrent Systemic Therapy/RT"", Entity2: ""Non-Nasopharyngeal Cancers"", Relationship: ""treatment for""

Causalities:-
1. **See Principles of Radiation Techniques (RAD-A) and Discussion.**
2. <CO>For select T1–2, N0 tumors</CO>, <A>accelerated fractionation may be used</A>.
3. <CO>For doses >70 Gy</CO>, <A>some clinicians feel that the fractionation should be slightly modified (e.g., <2.0 Gy/fraction for at least some of the treatment)</A> <E>to minimize toxicity</E>. An additional 2–3 doses can be added depending on clinical circumstances.
4. <A>Suggest 44–50 Gy in 3D-CRT and sequentially planned IMRT or 54–63 Gy with IMRT dose painting technique</A> <CO>(dependent on dose per fraction)</CO>.
5. **Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A).**
6. <C>Based on published data</C>, <A>concurrent systemic therapy/RT most commonly uses conventional fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks with single-agent cisplatin given every 3 weeks at 100 mg/m²</A>; <CO>2–3 cycles of chemotherapy are used depending on the radiation fractionation scheme (RTOG)</CO>. <CO>When carboplatin and 5-FU are used</CO>, <A>the recommended regimen is standard fractionation plus 3 cycles of chemotherapy</A>. <A>Other fraction sizes, multiagent chemotherapy, other dosing schedules of cisplatin, or altered fractionation with chemotherapy are efficacious</A>, and <CO>there is no consensus on the optimal approach</CO>. <C>In general, the use of concurrent systemic therapy/RT</C> <E>carries a high toxicity burden</E>; <C>multiagent chemotherapy</C> <E>will likely further increase the toxicity burden</E>. <A>For any systemic therapy/RT approach, close attention should be paid to published reports for the specific chemotherapy agent, dose, and schedule of administration</A>. <A>Systemic therapy/RT should be performed by an experienced team and should include substantial supportive care</A>.

Section Name: PRINCIPLES OF RADIATION THERAPY
====================
Entities:-
Radiation Therapy : The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors.
Planning Target Volume : A volume that includes the gross tumor volume and a margin to account for tumor motion and setup variations.
Intensity-Modulated Radiation Therapy : An advanced type of high-precision radiotherapy that uses computer-controlled linear accelerators to deliver precise radiation doses to a malignant tumor or specific areas within the tumor.
Proton Therapy : The use of a beam of protons to irradiate diseased tissue, most often in the treatment of cancer.

Relationships:-
1. Entity1: ""RT Alone"", Entity2: ""PTV"", Relationship: ""involves""
2. Entity1: ""Concurrent Systemic Therapy/RT"", Entity2: ""IMRT"", Relationship: ""involves""
3. Entity1: ""Proton Therapy"", Entity2: ""Photon-based Therapy"", Relationship: ""alternative to""

Causalities:-
1. **DEFINITIVE: RT Alone**
   - T1–3, N0–1: 66–70 Gy conventional (2.0 Gy/fraction)
   - **PTV**
     - <CO> High risk </CO>: <A> Primary tumor and involved lymph nodes [this includes possible local subclinical infiltration at the primary site and at the high-risk level lymph node(s)] </A>
       - <A> Fractionation: 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction); daily Monday–Friday in 6–7 weeks </A>
     - <A> Concomitant boost accelerated RT: </A>
       - <A> 72 Gy/6 weeks (1.8 Gy/fraction, large field; 1.5 Gy boost as second daily fraction during last 12 treatment days) </A>
       - <A> 66–70 Gy (2.0 Gy/fraction; 6 fractions/wk accelerated) </A>
     - <A> Hyperfractionation: 79.2–81.6 Gy/7 weeks (1.2 Gy/fraction twice daily) </A>
     - <CO> Low to intermediate risk </CO>: <A> Sites of suspected subclinical spread </A>
       - <A> 44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </A>

2. **CONCURRENT SYSTEMIC THERAPY/RT:**
   - **PTV**
     - <CO> High risk </CO>: <A> Typically 70 Gy (2.0 Gy/fraction) </A>
     - <CO> Low to intermediate and low risk </CO>: <A> 44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </A>
   - <A> Either IMRT (preferred) or 3D-CRT is recommended. </A> <CO> Use of proton therapy is an area of active investigation. </CO> <A> Proton therapy may be considered </A> <CO> when normal tissue constraints cannot be met by photon-based therapy, or when photon-based therapy causes compromise of standard radiation dosing to tumor or postoperative volumes. </CO>


Among these two options which one is the most likely true:

(A) `N_Staging_1` increases risk `Lymph_Node_Ratio_6`
(B) `Lymph_Node_Ratio_6` `increases risk `N_Staging_1`

The answer is: ...

1. State the evidences in detail of the validity of option (A) or (B) by cross referencing
NCCN Clinical Practitioner’s Guidelines for Head and Neck Cancer.
2. If the evidences are obtained from `INFORMATION FROM KNOWLEDGE BASE`,
mention their corresponding Page Numbers, Section Name, entities, relationships and causalities.

DESIRED OUTPUT FORMAT:
<thinking>
...
</thinking>
<answer>
{
   ""thinking"": [""..."", ...],
   ""evidences"": [""..."", ...],
   ""answer"": ...
}
</answer>

Before providing the answer in <answer> tags, think step by step in detail in <thinking> tags and analyze every part.
Output inside <answer> tag in JSON format. Only output valid JSON.
DO NOT HALLUCINATE. DO NOT MAKE UP FACTUAL INFORMATION.
","1. The edge '(N_Staging_1) causes (Lymph_Node_Ratio_6)' suggests that the staging of cancer in nearby lymph nodes directly influences the lymph node ratio. This is because the presence of cancer in lymph nodes indicates a higher level of lymphatic involvement, which would likely result in a higher lymph node ratio.
2. The causal direction for EDGE1 is positive, meaning that an increase in the staging of cancer in nearby lymph nodes would lead to an increase in the lymph node ratio.
3. The causal factor for EDGE1 is neither necessary nor sufficient, indicating that while the staging of cancer in lymph nodes can influence the lymph node ratio, it is not the only factor, nor does it guarantee a specific ratio category.
4. The causal distance for EDGE1 is proximal, suggesting a direct relationship between the staging of cancer in lymph nodes and the lymph node ratio.
5. The edge '(Lymph_Node_Ratio_6) causes (N_Staging_1)' suggests that the lymph node ratio is a direct measure of lymphatic involvement, which is a key factor in cancer staging.
6. The causal direction for EDGE2 is also positive, meaning that an increase in the lymph node ratio would likely lead to a higher N stage, indicating more advanced cancer spread.
7. The causal factor for EDGE2 is not necessary but might be sufficient if a high lymph node ratio guarantees a certain N stage.
8. The causal distance for EDGE2 is proximal, indicating a direct relationship between the lymph node ratio and the staging of cancer in the lymph nodes.
9. From the NCCN Clinical Practitioner's Guidelines for Head and Neck Cancer, the TNM staging system includes lymph node involvement as a critical factor in determining the extent of cancer spread.
10. The TNM staging system describes the extent of cancer in a standardized way, with 'N' referring to the involvement of lymph nodes.
11. The knowledge base information on page 130, section 'Pathological N (pN)', describes the involvement of lymph nodes in the TNM staging system, indicating that lymph node involvement is a key factor in cancer staging.
","1. Page 130, Section 'Pathological N (pN)': Describes the involvement of lymph nodes in the TNM staging system, indicating that lymph node involvement is a key factor in cancer staging.
2. The TNM staging system includes lymph node involvement as a critical factor in determining the extent of cancer spread.
",B,"{'A': 2.6, 'B': 97.4}",yes,B,"1. The AI assistant's reasoning for EDGE1 suggests that the staging of cancer in nearby lymph nodes (N_Staging_1) directly influences the lymph node ratio (Lymph_Node_Ratio_6). This is based on the idea that the presence of cancer in lymph nodes indicates a higher level of lymphatic involvement, which would likely result in a higher lymph node ratio. The causal direction is positive, meaning an increase in the staging of cancer in nearby lymph nodes would lead to an increase in the lymph node ratio.
2. For EDGE2, the AI assistant suggests that the lymph node ratio (Lymph_Node_Ratio_6) is a direct measure of lymphatic involvement, which is a key factor in cancer staging (N_Staging_1). The causal direction is also positive, meaning an increase in the lymph node ratio would likely lead to a higher N stage, indicating more advanced cancer spread.
3. The AI assistant's final answer is (B), which states that 'Lymph_Node_Ratio_6' increases risk 'N_Staging_1'. This is consistent with the reasoning provided for EDGE2, where the lymph node ratio is seen as influencing the staging of cancer in nearby lymph nodes.
4. The evidence from the NCCN Clinical Practitioner's Guidelines for Head and Neck Cancer supports the idea that lymph node involvement is a critical factor in cancer staging, aligning with the reasoning for EDGE2.
5. The AI assistant's reasoning and final answer are consistent, as both suggest that the lymph node ratio influences the staging of cancer in nearby lymph nodes.
"
